[{'FullStudiesResponse': {'APIVrs': '1.01.05', 'DataVrs': '2023:03:07 23:50:15.670', 'Expression': 'cancer', 'NStudiesAvail': 444567, 'NStudiesFound': 108680, 'MinRank': 1, 'MaxRank': 99, 'NStudiesReturned': 99, 'FullStudies': [{'Rank': 1, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04318756', 'OrgStudyIdInfo': {'OrgStudyId': '2458 CWS'}, 'Organization': {'OrgFullName': 'Azienda Ospedaliera Universitaria Integrata Verona', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Italian Version of Cancer Worry Scale', 'OfficialTitle': 'The Italian Version of the Cancer Worry Scale . A Pancreatic Context Adaptation and Reliability Analysis', 'Acronym': 'CWS_Ita'}, 'StatusModule': {'StatusVerifiedDate': 'January 2020', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 1, 2020', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 30, 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'August 31, 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 20, 2020', 'StudyFirstSubmitQCDate': 'March 20, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 24, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 20, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 24, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Azienda Ospedaliera Universitaria Integrata Verona', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'An Italian language version of the Cancer Worry Scale is not available yet.\n\nThe aim of this study is to develop and validate the Italian version of Cancer Worry Scale through subjects at high risk of pancreatic cancer for familiarity/genetic predisposition, or suffering from premalignant cystic lesions.', 'DetailedDescription': "The Fear of Cancer remains a significant problem for subjects enrolled surveillance programs. This emotional condition can influence the patients' wellbeing and their adherence to treatments. No results coming from the application of Cancer Worry Scale on high-risk of Pancreatic cancer individuals have been provided yet.\n\nThe fear is an emotional reaction that can be the result of interpretation and cognitions of perceived internal cues and/or external cues. To objectify this emotion, a cancer worry scale, has been developed to investigate the fear in female breast cancer survivors. The proposed scale assesses the psychological distress caused by fear of cancer.\n\nThe detection of high level of fear can prevent problematic behaviours, including anxious preoccupation, avoidance, and excessive checking, and moreover it can help patients to reduce difficulties in performing the individual's daily and social activities. The scale could use to evaluate the psychological burden produced by the enrolment in a surveillance program due to a certain predisposition to Pancreatic cancer. One step forward will be to manage those individuals with high-level of Fear of cancer, providing them a proper psychological support.\n\nAt the General and Pancreatic Surgery Unit of the Pancreas Institute, some experimental self-made psychological support programs that investigate different psychologic distress through validated instruments, like anxiety, depression, perceived stress and global assessment or quality of life have been built up. It must be noted that the scale is not available specifically for Pancreatic cancer (originally it was created for breast cancer) , and for the Italian language, thus it has never been applied in an italian surveillance/follow-up program dealing with Pancreatic cancer. Nowadays, there is only a well-structured paper assessing psychological factors associated with cancer worries in high risk participants in a pancreatic cancer surveillance program. Differently than what has been already reported by Konings et al, the cohorts of patients that will be considered are heterogeneous, reflecting more accurately the real-life scenario of the subjects to whom the scale is administered to. In addition, this may help to identify those individuals that may benefit from a psychological support, in order to prevent a withdrawal from the surveillance program.\n\nHowever, a cut-off has not been provided yet. With next step study we'll aim at determining a cut-off for the detection clinically relevant worry for cancer."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer Fear', 'Pancreatic Cancer']}, 'KeywordList': {'Keyword': ['cancer worry scale', 'cancer fear', 'pancreatic cancer risk', 'pancreatic cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '50', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Italian patients suffering from mucinous neoplasms', 'ArmGroupDescription': "Italian patients suffering from mucinous neoplasms will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Translation and cultural adaptation go the cancer worry scale']}}, {'ArmGroupLabel': 'Italian patients with familiarity/genetic predisposition', 'ArmGroupDescription': "Italian patients with familiarity/genetic predisposition will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Translation and cultural adaptation go the cancer worry scale']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Translation and cultural adaptation go the cancer worry scale', 'InterventionDescription': 'To develop and validate the Italian version of Cancer worry scale using high risk subjects for familiarity/genetic predisposition and patients with premalignant lesions.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Italian patients suffering from mucinous neoplasms', 'Italian patients with familiarity/genetic predisposition']}, 'InterventionOtherNameList': {'InterventionOtherName': ['1) Preliminary pilot testing conducted on a pilot group on patients under surveillance for pancreatic cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': "Syntactic and semantic equivalence of Cancer worry scale' items between English and Italian language and vice versa", 'PrimaryOutcomeDescription': 'the Syntactic and semantic equivalence of scale between two languages will be verified through the evaluation of differential item functioning analysis', 'PrimaryOutcomeTimeFrame': '1 month'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Face Validity of cancer worry scale on Italian subjects', 'SecondaryOutcomeDescription': 'Face Validity will be measured through the evaluation of Clarity/ comprehensibility of each item of cancer worry scale (format and meaning)', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Exploratory comparison between Patients Health Questionnaire and Irritability Depression Anxiety Scale and cancer worry scale', 'SecondaryOutcomeDescription': 'the comparison will be done considering the total score of scales', 'SecondaryOutcomeTimeFrame': '9 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': "Inclusion Criteria:\n\nSubject will be recruited from the current outpatients' clinic activity of the General and Pancreatic Surgery Unit, Pancreas Institute, Verona University Hospital. Subjects must be able to read and write in Italian. After obtained informed consent we will ask them to participate to preliminary pilot phase.\n\nThe interview of the pilot group will be audio recorded to allow to investigate and track detail that will highlight the comprehension of scale and participants' suggestion.\n\nPatients affected by cynic neoplasm (group A) and high risk subjects for familiarity/genetic predisposition (group B) are currently enrolled at General and Pancreatic Surgery Unit of the Pancreas Institute of the University of Verona.\n\nGroup A Patients with premalignant lesions (such as intraductal papillary mucinous neoplasms) that are followed-up at our Institution, to detect any clinic-radiological progression. Subjects older than 18 will be enrolled.\n\nGroup B\n\nThe enrolment criteria were the following :\n\nHaving at least 45 years of age or 10 years younger than the age of the youngest relative with pancreatic cancer (only for subject with familiar history of pancreatic cancer)\nHaving at least 40 years of age or 5 years younger than the age of the youngest relative with pancreatic cancer (only for subject with familial pancreatitis and subject affected by Lynch syndrome with at least one relative first- or second-degree affected by pancreatic cancer and subject having a known genetic mutation with at least a first-degree relative or a second-degree relative affected by pancreatic cancer\nHaving at least 30 years of age for subject with Familial Multiple Melanoma Syndrome\nHaving at least 30 years of age for patients affected by Peutz-Jeghers syndrome.\n\nThe interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion.\n\nExclusion Criteria:\n\npatients who not meet eligibility criteria", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': "Subject will be recruited from the current outpatients' clinic activity of the General and Pancreatic Surgery Unit, Pancreas Institute, Verona University Hospital. Subjects must be able to read and write in Italian. After obtained informed consent we will ask them to participate to preliminary pilot phase.\n\nThe interview of the pilot group will be audio recorded to allow to investigate and track detail that will highlight the comprehension of scale and participants' suggestion.\n\nPatients affected by cynic neoplasm (group A) and high risk subjects for familiarity/genetic predisposition (group B) are currently enrolled at General and Pancreatic Surgery Unit of the Pancreas Institute of the University of Verona.", 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Salvotore Paiella, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '0458126669', 'CentralContactPhoneExt': '+39', 'CentralContactEMail': 'salvatore.paiella@univr.it'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010190', 'ConditionMeshTerm': 'Pancreatic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010182', 'ConditionAncestorTerm': 'Pancreatic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12262', 'ConditionBrowseLeafName': 'Pancreatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7015', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12254', 'ConditionBrowseLeafName': 'Pancreatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7014', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4387', 'ConditionBrowseLeafName': 'Pancreatic Cancer', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 2, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03581708', 'OrgStudyIdInfo': {'OrgStudyId': 'No.GDREC 2018009H'}, 'Organization': {'OrgFullName': "Guangdong Provincial People's Hospital", 'OrgClass': 'OTHER'}, 'BriefTitle': 'Venous Thromboembolism in Advanced Lung Cancer', 'OfficialTitle': 'Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism (VTE) in Chinese Advanced Stage Lung Cancer', 'Acronym': 'RIVAL'}, 'StatusModule': {'StatusVerifiedDate': 'May 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2018', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 25, 2018', 'StudyFirstSubmitQCDate': 'July 9, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 10, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 9, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 10, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': "Guangdong Provincial People's Hospital", 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This is a prospective observatory clinical study, aiming to establish and validate venous thromboembolism risk model in Chinese advanced non-small cell lung cancer.', 'DetailedDescription': 'VTE has high incidence in lung cancer and increases the mortality. Appropriate preventive measures contribute to 50% increase of incidence. The investigators are to investigate the VTE in advanced non-small cell lung cancer and delineate the risk factors to establish a VTE risk model system helping clinicians to differentiate VTE high risk population and apply early prevention in order to reduce the incidence of VTE.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Lung Neoplasms', 'Venous Thromboembolism']}, 'KeywordList': {'Keyword': ['lung cancer', 'Venous Thromboembolism']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': '4 ml of peripheral blood is drawn from each subject and mononuclear cells are separated for DNA extraction, and mutation of Factor V Leiden will be examined.'}, 'EnrollmentInfo': {'EnrollmentCount': '1400', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'advanced lung cancer', 'ArmGroupDescription': 'Patients diagnosed with advanced lung cancer', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: lung cancer']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'lung cancer', 'InterventionDescription': 'If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['advanced lung cancer']}, 'InterventionOtherNameList': {'InterventionOtherName': ['advance lung cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'VTE incidence risk evaluation', 'PrimaryOutcomeDescription': 'Real world VTE incidence risk evaluation in advanced lung cancer. Establish and validate VTE risk predictive model in Chinese advanced lung cancer.', 'PrimaryOutcomeTimeFrame': '12 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'VTE incidence', 'SecondaryOutcomeDescription': 'VTE incidence in advanced lung cancer.', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'VTE and overall survival', 'SecondaryOutcomeDescription': 'The influence on overall survival by VTE.', 'SecondaryOutcomeTimeFrame': '12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAge ≥ 18 years at the time of screening.\nEastern Cooperative Oncology Group performance status of ≤ 2.\nWritten informed consent obtained from the patient.\nHistologically and cytologically documented Stage 3B-4 lung cancer (according to Version 8 of the International Association for the Study of Lung Cancer Staging system).\nPatients with stage 1 to 3, who undergo radical therapy with disease free survival (DFS) >12 months.\nWillingness and ability to comply with scheduled visits and other study procedures.\n\nExclusion Criteria:\n\nHistory of another primary malignancy except for malignancy treated with curative intent with known active disease ≥ 5 years before date of the informed consent.\nWithout signed informed consent.\nUnwillingness or inability to comply with scheduled visits or other study procedures.\nPreviously diagnosed with VTE before signing informed consent.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients diagnosed with advanced staged lung cancer with written informed consent.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'ZHEN WANG, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '862083827812', 'CentralContactPhoneExt': '50811', 'CentralContactEMail': 'hunterol@163.com'}, {'CentralContactName': 'XIAOLING CHEN', 'CentralContactRole': 'Contact', 'CentralContactPhone': '8620-83827812', 'CentralContactPhoneExt': '50816', 'CentralContactEMail': 'chenxiaoling303@163.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'ZHEN WANG', 'OverallOfficialAffiliation': 'Guangdong General Hospital, Guangdong Academy of Medical Sciences', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Guangdong General Hospital', 'LocationCity': 'Guangzhou', 'LocationState': 'Guagndong', 'LocationZip': '510080', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'ZHEN WANG, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '862083827812', 'LocationContactPhoneExt': '50811', 'LocationContactEMail': 'hunterol@163.com'}, {'LocationContactName': 'XIAOLING CHEN', 'LocationContactRole': 'Contact', 'LocationContactPhone': '862083827812', 'LocationContactPhoneExt': '50812', 'LocationContactEMail': 'chenxiaoling303@163.com'}, {'LocationContactName': 'ZHEN WANG, PHD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '18216292', 'ReferenceType': 'background', 'ReferenceCitation': 'Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May 15;111(10):4902-7. doi: 10.1182/blood-2007-10-116327. Epub 2008 Jan 23.'}, {'ReferencePMID': '15701913', 'ReferenceType': 'result', 'ReferenceCitation': 'Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 Feb 9;293(6):715-22. doi: 10.1001/jama.293.6.715.'}, {'ReferencePMID': '17940477', 'ReferenceType': 'result', 'ReferenceCitation': 'Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med. 2007 Sep;13(5):362-7. doi: 10.1097/MCP.0b013e328209413c.'}, {'ReferencePMID': '10499070', 'ReferenceType': 'result', 'ReferenceCitation': 'Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999 Sep;78(5):285-91. doi: 10.1097/00005792-199909000-00001.'}, {'ReferencePMID': '12083490', 'ReferenceType': 'result', 'ReferenceCitation': 'Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002 Jun;87(6):1076-7. No abstract available.'}, {'ReferencePMID': '16431186', 'ReferenceType': 'result', 'ReferenceCitation': 'Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006 Jan;119(1):60-8. doi: 10.1016/j.amjmed.2005.06.058.'}, {'ReferencePMID': '18208538', 'ReferenceType': 'result', 'ReferenceCitation': 'Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008 Apr;6(4):601-8. doi: 10.1111/j.1538-7836.2008.02908.x. Epub 2008 Jan 17.'}, {'ReferencePMID': '25155313', 'ReferenceType': 'result', 'ReferenceCitation': 'Wang Z, Yan HH, Yang JJ, Wang BC, Chen HJ, Zhou Q, Xu CR, Jiang BY, Wu YL. Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. Support Care Cancer. 2015 Mar;23(3):635-41. doi: 10.1007/s00520-014-2405-y. Epub 2014 Aug 27.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000008175', 'ConditionMeshTerm': 'Lung Neoplasms'}, {'ConditionMeshId': 'D000013923', 'ConditionMeshTerm': 'Thromboembolism'}, {'ConditionMeshId': 'D000054556', 'ConditionMeshTerm': 'Venous Thromboembolism'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000012142', 'ConditionAncestorTerm': 'Respiratory Tract Neoplasms'}, {'ConditionAncestorId': 'D000013899', 'ConditionAncestorTerm': 'Thoracic Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}, {'ConditionAncestorId': 'D000016769', 'ConditionAncestorTerm': 'Embolism and Thrombosis'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10324', 'ConditionBrowseLeafName': 'Lung Neoplasms', 'ConditionBrowseLeafAsFound': 'Lung Neoplasms', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15834', 'ConditionBrowseLeafName': 'Thromboembolism', 'ConditionBrowseLeafAsFound': 'Thromboembolism', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M26933', 'ConditionBrowseLeafName': 'Venous Thromboembolism', 'ConditionBrowseLeafAsFound': 'Venous Thromboembolism', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14131', 'ConditionBrowseLeafName': 'Respiratory Tract Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15810', 'ConditionBrowseLeafName': 'Thoracic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10320', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14129', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15838', 'ConditionBrowseLeafName': 'Thrombosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6936', 'ConditionBrowseLeafName': 'Embolism', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M18280', 'ConditionBrowseLeafName': 'Embolism and Thrombosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16552', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}}, {'Rank': 3, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04834570', 'OrgStudyIdInfo': {'OrgStudyId': '32155120.7.0000.0072'}, 'Organization': {'OrgFullName': 'Instituto Brasileiro de Controle do Cancer', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Breast Cancer Survivors: Main Physical and Psychosocial Problems After Completion of Treatment', 'OfficialTitle': 'Breast Cancer Survivors: Main Physical and Psychosocial Problems After Completion of Treatment'}, 'StatusModule': {'StatusVerifiedDate': 'April 2021', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 5, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 1, 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'November 1, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 1, 2021', 'StudyFirstSubmitQCDate': 'April 6, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 8, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 6, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 8, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Thiago Vidal Brito', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Instituto Brasileiro de Controle do Cancer'}, 'LeadSponsor': {'LeadSponsorName': 'Instituto Brasileiro de Controle do Cancer', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Breast cancer directly affects women physically, psychologically and socially in the process of diagnosis, treatment and post-treatment. Despite the improvement in conventional breast cancer treatments that led to longer disease-free survival, many patients still suffer from physical, psychological, social and spiritual problems after treatment. The neglect of physical and psychosocial problems faced by patients who are between 1 and 2 years after the end of treatment negatively impacts the quality of life of this population.', 'DetailedDescription': 'The purpose of the study is to assess the overall quality of life and measure the impact on women who have survived breast cancer for at least 1 year (12 months) and 2 years (24 months) after the end of primary treatment and to identify possible repercussions of breast cancer and its treatments associated with Quality of Life.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['Quality of life', 'Survivorship', 'Oncology']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '105', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast Cancer Survivors', 'ArmGroupDescription': 'Women who have survived breast cancer for at least 1 year (12 months) and 2 years (24 months) after the end of primary treatment', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Quality of life in Breast Cancer Survivors']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Quality of life in Breast Cancer Survivors', 'InterventionDescription': 'The patient will receive the following questionnaires to be completed :\n\nEORTC QLQ-C30\nEORTC QLQ - BR-23\nFACT-B', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Breast Cancer Survivors']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Global Health Status by EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire)', 'PrimaryOutcomeDescription': "This questionnaire was designed to be cancer specific, and includes all emotional, social and physical aspects of the individual's life. The scores in each dimension are uniformly transformed to dimensions ranging from 0 to 100, with 0 denoting the negative (low functioning, high symptom burden) and 100 the positive end (high functioning, low symptom burden) of the continuum.", 'PrimaryOutcomeTimeFrame': '1 year after treatment ends; 2 years after treatment ends;'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quality of life specific for breast cancer by EORTC QLQ-BR23 (European Organization for Research and Treatment of Cancer Breast-Cancer-Specific Quality of Life Questionnaire)', 'SecondaryOutcomeDescription': 'The questionnaire contains 23-item, two breast cancer specific functional scales (body image and sexuality) and three symptom scales evaluating arm symptoms, breast symptoms, and systemic therapy symptoms. The minimum and maximum values are 0 and 100, and higher scores mean a better outcome.', 'SecondaryOutcomeTimeFrame': '1 year after treatment ends; 2 years after treatment ends;'}, {'SecondaryOutcomeMeasure': 'Quality of life by FACT-B+4 (Functional Assessment of Cancer Therapy-Breast)', 'SecondaryOutcomeDescription': 'The FACT-B+4 questionnaire (Functional Assessment of Cancer Therapy-Breast) consists of 40 questions: 27 about general quality of Life and 13 about breast cancer. It is fur-ther structured into five subscales: physical, family-social, emotional, functional well-being and a last part specific for breast cancer. The result given by the sum of the scores goes from zero to 164: a higher score corresponds to major well-being of the patient.', 'SecondaryOutcomeTimeFrame': '1 year after treatment ends; 2 years after treatment ends;'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nBreast cancer\nAdult women (age ≥ 20 years old and less than 60 years old)\nPatient who has been treated by surgery, with or without adjuvant chemotherapy\nClinical Stages I, II and III\nPatients considered cured, without history of recurrences\nPatients who completed treatment within a minimum of 1 year and are currently being undergoing outpatient follow-up\n\nExclusion Criteria:\n\nInitial diagnosis of another type of cancer, other than breast cancer\nBilateral breast cancer\nPatient unable to fill out the QoL questionnaire\nPatient with disease recurrence\nPatient with metastatic breast cancer', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '20 Years', 'MaximumAge': '60 Years', 'StdAgeList': {'StdAge': ['Adult']}, 'StudyPopulation': 'Recruitment of 100 breast cancer patients who have completed treatment within a minimum of 1 year and are currently undergoing outpatient follow-up', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Thiago Brito, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+55 21 97154-0865', 'CentralContactEMail': 'tcgvidal@hotmail.com'}, {'CentralContactName': 'Alayne Domingues Yamada, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+55 11 98141-7613', 'CentralContactEMail': 'alayne.pesquisa@ibcc-mooca.org.br'}]}, 'LocationList': {'Location': [{'LocationFacility': 'IBCC Oncologia', 'LocationStatus': 'Recruiting', 'LocationCity': 'São Paulo', 'LocationZip': '03102002', 'LocationCountry': 'Brazil', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Thiago Vidal Brito, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+55 21 97154-0865', 'LocationContactEMail': 'tcgvidal@hotmail.com'}, {'LocationContactName': 'Felipe José Silva Melo Cruz, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+5511994466537', 'LocationContactEMail': 'felipemcruz@yahoo.com.br'}, {'LocationContactName': 'Thiago Vidal Brito, MD', 'LocationContactRole': 'Principal Investigator'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T6034', 'ConditionBrowseLeafName': 'Quality of Life', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 4, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00897650', 'OrgStudyIdInfo': {'OrgStudyId': 'VICC THO 0547'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'P30CA068485', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/P30CA068485'}, {'SecondaryId': 'VU-VICC-THO-0547', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'VICC'}, {'SecondaryId': 'P50CA090949', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/P50CA090949'}]}, 'Organization': {'OrgFullName': 'Vanderbilt-Ingram Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer', 'OfficialTitle': 'Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy'}, 'StatusModule': {'StatusVerifiedDate': 'July 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 2005'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'July 2017', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 9, 2009', 'StudyFirstSubmitQCDate': 'May 9, 2009', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 12, 2009', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 18, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 19, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Christine Lovly, MD, PhD', 'ResponsiblePartyInvestigatorTitle': 'Assistant Professor of Medicine and Cancer Biology', 'ResponsiblePartyInvestigatorAffiliation': 'Vanderbilt-Ingram Cancer Center'}, 'LeadSponsor': {'LeadSponsorName': 'Vanderbilt-Ingram Cancer Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'RATIONALE: Studying samples of tumor tissue and blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in genetic material (DNA and RNA) and may also identify protein expression patterns related to cancer. It may also help doctors predict how patients will respond to treatment.\n\nPURPOSE: This research study evaluates changes in DNA, RNA, and proteins with the goal of predicting response to treatment in patients with lung cancer.', 'DetailedDescription': 'OBJECTIVES:\n\nTo determine protein and/or RNA expression patterns capable of predicting tumor response to therapy in tumor tissue samples from patients with lung cancer or suspected of having lung cancer.\nTo characterize the genes and proteins found to be predictive of response in order to help elucidate the molecular biology underlying cancer chemosensitivity.\nTo evaluate DNA mutations found within the lung cancer sample which may be predictive of response or resistance to certain therapeutic agents.\n\nOUTLINE: Patients undergo collection of tumor tissue by percutaneous fine needle aspiration, core biopsy, thoracentesis, or during any medically indicated procedure involving removal of lung cancer tissue. Tissue samples are analyzed by a variety of techniques, including DNA sequencing, RNA sequencing and expression levels, protein assessment [by immunohistochemistry, western blot, Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-MS]). The goal of these studies is to identify of gene mutations, gene expression levels, and proteins predictive of treatment response. Blood samples are also collected to obtain normal DNA for analysis.\n\nAfter completion of study, patients will be followed until their death.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Lung Cancer']}, 'KeywordList': {'Keyword': ['lung cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Lung tumor tissue and blood samples will be collected.'}, 'EnrollmentInfo': {'EnrollmentCount': '204', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Lung cancer', 'ArmGroupDescription': 'Patients with a diagnosis of invasive lung cancer.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: DNA/RNA sequencing and expression levels', 'Genetic: Protein expression analysis', 'Procedure: Lung tumor biopsy', 'Procedure: Blood sample']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Genetic', 'InterventionName': 'DNA/RNA sequencing and expression levels', 'InterventionDescription': 'Lung tumor tissue will be collected.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Lung cancer']}}, {'InterventionType': 'Genetic', 'InterventionName': 'Protein expression analysis', 'InterventionDescription': 'Lung tumor tissue will be collected.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Lung cancer']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI)', 'Immunohistochemistry', 'Western blot', 'RPPA']}}, {'InterventionType': 'Procedure', 'InterventionName': 'Lung tumor biopsy', 'InterventionDescription': 'Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Lung cancer']}}, {'InterventionType': 'Procedure', 'InterventionName': 'Blood sample', 'InterventionDescription': 'Patients will be asked for a venous blood sample', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Lung cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'DNA, RNA, and Protein expression patterns and mutational analysis', 'PrimaryOutcomeDescription': 'DNA, RNA, and Protein expression patterns and mutation status in lung tumor tissue that are capable of predicting tumor response to therapy', 'PrimaryOutcomeTimeFrame': 'After lung tumor tissue and blood collection.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Characterization of genes and proteins predictive of response to therapy', 'SecondaryOutcomeDescription': 'Identify genes and proteins predictive of response to therapy and that can be used to identify novel mechanisms underlying lung cancer behavior', 'SecondaryOutcomeTimeFrame': 'After lung tumor tissue and blood collection'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria\n\nDiagnosis of suspected lung cancer or lung cancer\n\nExclusion criteria\n\nInability to undergo therapy', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MaximumAge': '120 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'People who have or may have lung cancer.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Christine Lovly, MD, PhD', 'OverallOfficialAffiliation': 'Vanderbilt-Ingram Cancer Center', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Vanderbilt-Ingram Cancer Center', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37232-6838', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Vanderbilt-Ingram Cancer Center, Find a Clinical Trial', 'SeeAlsoLinkURL': 'http://www.vicc.org/ct/'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000008175', 'ConditionMeshTerm': 'Lung Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000012142', 'ConditionAncestorTerm': 'Respiratory Tract Neoplasms'}, {'ConditionAncestorId': 'D000013899', 'ConditionAncestorTerm': 'Thoracic Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10324', 'ConditionBrowseLeafName': 'Lung Neoplasms', 'ConditionBrowseLeafAsFound': 'Lung Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14131', 'ConditionBrowseLeafName': 'Respiratory Tract Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15810', 'ConditionBrowseLeafName': 'Thoracic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10320', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14129', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 5, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04494620', 'OrgStudyIdInfo': {'OrgStudyId': 'RCC-IEC-Sept 2002'}, 'Organization': {'OrgFullName': 'International Agency for Research on Cancer', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Evaluating Oral Visual Inspection in the Control of Oral Cancer', 'OfficialTitle': 'Randomized Intervention Trial to Evaluate Oral Visual Inspection in the Control of Oral Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'July 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 1, 1996', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2004', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2014', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 16, 2020', 'StudyFirstSubmitQCDate': 'July 28, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 31, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 28, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 31, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'International Agency for Research on Cancer', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Regional Cancer Centre Trivandrum', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Cluster-randomized controlled trial in Trivandrum district, Kerala, India to evaluate the effect of triennial screening for oral cavity cancer using visual inspection on oral cancer mortality.', 'DetailedDescription': 'The study population consisted of 13 administrative regions (clusters) in Trivandrum district, Kerala, southern Indian. 7 clusters were randomly assigned to the intervention arm (3 rounds of oral visual inspection conducted 3 years apart) and were compared to the remaining 6 clusters assigned to a control arm that received standard of care. The eligibility criteria were all healthy subjects aged 35 and older, without a personal history of oral cancer. Informed consent was signed by each participant. The intervention arm consisted of 96,517 participants and the control group consisted of 95,356 participants.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Oral Cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'The control group received standard of care while the intervention group received 3 rounds of screening with visual inspection, each 3 years apart. At the 9th year of the study, once significant oral cancer mortality reduction following 3 rounds of screening among the high-risk subjects in the intervention arm was confirmed, the control arm was offered 1 round of screening with visual inspection while the intervention group was offered a 4th round of screening.', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '191873', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Control Arm', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Standard of Care'}, {'ArmGroupLabel': 'Intervention Arm', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Visual Inspection of Oral Cavity for Precancers and Cancer', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Visual Inspection of Oral Cavity for Precancers and Cancer']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test', 'InterventionName': 'Visual Inspection of Oral Cavity for Precancers and Cancer', 'InterventionDescription': 'Participants were invited for 3 rounds of oral cavity cancer screening, conducted 3-years apart. Screening was conducted by health workers trained to perform visual inspection of the oral mucosa and identify potential precancerous lesions or oral cancer. Lesions found were referred to a weekly clinic for further evaluation by dentists and oncologists with experience in the diagnosis of oral lesions. Oral precancerous lesions were surgically excised whenever possible and those with confirmed oral cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention Arm']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Oral Cancer Death Rate', 'PrimaryOutcomeDescription': 'Information on all deaths were collected from the municipal and district death registers, hospital medical records, death records of churches and mosques, hospital visits by the population cancer registry staff and by project health workers. Cancer cases were coded by the ICD-O 3rd edition codes and cause of death was coded using ICD-10 by the registry and project staff blinded to study group allocation. Deaths were attributed to oral cancer if the patient had histologically or clinically confirmed oral cancer, lymph nodes or distant metastasis at the time of death or had died due to complications of oral cancer treatment.', 'PrimaryOutcomeTimeFrame': '15 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Oral Cavity Cancer Incidence', 'SecondaryOutcomeDescription': 'Information on incident oral cancer cases were obtained from the Trivandrum population-based cancer registry, hospital cancer registry of the RCC and medical records departments of other hospitals treating oral cancer patients. Collection of information was blinded to study group assignment of cases. The staging of oral cancers was done according to the UICC TNM staging system.', 'SecondaryOutcomeTimeFrame': '15 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria: Residing in 13 study clusters in Trivandrum City, Kerala\n\nExclusion Criteria:\n\nDiagnosis with oral cancer prior to study\nBedridden subjects\nSubjects suffering from open tuberculosis or other debilitating diseases', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '35 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kunnambath Ramadas, MD, PhD', 'OverallOfficialAffiliation': 'Regional Cancer Centre, Trivandrum, India', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Rengaswamy Sankaranarayanan, MD', 'OverallOfficialAffiliation': 'International Agency for Research on Cancer', 'OverallOfficialRole': 'Principal Investigator'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '23265945', 'ReferenceType': 'result', 'ReferenceCitation': 'Sankaranarayanan R, Ramadas K, Thara S, Muwonge R, Thomas G, Anju G, Mathew B. Long term effect of visual screening on oral cancer incidence and mortality in a randomized trial in Kerala, India. Oral Oncol. 2013 Apr;49(4):314-21. doi: 10.1016/j.oraloncology.2012.11.004. Epub 2012 Dec 21.'}, {'ReferencePMID': '15936419', 'ReferenceType': 'result', 'ReferenceCitation': 'Sankaranarayanan R, Ramadas K, Thomas G, Muwonge R, Thara S, Mathew B, Rajan B; Trivandrum Oral Cancer Screening Study Group. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet. 2005 Jun 4-10;365(9475):1927-33. doi: 10.1016/S0140-6736(05)66658-5.'}, {'ReferencePMID': '33449824', 'ReferenceType': 'derived', 'ReferenceCitation': 'Cheung LC, Ramadas K, Muwonge R, Katki HA, Thomas G, Graubard BI, Basu P, Sankaranarayanan R, Somanathan T, Chaturvedi AK. Risk-Based Selection of Individuals for Oral Cancer Screening. J Clin Oncol. 2021 Feb 20;39(6):663-674. doi: 10.1200/JCO.20.02855. Epub 2021 Jan 15.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000009062', 'ConditionMeshTerm': 'Mouth Neoplasms'}, {'ConditionMeshId': 'D000008048', 'ConditionMeshTerm': 'Lip Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000006258', 'ConditionAncestorTerm': 'Head and Neck Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000009059', 'ConditionAncestorTerm': 'Mouth Diseases'}, {'ConditionAncestorId': 'D000009057', 'ConditionAncestorTerm': 'Stomatognathic Diseases'}, {'ConditionAncestorId': 'D000008047', 'ConditionAncestorTerm': 'Lip Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M11174', 'ConditionBrowseLeafName': 'Mouth Neoplasms', 'ConditionBrowseLeafAsFound': 'Oral Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10202', 'ConditionBrowseLeafName': 'Lip Neoplasms', 'ConditionBrowseLeafAsFound': 'Oral Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8500', 'ConditionBrowseLeafName': 'Head and Neck Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11171', 'ConditionBrowseLeafName': 'Mouth Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11169', 'ConditionBrowseLeafName': 'Stomatognathic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4265', 'ConditionBrowseLeafName': 'Oral Cancer', 'ConditionBrowseLeafAsFound': 'Oral Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'T3466', 'ConditionBrowseLeafName': 'Lip and Oral Cavity Cancer', 'ConditionBrowseLeafAsFound': 'Oral Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC07', 'ConditionBrowseBranchName': 'Mouth and Tooth Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 6, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02890667', 'OrgStudyIdInfo': {'OrgStudyId': 'PHRC-K 14-158'}, 'Organization': {'OrgFullName': 'Assistance Publique - Hôpitaux de Paris', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Evaluation of Algorithms to Identify Incident Cancer Cases by Using French Health Administrative Databases', 'OfficialTitle': 'A Population Based Observational Study Conducted on the French Administrative Databases to Estimate Cancer Incidence Using Outpatient Care and Hospital Discharge'}, 'StatusModule': {'StatusVerifiedDate': 'August 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2015'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'August 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'September 1, 2016', 'StudyFirstSubmitQCDate': 'September 6, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 7, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 6, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 7, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Assistance Publique - Hôpitaux de Paris', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': '"This study is a population based observational study conducted on the French administrative databases to estimate cancer incidence in 2012 by using the "ECHANTILLON GENERALISTE DES BENEFICIAIRES" (EGB, a 1/97th dynamic random sample of the SNIIRAM).\n\nThe EGB database contains anonymous and prospectively recorded data about all beneficiaries\' medical reimbursements. Many algorithm definitions are defined to estimate the incident rate of cancer in 2012 from the EGB database. The incidence rates obtained by each algorithm definition are compared to national incidence rates by indirect age and sex standardization. National incidence rates are obtained from "FRANCE CANCER INCIDENCE ET MORTALITE" (FRANCIM): the French network of cancer registries."', 'DetailedDescription': '"This study is a population based observational study conducted on the French administrative databases to estimate cancer incidence in 2012 by using the "ECHANTILLON GENERALISTE DES BENEFICIAIRES" (EGB, a 1/97th dynamic random sample of the SNIIRAM).\n\nThe EGB database contains anonymous and prospectively recorded data about all beneficiaries\' medical reimbursements including age, gender, long-term chronic disease (LTD), date of death, all out-hospital health-spending reimbursements and all patients\' hospitalizations. Many algorithm definitions are defined to estimate the incident rate of cancer in 2012 from the EGB database and are applied separately for men and women. These algorithms use information from either out-hospital care only (LTD status, anticancer specific drugs, outpatient radiotherapy sessions), or inpatient stays only (primary or related diagnosis of cancer, cancer-related procedures) or combine both information. The incidence rates obtained by each algorithm definition are compared to national incidence rates by indirect age and sex standardization. National incidence rates are obtained from FRANCE CANCER INCIDENCE ET MORTALITE (FRANCIM): the French network of cancer registries that has collected cancer cases since 1975 from 21 French registries (general or specific) covering 17 of the 95 French metropolitan departments. The most recent estimation of the FRANCIM network was published for 2012 and included all cancer locations (C00-C97) excluding non-melanoma skin cancer (C44).\n\nFollow up All patients included are followed from January 1, 2012 until the occurrence of the first of death, cancer occurrence, moving out of the general insurance scheme or January 1, 2013.\n\nTo allow for comparison with data from cancer registries, only malignant neoplasms are considered: ICD-10 codes (C00-C97), excluding non-melanoma skin cancer (C44).\n\nStatistical analysis\n\nThe number of incident cancer cases obtained with each algorithm is compared to the expected number of cancer cases calculated by using national estimation for the same age and sex stratum. The standardized incidence ratio (SIR) with 95% confidence intervals is calculated by indirect age and sex standardization. Age- and sex-specific incident rates are compared to the incident rates in 2012 estimated by FRANCIM.\n\nThe investigators also apply the most accurate algorithm separately for men and women to the 3 most common cancers in the corresponding gender by restricting the involved cancer codes, procedures and drugs to those related to the cancer of interest. The investigators also restrict our population to the most-studied age groups in cancer etiological studies (40 to 75 years). All the analyses are performed using SAS Enterprise Guide, version 4.3."'}, 'ConditionsModule': {'ConditionList': {'Condition': ['All Cancer Incidence']}, 'KeywordList': {'Keyword': ['Cancer', 'incidence', 'health insurance data', 'algorithms']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Retrospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '447694', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Beneficiaries', 'ArmGroupDescription': 'Incident cancer for Beneficiaries present in the EGB on January 1, 2012.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Incident cancer']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Incident cancer', 'InterventionDescription': 'The number of incident cancer cases', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Beneficiaries']}, 'InterventionOtherNameList': {'InterventionOtherName': ['observation of a cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'All Cancer incidence', 'PrimaryOutcomeTimeFrame': '1 year'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Prostate cancer incidence', 'SecondaryOutcomeTimeFrame': '1 year'}, {'SecondaryOutcomeMeasure': 'Breast cancer incidence', 'SecondaryOutcomeTimeFrame': '1 year'}, {'SecondaryOutcomeMeasure': 'Lung cancer incidence', 'SecondaryOutcomeTimeFrame': '1 year'}, {'SecondaryOutcomeMeasure': 'Colorectal cancer incidence', 'SecondaryOutcomeTimeFrame': '1 year'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nBeneficiaries present in the EGB on January 1, 2012.\nBeneficiaries who are < 90 years old on January 1, 2012.\nBeneficiaries residing in metropolitan France.\nBeneficiaries affiliated with the general insurance scheme since January 1, 2011 or before.\n\nExclusion Criteria:\n\nNo prevalent cancer before January 1, 2012; ( hospital discharge with a primary, related or associated diagnosis of cancer (C00-C97), or personal history of cancer (Z85); LTD status related to cancer; reimbursement for any cancer-specific drug; or external radiotherapy session).', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MaximumAge': '90 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'Beneficiaries present in the " ECHANTILLON GENERALISTE DES BENEFICIAIRES (EGB)" on January 1, 2012.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Aya AJROUCHE, Pharm.D', 'OverallOfficialAffiliation': 'CEPHEPI, AP-HP', 'OverallOfficialRole': 'Principal Investigator'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}}}}, {'Rank': 7, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04875351', 'OrgStudyIdInfo': {'OrgStudyId': 'BTX-BCI-016-PRT'}, 'Organization': {'OrgFullName': 'Biotheranostics, Inc.', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Breast Cancer Index (BCI) Registry', 'OfficialTitle': 'Breast Cancer Index (BCI) Registry'}, 'StatusModule': {'StatusVerifiedDate': 'August 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 14, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2028', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2028', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 26, 2021', 'StudyFirstSubmitQCDate': 'May 4, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 6, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 17, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 19, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Biotheranostics, Inc.', 'LeadSponsorClass': 'INDUSTRY'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale, population-based prospective registry to evaluate long-term clinical outcome, clinical impact, medication adherence and quality of life in hormone receptor positive (HR+) early-stage breast cancer patients receiving BCI testing as part of routine clinical care to inform extended endocrine therapy.', 'DetailedDescription': "The BCI Registry is designed as a large-scale data registry and biospecimen repository to evaluate the clinical outcome of hormone receptor positive (HR+) early-stage breast cancer patients completing primary adjuvant endocrine therapy and are considering extended endocrine treatment. The impact of BCI test results on extended endocrine therapy decision-making and clinical use patterns will be characterized. Extended endocrine therapy-specific medication adherence will be assessed annually. Primary tumor tissue will be collected for scientific research purposes including molecular profiling and for correlative studies. The sample size will consist of approximately 3,000 subjects across 30-50 sites in the United States.\n\nThe BCI registry will recruit patients with HR+ stage I to III breast cancer following an initial 4-7 years of adjuvant endocrine therapy that will have BCI testing performed as part of routine clinical care and meet the inclusion/exclusion criteria. After signing the informed consent form (ICF) during screening, physicians and patients will complete the pre-test Decision Impact Questionnaire. Upon ordering BCI by the treating physician, primary tumor tissue obtained from the patient during previous breast-conserving surgery or mastectomy will be requested by Biotheranostics to perform BCI testing at Biotheranostics' CLIA certified and CAP accredited clinical laboratory in San Diego, CA. Following BCI testing, the physician will share and discuss the BCI results with their patients and recommend to either stop or extend endocrine therapy for an additional 5 years. The impact of the BCI test results on extended endocrine therapy decision-making will be assessed using the post-test Decision Impact Questionnaire, which will be completed by both physicians and patients. In addition, medication adherence will be evaluated in patients that are recommended for or elect to continue treatment to complete 10 years of adjuvant endocrine therapy.\n\nBCI reports both a prognostic and predictive result and has been shown to significantly stratify patients based on the risk of late distant recurrence as well as to predict the likelihood of benefit from endocrine therapy in multiple prospective-retrospective studies within randomized controlled trial cohorts. The BCI registry study will determine the long-term outcome and BCI test performance to add prospective validation for the prognostic and predictive capabilities of BCI. In this context, the impact of BCI test results on treatment decision-making and subsequently prescribed treatments will be characterized.\n\nAnalysis of BCI test performance with long-term outcome will be performed by Kaplan-Meier analysis with log-rank test to assess the statistical significance of the risk stratification by BCI risk groups. Cox proportional hazards regression will be used to derive the hazard ratios (HR) and the associated 95% confidence intervals for the comparison of BCI risk groups. Univariate and multivariate analysis adjusting for clinical factors such as age, tumor size, grade, and treatment background (adjuvant endocrine therapy and chemotherapy) will be conducted. Descriptive statistics will be used to evaluate the decision-impact and medication adherence scores of patients enrolled in the study.\n\nEach participating site will maintain appropriate medical and research records for this trial, in compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements for the protection of confidentiality of subjects. As part of participating in a Biotheranostics-sponsored study, each site will permit authorized representatives of the sponsor and regulatory agencies to examine clinical records for the purposes of quality assurance reviews, audits and evaluation of the study progress. The clinical trial manager will be in regular contact with the site research leader to check on progress and address any queries that they may have. Sites may be suspended from participating in the registry in the event of serious and persistent non-compliance with the protocol and/or Good Clinical Practice. Any major problems identified will be reported to the Trial Management Team and if necessary, the relevant regulatory bodies."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['Breast Neoplasm', 'Invasive Breast Carcinoma', 'Early Stage (I, II or III) Breast Cancer', 'Hormone Receptor positive (HR+) Breast Cancer', 'Extended Endocrine Therapy']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'Yes', 'TargetDuration': '5 Years', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Tumor Tissue'}, 'EnrollmentInfo': {'EnrollmentCount': '3000', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Testing', 'ArmGroupDescription': 'Female patients diagnosed with hormone receptor-positive (HR+), lymph node-negative (LN-) or lymph node-positive (LN+, with 1-3 positive nodes) early-stage invasive breast cancer, who are distant recurrence-free.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test', 'InterventionName': 'Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test', 'InterventionDescription': 'The BCI test provides a quantitative estimate of the risk for both late (post-5 years from diagnosis) distant recurrence and of the cumulative distant recurrence risk over 10 years (0-10y) in patients treated with adjuvant endocrine therapy (LN- patients) or adjuvant chemoendocrine therapy (LN+ patients), and prediction of the likelihood of benefit from extended (>5 year) endocrine therapy.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Testing']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Breast Cancer Index (BCI) Test']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'To determine BCI test performance by evaluating the long-term outcome of BCI risk groups over the follow-up period.', 'PrimaryOutcomeTimeFrame': '5 Years'}, {'PrimaryOutcomeMeasure': 'To determine medication adherence in patients undergoing extended endocrine therapy.', 'PrimaryOutcomeDescription': 'Patients will be asked to complete a Medication Adherence Questionnaire during routine follow-up visits. Medication adherence scores over time will be evaluated in patients that are recommended for or elect to continue treatment to complete 10 years of adjuvant endocrine therapy.', 'PrimaryOutcomeTimeFrame': '5 Years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'To prospectively assess the impact of BCI on extended endocrine therapy decision-making.', 'SecondaryOutcomeDescription': 'The impact of the BCI test results on extended endocrine therapy decision making will be measured using pre- and post-test Decision Impact Questionnaires, which will be completed by both physicians and patients.', 'SecondaryOutcomeTimeFrame': '5 Years'}, {'SecondaryOutcomeMeasure': 'To correlate BCI results with molecular tumor profiles in early stage breast cancer.', 'SecondaryOutcomeTimeFrame': '5 Years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nEarly stage (I, II or III) female breast cancer patients, who have completed 4-7 years of primary adjuvant endocrine therapy\nPatient was diagnosed with invasive breast carcinoma (ductal, lobular, or mixed ductal/lobular).\nThe primary tumor was hormone receptor positive (HR+), i.e. estrogen receptor-positive and/or progesterone receptor-positive.\nThe primary tumor was HER2 negative or positive and node-negative or node-positive with 1-3 positive lymph nodes.\nSubject has pre-treatment breast tumor tissue [formalin fixed and paraffin embedded (FFPE)] from a previous breast-conserving surgery, mastectomy or core needle biopsy available for testing by the Sponsor.\n\nExclusion Criteria:\n\nPatient has distant metastatic disease (M1).\nPatient was diagnosed with metaplastic breast cancer, carcinosarcoma, sarcoma, neuroendocrine carcinoma, adenoid cystic carcinoma, or phyllodes tumor.', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'GenderBased': 'Yes', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'The study will include patients with stage I-III HR+ breast cancer that have signed an informed consent. Patients seen within a physician practice participating in the registry are potential candidates after meeting eligibility criteria requirements.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': "Brandon N O'Neal, MS", 'CentralContactRole': 'Contact', 'CentralContactPhone': '858-314-9304', 'CentralContactEMail': 'brandon.oneal@biotheranostics.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': "Joyce A O'Shaughnessy, MD", 'OverallOfficialAffiliation': 'US Oncology Network', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Kai Treuner, PhD', 'OverallOfficialAffiliation': 'Biotheranostics, Inc.', 'OverallOfficialRole': 'Study Director'}, {'OverallOfficialName': 'Amanda KL Anderson, PhD', 'OverallOfficialAffiliation': 'Biotheranostics, Inc.', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Southern Cancer Center, P.C. - Daphne', 'LocationStatus': 'Recruiting', 'LocationCity': 'Daphne', 'LocationState': 'Alabama', 'LocationZip': '36526', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Karla Childers', 'LocationContactRole': 'Contact', 'LocationContactPhone': '251-433-9899', 'LocationContactEMail': 'karla.childers@usoncology.com'}, {'LocationContactName': 'Michael Meshad, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Southern Cancer Center, PC - Mobile Infirmary', 'LocationStatus': 'Recruiting', 'LocationCity': 'Mobile', 'LocationState': 'Alabama', 'LocationZip': '36607', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Karla Childers', 'LocationContactRole': 'Contact', 'LocationContactPhone': '251-433-9899', 'LocationContactEMail': 'karla.childers@usoncology.com'}, {'LocationContactName': 'Michael Meshad, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Southern Cancer Center, PC - Providence Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Mobile', 'LocationState': 'Alabama', 'LocationZip': '36608', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Karla Childers', 'LocationContactRole': 'Contact', 'LocationContactPhone': '251-433-9899', 'LocationContactEMail': 'karla.childers@usoncology.com'}, {'LocationContactName': 'Michael Meshad, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Southern Cancer Center, PC - Springhill Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Mobile', 'LocationState': 'Alabama', 'LocationZip': '36608', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Karla Childers', 'LocationContactRole': 'Contact', 'LocationContactPhone': '251-433-9899', 'LocationContactEMail': 'karla.childers@usoncology.com'}, {'LocationContactName': 'Michael Meshad, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Arizona Oncology Associates, PC - Glendale - Saguaro Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Glendale', 'LocationState': 'Arizona', 'LocationZip': '85308', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Theresa Thomas', 'LocationContactRole': 'Contact', 'LocationContactPhone': '623-487-4822', 'LocationContactEMail': 'theresa.thomas@usoncology.com'}, {'LocationContactName': 'Govardhanan Nagaiah, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Arizona Oncology Associates, PC - Goodyear', 'LocationStatus': 'Recruiting', 'LocationCity': 'Goodyear', 'LocationState': 'Arizona', 'LocationZip': '85395', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Theresa Thomas', 'LocationContactRole': 'Contact', 'LocationContactPhone': '623-269-4222', 'LocationContactEMail': 'theresa.thomas@usoncology.com'}, {'LocationContactName': 'Govardhanan Nagaiah, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Arizona Oncology Associates, PC - Phoenix - Biltmore Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationZip': '85016', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Theresa Thomas', 'LocationContactRole': 'Contact', 'LocationContactPhone': '602-277-4868', 'LocationContactEMail': 'theresa.thomas@usoncology.com'}, {'LocationContactName': 'Govardhanan Nagaiah, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Arizona Oncology Associates, PC - Phoenix - Deer Valley', 'LocationStatus': 'Recruiting', 'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationZip': '85027', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Theresa Thomas', 'LocationContactRole': 'Contact', 'LocationContactPhone': '623-879-4419', 'LocationContactEMail': 'theresa.thomas@usoncology.com'}, {'LocationContactName': 'Govardhanan Nagaiah, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Arizona Oncology Associates, PC - Scottsdale', 'LocationStatus': 'Recruiting', 'LocationCity': 'Scottsdale', 'LocationState': 'Arizona', 'LocationZip': '85258', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Theresa Thomas', 'LocationContactRole': 'Contact', 'LocationContactPhone': '480-860-2540', 'LocationContactEMail': 'theresa.thomas@usoncology.com'}, {'LocationContactName': 'Govardhanan Nagaiah, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Arizona Oncology Associates, PC - East Valley Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Tempe', 'LocationState': 'Arizona', 'LocationZip': '85284', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Theresa Thomas', 'LocationContactRole': 'Contact', 'LocationContactPhone': '480-256-1664', 'LocationContactEMail': 'theresa.thomas@usoncology.com'}, {'LocationContactName': 'Govardhanan Nagaiah, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Sansum Clinic - Ridley-Tree Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Santa Barbara', 'LocationState': 'California', 'LocationZip': '93105', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Heidi Heitkamp', 'LocationContactRole': 'Contact', 'LocationContactPhone': '805-879-0670', 'LocationContactEMail': 'hheitkam@ridleytreecc.org'}, {'LocationContactName': 'Gregg C Newman, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Sansum Clinic - Ridley-Tree Cancer Center (Solvang)', 'LocationStatus': 'Recruiting', 'LocationCity': 'Solvang', 'LocationState': 'California', 'LocationZip': '93463', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Heidi Heitkamp', 'LocationContactRole': 'Contact', 'LocationContactPhone': '805-686-5370', 'LocationContactEMail': 'hheitkam@ridleytreecc.org'}, {'LocationContactName': 'Gregg C Newman, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Center - Aurora', 'LocationStatus': 'Recruiting', 'LocationCity': 'Aurora', 'LocationState': 'Colorado', 'LocationZip': '80012', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '303-418-7639', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Center - Boulder', 'LocationStatus': 'Recruiting', 'LocationCity': 'Boulder', 'LocationState': 'Colorado', 'LocationZip': '80303', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '303-385-2000', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Center - Centennial', 'LocationStatus': 'Recruiting', 'LocationCity': 'Centennial', 'LocationState': 'Colorado', 'LocationZip': '80112', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '303-805-7744', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Center - Colorado Springs', 'LocationStatus': 'Recruiting', 'LocationCity': 'Colorado Springs', 'LocationState': 'Colorado', 'LocationZip': '80907', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '719-577-2555', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Center - Denver Midtown', 'LocationStatus': 'Recruiting', 'LocationCity': 'Denver', 'LocationState': 'Colorado', 'LocationZip': '80218', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '303-388-4876', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Center - Denver', 'LocationStatus': 'Recruiting', 'LocationCity': 'Denver', 'LocationState': 'Colorado', 'LocationZip': '80220', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '303-321-0302', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Center - Swedish Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Englewood', 'LocationState': 'Colorado', 'LocationZip': '80113', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '303-740-8200', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Centers - Lakewood', 'LocationStatus': 'Recruiting', 'LocationCity': 'Lakewood', 'LocationState': 'Colorado', 'LocationZip': '80228', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '303-430-2700', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Center - Littleton', 'LocationStatus': 'Recruiting', 'LocationCity': 'Littleton', 'LocationState': 'Colorado', 'LocationZip': '80120', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '303-730-4700', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Center - Lone Tree', 'LocationStatus': 'Recruiting', 'LocationCity': 'Lone Tree', 'LocationState': 'Colorado', 'LocationZip': '80124', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '303-925-0700', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Center - Longmont', 'LocationStatus': 'Recruiting', 'LocationCity': 'Longmont', 'LocationState': 'Colorado', 'LocationZip': '80501', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '303-684-1900', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Center - Pueblo', 'LocationStatus': 'Recruiting', 'LocationCity': 'Pueblo', 'LocationState': 'Colorado', 'LocationZip': '81008', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '719-296-6000', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Rocky Mountain Cancer Center - Thornton', 'LocationStatus': 'Recruiting', 'LocationCity': 'Thornton', 'LocationState': 'Colorado', 'LocationZip': '80260', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kelly Beland', 'LocationContactRole': 'Contact', 'LocationContactPhone': '303-386-7622', 'LocationContactEMail': 'kelly.beland@usoncology.com'}, {'LocationContactName': 'Jenny R Fox, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Cancer Care Centers of Brevard, Inc.', 'LocationStatus': 'Recruiting', 'LocationCity': 'Palm Bay', 'LocationState': 'Florida', 'LocationZip': '32901', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Deborah Schmitt', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'deborah.schmitt@usoncology.com'}, {'LocationContactName': 'Venkat Pavan R Kancharla, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Illinois Cancer Specialists - Arlington Heights', 'LocationStatus': 'Recruiting', 'LocationCity': 'Arlington Heights', 'LocationState': 'Illinois', 'LocationZip': '60005', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Andrea Glidden', 'LocationContactRole': 'Contact', 'LocationContactPhone': '847-259-4482', 'LocationContactEMail': 'andrea.glidden@usoncology.com'}, {'LocationContactName': 'Laura Palmisano', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'laura.palmisano@usoncology.com'}, {'LocationContactName': 'Kristen B Wendell, DO', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Affiliated Oncologists, LLC', 'LocationStatus': 'Recruiting', 'LocationCity': 'Chicago Ridge', 'LocationState': 'Illinois', 'LocationZip': '60415', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Angela Malone', 'LocationContactRole': 'Contact', 'LocationContactPhone': '708-424-9710', 'LocationContactEMail': 'angela.malone@usoncology.com'}, {'LocationContactName': 'Rami Y Haddad, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Illinois Cancer Specialists - Niles', 'LocationStatus': 'Recruiting', 'LocationCity': 'Niles', 'LocationState': 'Illinois', 'LocationZip': '60714', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lisbeth B Lynn', 'LocationContactRole': 'Contact', 'LocationContactPhone': '847-827-9060', 'LocationContactEMail': 'lisbeth.lynn@usoncology.com'}, {'LocationContactName': 'Sara Majcher', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'sara.majcher@usoncology.com'}, {'LocationContactName': 'Kristen B Wendell, DO', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Maryland Oncology Hematology, P.A. - Bethesda', 'LocationStatus': 'Recruiting', 'LocationCity': 'Bethesda', 'LocationState': 'Maryland', 'LocationZip': '20817', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Melissa Almand', 'LocationContactRole': 'Contact', 'LocationContactPhone': '301-424-6231', 'LocationContactEMail': 'missy.almand@usoncology.com'}, {'LocationContactName': 'Tejaswi R Sastry, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Maryland Oncology Hematology, P.A. - Brandywine', 'LocationStatus': 'Recruiting', 'LocationCity': 'Brandywine', 'LocationState': 'Maryland', 'LocationZip': '20613', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Melissa Almand', 'LocationContactRole': 'Contact', 'LocationContactPhone': '301-812-3900', 'LocationContactEMail': 'missy.almand@usoncology.com'}, {'LocationContactName': 'Tejaswi R Sastry, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Maryland Oncology Hematology, P.A. - Clinton', 'LocationStatus': 'Recruiting', 'LocationCity': 'Clinton', 'LocationState': 'Maryland', 'LocationZip': '20735', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Melissa Almand', 'LocationContactRole': 'Contact', 'LocationContactPhone': '301-868-7911', 'LocationContactEMail': 'missy.almand@usoncology.com'}, {'LocationContactName': 'Tejaswi R Sastry, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Maryland Oncology Hematology, P.A. - Columbia', 'LocationStatus': 'Recruiting', 'LocationCity': 'Columbia', 'LocationState': 'Maryland', 'LocationZip': '21044', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Melissa Almand', 'LocationContactRole': 'Contact', 'LocationContactPhone': '410-964-2212', 'LocationContactEMail': 'missy.almand@usoncology.com'}, {'LocationContactName': 'Tejaswi R Sastry, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Maryland Oncology Hematology, P.A. - Frederick', 'LocationStatus': 'Recruiting', 'LocationCity': 'Frederick', 'LocationState': 'Maryland', 'LocationZip': '21702', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Melissa Almand', 'LocationContactRole': 'Contact', 'LocationContactPhone': '301-695-6777', 'LocationContactEMail': 'missy.almand@usoncology.com'}, {'LocationContactName': 'Tejaswi R Sastry, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Maryland Oncology Hematology, P.A. - Lanham', 'LocationStatus': 'Recruiting', 'LocationCity': 'Lanham', 'LocationState': 'Maryland', 'LocationZip': '20706', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Melissa Almand', 'LocationContactRole': 'Contact', 'LocationContactPhone': '301-474-0427', 'LocationContactEMail': 'missy.almand@usoncology.com'}, {'LocationContactName': 'Tejaswi R Sastry, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Maryland Oncology Hematology, P.A. - Rockville - Aquilino Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Rockville', 'LocationState': 'Maryland', 'LocationZip': '20850', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Melissa Almand', 'LocationContactRole': 'Contact', 'LocationContactPhone': '301-424-6231', 'LocationContactEMail': 'missy.almand@usoncology.com'}, {'LocationContactName': 'Tejaswi R Sastry, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Maryland Oncology Hematology, P.A. - Silver Spring - White Oak Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Silver Spring', 'LocationState': 'Maryland', 'LocationZip': '20904', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Melissa Almand', 'LocationContactRole': 'Contact', 'LocationContactPhone': '301-933-3216', 'LocationContactEMail': 'missy.almand@usoncology.com'}, {'LocationContactName': 'Tejaswi R Sastry, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'New York Oncology Hematology, P.C. - Albany Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Albany', 'LocationState': 'New York', 'LocationZip': '12206', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Amy Zuchelkowski', 'LocationContactRole': 'Contact', 'LocationContactPhone': '518-489-2607', 'LocationContactEMail': 'amy.zuchelkowski@usoncology.com'}, {'LocationContactName': 'Karen L Tedesco, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'New York Oncology Hematology, P.C. - Albany Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Albany', 'LocationState': 'New York', 'LocationZip': '12208', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Amy Zuchelkowski', 'LocationContactRole': 'Contact', 'LocationContactPhone': '518-262-6696', 'LocationContactEMail': 'amy.zuchelkowski@usoncology.com'}, {'LocationContactName': 'Karen L Tedesco, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Broome Oncology, LLC - Binghamton', 'LocationStatus': 'Recruiting', 'LocationCity': 'Binghamton', 'LocationState': 'New York', 'LocationZip': '13905', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Driguneswar Pinnamaneni', 'LocationContactRole': 'Contact', 'LocationContactPhone': '607-763-8065', 'LocationContactEMail': 'epinnamaneni@broomeoncology.com'}, {'LocationContactName': 'Ronald P Harris, DO', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'New York Oncology Hematology, P.C. - Clifton Park Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Clifton Park', 'LocationState': 'New York', 'LocationZip': '12065', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Amy Zuchelkowski', 'LocationContactRole': 'Contact', 'LocationContactPhone': '518-831-4434', 'LocationContactEMail': 'amy.zuchelkowski@usoncology.com'}, {'LocationContactName': 'Karen L Tedesco, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Broome Oncology, LLC - Johnson City', 'LocationStatus': 'Recruiting', 'LocationCity': 'Johnson City', 'LocationState': 'New York', 'LocationZip': '13790', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Driguneswar Pinnamaneni', 'LocationContactRole': 'Contact', 'LocationContactPhone': '607-763-6850', 'LocationContactEMail': 'epinnamaneni@broomeoncology.com'}, {'LocationContactName': 'Ronald P Harris, DO', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Alliance Cancer Specialists, PC', 'LocationStatus': 'Recruiting', 'LocationCity': 'Bensalem', 'LocationState': 'Pennsylvania', 'LocationZip': '19020', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Rebecca Banas', 'LocationContactRole': 'Contact', 'LocationContactPhone': '215-645-1740', 'LocationContactEMail': 'becki.banas1@alliancecancer.com'}, {'LocationContactName': 'Joseph L Potz, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Consultants In Medical Oncology and Hematology, P.C.', 'LocationStatus': 'Recruiting', 'LocationCity': 'Broomall', 'LocationState': 'Pennsylvania', 'LocationZip': '19008', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Colleen Hopkins', 'LocationContactRole': 'Contact', 'LocationContactPhone': '610-492-5900', 'LocationContactEMail': 'Colleen.Hopkins@alliancecancer.com'}, {'LocationContactName': 'Laura K Austin, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Alliance Cancer Specialists, PC', 'LocationStatus': 'Recruiting', 'LocationCity': 'Horsham', 'LocationState': 'Pennsylvania', 'LocationZip': '19044', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Rebecca Banas', 'LocationContactRole': 'Contact', 'LocationContactPhone': '215-706-2034', 'LocationContactEMail': 'becki.banas1@alliancecancer.com'}, {'LocationContactName': 'Joseph L Potz, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Alliance Cancer Specialists, PC', 'LocationStatus': 'Recruiting', 'LocationCity': 'Langhorne', 'LocationState': 'Pennsylvania', 'LocationZip': '19047', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Rebecca Banas', 'LocationContactRole': 'Contact', 'LocationContactPhone': '215-750-5050', 'LocationContactEMail': 'becki.banas1@alliancecancer.com'}, {'LocationContactName': 'Joseph L Potz, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Alliance Cancer Specialists, PC', 'LocationStatus': 'Recruiting', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19115', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Rebecca Banas', 'LocationContactRole': 'Contact', 'LocationContactPhone': '215-706-2034', 'LocationContactEMail': 'becki.banas1@alliancecancer.com'}, {'LocationContactName': 'Joseph L Potz, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Alliance Cancer Specialists, PC', 'LocationStatus': 'Recruiting', 'LocationCity': 'Sellersville', 'LocationState': 'Pennsylvania', 'LocationZip': '18960', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Rebecca Banas', 'LocationContactRole': 'Contact', 'LocationContactPhone': '215-453-3300', 'LocationContactEMail': 'becki.banas1@alliancecancer.com'}, {'LocationContactName': 'Joseph L Potz, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Alliance Cancer Specialists, PC', 'LocationStatus': 'Recruiting', 'LocationCity': 'Wynnewood', 'LocationState': 'Pennsylvania', 'LocationZip': '19096', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Rebecca Banas', 'LocationContactRole': 'Contact'}, {'LocationContactName': 'Joseph L Potz, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Abilene', 'LocationStatus': 'Recruiting', 'LocationCity': 'Abilene', 'LocationState': 'Texas', 'LocationZip': '79606', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Rebecca S Garcia', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'becky.garcia@usoncology.com'}, {'LocationContactName': 'Ines J Sanchez-Rivera, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Allen', 'LocationStatus': 'Recruiting', 'LocationCity': 'Allen', 'LocationState': 'Texas', 'LocationZip': '75013', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shalane Durbin', 'LocationContactRole': 'Contact', 'LocationContactPhone': '469-467-4392', 'LocationContactEMail': 'shalane.durbin@usoncology.com'}, {'LocationContactName': 'Monte F Jones, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Amarillo', 'LocationStatus': 'Recruiting', 'LocationCity': 'Amarillo', 'LocationState': 'Texas', 'LocationZip': '79106', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'John McMahan', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'john.mcmahan@usoncology.com'}, {'LocationContactName': 'Ines J Sanchez-Rivera, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - DFWW', 'LocationStatus': 'Recruiting', 'LocationCity': 'Arlington', 'LocationState': 'Texas', 'LocationZip': '76012', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Deborah Arant-Daigle', 'LocationContactRole': 'Contact', 'LocationContactPhone': '817-664-9600', 'LocationContactEMail': 'deborah.arant-daigle@usoncology.com'}, {'LocationContactName': 'John W Adams, DO', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - DFWW', 'LocationStatus': 'Recruiting', 'LocationCity': 'Arlington', 'LocationState': 'Texas', 'LocationZip': '76014', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Deborah Arant-Daigle', 'LocationContactRole': 'Contact', 'LocationContactPhone': '817-467-6092', 'LocationContactEMail': 'deborah.arant-daigle@usoncology.com'}, {'LocationContactName': 'John W Adams, DO', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Beaumont', 'LocationStatus': 'Recruiting', 'LocationCity': 'Beaumont', 'LocationState': 'Texas', 'LocationZip': '77701', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Alana Brown', 'LocationContactRole': 'Contact', 'LocationContactPhone': '409-813-1686', 'LocationContactEMail': 'alana.brown@usoncology.com'}, {'LocationContactName': 'Scott A McKenney, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Beaumont Mamie McFaddin Ward Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Beaumont', 'LocationState': 'Texas', 'LocationZip': '77702', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Alana Brown', 'LocationContactRole': 'Contact', 'LocationContactPhone': '409-899-7180', 'LocationContactEMail': 'alana.brown@usoncology.com'}, {'LocationContactName': 'Scott A McKenney, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - DFWW', 'LocationStatus': 'Recruiting', 'LocationCity': 'Bedford', 'LocationState': 'Texas', 'LocationZip': '76022', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Debora Jimerson', 'LocationContactRole': 'Contact', 'LocationContactPhone': '817-359-9000', 'LocationContactEMail': 'debora.jimerson@usoncology.com'}, {'LocationContactName': 'John W Adams, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Carrollton', 'LocationStatus': 'Recruiting', 'LocationCity': 'Carrollton', 'LocationState': 'Texas', 'LocationZip': '75010', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kristen Tyree', 'LocationContactRole': 'Contact', 'LocationContactPhone': '972-537-4143', 'LocationContactEMail': 'kristen.tyree@usoncology.com'}, {'LocationContactName': 'Nieves Contreras Alcantara', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'nieves.contrerasalcantara@usoncology.com'}, {'LocationContactName': 'Vibha T Thomas, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - DFWW', 'LocationStatus': 'Recruiting', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75203', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Debora Jimerson', 'LocationContactRole': 'Contact', 'LocationContactPhone': '214-943-9911', 'LocationContactEMail': 'debora.jimerson@usoncology.com'}, {'LocationContactName': 'John W Adams, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Medical City Dallas', 'LocationStatus': 'Recruiting', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75230', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jason Brecher', 'LocationContactRole': 'Contact', 'LocationContactPhone': '972-566-4291', 'LocationContactEMail': 'jason.brecher@usoncology.com'}, {'LocationContactName': 'Jay G Courtright, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Presbyterian Cancer Center Dallas', 'LocationStatus': 'Recruiting', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75231', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Nancy Jones', 'LocationContactRole': 'Contact', 'LocationContactPhone': '214-265-2080', 'LocationContactEMail': 'nancy.jones@usoncology.com'}, {'LocationContactName': 'Cathy Barter', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'catherine.barter@usoncology.com'}, {'LocationContactName': 'Kristi J McIntyre, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - DFWW', 'LocationStatus': 'Recruiting', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75237', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Debora Jimerson', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'debora.jimerson@usoncology.com'}, {'LocationContactName': 'John W Adams, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Baylor Charles A. Sammons Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75246', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Marilyn Elliott', 'LocationContactRole': 'Contact', 'LocationContactPhone': '214-370-1000', 'LocationContactEMail': 'marilyn.elliott@usoncology.com'}, {'LocationContactName': 'Antoinette Matthews, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Denison', 'LocationStatus': 'Recruiting', 'LocationCity': 'Denison', 'LocationState': 'Texas', 'LocationZip': '75020', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jayne Mettetal', 'LocationContactRole': 'Contact', 'LocationContactPhone': '903-892-9455', 'LocationContactEMail': 'jayne.mettetal@usoncology.com'}, {'LocationContactName': 'Tammy E Roque, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Denton', 'LocationStatus': 'Recruiting', 'LocationCity': 'Denton', 'LocationState': 'Texas', 'LocationZip': '76201', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Nancy Smith', 'LocationContactRole': 'Contact', 'LocationContactPhone': '940-382-1022', 'LocationContactEMail': 'nancy.smith2@usoncology.com'}, {'LocationContactName': 'Charles V Kurkul, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - El Paso Cancer Treatment Center Grandview', 'LocationStatus': 'Recruiting', 'LocationCity': 'El Paso', 'LocationState': 'Texas', 'LocationZip': '79902', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Tanya Jauch-Worley', 'LocationContactRole': 'Contact', 'LocationContactPhone': '915-544-6750', 'LocationContactEMail': 'tanya.jauchworley@usoncology.com'}, {'LocationContactName': 'Michelle Linley', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'michelle.linley@usoncology.com'}, {'LocationContactName': 'Ines J Sanchez-Rivera, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - El Paso Cancer Treatment Center Gateway', 'LocationStatus': 'Recruiting', 'LocationCity': 'El Paso', 'LocationState': 'Texas', 'LocationZip': '79915', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Tanya Jauch-Worley', 'LocationContactRole': 'Contact', 'LocationContactPhone': '915-599-1313', 'LocationContactEMail': 'tanya.jauchworley@usoncology.com'}, {'LocationContactName': 'Michelle Linley', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'michelle.linley@usoncology.com'}, {'LocationContactName': 'Ines J Sanchez-Rivera, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - El Paso Cancer Treatment Center Joe Battle', 'LocationStatus': 'Recruiting', 'LocationCity': 'El Paso', 'LocationState': 'Texas', 'LocationZip': '79938', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Tanya Jauch-Worley', 'LocationContactRole': 'Contact', 'LocationContactPhone': '915-849-2700', 'LocationContactEMail': 'tanya.jauchworley@usoncology.com'}, {'LocationContactName': 'Michelle Linley', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'michelle.linley@usoncology.com'}, {'LocationContactName': 'Ines J Sanchez-Rivera, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Flower Mound', 'LocationStatus': 'Recruiting', 'LocationCity': 'Flower Mound', 'LocationState': 'Texas', 'LocationZip': '75028', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kristen Tyree', 'LocationContactRole': 'Contact', 'LocationContactPhone': '972-537-4100', 'LocationContactEMail': 'kristen.tyree@usoncology.com'}, {'LocationContactName': 'Nieves Contreras Alcantara', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'nieves.contrerasalcantara@usoncology.com'}, {'LocationContactName': 'Vibha T Thomas, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - DFWW', 'LocationStatus': 'Recruiting', 'LocationCity': 'Grapevine', 'LocationState': 'Texas', 'LocationZip': '76051', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Debora Jimerson', 'LocationContactRole': 'Contact', 'LocationContactPhone': '817-251-9080', 'LocationContactEMail': 'debora.jimerson@usoncology.com'}, {'LocationContactName': 'John W Adams, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Harlingen', 'LocationStatus': 'Recruiting', 'LocationCity': 'Harlingen', 'LocationState': 'Texas', 'LocationZip': '78550', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Monica Myers', 'LocationContactRole': 'Contact', 'LocationContactPhone': '956-425-8845', 'LocationContactEMail': 'monica.myers@usoncology.com'}, {'LocationContactName': 'Norma Magallan', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'norma.magallan@usoncology.com'}, {'LocationContactName': 'Alvaro Restrepo, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Memorial City', 'LocationStatus': 'Recruiting', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77024', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Nina Fru', 'LocationContactRole': 'Contact', 'LocationContactPhone': '713-467-1722', 'LocationContactEMail': 'nina.fru@usoncology.com'}, {'LocationContactName': 'Michelina Cairo, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Willowbrook', 'LocationStatus': 'Recruiting', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77070', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kerrie M Shojaie', 'LocationContactRole': 'Contact', 'LocationContactPhone': '281-894-8822', 'LocationContactEMail': 'kerrie.shojaie@usoncology.com'}, {'LocationContactName': 'Henna M Malik, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Northeast Texas', 'LocationStatus': 'Recruiting', 'LocationCity': 'Longview', 'LocationState': 'Texas', 'LocationZip': '75601', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shelly Maxfield', 'LocationContactRole': 'Contact', 'LocationContactPhone': '903-757-2122', 'LocationContactEMail': 'shelly.maxfield@usoncology.com'}, {'LocationContactName': 'Sasha Davis, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - McAllen', 'LocationStatus': 'Recruiting', 'LocationCity': 'McAllen', 'LocationState': 'Texas', 'LocationZip': '78503', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Monica Myers', 'LocationContactRole': 'Contact', 'LocationContactPhone': '956-687-5150', 'LocationContactEMail': 'monica.myers@usoncology.com'}, {'LocationContactName': 'Norma Magallan', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'norma.magallan@usoncology.com'}, {'LocationContactName': 'Alvaro Restrepo, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - McKinney', 'LocationStatus': 'Recruiting', 'LocationCity': 'McKinney', 'LocationState': 'Texas', 'LocationZip': '75071', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shalane Durbin', 'LocationContactRole': 'Contact', 'LocationContactPhone': '972-542-8609', 'LocationContactEMail': 'shalane.durbin@usoncology.com'}, {'LocationContactName': 'Monte F Jones, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Midland', 'LocationStatus': 'Recruiting', 'LocationCity': 'Midland', 'LocationState': 'Texas', 'LocationZip': '79701', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Mary Williams', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'mary.williams2@usoncology.com'}, {'LocationContactName': 'Ines J Sanchez-Rivera, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - New Braunfels', 'LocationStatus': 'Recruiting', 'LocationCity': 'New Braunfels', 'LocationState': 'Texas', 'LocationZip': '78130', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Debora E Lind', 'LocationContactRole': 'Contact', 'LocationContactPhone': '830-643-1762', 'LocationContactEMail': 'debora.lind@usoncology.com'}, {'LocationContactName': 'Emmalind Aponte, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Odessa', 'LocationStatus': 'Recruiting', 'LocationCity': 'Odessa', 'LocationState': 'Texas', 'LocationZip': '79761', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Mary Williams', 'LocationContactRole': 'Contact', 'LocationContactPhone': '432-335-8275', 'LocationContactEMail': 'mary.williams2@usoncology.com'}, {'LocationContactName': 'Ines J Sanchez-Rivera, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Northeast Texas', 'LocationStatus': 'Recruiting', 'LocationCity': 'Palestine', 'LocationState': 'Texas', 'LocationZip': '75801', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shelly Maxfield', 'LocationContactRole': 'Contact', 'LocationContactPhone': '903-727-2200', 'LocationContactEMail': 'shelly.maxfield@usoncology.com'}, {'LocationContactName': 'Sasha Davis, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Northeast Texas', 'LocationStatus': 'Recruiting', 'LocationCity': 'Paris', 'LocationState': 'Texas', 'LocationZip': '75460', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Sue J Crumpler', 'LocationContactRole': 'Contact', 'LocationContactPhone': '903-785-0031', 'LocationContactEMail': 'sue.crumpler@usoncology.com'}, {'LocationContactName': 'Sasha Davis, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Plano West', 'LocationStatus': 'Recruiting', 'LocationCity': 'Plano', 'LocationState': 'Texas', 'LocationZip': '75093', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yue Feng', 'LocationContactRole': 'Contact', 'LocationContactPhone': '972-596-7801', 'LocationContactEMail': 'yue.feng@usoncology.com'}, {'LocationContactName': 'Philip A Kovoor, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - San Antonio Downtown', 'LocationStatus': 'Recruiting', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78212', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Debora E Lind', 'LocationContactRole': 'Contact', 'LocationContactPhone': '210-224-6531', 'LocationContactEMail': 'debora.lind@usoncology.com'}, {'LocationContactName': 'Emmalind Aponte, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - San Antonio Northeast', 'LocationStatus': 'Recruiting', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78217', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Debora E Lind', 'LocationContactRole': 'Contact', 'LocationContactPhone': '210-656-7177', 'LocationContactEMail': 'debora.lind@usoncology.com'}, {'LocationContactName': 'Emmalind Aponte, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - San Antonio', 'LocationStatus': 'Recruiting', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78240', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Debora E Lind', 'LocationContactRole': 'Contact', 'LocationContactPhone': '210-595-5300', 'LocationContactEMail': 'debora.lind@usoncology.com'}, {'LocationContactName': 'Emmalind Aponte, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - San Antonio Stone Oak', 'LocationStatus': 'Recruiting', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78258', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Debora E Lind', 'LocationContactRole': 'Contact', 'LocationContactPhone': '210-545-6972', 'LocationContactEMail': 'debora.lind@usoncology.com'}, {'LocationContactName': 'Emmalind Aponte, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Sugar Land', 'LocationStatus': 'Recruiting', 'LocationCity': 'Sugar Land', 'LocationState': 'Texas', 'LocationZip': '77479', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Melissa Howell', 'LocationContactRole': 'Contact', 'LocationContactPhone': '281-277-5200', 'LocationContactEMail': 'melissa.howell@usoncology.com'}, {'LocationContactName': 'Caesar K Tin-U, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - The Woodlands', 'LocationStatus': 'Recruiting', 'LocationCity': 'The Woodlands', 'LocationState': 'Texas', 'LocationZip': '77380', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ruth Lopez', 'LocationContactRole': 'Contact', 'LocationContactPhone': '281-296-0365', 'LocationContactEMail': 'ruth.lopez1@usoncology.com'}, {'LocationContactName': 'Veta Clayton', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'veta.clayton@usoncology.com'}, {'LocationContactName': 'Paula D Ryan, MD, PhD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Northeast Texas', 'LocationStatus': 'Recruiting', 'LocationCity': 'Tyler', 'LocationState': 'Texas', 'LocationZip': '75702', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shelly Maxfield', 'LocationContactRole': 'Contact', 'LocationContactPhone': '903-579-9800', 'LocationContactEMail': 'shelly.maxfield@usoncology.com'}, {'LocationContactName': 'Sasha Davis, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Austin', 'LocationStatus': 'Recruiting', 'LocationCity': 'Waco', 'LocationState': 'Texas', 'LocationZip': '76712', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Laura Fonseca', 'LocationContactRole': 'Contact', 'LocationContactPhone': '254-399-0741', 'LocationContactEMail': 'laura.fonseca@usoncology.com'}, {'LocationContactName': 'Carlos A Encarnacion, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Horizon Circle', 'LocationStatus': 'Recruiting', 'LocationCity': 'Waco', 'LocationState': 'Texas', 'LocationZip': '76712', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Laura Fonseca', 'LocationContactRole': 'Contact', 'LocationContactPhone': '254-399-0741', 'LocationContactEMail': 'laura.fonseca@usoncology.com'}, {'LocationContactName': 'Carlos A Encarnacion, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Deke Slayton Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Webster', 'LocationState': 'Texas', 'LocationZip': '77598', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Tara Gray', 'LocationContactRole': 'Contact', 'LocationContactPhone': '281-332-7505', 'LocationContactEMail': 'tara.gray@usoncology.com'}, {'LocationContactName': 'Dhatri Kodali, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Weslaco', 'LocationStatus': 'Recruiting', 'LocationCity': 'Weslaco', 'LocationState': 'Texas', 'LocationZip': '78596', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Nereida Salinas', 'LocationContactRole': 'Contact', 'LocationContactPhone': '956-969-0021', 'LocationContactEMail': 'nereida.salinas@usoncology.com'}, {'LocationContactName': 'Aide Borrego', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'aide.borrego@usoncology.com'}, {'LocationContactName': 'Alvaro Restrepo, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Texas Oncology - Wichita Falls', 'LocationStatus': 'Recruiting', 'LocationCity': 'Wichita Falls', 'LocationState': 'Texas', 'LocationZip': '76310', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Toni Scott', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'toni.scott@usoncology.com'}, {'LocationContactName': 'Ines J Sanchez-Rivera, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Virginia Cancer Specialists, PC - Alexandria', 'LocationStatus': 'Recruiting', 'LocationCity': 'Alexandria', 'LocationState': 'Virginia', 'LocationZip': '22304', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Marcy Sullivan', 'LocationContactRole': 'Contact', 'LocationContactPhone': '703-832-5322', 'LocationContactEMail': 'marcy.sullivan@usoncology.com'}, {'LocationContactName': 'Mitul Gandhi, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Virginia Cancer Specialists, PC - Arlington', 'LocationStatus': 'Recruiting', 'LocationCity': 'Arlington', 'LocationState': 'Virginia', 'LocationZip': '22205', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Marcy Sullivan', 'LocationContactRole': 'Contact', 'LocationContactPhone': '703-528-7303', 'LocationContactEMail': 'marcy.sullivan@usoncology.com'}, {'LocationContactName': 'Mitul Gandhi, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Virginia Oncology Associates', 'LocationStatus': 'Recruiting', 'LocationCity': 'Chesapeake', 'LocationState': 'Virginia', 'LocationZip': '23320', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Wendi Gobhardt', 'LocationContactRole': 'Contact', 'LocationContactPhone': '757-549-4403', 'LocationContactEMail': 'wendi.gobhardt@usoncology.com'}, {'LocationContactName': 'Michael A Danso, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Virginia Cancer Specialists, PC - Fairfax', 'LocationStatus': 'Recruiting', 'LocationCity': 'Fairfax', 'LocationState': 'Virginia', 'LocationZip': '22031', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Marcy Sullivan', 'LocationContactRole': 'Contact', 'LocationContactPhone': '703-280-5390', 'LocationContactEMail': 'marcy.sullivan@usoncology.com'}, {'LocationContactName': 'Mitul Gandhi, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Virginia Cancer Specialists, PC - Gainesville', 'LocationStatus': 'Recruiting', 'LocationCity': 'Gainesville', 'LocationState': 'Virginia', 'LocationZip': '20155', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Marcy Sullivan', 'LocationContactRole': 'Contact', 'LocationContactPhone': '571-222-2200', 'LocationContactEMail': 'marcy.sullivan@usoncology.com'}, {'LocationContactName': 'Mitul Gandhi, MD', 'LocationContactRole': 'Sub-Investigator'}]}}, {'LocationFacility': 'Virginia Cancer Specialists, PC - Loudoun', 'LocationStatus': 'Recruiting', 'LocationCity': 'Leesburg', 'LocationState': 'Virginia', 'LocationZip': '20176', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Marcy Sullivan', 'LocationContactRole': 'Contact', 'LocationContactPhone': '703-554-6800', 'LocationContactEMail': 'marcy.sullivan@usoncology.com'}, {'LocationContactName': 'Mitul Gandhi, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Virginia Oncology Associates', 'LocationStatus': 'Recruiting', 'LocationCity': 'Newport News', 'LocationState': 'Virginia', 'LocationZip': '23606', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jacquelyn Steiner', 'LocationContactRole': 'Contact', 'LocationContactPhone': '757-873-9810', 'LocationContactEMail': 'jacquelyn.steiner@usoncology.com'}, {'LocationContactName': 'Michael A Danso, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Virginia Oncology Associates', 'LocationStatus': 'Recruiting', 'LocationCity': 'Norfolk', 'LocationState': 'Virginia', 'LocationZip': '23502', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Wendi Gobhardt', 'LocationContactRole': 'Contact', 'LocationContactPhone': '757-466-8663', 'LocationContactEMail': 'wendi.gobhardt@usoncology.com'}, {'LocationContactName': 'Michael A Danso, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Virginia Oncology Associates', 'LocationStatus': 'Recruiting', 'LocationCity': 'Virginia Beach', 'LocationState': 'Virginia', 'LocationZip': '23456', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Brittany Sawyer', 'LocationContactRole': 'Contact', 'LocationContactPhone': '757-368-0437', 'LocationContactEMail': 'brittany.sawyer@usoncology.com'}, {'LocationContactName': 'Michael A Danso, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Virginia Oncology Associates', 'LocationStatus': 'Recruiting', 'LocationCity': 'Williamsburg', 'LocationState': 'Virginia', 'LocationZip': '23188', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Wendi Gobhardt', 'LocationContactRole': 'Contact', 'LocationContactPhone': '757-229-2236', 'LocationContactEMail': 'wendi.gobhardt@usoncology.com'}, {'LocationContactName': 'Michael A Danso, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Shenandoah Oncology, P.C.', 'LocationStatus': 'Recruiting', 'LocationCity': 'Winchester', 'LocationState': 'Virginia', 'LocationZip': '22601', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'William A Houck III, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '540-662-1108', 'LocationContactEMail': 'william.houck@usoncology.com'}, {'LocationContactName': 'William A Houck III, MD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '33109739', 'ReferenceType': 'background', 'ReferenceCitation': 'Noordhoek I, Treuner K, Putter H, Zhang Y, Wong J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, van de Velde CJH, Schnabel CA, Liefers GJ. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy. Clin Cancer Res. 2021 Jan 1;27(1):311-319. doi: 10.1158/1078-0432.CCR-20-2737. Epub 2020 Oct 27.'}, {'ReferencePMID': '31504126', 'ReferenceType': 'background', 'ReferenceCitation': 'Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Ahmed I, Piper T, Salunga R, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol. 2019 Nov 1;30(11):1776-1783. doi: 10.1093/annonc/mdz289.'}, {'ReferencePMID': '23757354', 'ReferenceType': 'background', 'ReferenceCitation': 'Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC, Fornander T, Stal O, Brufsky AM, Sgroi D, Erlander MG. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res. 2013 Aug 1;19(15):4196-205. doi: 10.1158/1078-0432.CCR-13-0804. Epub 2013 Jun 11.'}, {'ReferencePMID': '24035531', 'ReferenceType': 'background', 'ReferenceCitation': 'Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013 Oct;14(11):1067-1076. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12. Erratum In: Lancet Oncol. 2018 Apr;19(4):e184.'}, {'ReferencePMID': '23812955', 'ReferenceType': 'background', 'ReferenceCitation': 'Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst. 2013 Jul 17;105(14):1036-42. doi: 10.1093/jnci/djt146. Epub 2013 Jun 28.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4686', 'ConditionBrowseLeafName': 'Carcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M8941', 'InterventionBrowseLeafName': 'Hormones', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 8, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00512551', 'OrgStudyIdInfo': {'OrgStudyId': 'IDP00-075'}, 'Organization': {'OrgFullName': 'M.D. Anderson Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'DNA Array Analysis of Patients With Cervical Cancer', 'OfficialTitle': 'A Pilot Study of Early Changes in DNA Array Expression Following Chemo-Radiation Treatment of Cervical Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'November 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 20, 2000', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 20, 2017', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 20, 2017', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 3, 2007', 'StudyFirstSubmitQCDate': 'August 3, 2007', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 7, 2007', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 28, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 30, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'M.D. Anderson Cancer Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The goal of this clinical research study is to find out if the expression of certain genes is linked with the response of cervical cancer to radiation. Researchers will study a large number of genes located in tumor material to learn this information.', 'DetailedDescription': 'Patients in this study are already scheduled to begin radiation therapy. Researchers will get tumor cells by taking two biopsies of the cervix. The first biopsy of the cervical tumor will be done before any treatment is given. The second biopsy will be performed about 48 hours after the radiation treatment has begun. They will then study the cells in the lab with a new technique for studying gene expression called DNA array, as well as human papillomavirus (HPV) analysis, quantification of apoptosis levels, hematoxylin and eosin staining, and storage of tissue for future research.\n\nThe patterns of gene expression in the biopsies will be compared with the success of radiation treatments.\n\nSome of the material will also be stored and used in the future for other research projects.\n\nThis is an investigational study. A total of 18 patients will take part in this study. All will be enrolled at UTMDACC.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cervical Cancer']}, 'KeywordList': {'Keyword': ['Cervical Cancer', 'DNA Array Analysis', 'Gene Expression', 'DNA']}}, 'DesignModule': {'StudyType': 'Observational', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Two biopsies of the cervix will be performed to obtain tumor cells.'}, 'EnrollmentInfo': {'EnrollmentCount': '18', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cervical cancer tumor biopsy + radiation therapy', 'ArmGroupDescription': 'Cervical cancer tumor biopsy + radiation therapy.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Tumor Biopsies']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'Tumor Biopsies', 'InterventionDescription': 'Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cervical cancer tumor biopsy + radiation therapy']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The goal of this clinical research study is to find out if the expression of certain genes is linked with the response of cervical cancer to radiation.', 'PrimaryOutcomeTimeFrame': '8 Years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Researchers will study a large number of genes located in tumor material to learn this information.', 'SecondaryOutcomeTimeFrame': '8 Years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nNewly diagnosed cervical cancer: clinical Stage IB -IIIB\nInvasive pure squamous cell carcinoma\nPlanned treatment with concurrent cisplatinum/5-fluorouracil chemotherapy and pelvic radiation\n\nExclusion Criteria:\n\n1. Previous cervical cancer treatment including but not limited to transvaginal cone irradiation', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'Patients with cervical cancer already scheduled to begin radiation therapy.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Anuja Jhingran, MD', 'OverallOfficialAffiliation': 'M.D. Anderson Cancer Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Texas MD Anderson Cancer Center', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'The University of Texas M.D.Anderson Cancer Center', 'SeeAlsoLinkURL': 'http://www.mdanderson.org'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000002583', 'ConditionMeshTerm': 'Uterine Cervical Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000014594', 'ConditionAncestorTerm': 'Uterine Neoplasms'}, {'ConditionAncestorId': 'D000005833', 'ConditionAncestorTerm': 'Genital Neoplasms, Female'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000002577', 'ConditionAncestorTerm': 'Uterine Cervical Diseases'}, {'ConditionAncestorId': 'D000014591', 'ConditionAncestorTerm': 'Uterine Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4982', 'ConditionBrowseLeafName': 'Uterine Cervical Neoplasms', 'ConditionBrowseLeafAsFound': 'Cervical Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16494', 'ConditionBrowseLeafName': 'Uterine Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8097', 'ConditionBrowseLeafName': 'Genital Neoplasms, Female', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4977', 'ConditionBrowseLeafName': 'Uterine Cervical Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16491', 'ConditionBrowseLeafName': 'Uterine Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 9, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03687151', 'OrgStudyIdInfo': {'OrgStudyId': '18-DSP-04'}, 'Organization': {'OrgFullName': 'Centre Hospitalier Universitaire de Nice', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Population-based Cancer Observatory', 'OfficialTitle': "Population-based Cancer Observatory of the French Region Sud-Provence-Alpes-Côte d'Azur Recruiting Incident Cases of Cancer Since 2005", 'Acronym': 'cancer observ'}, 'StatusModule': {'StatusVerifiedDate': 'September 2018', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 1, 2005', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2050', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2050', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'September 20, 2018', 'StudyFirstSubmitQCDate': 'September 25, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 27, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'September 25, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 27, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Centre Hospitalier Universitaire de Nice', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': "Cancer is the leading cause of death in Western countries. In France cancer control plans (National screening programmes) and recommendations for the management of cancer patients (multidisciplinary team meetings), have been implemented. Evaluating the effectiveness of these policies aiming for improved prevention and management is essential. However to conduct such an evaluation, a baseline reference requiring ongoing, reliable and complete data collection is necessary and can be used for epidemiological research.\n\nThere is no cancer registry in the French Region Sud-Provence-Alpes-Côte d'Azur. In view of this situation, the regional Health Agency appointed the public health department of the Nice Côte d'Azur University and the Centre for computerized pathology data collection (CRISAP-PACA) to develop a Cancer Observatory. Since 2005, the public health department collects data concerning invasive and in situ cancers from all the histopathology labs in the French Region Sud-Provence-Alpes-Côte d'Azur, gathered in the CRISAP-PACA, and transmits incidence cancer rates to the regional Health Agency. In 2007, a quality control procedure, comparing a random sample of data collected by the Cancer Observatory with pathology lab reports, confirmed the validity of the collected data with fewer than 3% in disagreement with the report's conclusions. In 2008, the estimated completeness of cancer records collected from histopathology laboratories was higher than 90% for new cases of breast and colorectal cancer within the age range concerned by the screening programme. Since 2012, public and private hospitals treating cancer patients as well as the regional cancer network ONCOPACA, coordinating multiple team meetings, have been contacted to transmit to the public health department cases of cancer without histological diagnosis. In addition, patients with cancer have been geolocated to study the influence of environmental exposures on the occurrence of cancers (patients living near of waste incinerator, highways)."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'patients with a diagnosis of invasive or in situ cancer', 'ArmGroupDescription': "patients with a diagnosis of invasive or in situ cancer living in the French Region Sud-Provence-Alpes-Côte d'Azur since 2005", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: non intervention / observationnal']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'non intervention / observationnal', 'InterventionDescription': 'non intervention / observationnal', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with a diagnosis of invasive or in situ cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': "number of each cancer of the French Region Sud-Provence-Alpes-Côte d'Azur", 'PrimaryOutcomeDescription': 'each cancer is definite by :number of Date of diagnosis, Tumor location, Histology, ADICAP codes, CIM-O codes, Age, Gender and Geolocation.\n\nnumber of classification of cancer.', 'PrimaryOutcomeTimeFrame': '50 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': "Inclusion Criteria:\n\nAll subjects with a diagnosis of invasive or in situ cancer living in the French Region Sud-Provence-Alpes-Côte d'Azur.\n\nExclusion Criteria:\n\n-", 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'patient with cancer', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'eugenia MARINE BARJOAN, PH', 'CentralContactRole': 'Contact', 'CentralContactPhone': '33492035635', 'CentralContactEMail': 'marine-barjoan.e@chu-nice.fr'}, {'CentralContactName': 'laurent BAILLY, PH', 'CentralContactRole': 'Contact', 'CentralContactPhone': '33492035635', 'CentralContactEMail': 'bailly.l@chu-nice.fr'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Nice University Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Nice', 'LocationZip': '06000', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'eugenia MARINE BARJOAN, PH', 'LocationContactRole': 'Contact', 'LocationContactPhone': '33492035635', 'LocationContactEMail': 'marine-barjoan.e@chu-nice.fr'}, {'LocationContactName': 'laurent BAILLY, PH', 'LocationContactRole': 'Contact', 'LocationContactPhone': '33492035635', 'LocationContactEMail': 'bailly.l@chu-nice.fr'}, {'LocationContactName': 'eugenia MARINE BARJOAN', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}}}}, {'Rank': 10, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02053662', 'OrgStudyIdInfo': {'OrgStudyId': 'OSU-12158'}, 'Organization': {'OrgFullName': 'Ohio State University Comprehensive Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Biomarker Identification for Bladder Cancer Patients', 'OfficialTitle': 'Biomarker Identification for Bladder Cancer Patients'}, 'StatusModule': {'StatusVerifiedDate': 'March 2021', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 21, 2014', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'January 30, 2014', 'StudyFirstSubmitQCDate': 'January 31, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 4, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 11, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 15, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Arnab Chakravarti', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Ohio State University Comprehensive Cancer Center'}, 'LeadSponsor': {'LeadSponsorName': 'Ohio State University Comprehensive Cancer Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'To develop a simple blood and urine test that we would perform before patients start their treatment to predict the risk that their bladder cancer might come back. To develop this test the investigators plan to analyze blood, urine and cancer tissue from bladder cancer patients and follow them closely during and after treatment. This will include looking for changes in proteins and genes that might play a role in bladder cancer biology. The investigators will then compare the information obtained from the studies of blood, urine and cancer tissue between patients that are cured and those whose cancer comes back. The knowledge about these differences between patients can then potentially be used to develop a blood or urine test to tell us who has a high risk for having bladder cancer come back.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Bladder Cancer']}, 'KeywordList': {'Keyword': ['Bladder Cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'bladder cancer tissue samples, blood, urine'}, 'EnrollmentInfo': {'EnrollmentCount': '179', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Bladder Cancer Patients', 'ArmGroupDescription': 'Patients with muscle invasive bladder cancer. A sample collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Sample Collection']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'Sample Collection', 'InterventionDescription': 'A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Bladder Cancer Patients']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Identify novel biomarkers for bladder cancer', 'PrimaryOutcomeDescription': 'Predict and detect bladder cancer recurrence, specifically through development of biomarkers using bladder cancer tissue samples as well as blood and urine samples. Detect the recurrence of disease through development of blood and urine biomarkers using pre-therapy and post-therapy biospecimens.', 'PrimaryOutcomeTimeFrame': 'up to 5 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAdult patients ≥18 years old.\nPatients suspected, clinically diagnosed, or histologically diagnosed bladder cancer.\nPatients undergoing cystoscopy without cancer suspicion.\nAbility to give an informed consent.\n\nExclusion Criteria:\n\nPatients receiving concurrent therapy for a second malignancy.\n< 18 years old.\nInability to give an informed consent.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients with suspected muscle-invasive bladder cancer and appropriate control population', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Arna Chakravarti, MD', 'OverallOfficialAffiliation': 'The Ohio State University Cancer Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'The Ohio State University Comprehensive Cancer Center', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43210', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'The Jamesline', 'SeeAlsoLinkURL': 'http://cancer.osu.edu'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001749', 'ConditionMeshTerm': 'Urinary Bladder Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000014571', 'ConditionAncestorTerm': 'Urologic Neoplasms'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001745', 'ConditionAncestorTerm': 'Urinary Bladder Diseases'}, {'ConditionAncestorId': 'D000014570', 'ConditionAncestorTerm': 'Urologic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4182', 'ConditionBrowseLeafName': 'Urinary Bladder Neoplasms', 'ConditionBrowseLeafAsFound': 'Bladder Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16472', 'ConditionBrowseLeafName': 'Urologic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4178', 'ConditionBrowseLeafName': 'Urinary Bladder Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16471', 'ConditionBrowseLeafName': 'Urologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 11, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05400408', 'OrgStudyIdInfo': {'OrgStudyId': 'CRCPC-SMC-2021'}, 'Organization': {'OrgFullName': 'Scentech Medical Technologies Ltd', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Chemical Profiling of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study', 'OfficialTitle': 'Detection of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study.', 'Acronym': 'Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'May 2022', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 30, 2022', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 30, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'January 31, 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 24, 2022', 'StudyFirstSubmitQCDate': 'May 26, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 1, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 8, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 9, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Scentech Medical Technologies Ltd', 'LeadSponsorClass': 'INDUSTRY'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Detection of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study', 'DetailedDescription': 'A diagnostic prospective study with no anticipated risks or constraints. Main Objective: To quantify differences in exhaled breath VOCs of patients with colorectal or pancreatic cancers compared with cohorts without cancer.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Colorectal Cancer', 'Pancreatic Cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Diagnostic', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '250', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Colorectal Cancer', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Subjects who were diagnosed as Colorectal Cancer patients by colonoscopy.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: VOX']}}, {'ArmGroupLabel': 'Pancreatic Cancer', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Subjects who were diagnosed as Pancreatic Cancer patients by Endoscopic Retrograde Cholangio Pancreatography.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: VOX']}}, {'ArmGroupLabel': 'Healthy volunteers', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Subjects who were found with no Colorectal or Pancreatic malignancies, by either colonoscopy or by Endoscopic Retrograde Cholangio Pancreatography.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: VOX']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test', 'InterventionName': 'VOX', 'InterventionDescription': 'Breath Biopsy Analysis', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Colorectal Cancer', 'Healthy volunteers', 'Pancreatic Cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'identification of Volatile Organic Compounds that can be related to Colorectal malignancy.', 'PrimaryOutcomeDescription': 'Comparison of identity and concentration of Volatile Organic Compounds profile found among colorectal patients and the identity and concentration of Volatile Organic Compounds profile found among Healthy controls.', 'PrimaryOutcomeTimeFrame': 'Through the study completion, up to 1 year.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Test Sensitivity and specificity for colorectal polyps.', 'SecondaryOutcomeDescription': 'Comparison of Volatile Organic Compounds found among subjects with and without colorectal polyps.', 'SecondaryOutcomeTimeFrame': 'Through the study completion, up to 1 year.'}, {'SecondaryOutcomeMeasure': 'Test Sensitivity and specificity for pancreatic cancer.', 'SecondaryOutcomeDescription': 'Comparison of Volatile Organic Compounds found among pancreatic patients and Healthy controls.', 'SecondaryOutcomeTimeFrame': 'Through the study completion, up to 1 year.'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAge 18 to 85 years at the time of consent.\nScheduled for colonoscopy or Endoscopic Retrograde Cholangio Pancreatography.\nFasted >6 hours, consuming water only.\nAble to provide informed written consent.\n\nExclusion Criteria:\n\nLacks capacity or is unable to provide informed written consent.\nPregnant or lactating woman.\nHistologically confirmed cancer in any organ.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Natalie Dror, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+972528264282', 'CentralContactEMail': 'natalie@scentech-medical.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Haim Shirin, MD', 'OverallOfficialAffiliation': 'Shamir Medical Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Shamir Medical Center', 'LocationCity': "Be'er Ya'aqov", 'LocationCountry': 'Israel', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Haim Shirin, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+972505191475', 'LocationContactEMail': 'Haimsh@shamir.gov.il'}, {'LocationContactName': 'Haim Shirin, MD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': 'No IPD is to be shared with other researchers.'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010190', 'ConditionMeshTerm': 'Pancreatic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000010182', 'ConditionAncestorTerm': 'Pancreatic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12262', 'ConditionBrowseLeafName': 'Pancreatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7015', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12254', 'ConditionBrowseLeafName': 'Pancreatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7014', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4387', 'ConditionBrowseLeafName': 'Pancreatic Cancer', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 12, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04972201', 'OrgStudyIdInfo': {'OrgStudyId': 'RSCD2020006'}, 'Organization': {'OrgFullName': 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Proof of Concept Study of Pan-cancer Early Detection by Liquid Biopsy', 'OfficialTitle': 'The Performance of a Pan-cancer Early Detection Model Based on Liquid Biopsy of Various-omics Biomarkers: a Proof of Concept Study', 'Acronym': 'PROMISE'}, 'StatusModule': {'StatusVerifiedDate': 'July 2021', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 5, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'March 31, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 15, 2021', 'StudyFirstSubmitQCDate': 'July 15, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 22, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 15, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 22, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Guangzhou Burning Rock Dx Co., Ltd.', 'CollaboratorClass': 'INDUSTRY'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'PROMISE is a multi-center, prospective and proof of concept study aimed to evaluate the performance of 3 prototype assays of cell-free DNA (cfDNA) mutation, cfDNA methylation and microRNA (miRNA) expression in early detection of multi-cancer. Assay(s) will be selected for further development. The study will enroll approximately 2035 participants, including participants with cancers and healthy participants.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer']}, 'KeywordList': {'Keyword': ['cancer', 'liquid biopsy', 'cell-free DNA (cfDNA)', 'microRNA (miRNA)', 'early detection']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '2305', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer Arm', 'ArmGroupDescription': 'Participants with new diagnosis of cancer, from whom blood samples will be collected.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Multi-cancer early detection test']}}, {'ArmGroupLabel': 'Healthy Arm', 'ArmGroupDescription': 'Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Multi-cancer early detection test']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Multi-cancer early detection test', 'InterventionDescription': 'Blood collection and multi-cancer early detection test', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer Arm', 'Healthy Arm']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Sensitivity of early detection of cancers and Tissue of origin (TOO) accuracy of 3 assays of cfDNA mutation, cfDNA methylation and miRNA expression when specificity was 90%, 95% or 98% in healthy participants', 'PrimaryOutcomeTimeFrame': '9 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Sensitivity, specificity and TOO accuracy of an assay of cfDNA mutation in various types of cancer in different stages', 'SecondaryOutcomeTimeFrame': '9 months'}, {'SecondaryOutcomeMeasure': 'Sensitivity, specificity and TOO accuracy of an assay of cfDNA methylation in various types of cancer in different stages', 'SecondaryOutcomeTimeFrame': '9 months'}, {'SecondaryOutcomeMeasure': 'Sensitivity, specificity and TOO accuracy of an assay of miRNA expression in various types of cancer in different stages', 'SecondaryOutcomeTimeFrame': '9 months'}, {'SecondaryOutcomeMeasure': 'Sensitivity, specificity and TOO accuracy of combined assays of cfDNA mutation, cfDNA methylation and/or miRNA expression in early detection of cancers', 'SecondaryOutcomeTimeFrame': '9 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria for Cancer Arm Participants:\n\nAbility to provide a written informed consent\n40-75 years old\nAbility to comply with study procedures\nConfirmed diagnosis or suspicious cases of one of the 9 types of cancers within 42 days prior to study blood draw.\nNo prior anti-cancer therapy (local or systematic) prior to study blood draw\n\nExclusion Criteria for Cancer Arm Participants:\n\nPregnancy or lactating women\nRecipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant\nRecipients of blood transfusion within 7 days prior to study blood draw\nRecipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer\nKnown prior diagnosis of malignancies, other current malignant diseases or multiple primary tumors\nNo confirmed diagnosis of cancer by histopathological or radiological assessments within 42 days of study blood draw, or diagnosis of a benign disease or precancerous lesions by histopathological assessments, or inability to characterize whether the lesion is malignant or benign\n\nInclusion Criteria for Healthy Arm Participants:\n\nAbility to provide a written informed consent\n40-75 years old\nNo cancer-related symptoms or discomfort within 30 days prior to study blood draw\nAbility to comply with study procedures\nNo clinically significant finding by laboratory tests and radiology examinations\n\nExclusion Criteria for Healthy Arm Participants:\n\nPregnancy or lactating women\nRecipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant\nRecipients of blood transfusion within 7 days prior to study blood draw\nClinically significant or uncontrolled comorbidities\nPrior or ongoing treatment of cancer within 3 years prior to study blood draw', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Eligible participants will be re recruited from medical centers and assigned into two arms, including participants with new diagnosis of cancers and healthy participants.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Jiachen Xu, M.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+86-10-87788029', 'CentralContactEMail': 'XJCwelcome@126.com'}, {'CentralContactName': 'Shangli Cai, Ph.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+86-21-61631938', 'CentralContactEMail': 'shangli.cai@brbiotech.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jie Wang, M.D., Ph.D.', 'OverallOfficialAffiliation': 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'LocationStatus': 'Recruiting', 'LocationCity': 'Beijing', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jiachen Xu, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+86-10-87788029', 'LocationContactEMail': 'XJCwelcome@126.com'}, {'LocationContactName': 'Jie Wang, M.D., Ph.D.', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}}}}, {'Rank': 13, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04822792', 'OrgStudyIdInfo': {'OrgStudyId': 'RSCD2020002'}, 'Organization': {'OrgFullName': 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT', 'OfficialTitle': 'Pan-cancer Early-stage Detection by Liquid Biopsy in Peripheral Blood: a Multi-center, Prospective Observational Study', 'Acronym': 'PRESCIENT'}, 'StatusModule': {'StatusVerifiedDate': 'May 2021', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 23, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 31, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 30, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 29, 2021', 'StudyFirstSubmitQCDate': 'March 29, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 30, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 29, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 2, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Guangzhou Burning Rock Dx Co., Ltd.', 'CollaboratorClass': 'INDUSTRY'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'PRESCIENT is a multi-center, prospective observational study aimed to detect cancers early by combined assays for serum protein markers and cell-free DNA (cfDNA) methylation markers. Blood RNA markers will also be evaluated. The study will enroll approximately 11879 participants, including participants with malignancies or benign diseases, and healthy participants.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer']}, 'KeywordList': {'Keyword': ['Cancer', 'Liquid biopsy', 'Cell-free DNA (cfDNA)', 'Early detection']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '11879', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer Arm', 'ArmGroupDescription': 'Participants with new diagnosis of cancer, from whom blood samples will be collected', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Multi-cancer early detection test']}}, {'ArmGroupLabel': 'Benign Diseases Arm', 'ArmGroupDescription': 'Participants with benign diseases corresponding to the tumor types in the Cancer Arm, from whom blood samples will be collected', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Multi-cancer early detection test']}}, {'ArmGroupLabel': 'Healthy Arm', 'ArmGroupDescription': 'Participants without known presence of malignancies or benign disease, from whom blood samples will be collected', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Multi-cancer early detection test']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Multi-cancer early detection test', 'InterventionDescription': 'Blood collection and multi-cancer early detection test', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Benign Diseases Arm', 'Cancer Arm', 'Healthy Arm']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Sensitivity and specificity of early detection of 22 types of cancers and Tissue of origin (TOO) accuracy of a cfDNA methylation-based model, in combination with serum tumor markers', 'PrimaryOutcomeTimeFrame': '22 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Sensitivity and specificity of a cfDNA methylation-based model combined with serum tumor markers in participants with cancers or benign diseases', 'SecondaryOutcomeTimeFrame': '22 months'}, {'SecondaryOutcomeMeasure': 'Sensitivity and specificity of serum tumor markers, cfDNA methylation-based model, and a cfDNA methylation-based model combined with serum tumor markers, in participants with cancers and healthy participants', 'SecondaryOutcomeTimeFrame': '22 months'}, {'SecondaryOutcomeMeasure': 'Sensitivity and specificity of early detection of cancer in different stages', 'SecondaryOutcomeTimeFrame': '22 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria for All the Participants:\n\nAbility to provide a written informed consent\n40-75 years old\n\nExclusion Criteria for All the Participants:\n\nInability to comply with study procedures\nPregnancy or lactating women\nRecipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant\nRecipients of blood transfusion within 7 days prior to study blood draw\nRecipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer\n\nInclusion Criteria for Cancer Arm Participants:\n\nConfirmed diagnosis or suspicious cases of one of the 22 types of malignancies within 42 days prior to study blood draw\nNo prior or ongoing anti-cancer therapy (local or systematic) prior to study blood draw\n\nExclusion Criteria for Cancer Arm Participants:\n\nKnown prior diagnosis of malignancies\nOther current malignant diseases or multiple primary tumors\nNo confirmed diagnosis of cancer by histopathological or radiological assessments within 42 days of study blood draw, or diagnosis of a benign disease by histopathological assessments, or inability to characterize whether the lesion is malignant or benign\nNon-small-cell lung cancer patients with ground-class nodularity by radiological examination\n\nInclusion Criteria for Benign Diseases Arm Participants:\n\nConfirmed diagnosis of benign diseases corresponding to the tumor types in the Cancer Arm by histopathological or radiological assessments within 90 days prior to study blood draw\nNo prior treatment of benign diseases prior to study blood draw\n\nExclusion Criteria for Benign Diseases Arm Participants:\n\nHistory of malignancies\nCurrent malignancies or precancerous lesions\nNo confirmed diagnosis of a benign disease by radiological, endoscopic or histopathological assessments within 42 days of study blood draw, or inability to characterize whether the lesion is malignant or benign\n\nInclusion Criteria for Non-tumor (Healthy) Arm Participants:\n\nNo cancer-related symptoms or discomfort within 30 days prior to study blood draw\nNo clinically significant finding by LDCT or ultrasound\nNo clinically significant finding by breast ultrasound or Molybdenum Target Mammography Detection, or Thinprep cytologic test (TCT) detection for female participants\nNo active hepatitis B or hepatitis C infection\n\nExclusion Criteria for Non-tumor (Healthy) Arm Participants:\n\nPrior or ongoing treatment of cancer within 3 years prior to study blood draw\nClinically significant or uncontrolled comorbidities', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Eligible participants will be re recruited from medical centers and assigned into three arms, including participants with new diagnosis of malignancies or corresponding benign diseases, and participants without the presence of malignancies or benign diseases.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Jiachen Xu, M.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+86-010-87788029', 'CentralContactEMail': 'XJCwelcome@126.com'}, {'CentralContactName': 'Shangli Cai, Ph.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+86-021-61631938', 'CentralContactEMail': 'shangli.cai@brbiotech.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jie Wang, M.D., Ph.D', 'OverallOfficialAffiliation': 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Cancer Hospital Chinese Academy of Medical Sciences', 'LocationStatus': 'Recruiting', 'LocationCity': 'Beijing', 'LocationState': 'Beijing', 'LocationZip': '100021', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jiachen Xu, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+86-10-87788029', 'LocationContactEMail': 'XJCwelcome@126.com'}, {'LocationContactName': 'Jie Wang, M.D., Ph.D', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}}}}, {'Rank': 14, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02783235', 'OrgStudyIdInfo': {'OrgStudyId': 'TMH1605 Video Based Tutorials'}, 'Organization': {'OrgFullName': 'Tata Memorial Hospital', 'OrgClass': 'OTHER_GOV'}, 'BriefTitle': 'Cervical Cancer Screening : Video Based Tutorials for ANMs/ASHAs/PHWs', 'OfficialTitle': 'Cervical Cancer Screening: Video-based Tutorials for Skills Development of ANMs/ASHAs/PHWs'}, 'StatusModule': {'StatusVerifiedDate': 'August 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 29, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2018', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 2018', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 16, 2016', 'StudyFirstSubmitQCDate': 'May 25, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 26, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 3, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 6, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Gauravi Ashish Mishra', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor Dept of Preventive Oncology', 'ResponsiblePartyInvestigatorAffiliation': 'Tata Memorial Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Tata Memorial Hospital', 'LeadSponsorClass': 'OTHER_GOV'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': "This study aims at creating video-based tutorials for developing skills in performing cervical cancer screening using VIA for the Auxillary Nurse Midwives (ANMs), Accredited Social Health Activists (ASHAs) and Primary Health Workers (PHWs). Cervical cancer screening is mainly done by the following three methods: Visual inspection with acetic acid (VIA), Cervical Smear Cytology (PAP) and HPV DNA test. VIA is a low cost, low resource cervical cancer screening method and especially useful for low middle income countries (LMICs) like India.\n\nWe propose to develop video-based tutorials, such that the ANMs/ASHAs/PHWs could be trained in performing and interpreting VIA with the use of this tutorial. The ANMs/ASHAs/PHWs have important roles in delivering health in rural/ semi urban areas and they will be trained using this tutorial.\n\nThe video-based tutorials will be made according to the 'Spoken Tutorials' methodology, developed at IIT Bombay. Video-based Tutorials has given skills based training to over 2 lakh students in the past four years on IT based topics. The tutorials are made available online free of cost. They are designed to be used without the need of an expert being physically present.", 'DetailedDescription': 'Aim of the study:\n\nTo develop video-based tutorials to train ANMs/ASHAs/PHWs in conducting cervical cancer related health education, screening for cervical cancers using VIA, collection of PAP smears and HPV samples.\nTo reduce the training time required by an expert to train ANMs/ASHA/PHWs as compared to the traditional training methods.\nTo evaluate the efficacy of the training tool by conducting a pre-test and post-test and practical test for lesion identification.\nTo assess the satisfaction levels of ANMs/ASHAs/PHWs for learning through video-based tutorials.\n\nMethodology:\n\nA. Creating the Tutorials\n\n1) The video-based tutorials will be created with the help of domain experts, Content generators and Animators.\n\nB. Conducting the Training\n\nTMH will recruit Medical Social Workers and Health Workers to provide training to 50 ANMs/ASHAs/PHWs at their own centres.\nThe training will be staggered into different modules, and will be completed for each trainee over a period of approximately 3 months.\n\nThe investigators will also obtain images after due permissions, of the clinic, preparations for examination like arrangements of trolleys, preparation of dilute acetic acid, etc. and the cervical pictures/ videos of the patients before and after VIA after obtaining due consents (there will be no revealing of identity) to aid the animation and the tutorials.\n\nThe effectiveness of the tutorials will be checked by a pre- and post- tutorial assessment quiz.\n\nSample Size and power estimates:\n\nFor this study, sampling method is a convenience sample of 50 ANMs/ASHAs/PHWs attached to the TMC, District, Municipal Hospitals and PHCs who have not learned VIA based cervical cancer screening before.\n\nThree MSWs will be appointed to co-ordinate with the respective officials of BMC, State Government, District hospitals etc. and explain the importance of the project.\n\nThe Social Workers will approach different BMC hospitals in Mumbai and PHCs and district hospitals around Mumbai to relieve their ANMs/ASHAs/PHWs to participate in this training. Newly recruited PHWs in the Preventive Oncology projects will also be enrolled for this training.\n\nPre training knowledge about various aspects of cervical cancer viz., causes, various cervical cancer screening techniques, steps required to perform VIA etc.\nThe satisfaction level and feed back of the trainees with the course provided.\n\nImprovement in the Post training knowledge about various aspects of cervical cancer viz., causes, various cervical cancer screening techniques, steps required to perform VIA etc.\n\nThese will be measured with the help of test scores. Each question in the test will have marks assigned to it based on difficulty level. (Easy 1 mark, Intermediate 2 marks, Hard 3 marks, Very hard 4 marks). The ANMs will be assigned marks depending on the number of correct responses.\n\nThe ANMs will have to take the tests before the training, immediately after the training, and three months after the training is complete.\n\nThe satisfaction level with the mode of teaching will be done on a survey based on a likert scale.\n\nAbility to correctly identify a VIA positive lesion.\n\nThis will be measured based on marks they score during the tests and assignments, where they will do an image based diagnosis of 15 VIA cases. This will also be scored based on observation sessions they will have with a doctor who performs VIA on 10 patients. They will be assessed based on the number of correct identifications of VIA lesions.\n\nData entry and analysis:\n\nData entry will be done in IIT Bombay and in the Department of Preventive Oncology, Tata Memorial Hospital, using SPSS version 18. Checks for consistency, data safety and analysis will be carried out at regular intervals. Both descriptive and inferential statistics will be generated for describing variables under the study objectives.\n\nAgreement of test scores, pre-training and post-training will be estimated using kappa statistics.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cervical Cancer']}, 'KeywordList': {'Keyword': ['VIA', 'Cervical Cancer', 'Training']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '50', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'cervical cancer', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'cervical cancer screening and training for ANMs/ASHAs/PHWs To develop video-based tutorials to train ANMs/ASHAs/PHWs in conducting cervical cancer related health education, screening for cervical cancers using VIA, collection of PAP smears and HPV samples.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: cervical cancer screening']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'cervical cancer screening', 'InterventionDescription': 'for 50 ANMs/ASHAs/PHWs/ in conducting cervical cancer related health education , screening for cervical cancers using VIA, collection of PAP smears and HPV samples.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['cervical cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Improvement in the Post training knowledge about cancer', 'PrimaryOutcomeDescription': 'Questionnaire: that will compare pre-training knowledge with post training and assess the improvement in the Post training knowledge about various aspects of cervical cancer viz., causes, various cervical cancer screening techniques, steps required to perform VIA etc.\n\nThese will be measured with the help of test scores. Each question in the test will have marks assigned to it based on difficulty level. (Easy 1 mark, Intermediate 2 marks, Hard 3 marks, Very hard 4 marks). The ANMs will be assigned marks depending on the number of correct responses.\n\nThe ANMs will have to take the tests before the training, immediately after the training, and three months after the training is complete.', 'PrimaryOutcomeTimeFrame': '1 year'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Satisfaction to the video based tutorials', 'SecondaryOutcomeDescription': 'Questionnaire: that will assess the satisfaction level and feed back of the trainees with the course provided.\n\nThe satisfaction level with the mode of teaching will be done on a survey based on a likert scale.', 'SecondaryOutcomeTimeFrame': '1 year'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Clinical skills development', 'OtherOutcomeDescription': 'Scores will be assigned and the ability to correctly identify a VIA positive lesion will be assessed.', 'OtherOutcomeTimeFrame': '1 year'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria: ANMs /ASHAs/PHWs attached to the TMC, District Hospitals and PHCs who have not learned VIA based cervical cancer screening before.\n\nExclusion Criteria: ANMs /ASHAs/PHWs attached to the TMC, District Hospitals and PHCs who have learnt VIA based cervical cancer screening before.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '45 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Gauravi A Mishra, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+912224177000', 'CentralContactPhoneExt': '4634', 'CentralContactEMail': 'gauravi2005@yahoo.co.in'}, {'CentralContactName': 'Sharmila A Pimple, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+912224177000', 'CentralContactPhoneExt': '4631', 'CentralContactEMail': 'pimplesharmila@gmail.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Gauravi A Mishra, MD', 'OverallOfficialAffiliation': 'Tata Memorial Hospital, Mumbai.', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Gauravi A Mishra, MD', 'OverallOfficialAffiliation': 'ata Memorial Hospital, Mumbai.', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Tata Memorial Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Mumbai', 'LocationState': 'Maharashtra', 'LocationZip': '400012', 'LocationCountry': 'India', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Gauravi A Mishra, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+912224177000', 'LocationContactPhoneExt': '4634', 'LocationContactEMail': 'gauravi2005@yahoo.co.in'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided', 'IPDSharingDescription': 'Data entry will be done in IIT Bombay and in the Department of Preventive Oncology, Tata Memorial Hospital, using SPSS version 18.'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000002583', 'ConditionMeshTerm': 'Uterine Cervical Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000014594', 'ConditionAncestorTerm': 'Uterine Neoplasms'}, {'ConditionAncestorId': 'D000005833', 'ConditionAncestorTerm': 'Genital Neoplasms, Female'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000002577', 'ConditionAncestorTerm': 'Uterine Cervical Diseases'}, {'ConditionAncestorId': 'D000014591', 'ConditionAncestorTerm': 'Uterine Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4982', 'ConditionBrowseLeafName': 'Uterine Cervical Neoplasms', 'ConditionBrowseLeafAsFound': 'Cervical Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16494', 'ConditionBrowseLeafName': 'Uterine Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8097', 'ConditionBrowseLeafName': 'Genital Neoplasms, Female', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4977', 'ConditionBrowseLeafName': 'Uterine Cervical Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16491', 'ConditionBrowseLeafName': 'Uterine Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 15, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02147080', 'OrgStudyIdInfo': {'OrgStudyId': '1R01CA154928-01', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://reporter.nih.gov/quickSearch/1R01CA154928-01'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R01CA154928', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/1R01CA154928'}]}, 'Organization': {'OrgFullName': 'Fox Chase Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults', 'OfficialTitle': 'A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults', 'Acronym': 'UV4me'}, 'StatusModule': {'StatusVerifiedDate': 'June 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2011'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2014', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 2014', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 22, 2014', 'StudyFirstSubmitQCDate': 'May 22, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 26, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'June 29, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 3, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Carolyn Heckman', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Fox Chase Cancer Center'}, 'LeadSponsor': {'LeadSponsorName': 'Fox Chase Cancer Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Skin cancer is the most common cancer in the US, with over a million new cases diagnosed yearly. Young adults are increasingly at risk of melanoma. Contributing to the increasing skin cancer risk is the fact that US adolescents have the lowest skin protection rates of all age groups and also demonstrate increased exposure to natural and artificial UV radiation. Innovative interventions are needed to have an impact on skin cancer risk among young people. Unlike previous interventions, our skin cancer risk reduction intervention will be tailored (or personalized) to each individual participant and delivered via the Internet. The intervention will emphasize appearance concerns, which are known to be the primary motivation for UV exposure and lack of skin protection among young adults. This will be accomplished in part through the use of personalized facial images showing UV damage as well as computerized age progression demonstrations.\n\nPrimary Aim 1. To examine the efficacy of a tailored intervention delivered via the Internet designed to increase skin protection and decrease sun exposure behavior among young adults at moderate to high risk of developing skin cancer. Participants will be randomized to the tailored intervention, the Skin Cancer Foundation website, or an assessment only condition.\n\nAim 2. To evaluate whether sociodemographic variables (sex, race/ethnicity, skin type, family history of skin cancer), appearance consciousness, and past exposure and protective behaviors moderate intervention effects.\n\nAim 3. To evaluate whether Integrative Model constructs (UV-related knowledge, risk perception, beliefs, norms, self-efficacy, and intentions) mediate intervention effects.\n\nThe goals of future research would be to enhance the tailored intervention, for example, by adding additional contacts or Internet technologies or features, disseminate the intervention, assess the longevity of effects, and/or adapt the tailored intervention for use with other cancer risk behaviors or at risk groups.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Skin Neoplasms']}, 'KeywordList': {'Keyword': ['prevention or control']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '1234', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Tailored Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Subject has access to the tailored web intervention', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: UV4me']}}, {'ArmGroupLabel': 'Skin Cancer Foundation Website', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Subject has access to the pre-existing Skin Cancer Foundation website', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Skin Cancer Foundation website']}}, {'ArmGroupLabel': 'Assessment Only Condition', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Subjects will only complete assessments'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'UV4me', 'InterventionDescription': 'Tailored website includes: personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individual, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Tailored Intervention']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Tailored Intervention for Skin Cancer Risk Reduction']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Skin Cancer Foundation website', 'InterventionDescription': 'Current best practice website for skin cancer and prevention. Includes information, images, news, and opportunities for advocacy.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Skin Cancer Foundation Website']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Sun protection', 'PrimaryOutcomeDescription': 'Continuous measure examining frequency of sun protection behaviors (e.g., sunscreen use, clothing, shade, sunglasses), using items adapted from Glanz and colleagues (2008)', 'PrimaryOutcomeTimeFrame': 'Follow-up 1 (3 weeks after baseline)'}, {'PrimaryOutcomeMeasure': 'Sun protection', 'PrimaryOutcomeDescription': 'Continuous measure examining frequency of sun protection behaviors (e.g., sunscreen use, clothing, shade, sunglasses), using items adapted from Glanz and colleagues (2008)', 'PrimaryOutcomeTimeFrame': 'Follow-up 2 (12 weeks after baseline)'}, {'PrimaryOutcomeMeasure': 'Outdoor UV Exposure', 'PrimaryOutcomeDescription': 'How many hours participants spend in the sun during peak daylight hours during the week', 'PrimaryOutcomeTimeFrame': 'Follow-up 1 (3 weeks after baseline)'}, {'PrimaryOutcomeMeasure': 'Outdoor UV exposure', 'PrimaryOutcomeDescription': 'How many hours participants spend in the sun during peak daylight hours during the week', 'PrimaryOutcomeTimeFrame': 'Follow-up 2 (12 weeks after baseline)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Indoor Tanning', 'SecondaryOutcomeDescription': 'Number of indoor tanning sessions in past month', 'SecondaryOutcomeTimeFrame': 'Follow-up 1 (3 weeks after baseline)'}, {'SecondaryOutcomeMeasure': 'Indoor Tanning', 'SecondaryOutcomeDescription': 'Number of indoor tanning sessions in past month', 'SecondaryOutcomeTimeFrame': 'Follow-up 2 (12 weeks after baseline)'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Spray-on tan', 'OtherOutcomeDescription': 'Number of spray-on tanning sessions in past month', 'OtherOutcomeTimeFrame': 'Follow-up 1 (3 weeks after baseline)'}, {'OtherOutcomeMeasure': 'Spray-on tan', 'OtherOutcomeDescription': 'Number of spray-on tanning sessions in past month', 'OtherOutcomeTimeFrame': 'Follow-up 2 (12 weeks after baseline)'}, {'OtherOutcomeMeasure': 'Sunless tanning creams', 'OtherOutcomeDescription': 'Number of times sunless tanning cream has been used in the past month', 'OtherOutcomeTimeFrame': 'Follow-up 1 (3 weeks after baseline)'}, {'OtherOutcomeMeasure': 'Sunless tanning creams', 'OtherOutcomeDescription': 'Number of times sunless tanning cream has been used in the past month', 'OtherOutcomeTimeFrame': 'Follow-up 2 (12 weeks after baseline)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAge 18-25 years old\nModerate to high risk of skin cancer (cut-off of >=27 on the Brief Skin Cancer Risk Assessment Tool)\n\nExclusion Criteria:\n\nHistory of skin cancer', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '25 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Carolyn Heckman, Ph.D', 'OverallOfficialAffiliation': 'Fox Chase Cancer Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Fox Chase Cancer Center', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19111', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '27819460', 'ReferenceType': 'derived', 'ReferenceCitation': 'Heckman CJ, Handorf EA, Darlow SD, Ritterband LM, Manne SL. An online skin cancer risk-reduction intervention for young adults: Mechanisms of effects. Health Psychol. 2017 Mar;36(3):215-225. doi: 10.1037/hea0000420. Epub 2016 Nov 7.'}, {'ReferencePMID': '26810358', 'ReferenceType': 'derived', 'ReferenceCitation': 'Heckman CJ, Darlow SD, Ritterband LM, Handorf EA, Manne SL. Efficacy of an Intervention to Alter Skin Cancer Risk Behaviors in Young Adults. Am J Prev Med. 2016 Jul;51(1):1-11. doi: 10.1016/j.amepre.2015.11.008. Epub 2016 Jan 22.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000012878', 'ConditionMeshTerm': 'Skin Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M14833', 'ConditionBrowseLeafName': 'Skin Neoplasms', 'ConditionBrowseLeafAsFound': 'Skin Neoplasms', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 16, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04660097', 'OrgStudyIdInfo': {'OrgStudyId': 'HXNI-DA001'}, 'Organization': {'OrgFullName': 'Henan Cancer Hospital', 'OrgClass': 'OTHER_GOV'}, 'BriefTitle': 'Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer', 'OfficialTitle': 'Durvalumab+ Anlotinib + Standard Chemotherapy in First-line Treatment of Extensive Small-cell Lung Cancer: a Single-arm, Single-center, Phase II Clinical Study'}, 'StatusModule': {'StatusVerifiedDate': 'April 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 20, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 20, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'November 20, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 12, 2020', 'StudyFirstSubmitQCDate': 'December 2, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 9, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 10, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 12, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Yanqiu Zhao', 'ResponsiblePartyInvestigatorTitle': 'Head of Oncology', 'ResponsiblePartyInvestigatorAffiliation': 'Henan Cancer Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Henan Cancer Hospital', 'LeadSponsorClass': 'OTHER_GOV'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Small Cell Lung cancer (SCLC) is a highly aggressive tumor that accounts for about 15 percent of all lung cancer cases. SCLC disease progresses rapidly, and about 2/3 of the patients have extensive stage (ES-SCLC) at the time of diagnosis, with extremely poor prognosis. However, the overall survival (OS) of ES-SCLC patients was not significantly prolonged, with platinum combined with etoposide chemotherapy as the standard treatment. In recent years, the emergence of Immune checkpoint inhibitor (ICI) has made the treatment of ES-SCLC appear at the dawn. In Impower133 study, Atezolizumab combined with chemotherapy significantly prolonged OS(median OS 12.3 months vs 10.3 months, HR=0.70, 95%CI 0.54-0.91, P = 0.007). Durvalumab combined with chemotherapy (CASPIAN study) is the first study in 20 years in which the total survival time of ES-SCLC treated by first-line therapy is 13 months, and there is no significant increase in adverse reactions compared with chemotherapy. Therefore, in 2019, NCCN also recommended Atezolizumab or Durvalumab+ EC regimens as a category 1 preferred option for first-line treatment of ES-SCLC.', 'DetailedDescription': 'Small Cell Lung cancer (SCLC) is a highly aggressive tumor that accounts for about 15 percent of all lung cancer cases. SCLC disease progresses rapidly, and about 2/3 of the patients have extensive stage (ES-SCLC) at the time of diagnosis, with extremely poor prognosis. However, the overall survival (OS) of ES-SCLC patients was not significantly prolonged, with platinum combined with etoposide chemotherapy as the standard treatment. In recent years, the emergence of Immune checkpoint inhibitor (ICI) has made the treatment of ES-SCLC appear at the dawn. In Impower133 study, Atezolizumab combined with chemotherapy significantly prolonged OS(median OS 12.3 months vs 10.3 months, HR=0.70, 95%CI 0.54-0.91, P = 0.007). Durvalumab combined with chemotherapy (CASPIAN study) is the first study in 20 years in which the total survival time of ES-SCLC treated by first-line therapy is 13 months, and there is no significant increase in adverse reactions compared with chemotherapy. Therefore, in 2019, NCCN also recommended Atezolizumab or Durvalumab+ EC regimens as a category 1 preferred option for first-line treatment of ES-SCLC.\n\nAlthough THE TMB of SCLC is higher in solid tumors, the objective remission rate (ORR) of SCLC using PD-1 or PD-L1 inhibitors is slightly lower than that of non-small cell lung cancer, and frequent drug resistance becomes the bottleneck of treatment. Some recent studies have shown that anti-angiogenesis drugs can also reverse the immunosuppressive state of tumor microenvironment while anti-tumor therapy, and improve the efficacy of ICI, so as to play a synergistic role. Therefore, anti-angiogenesis therapy combined with immunotherapy is expected to be a new strategy for the treatment of SCLC. Amlotinib is a multi-target anti-angiogenic drug, which has been approved for third-line treatment of SCLC with mild adverse reactions. Anlotinib combined with Durvalumab may have a synergistic antitumor effect, but no studies have been reported so far. Therefore, on the basis of the CASPIAN research study, we designed the Durvalumab + chemotherapy + ernesto, first-line treatment for extensive stage small cell lung cancer with single arm, open, multicenter, phase II clinical research, expected in domestic five cancer center, into the group of 120 ES - SCLC patients with untreated, research Durvalumab + chemotherapy + ROM for efficacy and safety of Ann, and further explore the curative effect of predictive biomarkers.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['SCLC, Extensive Stage']}, 'KeywordList': {'Keyword': ['small cell lung cancer, Durvalumab']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Outcome of Durvalumab-Etoposide-platinum in untreated ES-SCLC(CASPIAN trial)', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'The outcome of CASPIAN', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer', 'InterventionDescription': 'This trial is single-armed IIb stage clinical trial to study the efficacy and safety of Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer . We use the outcome of CASPIAN trial as control group. The primary endpoint is ORR according to the RECIST 1.1, and secondary endpoints are PFS, OS, satety and life quality.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Outcome of Durvalumab-Etoposide-platinum in untreated ES-SCLC(CASPIAN trial)']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Anlotinib Plus Durvalumab-Platinum-Etoposide Versus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'A Phase II, Multicenter Study to Determine the Efficacy of Anlotinib and Durvalumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease Small-Cell Lung Cancer (SCLC) .', 'PrimaryOutcomeDescription': 'The primary Objective of this observational study was to evaluate the Overall Survival(OS) of Durvalumab+ chemotherapy + anlotinib regimen in first-line treatment of ES-SCLC', 'PrimaryOutcomeTimeFrame': '24 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nHistologically confirmed primary treatment of ES-SCLC (small cell lung cancer) in male or female patients aged ≥18 and <75 years.\nThe ECOG energy status is 0 or 1.\nAppropriate hematologic and terminal organ functions.\n\nExclusion Criteria:\n\nPrior to systemic treatment, the patient had a history of chest radiation therapy or planned to undergo intensive chest radiation therapy.\nSpinal cord compression not explicitly treated by surgery and/or radiation, or previously diagnosed and treated, with no evidence of clinical stabilization of >2 weeks prior to randomization. Active brain metastases (stable brain metastases may be admitted after treatment) occurred within one month prior to enrollment.\nUncontrolled or symptomatic hypercalcemia, active tuberculosis, major cardiovascular disease.\nA history of autoimmune diseases, idiopathic pulmonary fibrosis, organized pneumonia, HIV positive, active hepatitis B, radiographic findings of tumor infiltration of the large vessels in the chest and significant pulmonary cavitation lesions, a previous history of hypertensive crisis or hypertensive encephalopathy.\nHistory of hemoptysis within 1 month prior to randomization (≥0.5 TSP of bright red blood per episode).\nMajor surgery within 28 days or needle core biopsy or other minor surgical procedures within 7 days.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Yanqiu Zhao, MS', 'CentralContactRole': 'Contact', 'CentralContactPhone': '13938252350', 'CentralContactPhoneExt': '0086', 'CentralContactEMail': '13938252350@163.com'}, {'CentralContactName': 'Baoxia He, MS', 'CentralContactRole': 'Contact', 'CentralContactPhone': '0371-65587418', 'CentralContactPhoneExt': '0086', 'CentralContactEMail': 'hnszlyygcp@163.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Yanqiu Zhao, MS', 'OverallOfficialAffiliation': 'Henan Tumor Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Henan Tumor Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Zhengzhou', 'LocationState': 'Henan', 'LocationZip': '450000', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yanqiu Zhao, MS', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13938252350', 'LocationContactPhoneExt': '0086', 'LocationContactEMail': '13938252350@163.com'}, {'LocationContactName': 'Baoxia He, MS', 'LocationContactRole': 'Contact', 'LocationContactPhone': '0371-65587418', 'LocationContactPhoneExt': '0086', 'LocationContactEMail': 'hnszlyygcp@163.com'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000008175', 'ConditionMeshTerm': 'Lung Neoplasms'}, {'ConditionMeshId': 'D000055752', 'ConditionMeshTerm': 'Small Cell Lung Carcinoma'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000012142', 'ConditionAncestorTerm': 'Respiratory Tract Neoplasms'}, {'ConditionAncestorId': 'D000013899', 'ConditionAncestorTerm': 'Thoracic Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}, {'ConditionAncestorId': 'D000002283', 'ConditionAncestorTerm': 'Carcinoma, Bronchogenic'}, {'ConditionAncestorId': 'D000001984', 'ConditionAncestorTerm': 'Bronchial Neoplasms'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10324', 'ConditionBrowseLeafName': 'Lung Neoplasms', 'ConditionBrowseLeafAsFound': 'Lung Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M27476', 'ConditionBrowseLeafName': 'Small Cell Lung Carcinoma', 'ConditionBrowseLeafAsFound': 'Small Cell Lung Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4686', 'ConditionBrowseLeafName': 'Carcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14131', 'ConditionBrowseLeafName': 'Respiratory Tract Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15810', 'ConditionBrowseLeafName': 'Thoracic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10320', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14129', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4692', 'ConditionBrowseLeafName': 'Carcinoma, Bronchogenic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4412', 'ConditionBrowseLeafName': 'Bronchial Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T5271', 'ConditionBrowseLeafName': 'Small Cell Lung Cancer', 'ConditionBrowseLeafAsFound': 'Small Cell Lung Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000005047', 'InterventionMeshTerm': 'Etoposide'}, {'InterventionMeshId': 'C000061400', 'InterventionMeshTerm': 'Etoposide phosphate'}, {'InterventionMeshId': 'C000613593', 'InterventionMeshTerm': 'Durvalumab'}, {'InterventionMeshId': 'D000000911', 'InterventionMeshTerm': 'Antibodies, Monoclonal'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000972', 'InterventionAncestorTerm': 'Antineoplastic Agents, Phytogenic'}, {'InterventionAncestorId': 'D000000970', 'InterventionAncestorTerm': 'Antineoplastic Agents'}, {'InterventionAncestorId': 'D000059005', 'InterventionAncestorTerm': 'Topoisomerase II Inhibitors'}, {'InterventionAncestorId': 'D000059003', 'InterventionAncestorTerm': 'Topoisomerase Inhibitors'}, {'InterventionAncestorId': 'D000004791', 'InterventionAncestorTerm': 'Enzyme Inhibitors'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000074322', 'InterventionAncestorTerm': 'Antineoplastic Agents, Immunological'}, {'InterventionAncestorId': 'D000007155', 'InterventionAncestorTerm': 'Immunologic Factors'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M7343', 'InterventionBrowseLeafName': 'Etoposide', 'InterventionBrowseLeafAsFound': 'Early', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M272414', 'InterventionBrowseLeafName': 'Durvalumab', 'InterventionBrowseLeafAsFound': 'Mobile', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M341694', 'InterventionBrowseLeafName': 'Etoposide phosphate', 'InterventionBrowseLeafAsFound': 'Early', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M3377', 'InterventionBrowseLeafName': 'Antibodies', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3382', 'InterventionBrowseLeafName': 'Antibodies, Monoclonal', 'InterventionBrowseLeafAsFound': 'Mobile', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M9336', 'InterventionBrowseLeafName': 'Immunoglobulins', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M7103', 'InterventionBrowseLeafName': 'Enzyme Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M1346', 'InterventionBrowseLeafName': 'Antineoplastic Agents, Immunological', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M9353', 'InterventionBrowseLeafName': 'Immunologic Factors', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 17, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04587258', 'OrgStudyIdInfo': {'OrgStudyId': '1613494-3'}, 'Organization': {'OrgFullName': 'Rhode Island Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island', 'OfficialTitle': 'Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island: A Community Based Quality Improvement Project of the Lifespan Cancer Institute'}, 'StatusModule': {'StatusVerifiedDate': 'September 2020', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 28, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 1, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 1, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'October 8, 2020', 'StudyFirstSubmitQCDate': 'October 13, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 14, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'October 13, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 14, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Rhode Island Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Blackstone Valley Community Health Care', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': "Lifespan Cancer Institute serves over 50% of cancer patients in the state. Rhode Island is known for strong medical care and high rates of cancer screening with mammography and colonoscopy. However, cancer screening has plummeted during the COVID-19 pandemic, in part to closing physician offices and stopping non-urgent medical procedures. In addition, anecdotal reports suggest the public remains concerned about returning to physician's offices and risking possible exposure to COVID-19. As in the United States as a whole, COVID-19 has disproportionately impacted ethnic and minority individuals within underserved communities; and in Rhode Island, African Americans, Hispanics and undocumented individuals living in communities such as Central Falls, Pawtucket, Providence, East Providence and North Providence have had the highest rate of COVID-19. These communities are also impacted by healthcare disparities to access and affordability of healthcare, and as such, may be among the least likely to resume cancer screening.\n\nThe Lifespan Cancer Institute will institute a project to address health disparities in cancer screening during the pandemic through the use of a targeted campaign involving social media. The goals will be to re-establish screening in the era of COVID-19 and ensure timeliness of care for those found to be at risk, or are positive for, cancer.", 'DetailedDescription': 'This project will focus on improving breast and colorectal cancer screening during the COVID-19 pandemic in underserved populations of Rhode Island. The investigators will engage the Blackstone Valley Community Health Center. Dr. Don Dizon, a national leader in social media, will be a key participant.\n\nDr. Don Dizon is a world expert using electronic communication and social media in the oncology practice. Dr. Dizon chairs the Digital Engagement Committee for the Southwest Oncology Group (SWOG) a national cancer institute cooperative group. He is a co-principal investigator of an NIH grant studying electronic patient reported outcomes - the SIMPRO Research Consortium. Dr. Dizon is also head of the American Society of Oncology (ASCO) Educational Committee and is well positioned to disseminate the knowledge gathered from the current project through ASCO activities.\n\nThe initial project may be to discuss with the Blackstone Valley Community Health Center the possibility of developing short videos in multiple languages on the importance of cancer screening. The investigators will engage staff and patients of the BVCHC and the community to participate within the videos as a model of community-based participation. These informational videos could be distributed directly to the community via social media platforms. Data will be collecting on the rates of cancer screening including age, sex and race. These data could be compared to different cities within Rhode Island and the United States'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer', 'Colorectal Cancer', 'Covid19']}, 'KeywordList': {'Keyword': ['Cancer screening', 'COVID19', 'Underserved communities', 'Community based-participation', 'Social Media', 'Informational videos', 'Facebook', 'Instagram', 'TikTok', 'Lifespan', 'Blackstone Valley', 'Central Falls', 'Pawtucket', 'Providence', 'Minorities', 'Equitable healthcare']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Ecologic or Community']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '100', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast Cancer', 'ArmGroupDescription': 'Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using mammograms.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Informational videos and social media campaigns encouraging cancer screening.']}}, {'ArmGroupLabel': 'Colorectal Cancer', 'ArmGroupDescription': 'Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using colonoscopies', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Informational videos and social media campaigns encouraging cancer screening.']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Informational videos and social media campaigns encouraging cancer screening.', 'InterventionDescription': 'Informational videos will be made using community members and will be played in the Blackstone Valley Health Center, as well as posted on social media platforms, such as Facebook and Instagram. These videos will encourage at risk populations in the selected areas to visit their physicians to discuss the possibility of undergoing screening procedures for either breast or colorectal cancer. Data will then be collected about the rates of screening and will be compared to the screening rates from the time period of March 9th 2020 to May 31st 2020, with the goal of increasing screening rates by 25%.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Breast Cancer', 'Colorectal Cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Increase screening rates for breast and colorectal cancer', 'PrimaryOutcomeDescription': 'Increase screening rates for breast and colorectal cancer among underserved populations by 25% using March 9 through May 31 as a benchmark, coinciding the Executive Orders for COVID19 announced by Governor Raimondo.', 'PrimaryOutcomeTimeFrame': '2 years'}, {'PrimaryOutcomeMeasure': 'Impact of screening on cancer care', 'PrimaryOutcomeDescription': "Evaluate the impact of screening on timeliness of cancer care among these populations by comparing to the American Society of Clinical Oncology's Quality Oncology Performance Initiative (QOPI) guidelines in breast and colorectal cancer.", 'PrimaryOutcomeTimeFrame': '2 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Community Engagement', 'SecondaryOutcomeDescription': 'Evaluate strategies of engagement in these communities as it relates to:\n\n-Social media platform (Twitter, Facebook, Instagram, TikTok) These metrics will be determined by social media statistics for engagement and the number of calls/queries to the designated information lines.', 'SecondaryOutcomeTimeFrame': '2 Years'}, {'SecondaryOutcomeMeasure': 'Barriers to cancer screening during COVID19.', 'SecondaryOutcomeDescription': 'Evaluate barriers to cancer screening in these populations as it particularly relates to COVID19.', 'SecondaryOutcomeTimeFrame': '2 Years'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Educate the community on the importance of cancer screening', 'OtherOutcomeDescription': 'We will educate staff, community physicians and Rhode Island residents on the importance of cancer screening. We will use community-based partnerships to overcome distrust of institutions and develop an engaged community network. Long term academic goals include publication of data and successfully receiving local and federal funding for continued research.', 'OtherOutcomeTimeFrame': '5-10 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nIncreased risk of either colorectal or breast cancer\nLiving in an under-served area of Rhode Island\n\nExclusion Criteria:\n\n- None', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients that are at risk of colorectal or breast cancer from under-served or vulnerable communities in Rhode Island.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Howard Safran, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '1 (844) 222-2881', 'CentralContactEMail': 'HSafran@lifespan.org'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Howard Safran, MD', 'OverallOfficialAffiliation': 'Lifespan', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Don Dizon, MD', 'OverallOfficialAffiliation': 'Lifespan', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Blackstone Valley Community Health Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Pawtucket', 'LocationState': 'Rhode Island', 'LocationZip': '02860', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Cristina Pacheco, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '401-312-9898', 'LocationContactEMail': 'cpacheco@bvchc.org'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '30620402', 'ReferenceType': 'background', 'ReferenceCitation': 'Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.'}, {'ReferencePMID': '20147663', 'ReferenceType': 'background', 'ReferenceCitation': 'Wallerstein N, Duran B. Community-based participatory research contributions to intervention research: the intersection of science and practice to improve health equity. Am J Public Health. 2010 Apr 1;100 Suppl 1(Suppl 1):S40-6. doi: 10.2105/AJPH.2009.184036. Epub 2010 Feb 10.'}, {'ReferencePMID': '22095340', 'ReferenceType': 'background', 'ReferenceCitation': "Braun KL, Nguyen TT, Tanjasiri SP, Campbell J, Heiney SP, Brandt HM, Smith SA, Blumenthal DS, Hargreaves M, Coe K, Ma GX, Kenerson D, Patel K, Tsark J, Hebert JR. Operationalization of community-based participatory research principles: assessment of the national cancer institute's community network programs. Am J Public Health. 2012 Jun;102(6):1195-203. doi: 10.2105/AJPH.2011.300304. Epub 2011 Nov 28."}, {'ReferencePMID': '23680507', 'ReferenceType': 'background', 'ReferenceCitation': 'Simonds VW, Wallerstein N, Duran B, Villegas M. Community-based participatory research: its role in future cancer research and public health practice. Prev Chronic Dis. 2013 May 16;10:E78. doi: 10.5888/pcd10.120205.'}, {'ReferencePMID': '12527563', 'ReferenceType': 'background', 'ReferenceCitation': 'Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003 Jan;123(1 Suppl):21S-49S. doi: 10.1378/chest.123.1_suppl.21s.'}, {'ReferencePMID': '21714641', 'ReferenceType': 'background', 'ReferenceCitation': 'National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Pham D, Bhandari S, Oechsli M, et al, Lung cancer screening rates: Data from the lung cancer screening registry. J Clin Oncol 36, 2018 (suppl; abstr 6504)'}, {'ReferencePMID': '32302078', 'ReferenceType': 'background', 'ReferenceCitation': 'Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, Satlin MJ, Campion TR Jr, Nahid M, Ringel JB, Hoffman KL, Alshak MN, Li HA, Wehmeyer GT, Rajan M, Reshetnyak E, Hupert N, Horn EM, Martinez FJ, Gulick RM, Safford MM. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020 Jun 11;382(24):2372-2374. doi: 10.1056/NEJMc2010419. Epub 2020 Apr 17. No abstract available.'}, {'ReferencePMID': '32171076', 'ReferenceType': 'background', 'ReferenceCitation': 'Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum In: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Blackstone Valley Community Health Center', 'SeeAlsoLinkURL': 'http://www.bvchc.org/'}, {'SeeAlsoLinkLabel': 'Lifespan Cancer Institute', 'SeeAlsoLinkURL': 'https://www.lifespan.org/centers-services/lifespan-cancer-institute'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000086382', 'ConditionMeshTerm': 'COVID-19'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000012141', 'ConditionAncestorTerm': 'Respiratory Tract Infections'}, {'ConditionAncestorId': 'D000007239', 'ConditionAncestorTerm': 'Infections'}, {'ConditionAncestorId': 'D000011024', 'ConditionAncestorTerm': 'Pneumonia, Viral'}, {'ConditionAncestorId': 'D000011014', 'ConditionAncestorTerm': 'Pneumonia'}, {'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}, {'ConditionAncestorId': 'D000018352', 'ConditionAncestorTerm': 'Coronavirus Infections'}, {'ConditionAncestorId': 'D000003333', 'ConditionAncestorTerm': 'Coronaviridae Infections'}, {'ConditionAncestorId': 'D000030341', 'ConditionAncestorTerm': 'Nidovirales Infections'}, {'ConditionAncestorId': 'D000012327', 'ConditionAncestorTerm': 'RNA Virus Infections'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2562', 'ConditionBrowseLeafName': 'COVID-19', 'ConditionBrowseLeafAsFound': 'COVID-19', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9435', 'ConditionBrowseLeafName': 'Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5520', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14130', 'ConditionBrowseLeafName': 'Respiratory Tract Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Pneumonia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13066', 'ConditionBrowseLeafName': 'Pneumonia, Viral', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16674', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M19643', 'ConditionBrowseLeafName': 'Coronavirus Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5707', 'ConditionBrowseLeafName': 'Coronaviridae Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22838', 'ConditionBrowseLeafName': 'Nidovirales Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14301', 'ConditionBrowseLeafName': 'RNA Virus Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10320', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14129', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Infections'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 18, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04903665', 'OrgStudyIdInfo': {'OrgStudyId': 'FDZL-2021002'}, 'Organization': {'OrgFullName': 'Fudan University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-I', 'OfficialTitle': 'Gynecologic Malignancies Early-stage Detection by Liquid Biopsy in Peripheral Blood: a Prospective, Observational Study'}, 'StatusModule': {'StatusVerifiedDate': 'July 2022', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 11, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 22, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 24, 2021', 'StudyFirstSubmitQCDate': 'May 24, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 26, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 26, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 28, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Xiaohua Wu MD', 'ResponsiblePartyInvestigatorTitle': 'Director', 'ResponsiblePartyInvestigatorAffiliation': 'Fudan University'}, 'LeadSponsor': {'LeadSponsorName': 'Fudan University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Guangzhou Burning Rock Bioengineering Ltd.', 'CollaboratorClass': 'INDUSTRY'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study is a prospective study aimed to develop and validate the performance of combined multi-omitcs assays for early detection of gynecologic cancers. Biomarkers of cfDNA methylation, ctDNA mutation and blood miRNA markers will be evaluated. The study will enroll approximately 495 female participants, including participants with gynecologic cancers or benign diseases.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Gynecologic Cancer']}, 'KeywordList': {'Keyword': ['gynecologic cancer', 'early detection', 'liquid biopsy', 'cell-free DNA']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Plasma, white blood cells and formalin fixed, paraffin embedded (FFPE) tumor tissue'}, 'EnrollmentInfo': {'EnrollmentCount': '495', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer Arm', 'ArmGroupDescription': 'Participants with new diagnosis of gynecologic cancers, from whom blood samples will be collected.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Multi-cancer early detection test']}}, {'ArmGroupLabel': 'Benign Arm', 'ArmGroupDescription': 'Participants with new diagnosis of benign gynecologic diseases, from whom blood samples will be collected.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Multi-cancer early detection test']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Multi-cancer early detection test', 'InterventionDescription': 'Blood collection and multi-cancer early detection testing', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Benign Arm', 'Cancer Arm']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Sensitivity,specificity and tissue of origin accuracy of the multi-omics model as early detection for gynecologic cancers.', 'PrimaryOutcomeTimeFrame': '12 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Sensitivity and specificity of the multi-omics model in early detection of gynecologic cancers in different stages.', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Sensitivity and specificity of the multi-omics model in early detection of different gynecologic cancer diseases', 'SecondaryOutcomeTimeFrame': '12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria for Cancer Arm Participants:\n\nAge 18 years or older\nAble to provide a written informed consent\nConfirmed diagnosis or highly suspicious cases of gynecologic malignancies\nNo prior or ongoing anti-cancer therapy (local or systematic) prior to study blood draw\n\nExclusion Criteria for Cancer Arm Participants:\n\nPregnancy or lactating women\nRecipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant\nRecipients of blood transfusion within 7 days prior to study blood draw\nRecipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer\n\nInclusion Criteria for Benign Arm Participants:\n\nAge 18 years or older\nAble to provide a written informed consent\nConfirmed diagnosis of benign gynecologic diseases\nNo prior radical treatment of the benign diseases prior to study blood draw\n\nExclusion Criteria for Benign Arm Participants:\n\nPregnancy or lactating women\nRecipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant\nRecipients of blood transfusion within 7 days prior to study blood draw\nRecipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Eligible participants will be recruited from the participating medical center and assigned into two arms, including participants with new diagnosis of gynecologic malignancies and benign gynecologic diseases.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Xiaohua Wu, M.D.&Ph.D', 'OverallOfficialAffiliation': 'Department of Gynecological Oncology, Fudan University Shanghai Cancer Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Fudan University Shanghai Cancer Center', 'LocationCity': 'Shanghai', 'LocationState': 'Shanghai', 'LocationZip': '200032', 'LocationCountry': 'China'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}}}}, {'Rank': 19, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01914107', 'OrgStudyIdInfo': {'OrgStudyId': 'GPM-ward'}, 'Organization': {'OrgFullName': 'Sun Yat-sen University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Real-time Cancer Pain Assessment and Intervention', 'OfficialTitle': 'A Randomized, Controlled Clinical Study: Assess and Intervene Cancer Pain of Advanced Malignant Tumor Patients in Real-Time, Using the Real-time Cancer Pain Assessment and Intervention System Based on Cloud Computing Concept.'}, 'StatusModule': {'StatusVerifiedDate': 'August 2015', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2012'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2017', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 2018', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 29, 2013', 'StudyFirstSubmitQCDate': 'July 30, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 1, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 26, 2015', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 27, 2015', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Li Zhang', 'ResponsiblePartyInvestigatorTitle': 'Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Sun Yat-sen University'}, 'LeadSponsor': {'LeadSponsorName': 'Sun Yat-sen University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study aim at the advanced malignant tumor patients who suffer from cancer pain, investigate the current status of cancer pain treatment, and study the effects in pain control and quality of life improvement using the method of real-time monitoring and treatment instruction of cancer pain. This study is a randomized, controlled, single center clinical study. After recruitment, the subjects will randomly assign to standard cancer pain treatment group and standard cancer pain treatment plus real-time dynamic monitoring and treatment intervention of cancer pain using the cloud computing concept system. And then, assess the alleviation of cancer pain and quality of live. The assumption is the system will alleviate the cancer pain efficiently.', 'DetailedDescription': 'Cancer pain is a common symptom exists in malignant tumor patients, which bother the patients and decrease the quality of life.\nThe goal of the study is that using the real-time monitoring and intervention system will alleviate cancer pain better than the standard cancer pain treatment.\nThe cloud computing concept is developed by Sun Yat-sen University cancer center, and accord with clinical practice.\nThe subjects receive the real-time monitoring and intervention system will install the software and report in the contents of cancer pain in the software correspondingly to the doctors, and advices will be given by the software as well.\nThe quality of life and overall survival follow-up is also required.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Malignancy', 'Pain']}, 'KeywordList': {'Keyword': ['malignancy', 'solid tumor', 'cancer pain']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '200', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'standard cancer pain care', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': "the standard cancer pain care group: 1.will be follow-up by the cancer nurse once a week to acknowledge the cancer pain intensity, the current analgesic medication, and the side effects. and also give recommendations. 2.filled in the patient'diary and hand over to researchers.", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: standard cancer pain care']}}, {'ArmGroupLabel': 'real-time monitoring and instruction of cancer pain', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'real-time monitoring and treatment instruction of cancer pain group\n\n1.follow the same pattern of standard cancer pain care. 2. using the cloud computing concept system, install the software in the mobile phone of patients. the patients will fill in the content of brief pain inventory, medication and side effect, and upload to researchers every 2 days. 3. Researcher monitor the cancer pain treatment in realtime and give instructions.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: real-time monitoring and instruction of cancer pain']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'real-time monitoring and instruction of cancer pain', 'InterventionDescription': 'as description in arm', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['real-time monitoring and instruction of cancer pain']}, 'InterventionOtherNameList': {'InterventionOtherName': ['the cloud computing concept based real-time cancer pain assessment and intervetion system']}}, {'InterventionType': 'Procedure', 'InterventionName': 'standard cancer pain care', 'InterventionDescription': 'as description in arm', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['standard cancer pain care']}, 'InterventionOtherNameList': {'InterventionOtherName': ['standard cancer pain care according to National Comprehensive Cancer Network adult cancer pain guideline']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'pain intensity', 'PrimaryOutcomeDescription': 'the numeric rating scale and visual analogue scale of pain during the chemotherapy. using brief pain inventory scales.\n\nin this case, once 2 days in intervention group; once a weeks in control group; and a comprehensive cancer pain assessment according to national comprehensive cancer network adult pain guidance every cycle. within 3 weeks after withdraw, all of the statistics will be analyzed.', 'PrimaryOutcomeTimeFrame': 'up to 9 weeks'}, {'PrimaryOutcomeMeasure': 'duration of pain', 'PrimaryOutcomeDescription': 'the numeric rating scale and visual analogue scale of pain during the chemotherapy. using brief pain inventory scales.\n\nin this case, once 2 days in intervention group; once a weeks in control group; and a comprehensive cancer pain assessment according to national comprehensive cancer network adult pain guidance every cycle. within 3 weeks after withdraw, all of the statistics will be analyzed.', 'PrimaryOutcomeTimeFrame': 'up to 9 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'quality of life', 'SecondaryOutcomeDescription': 'the quality of life assessment will be conducted before the chemotherapy, after 1st cycle chemotherapy, and after 2nd cycle of chemotherapy.', 'SecondaryOutcomeTimeFrame': 'change from baseline of quality of life at 6 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nSolid tumors confirmed by pathology or cytology\nEastern Cooperative Oncology Group Performance Status: 0-2\nsign the informed consent form\ngood compliance, willing to comply with the requirements of the study\nanticipate survival time more than 3 months\npain intensity is greater than 2 points according to numerical rating scale on enrollment; have indication of opioid analgesic drugs.\ncan express subjective feelings of pain intensity clearly.\nown a smartphone or tablet device which can install and use the application program software, and can operate the software proficiently.\n\nExclusion Criteria:\n\npoor compliance, refuse to sign the informed consent form, or difficult to comply with the requirement of the study.\nslight pain or no pain, no indication of opioid analgesic drugs.\ncontraindication of opioid analgesic drugs\nno other medical workers give instructions during the study.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'YuXiang Ma, M.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '86-020-87343786', 'CentralContactEMail': 'mayx@sysucc.org.cn'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Li Zhang, professor', 'OverallOfficialAffiliation': 'Sun Yat-sen University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Sun Yat-sen University Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationZip': '510060', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yuxiang Ma, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '86-020-87343894', 'LocationContactEMail': 'mayx@sysucc.org.cn'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '17355955', 'ReferenceType': 'background', 'ReferenceCitation': 'van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007 Sep;18(9):1437-49. doi: 10.1093/annonc/mdm056. Epub 2007 Mar 12.'}, {'ReferencePMID': '15813511', 'ReferenceType': 'background', 'ReferenceCitation': 'Goudas LC, Bloch R, Gialeli-Goudas M, Lau J, Carr DB. The epidemiology of cancer pain. Cancer Invest. 2005;23(2):182-90.'}, {'ReferencePMID': '7659438', 'ReferenceType': 'background', 'ReferenceCitation': 'Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995 May;61(2):277-284. doi: 10.1016/0304-3959(94)00178-H.'}, {'ReferencePMID': '18632721', 'ReferenceType': 'background', 'ReferenceCitation': 'Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008 Dec;19(12):1985-91. doi: 10.1093/annonc/mdn419. Epub 2008 Jul 15.'}, {'ReferencePMID': '19164455', 'ReferenceType': 'background', 'ReferenceCitation': "Costantini M, Ripamonti C, Beccaro M, Montella M, Borgia P, Casella C, Miccinesi G. Prevalence, distress, management, and relief of pain during the last 3 months of cancer patients' life. Results of an Italian mortality follow-back survey. Ann Oncol. 2009 Apr;20(4):729-35. doi: 10.1093/annonc/mdn700. Epub 2009 Jan 22."}, {'ReferencePMID': '19401688', 'ReferenceType': 'background', 'ReferenceCitation': 'Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco MT; Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer. 2009 May 19;100(10):1566-74. doi: 10.1038/sj.bjc.6605053. Epub 2009 Apr 28.'}, {'ReferencePMID': '22508819', 'ReferenceType': 'background', 'ReferenceCitation': 'Fisch MJ, Lee JW, Weiss M, Wagner LI, Chang VT, Cella D, Manola JB, Minasian LM, McCaskill-Stevens W, Mendoza TR, Cleeland CS. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol. 2012 Jun 1;30(16):1980-8. doi: 10.1200/JCO.2011.39.2381. Epub 2012 Apr 16.'}, {'ReferencePMID': '7508092', 'ReferenceType': 'background', 'ReferenceCitation': 'Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994 Mar 3;330(9):592-6. doi: 10.1056/NEJM199403033300902.'}, {'ReferencePMID': '8099769', 'ReferenceType': 'background', 'ReferenceCitation': 'Von Roenn JH, Cleeland CS, Gonin R, Hatfield AK, Pandya KJ. Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med. 1993 Jul 15;119(2):121-6. doi: 10.7326/0003-4819-119-2-199307150-00005.'}, {'ReferencePMID': '22084372', 'ReferenceType': 'background', 'ReferenceCitation': "Breuer B, Fleishman SB, Cruciani RA, Portenoy RK. Medical oncologists' attitudes and practice in cancer pain management: a national survey. J Clin Oncol. 2011 Dec 20;29(36):4769-75. doi: 10.1200/JCO.2011.35.0561. Epub 2011 Nov 14."}, {'ReferencePMID': '16632078', 'ReferenceType': 'background', 'ReferenceCitation': 'Morita T, Miyashita M, Shibagaki M, Hirai K, Ashiya T, Ishihara T, Matsubara T, Miyoshi I, Nakaho T, Nakashima N, Onishi H, Ozawa T, Suenaga K, Tajima T, Akechi T, Uchitomi Y. Knowledge and beliefs about end-of-life care and the effects of specialized palliative care: a population-based survey in Japan. J Pain Symptom Manage. 2006 Apr;31(4):306-16. doi: 10.1016/j.jpainsymman.2005.09.004.'}, {'ReferencePMID': '18785917', 'ReferenceType': 'background', 'ReferenceCitation': 'Jacobsen R, Moldrup C, Christrup L, Sjogren P. Patient-related barriers to cancer pain management: a systematic exploratory review. Scand J Caring Sci. 2009 Mar;23(1):190-208. doi: 10.1111/j.1471-6712.2008.00601.x. Epub 2008 Sep 10.'}, {'ReferencePMID': '7816490', 'ReferenceType': 'background', 'ReferenceCitation': 'Ward SE, Hernandez L. Patient-related barriers to management of cancer pain in Puerto Rico. Pain. 1994 Aug;58(2):233-238. doi: 10.1016/0304-3959(94)90203-8.'}, {'ReferencePMID': '11343734', 'ReferenceType': 'background', 'ReferenceCitation': 'Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ. Understanding the experience of pain in terminally ill patients. Lancet. 2001 Apr 28;357(9265):1311-5. doi: 10.1016/S0140-6736(00)04515-3.'}, {'ReferencePMID': '12007757', 'ReferenceType': 'background', 'ReferenceCitation': 'Yates PM, Edwards HE, Nash RE, Walsh AM, Fentiman BJ, Skerman HM, Najman JM. Barriers to effective cancer pain management: a survey of hospitalized cancer patients in Australia. J Pain Symptom Manage. 2002 May;23(5):393-405. doi: 10.1016/s0885-3924(02)00387-1.'}, {'ReferencePMID': '11965937', 'ReferenceType': 'background', 'ReferenceCitation': 'Morita T, Tsunoda J, Inoue S, Chihara S. Concerns of Japanese hospice inpatients about morphine therapy as a factor in pain management: a pilot study. J Palliat Care. 2000 Winter;16(4):54-8. No abstract available.'}, {'ReferencePMID': '22479880', 'ReferenceType': 'background', 'ReferenceCitation': 'Simone CB 2nd, Vapiwala N, Hampshire MK, Metz JM. Palliative care in the management of lung cancer: analgesic utilization and barriers to optimal pain management. J Opioid Manag. 2012 Jan-Feb;8(1):9-16. doi: 10.5055/jom.2012.0091.'}, {'ReferencePMID': '22674404', 'ReferenceType': 'background', 'ReferenceCitation': 'Zhu J, Davis RB, Stuver SO, Berry DL, Block S, Weeks JC, Weingart SN. A longitudinal study of pain variability and its correlates in ambulatory patients with advanced stage cancer. Cancer. 2012 Dec 15;118(24):6278-86. doi: 10.1002/cncr.27673. Epub 2012 Jun 6.'}, {'ReferencePMID': '14622723', 'ReferenceType': 'background', 'ReferenceCitation': 'Jensen MP. The validity and reliability of pain measures in adults with cancer. J Pain. 2003 Feb;4(1):2-21. doi: 10.1054/jpai.2003.1.'}, {'ReferencePMID': '2007792', 'ReferenceType': 'background', 'ReferenceCitation': 'Grossman SA, Sheidler VR, Swedeen K, Mucenski J, Piantadosi S. Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage. 1991 Feb;6(2):53-7. doi: 10.1016/0885-3924(91)90518-9.'}, {'ReferencePMID': '1735074', 'ReferenceType': 'background', 'ReferenceCitation': 'Clipp EC, George LK. Patients with cancer and their spouse caregivers. Perceptions of the illness experience. Cancer. 1992 Feb 15;69(4):1074-9. doi: 10.1002/1097-0142(19920215)69:43.0.co;2-l.'}, {'ReferencePMID': '22256803', 'ReferenceType': 'background', 'ReferenceCitation': 'Lamas D, Rosenbaum L. Painful inequities--palliative care in developing countries. N Engl J Med. 2012 Jan 19;366(3):199-201. doi: 10.1056/NEJMp1113622. No abstract available.'}, {'ReferencePMID': '22312101', 'ReferenceType': 'background', 'ReferenceCitation': 'Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM, Ferrell BR, Loscalzo M, Meier DE, Paice JA, Peppercorn JM, Somerfield M, Stovall E, Von Roenn JH. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012 Mar 10;30(8):880-7. doi: 10.1200/JCO.2011.38.5161. Epub 2012 Feb 6.'}, {'ReferencePMID': '22987079', 'ReferenceType': 'background', 'ReferenceCitation': 'Charalambous H, Silbermann M. Clinically based palliative care training is needed urgently for all oncologists. J Clin Oncol. 2012 Nov 10;30(32):4042-3; author reply 4043-4. doi: 10.1200/JCO.2012.45.3548. Epub 2012 Sep 17. No abstract available.'}, {'ReferencePMID': '21263086', 'ReferenceType': 'background', 'ReferenceCitation': 'Peppercorn JM, Smith TJ, Helft PR, Debono DJ, Berry SR, Wollins DS, Hayes DM, Von Roenn JH, Schnipper LE; American Society of Clinical Oncology. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol. 2011 Feb 20;29(6):755-60. doi: 10.1200/JCO.2010.33.1744. Epub 2011 Jan 24.'}, {'ReferencePMID': '9414057', 'ReferenceType': 'background', 'ReferenceCitation': 'de Wit R, van Dam F, Zandbelt L, van Buuren A, van der Heijden K, Leenhouts G, Loonstra S. A pain education program for chronic cancer pain patients: follow-up results from a randomized controlled trial. Pain. 1997 Oct;73(1):55-69. doi: 10.1016/s0304-3959(97)00070-5.'}, {'ReferencePMID': '15117994', 'ReferenceType': 'background', 'ReferenceCitation': 'Miaskowski C, Dodd M, West C, Schumacher K, Paul SM, Tripathy D, Koo P. Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol. 2004 May 1;22(9):1713-20. doi: 10.1200/JCO.2004.06.140.'}, {'ReferencePMID': '22871509', 'ReferenceType': 'background', 'ReferenceCitation': "Koller A, Miaskowski C, De Geest S, Opitz O, Spichiger E. A systematic evaluation of content, structure, and efficacy of interventions to improve patients' self-management of cancer pain. J Pain Symptom Manage. 2012 Aug;44(2):264-84. doi: 10.1016/j.jpainsymman.2011.08.015."}, {'ReferencePMID': '22974435', 'ReferenceType': 'background', 'ReferenceCitation': 'Kim EB, Han HS, Chung JH, Park BR, Lim SN, Yim KH, Shin YD, Lee KH, Kim WJ, Kim ST. The effectiveness of a self-reporting bedside pain assessment tool for oncology inpatients. J Palliat Med. 2012 Nov;15(11):1222-33. doi: 10.1089/jpm.2012.0183. Epub 2012 Sep 13.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000009369', 'ConditionMeshTerm': 'Neoplasms'}, {'ConditionMeshId': 'D000072716', 'ConditionMeshTerm': 'Cancer Pain'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010146', 'ConditionAncestorTerm': 'Pain'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12218', 'ConditionBrowseLeafName': 'Pain', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M1091', 'ConditionBrowseLeafName': 'Cancer Pain', 'ConditionBrowseLeafAsFound': 'Cancer Pain', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11556', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M3184', 'InterventionBrowseLeafName': 'Analgesics', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Analg', 'InterventionBrowseBranchName': 'Analgesics'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 20, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01470586', 'OrgStudyIdInfo': {'OrgStudyId': 'GH-1948-08'}, 'Organization': {'OrgFullName': 'G. Hatzikosta General Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Surgical Resection Lowers Oxidative Stress Markers in Patients With Colorectal Cancer', 'OfficialTitle': 'Surgical Resection Lowers Oxidative Stress Markers in Patients With Colorectal Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'November 2011', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2010', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2011', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 5, 2011', 'StudyFirstSubmitQCDate': 'November 10, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 11, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 10, 2011', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 11, 2011', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'E.Tsimoyiannis', 'ResponsiblePartyInvestigatorTitle': 'Head of Department of Surgery, G.Hatzikosta General Hospital', 'ResponsiblePartyInvestigatorAffiliation': 'G. Hatzikosta General Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'G. Hatzikosta General Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Ioannina', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Study of Oxidative stress Markers (F2 Isoprostanes for lipid peroxidation, Carbonyl groups for protein peroxidation, 3 Nitrotyrosine for damage by nitrogens, and 8-Hydroxyguanosine for RNA peroxidation)in patients with colorectal cancer undergo surgical treatment (preoperatively during the intervention and postoperatively) and controls.', 'DetailedDescription': 'Study of the impact of surgery on Lipid peroxidation, Protein peroxidation, damage by nitrogens, and RNA peroxidation, in patients undergo surgical resection for colorectal cancer and compared with controls, and validation of the responsiveness of oxidative stress markers on surgery'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Colorectal Cancer', 'Colon Rectal Resection', 'Oxidative Stress']}, 'KeywordList': {'Keyword': ['Colorectal cancer', 'Surgical resection', 'Oxidative Stress Markers', 'Controls']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Factorial Assignment', 'DesignMaskingInfo': {'DesignMasking': 'Triple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider', 'Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '60', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Surgery for colorectal cancer', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Colorectal cancer patients', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Surgery for colorectal cancer']}}, {'ArmGroupLabel': 'Controls', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Controls'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'Surgery for colorectal cancer', 'InterventionDescription': 'Surgical resection of colorectal cancer', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Surgery for colorectal cancer']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Open or Laparoscopic resection for colorectal cancer', 'Low anterior resection', 'Sigmoidectomy', 'Left colectomy', 'Trasverse colectomy', 'Right colectomy']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Comparison of Oxidative stress markers in patients with colorectal cancer and controls', 'PrimaryOutcomeDescription': 'Oxidative stress markers variation (8-PGF2α, Protein Carboyls, 3-Nitrotyrosine, 8-OHG) during and after surgery for colorectal cancer, and compare with controls', 'PrimaryOutcomeTimeFrame': 'up to 2 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Validation of oxidative stress markers in patients with colorectal cancer undergo surgical resection', 'SecondaryOutcomeDescription': 'Validation of the responsiveness of markers of oxidative stress 8-PGF2α, Protein Carboyls, 3-Nitrotyrosine, 8-OHG)on surgery', 'SecondaryOutcomeTimeFrame': 'up to 2 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nPatients with colorectal cancer\nControls\n\nExclusion Criteria:\n\nASA>3\nMetastatic Disease\nAcute bowel obstruction\nAcute bowel perforation\nBMI<30\nChronic Systemic or Autoimmune Diseases\nSmokers\nAlcohol consumers', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '25 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'George Pappas-Gogos, MD', 'OverallOfficialAffiliation': 'G. Hatzikosta General Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'G. Hatzikosta General Hospital', 'LocationCity': 'Ioannina', 'LocationState': 'Epirus', 'LocationZip': '45001', 'LocationCountry': 'Greece'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000015179', 'ConditionMeshTerm': 'Colorectal Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000012002', 'ConditionAncestorTerm': 'Rectal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafAsFound': 'Colorectal Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13996', 'ConditionBrowseLeafName': 'Rectal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 21, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00283075', 'OrgStudyIdInfo': {'OrgStudyId': '0407007343'}, 'Organization': {'OrgFullName': 'The Rogosin Institute', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer', 'OfficialTitle': 'Use of Mouse Renal Adenocarcinoma Cell-containing Agarose-agarose Macrobeads in the Treatment of Patients With End-stage, Treatment-resistant Epithelial-derived Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'January 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2005'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'February 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 26, 2006', 'StudyFirstSubmitQCDate': 'January 26, 2006', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 27, 2006', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'October 26, 2015', 'ResultsFirstSubmitQCDate': 'February 11, 2016', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'March 10, 2016', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 7, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 16, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'The Rogosin Institute', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'This is a phase 1 trial to evaluate the safety and toxicity of mouse kidney cancer cell-containing agarose-agarose macrobeads that are implanted in the abdominal cavity as a proposed biological treatment of patients with end-stage, treatment-resistant cancer. The macrobeads have been extensively tested in tumor models in mice and rats, as well as in forty-five veterinary patients (cats and dogs) with naturally occurring tumors of various types including breast cancer, prostate cancer, liver cancer, and lymphoma with clear tumor responses and no significant detectable toxicity.', 'DetailedDescription': 'Cancer in its various forms continues to be a major U.S. health problem, accounting for 550,000 deaths a year, as well as much disability and suffering. Treatment for cancer has traditionally consisted of three modalities: surgery, radiation therapy, and chemotherapy. Advances with all three modalities over the years have produced long-term remissions and/or cures in certain types of cancer such as the leukemias, and prolonged survival for many other patients. Much remains to be accomplished, however, especially with respect to the treatment of solid tumors, including some of the most common cancers such as those of the lung, colon, breast, ovary, prostate and kidney. New types of less toxic and debilitating therapy are needed.\n\nAmong the therapeutic possibilities currently being explored, those that involve biological control mechanisms seem both promising and attractive. Although it has long been thought that cancer cells are not subject to the same regulatory growth control mechanisms that function in normal cells, there is a substantial body of evidence that they can respond to feedback signals telling them to slow or stop their growth. In addition, it has been determined that a relatively small population of cells within a tumor (cancer "stem" or progenitor cells) are responsible for continued tumor growth and that it is these cells that must be controlled if biological anti-tumor therapy is to be effective.\n\nThe proposed cancer treatment being tested in this Phase 1 clinical trial is based on the concept that tumor growth can be controlled by tumor mass or signals that indicate that such mass is present. In this case, however, the induction of the growth-slowing signals is brought about not by tumor mass, but by placing mouse kidney cancer cells in an agarose matrix, which both selects for cancer progenitor cells and also causes them to produce and release signals that inhibit the growth of freely growing cancer cells of the same or different type in a laboratory dish or in a tumor-bearing animal or human (i.e. is also not species-specific). This approach has proven both safe and effective in animal models and veterinary patients, and it is now in the first stage of human testing. With Phase 1 completed, we are now implementing Phase 2 efficacy trials that for the present are focused on colorectal cancer, pancreatic cancer, and prostate cancer. The Phase 1 trial remains open to a range of epithelial-derived cancer.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Intraabdominal Cancers (Various Types)']}, 'KeywordList': {'Keyword': ['intraabdominal cancer (carcinomas)', 'agarose macrobeads', 'mouse kidney cancer cells', 'cancer cell growth inhibition']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '56', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer macrobeads', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Cancer Macrobead placement in abdominal cavity', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Cancer Macrobead placement in abdominal cavity']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Biological', 'InterventionName': 'Cancer Macrobead placement in abdominal cavity', 'InterventionDescription': '8 macrobeads per kg', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer macrobeads']}, 'InterventionOtherNameList': {'InterventionOtherName': ['cancer macrobead']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Maximum Tolerated Dose (MTD) of RENCA Macrobeads', 'PrimaryOutcomeDescription': 'Dose limiting toxicity (DLT) was defined as:\n\nany Grade 2 allergic reaction of generalized urticaria or any other Grade ≥ 3 allergic reaction;\nany Grade ≥ 3 infection and\nany Grade ≥ 3 local (intraperitoneal) reaction and any Grade ≥ 3 hematologic or non- hematologic reaction.\n\nThis definition of DLT is in accord with the NCI CTCAE v3.0.\n\nMaximum tolerated dose (MTD) was to be identified if, within a cohort, > 1 subject out of the first 3, or 2 subjects out of 5 experienced DLT. In such a case, the MTD will have been exceeded, and the administration of the study agent was to cease. MTD would not be considered to have been reached if no DLTs were observed.', 'PrimaryOutcomeTimeFrame': '6 months'}, {'PrimaryOutcomeMeasure': 'Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)', 'PrimaryOutcomeDescription': 'Dose limiting toxicity (DLT) was defined as:\n\nany Grade 2 allergic reaction of generalized urticaria or any other Grade ≥ 3 allergic reaction;\nany Grade ≥ 3 infection and\nany Grade ≥ 3 local (intraperitoneal) reaction and any Grade ≥ 3 hematologic or non- hematologic reaction.\n\nThis definition of DLT is in accord with the NCI CTCAE v3.0.', 'PrimaryOutcomeTimeFrame': '6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Overall Survival', 'SecondaryOutcomeDescription': 'Overall Survival (OS) was measured as date of first implantation to date of death of any cause, and was analyzed using the Kaplan-Meier method.', 'SecondaryOutcomeTimeFrame': 'From date of RENCA macrobeads implantation until date of death from any cause'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Tumor Marker Response', 'OtherOutcomeDescription': 'Tumor marker response after the first implantation with RENCA macrobeads. Responders showed at least a 20% decrease from baseline in Cancer Antigen 19-9 (CA19-9) or Carcinoembryonic Antigen (CEA); Non-responders do not show at least a 20% decrease from baseline in CA19-9 or CEA.', 'OtherOutcomeTimeFrame': 'Prior to Implantation and Day 7, Day 14, Day 21 and Day 28 after each implantation'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nEnd-stage, treatment resistant epithelial-derived cancer (carcinoma) arising originally within the abdominal cavity with expected minimum six-month survival\n\nExclusion Criteria:\n\nMultiple intraabdominal metastases or carcinomatosis or other medical conditions indicating that the procedure would be of too high a risk for the individual', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Barry H Smith, MD, PhD', 'OverallOfficialAffiliation': 'The Rogosin Institute', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'NewYork Presbyterian Weill Cornell Medical Center', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10021', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '4258017', 'ReferenceType': 'background', 'ReferenceCitation': 'DeWys WD. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res. 1972 Feb;32(2):374-9. No abstract available.'}, {'ReferencePMID': '2702641', 'ReferenceType': 'background', 'ReferenceCitation': 'Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 1989 Apr 15;49(8):1996-2001.'}, {'ReferencePMID': '1988084', 'ReferenceType': 'background', 'ReferenceCitation': 'Prehn RT. The inhibition of tumor growth by tumor mass. Cancer Res. 1991 Jan 1;51(1):2-4.'}, {'ReferencePMID': '11689955', 'ReferenceType': 'background', 'ReferenceCitation': 'Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001 Nov 1;414(6859):105-11. doi: 10.1038/35102167.'}, {'ReferencePMID': '12629218', 'ReferenceType': 'background', 'ReferenceCitation': 'Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8. doi: 10.1073/pnas.0530291100. Epub 2003 Mar 10. Erratum In: Proc Natl Acad Sci U S A. 2003 May 27;100(11):6890.'}, {'ReferencePMID': '21266362', 'ReferenceType': 'background', 'ReferenceCitation': 'Smith BH, Gazda LS, Conn BL, Jain K, Asina S, Levine DM, Parker TS, Laramore MA, Martis PC, Vinerean HV, David EM, Qiu S, North AJ, Couto CG, Post GS, Waters DJ, Cordon-Cardo C, Hall RD, Gordon BR, Diehl CH, Stenzel KH, Rubin AL. Hydrophilic agarose macrobead cultures select for outgrowth of carcinoma cell populations that can restrict tumor growth. Cancer Res. 2011 Feb 1;71(3):725-35. doi: 10.1158/0008-5472.CAN-10-2258. Epub 2011 Jan 24.'}, {'ReferencePMID': '21266363', 'ReferenceType': 'background', 'ReferenceCitation': 'Smith BH, Gazda LS, Conn BL, Jain K, Asina S, Levine DM, Parker TS, Laramore MA, Martis PC, Vinerean HV, David EM, Qiu S, Cordon-Cardo C, Hall RD, Gordon BR, Diehl CH, Stenzel KH, Rubin AL. Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties. Cancer Res. 2011 Feb 1;71(3):716-24. doi: 10.1158/0008-5472.CAN-10-2254. Epub 2011 Jan 24.'}, {'ReferencePMID': '24025409', 'ReferenceType': 'background', 'ReferenceCitation': 'Gazda LS, Martis PC, Laramore MA, Bautista MA, Dudley A, Vinerean HV, Smith BH. Treatment of agarose-agarose RENCA macrobeads with docetaxel selects for OCT4(+) cells with tumor-initiating capability. Cancer Biol Ther. 2013 Dec;14(12):1147-57. doi: 10.4161/cbt.26455. Epub 2013 Sep 12.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowRecruitmentDetails': 'Fifty-six subjects provided informed consent to participate in this study; of these 31 subjects underwent the implantation of macrobeads that contain mouse renal adenocarcinoma cells (RENCA macrobeads). The first subject was implanted on 6 April 2005 and the last subject was implanted on 1 November 2011.', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': '8 RENCA Macrobeads/kg Body Weight Implantation', 'FlowGroupDescription': 'RENCA macrobeads placement in abdominal cavity at 8 RENCA macrobeads/kg body weight.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': '16 RENCA Macrobeads/kg Body Weight Implantation', 'FlowGroupDescription': 'RENCA macrobeads placement in abdominal cavity at 16 RENCA macrobeads/kg body weight.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '25'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '6'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '25'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '6'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '0'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'All Participants', 'BaselineGroupDescription': 'All participants who had at least one implantation of RENCA macrobeads, either at 8 RENCA macrobeads/kg body weight or 16 RENCA macrobeads/kg body weight.'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '31'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '59.1', 'BaselineMeasurementSpread': '8.53'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '16'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '15'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race/Ethnicity, Customized', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'White', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '12'}]}}]}}, {'BaselineClassTitle': 'Hispanic', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2'}]}}]}}, {'BaselineClassTitle': 'Asian', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}]}}]}}, {'BaselineClassTitle': 'Not Available', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '16'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Maximum Tolerated Dose (MTD) of RENCA Macrobeads', 'OutcomeMeasureDescription': 'Dose limiting toxicity (DLT) was defined as:\n\nany Grade 2 allergic reaction of generalized urticaria or any other Grade ≥ 3 allergic reaction;\nany Grade ≥ 3 infection and\nany Grade ≥ 3 local (intraperitoneal) reaction and any Grade ≥ 3 hematologic or non- hematologic reaction.\n\nThis definition of DLT is in accord with the NCI CTCAE v3.0.\n\nMaximum tolerated dose (MTD) was to be identified if, within a cohort, > 1 subject out of the first 3, or 2 subjects out of 5 experienced DLT. In such a case, the MTD will have been exceeded, and the administration of the study agent was to cease. MTD would not be considered to have been reached if no DLTs were observed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'RENCA Macrobeads/kg', 'OutcomeMeasureTimeFrame': '6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'All Participants', 'OutcomeGroupDescription': 'All participants who had at least one implantation of RENCA macrobeads, either at 8 RENCA macrobeads/kg body weight or 16 RENCA macrobeads/kg body weight.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '31'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': 'NA', 'OutcomeMeasurementComment': 'MTD of of RENCA macrobeads has not been reached because no DLTs were observed.'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Overall Survival', 'OutcomeMeasureDescription': 'Overall Survival (OS) was measured as date of first implantation to date of death of any cause, and was analyzed using the Kaplan-Meier method.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'months', 'OutcomeMeasureTimeFrame': 'From date of RENCA macrobeads implantation until date of death from any cause', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'All Participants', 'OutcomeGroupDescription': 'All participants who had at least one implantation of RENCA macrobeads, either at 8 macrobeads/kg body weight or 16 macrobeads/kg body weight.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '31'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'All Cancer Type', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5.4', 'OutcomeMeasurementLowerLimit': '2.2', 'OutcomeMeasurementUpperLimit': '7.0'}]}}]}}, {'OutcomeClassTitle': 'Colorectal Cancer', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '7.0', 'OutcomeMeasurementLowerLimit': '1.1', 'OutcomeMeasurementUpperLimit': '9.7'}]}}]}}, {'OutcomeClassTitle': 'Pancreatic Cancer', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.1', 'OutcomeMeasurementLowerLimit': '1.0', 'OutcomeMeasurementUpperLimit': '2.2'}]}}]}}, {'OutcomeClassTitle': 'Other Cancer', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5.7', 'OutcomeMeasurementLowerLimit': '2.0', 'OutcomeMeasurementUpperLimit': '7.0'}]}}]}}]}}, {'OutcomeMeasureType': 'Other Pre-specified', 'OutcomeMeasureTitle': 'Tumor Marker Response', 'OutcomeMeasureDescription': 'Tumor marker response after the first implantation with RENCA macrobeads. Responders showed at least a 20% decrease from baseline in Cancer Antigen 19-9 (CA19-9) or Carcinoembryonic Antigen (CEA); Non-responders do not show at least a 20% decrease from baseline in CA19-9 or CEA.', 'OutcomeMeasurePopulationDescription': 'All participants who had at least one implantation of RENCA macrobeads, either at 8 macrobeads/kg body weight or 16 macrobeads/kg body weight.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'participants', 'OutcomeMeasureTimeFrame': 'Prior to Implantation and Day 7, Day 14, Day 21 and Day 28 after each implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Day 7', 'OutcomeGroupDescription': 'Tumor marker response at Day 7 after the first implantation.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Day 14', 'OutcomeGroupDescription': 'Tumor marker response at Day 14 after the first implantation.'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Day 21', 'OutcomeGroupDescription': 'Tumor marker response at Day 21 after the first implantation.'}, {'OutcomeGroupId': 'OG003', 'OutcomeGroupTitle': 'Day 28', 'OutcomeGroupDescription': 'Tumor marker response at Day 28 after the first implantation.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '20'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '21'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '13'}, {'OutcomeDenomCountGroupId': 'OG003', 'OutcomeDenomCountValue': '17'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Responder', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '13'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '9'}, {'OutcomeMeasurementGroupId': 'OG003', 'OutcomeMeasurementValue': '10'}]}}]}}, {'OutcomeClassTitle': 'Non-Responder', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '15'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '8'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '4'}, {'OutcomeMeasurementGroupId': 'OG003', 'OutcomeMeasurementValue': '7'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)', 'OutcomeMeasureDescription': 'Dose limiting toxicity (DLT) was defined as:\n\nany Grade 2 allergic reaction of generalized urticaria or any other Grade ≥ 3 allergic reaction;\nany Grade ≥ 3 infection and\nany Grade ≥ 3 local (intraperitoneal) reaction and any Grade ≥ 3 hematologic or non- hematologic reaction.\n\nThis definition of DLT is in accord with the NCI CTCAE v3.0.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Participants who observed DLT', 'OutcomeMeasureTimeFrame': '6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': '8 RENCA Macrobeads/kg Body Weight Implantation', 'OutcomeGroupDescription': 'RENCA macrobeads placement in abdominal cavity at 8 RENCA macrobeads/kg body weight.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': '16 RENCA Macrobeads/kg Body Weight Implantation', 'OutcomeGroupDescription': 'RENCA macrobeads placement in abdominal cavity at 16 RENCA macrobeads/kg body weight.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '25'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '6'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '5', 'EventsTimeFrame': '6 months', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'All Participants', 'EventGroupDescription': 'All participants who had at least one implantation of RENCA macrobeads, either at 8 macrobeads/kg body weight or 16 macrobeads/kg body weight.', 'EventGroupSeriousNumAffected': '20', 'EventGroupSeriousNumAtRisk': '31', 'EventGroupOtherNumAffected': '27', 'EventGroupOtherNumAtRisk': '31'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Implant site fluid collection', 'SeriousEventOrganSystem': 'Surgical and medical procedures', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Tear from mesh s/p hernia repair', 'SeriousEventOrganSystem': 'Surgical and medical procedures', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Intermittent fever', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Disease progression', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Diarrhea', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Vomiting', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Hypophagia', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Pleurodesis', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Pericardial effusion', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Hypotension, poor nutrition', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Aspiration', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Jaundice', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Abdominal distension', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Abdominal pain', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Transfusion', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Dehydration', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Gastrointestinal obstruction', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Pulmonary embolism', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Asthenia', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Blood creatinine increased', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Small intestinal obstruction', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Melena', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Hypotension', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Anemia', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Incision site pain', 'SeriousEventOrganSystem': 'Surgical and medical procedures', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Wound complication', 'SeriousEventOrganSystem': 'Surgical and medical procedures', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Hyponatremia', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Pain', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}, {'SeriousEventTerm': 'Hydronephrosis', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '31'}]}}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Abdominal distension', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Abdominal pain', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Abdominal pain upper', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Ascites', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Constipation', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Vomiting', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Asthenia', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '15', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Inflammation', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Pyrexia', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '11', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Incision site pain', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Hemoglobin decreased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Decreased appetite', 'OtherEventOrganSystem': 'Metabolism and nutrition disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Musculoskeletal chest pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Myalgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Dizziness', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Hemoptysis', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Hyperhidrosis', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Night sweats', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Rash', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Umbilical erythema', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '31'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Dr. Barry H. Smith, CEO', 'PointOfContactOrganization': 'The Rogosin Institute', 'PointOfContactEMail': 'bas2005@nyp.org', 'PointOfContactPhone': '212-746-1551'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4686', 'ConditionBrowseLeafName': 'Carcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4700', 'ConditionBrowseLeafName': 'Carcinoma, Renal Cell', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2737', 'ConditionBrowseLeafName': 'Adenocarcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9855', 'ConditionBrowseLeafName': 'Kidney Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4906', 'ConditionBrowseLeafName': 'Renal Cell Carcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4400', 'ConditionBrowseLeafName': 'Papillary Renal Cell Carcinoma', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 22, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03992833', 'OrgStudyIdInfo': {'OrgStudyId': '2016YFE0103000'}, 'Organization': {'OrgFullName': 'Tianjin Medical University Cancer Institute and Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Methods of Computed Tomography Screening and Management of Lung Cancer', 'OfficialTitle': 'Methods of Computed Tomography Screening and Management of Lung Cancer in Tianjin: A Population-based Cohort Study'}, 'StatusModule': {'StatusVerifiedDate': 'June 2019', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 1, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 18, 2019', 'StudyFirstSubmitQCDate': 'June 19, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 20, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 19, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 20, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Tianjin Medical University Cancer Institute and Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University Medical Center Groningen', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Shanghai Changzheng Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'European lung cancer screening studies using computed tomography (CT) have shown that a management protocol based on measuring lung nodule volume and volume doubling time (VDT) is more specific for early lung cancer detection than a diameter-based protocol. However, whether this also applies to a Chinese population is unclear. The aim of this study is to compare the diagnostic performance of a volume-based protocol with a diameter-based protocol for lung cancer detection and optimize the nodule management criteria for a Chinese population.', 'DetailedDescription': 'In this population-based study, participants will undergo a low-dose chest CT scan for two rounds. At baseline, the first CT scan will be performed in all participants and their data will be collected. One-year after the baseline, a second CT scan will be performed and data will be collected again. CT images of each participant will be read twice independently by two groups of readers after the baseline and 1-year follow-up scans. In the first reading, the detected lung nodules are evaluated for diameter and managed according to a routine diameter-based protocol. The clinical management of participants are based on the first reading. In the second reading, each scan will be interpreted again by radiologists, blinded to the first reading. Semi-automated volumetry software will be used. The lung nodules will be evaluated for volume and management will be simulated according to a European volume-based protocol. Participants will be followed up and any diagnosis of lung cancer and related information will be collected at the fourth year through the hospital information system and by contacting the participants or their relatives.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Lung Neoplasms', 'Computed Tomography', 'Mass Screening', 'Lung Nodules']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '4000', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'lung cancer screening', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will undergo a chest CT scan in the Department of Radiology at Tianjin Cancer Hospital. All scans will be performed using the same CT system: Definition AS. Two readings of the images will be performed. In the first image reading, the CT images will be read by specially trained Chinese resident radiologist and checked by one of two senior Chinese radiologists. Lung Cancer Screening (version 2. 2018) Guidelines of the National Comprehensive Cancer Network (NCCN) will be used for the management of lung nodules. This guideline recommends management of lung nodules based on diameter. In the second reading, a semi-automated volumetry software will be used to measure the volume and evaluate the other parameters of lung nodules.\n\nAt baseline and one year after baseline, data about general characteristics, risk factors of lung cancer, and health status of the participants will be collected.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: lung cancer screening']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'lung cancer screening', 'InterventionDescription': 'In the first reading, according to the NCCN lung cancer screening guideline, participants with a solid nodule≤ 5 mm in diameter will be referred to undergo follow-up CT 1 year after the baseline. Participants with a solid nodule 6-14 mm will be referred to undergo follow-up thorax CT 3-6 months after the baseline. Participants with a solid nodule ≥ 15 mm will be referred to a multidisciplinary team for clinical investigation.\n\nThe simulated management will be based on the volume of lung nodule and volume doubling time from the second reading, lung nodules will be reclassified according to the reference values from the European volume-based lung nodule management protocol. According to the European volume-based protocol, the solid and part-solid lung nodules will be reclassified into three groups: nodules with a volume < 100 mm3 (negative), nodules with a volume of 100-300 mm3 (indeterminate), and nodules with a volume > 300 mm3 (positive).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['lung cancer screening']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'number of clinically diagnosed lung cancer', 'PrimaryOutcomeDescription': 'The number of clinically diagnosed lung cancer will be collected through the hospital information system and by contacting the participants or their relatives using a questionnaire.', 'PrimaryOutcomeTimeFrame': 'at the fourth year from baseline'}, {'PrimaryOutcomeMeasure': 'number of lung cancer death', 'PrimaryOutcomeDescription': 'The number of lung cancer death will be collected through the hospital information system and by contacting the relatives of the participants using a questionnaire.', 'PrimaryOutcomeTimeFrame': 'at the fourth year from baseline'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAged 40-74 years;\nResident in the Hexi district of Tianjin city for at least 3 years;\nHaving no self-reported history of any malignant tumor.\n\nExclusion Criteria:\n\nPregnant woman will be excluded.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '74 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Zhaoxiang Ye, Professor', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+8622-23340123', 'CentralContactEMail': 'yezhaoxiang@163.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Zhaoxiang Ye, Professor', 'OverallOfficialAffiliation': 'Tianjin Medical University Cancer Institute and Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Tianjin Medical University Cancer Institute And Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Tianjin', 'LocationState': 'Tianjin', 'LocationZip': '300060', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zhaoxiang Ye, M.D. & Ph.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '8622-23340123', 'LocationContactEMail': 'yezhaoxiang@163.com'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000008175', 'ConditionMeshTerm': 'Lung Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000012142', 'ConditionAncestorTerm': 'Respiratory Tract Neoplasms'}, {'ConditionAncestorId': 'D000013899', 'ConditionAncestorTerm': 'Thoracic Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10324', 'ConditionBrowseLeafName': 'Lung Neoplasms', 'ConditionBrowseLeafAsFound': 'Lung Neoplasms', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14131', 'ConditionBrowseLeafName': 'Respiratory Tract Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15810', 'ConditionBrowseLeafName': 'Thoracic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10320', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14129', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 23, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01178736', 'OrgStudyIdInfo': {'OrgStudyId': 'WCF-2011-BRA-IND-CAM'}, 'Organization': {'OrgFullName': "Woman's Cancer Foundation", 'OrgClass': 'OTHER'}, 'BriefTitle': 'Early Detection of Cancers in Low Resource Countries', 'OfficialTitle': 'Efficacy of a Combined Program for Early Detection of Breast and Gynecological Cancers in Low Resource Countries'}, 'StatusModule': {'StatusVerifiedDate': 'August 2010', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2011'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2014', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'March 2014', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'August 6, 2010', 'StudyFirstSubmitQCDate': 'August 8, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 10, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 8, 2010', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 10, 2010', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyOldNameTitle': 'Mahesh Shetty, MD/President', 'ResponsiblePartyOldOrganization': "Woman's Cancer Foundation"}, 'LeadSponsor': {'LeadSponsorName': "Woman's Cancer Foundation", 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to implement a community-based combined program for early detection of breast, cervical, ovarian and endometrial cancer in low-resource countries delivered through a free standing or a mobile Well Woman Clinic. The goals of this program are to downstage cancers and improve mortality rates using low-cost early detection methods. These programs will be implemented in regions where early cancer detection strategies are not in place and cancers present at advanced stages with resultant high mortality. Currently, there are three target project sites: Cambodia (June 2011), India (June 2011), and Brazil (March 2011). Memorandums of Understanding have been secured with local health organizations in each region to establish clinic operations. Each clinic would serve an approximate target population of 100,000 amongst whom about 12,000 eligible women (4-5,000 annually) will be invited to be screened for breast and cervical cancer over a three-year time span.', 'DetailedDescription': 'We will study the use of sonographic screening in addition to Clinical Breast Examination in low resource settings where screening programs are not currently in place and establishing a population based mammographic screening would be expensive, resource intensive, and difficult if not impossible to implement. The effectiveness of the screening and diagnostic methodology used for early detection of breast, cervical, ovarian and endometrial cancers in low resource settings will be studied. The program would involve screening of asymptomatic women for Breast and Cervical cancer and diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer. Women in the age group of 30-59 yrs will be screened once every three years utilizing the following methods: Breast - clinical breast examination [CBE] and Sonography, followed by Fine needle aspiration biopsy (FNAB) of screen positive cases; Cervical - Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases (Single visit, screen and treat approach); Ovarian - Transvaginal sonogram and clinical evaluation; Endometrial - Transvaginal sonographic assessment of the endometrial stripe.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Neoplasms', 'Uterine Cervical Neoplasms', 'Ovarian Neoplasms', 'Endometrial Neoplasms']}, 'KeywordList': {'Keyword': ['neoplasms']}}, 'DesignModule': {'StudyType': 'Observational', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '36000', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer Screening and Diagnosis', 'ArmGroupDescription': 'Screening of asymptomatic women for Breast and Cervical cancer in the age group of 35-64 years. Diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer in the age group of 50-64 years.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Breast Cancer Screening and Diagnosis', 'Procedure: Cervical Cancer Screening and Diagnosis', 'Procedure: Ovarian Cancer Screening and Diagnosis', 'Procedure: Endometrial Cancer Screening and Diagnosis']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'Breast Cancer Screening and Diagnosis', 'InterventionDescription': 'Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer Screening and Diagnosis']}, 'InterventionOtherNameList': {'InterventionOtherName': ['FNAB', 'CBE', 'Ultrasound']}}, {'InterventionType': 'Procedure', 'InterventionName': 'Cervical Cancer Screening and Diagnosis', 'InterventionDescription': 'Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer Screening and Diagnosis']}, 'InterventionOtherNameList': {'InterventionOtherName': ['HPV DNA']}}, {'InterventionType': 'Procedure', 'InterventionName': 'Ovarian Cancer Screening and Diagnosis', 'InterventionDescription': 'Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer Screening and Diagnosis']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Ultrasound']}}, {'InterventionType': 'Procedure', 'InterventionName': 'Endometrial Cancer Screening and Diagnosis', 'InterventionDescription': 'Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer Screening and Diagnosis']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Ultrasound']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The Effectiveness of an Innovative, Low-Cost Screening and Diagnostic Methodology', 'PrimaryOutcomeDescription': 'This study will examine the effectiveness of an innovative, low-cost screening and diagnostic methodology used for combined early detection of breast and gynecological cancers in low resource regions where early cancer detection strategies are not in place and cancers currently are diagnosed at advanced stages with resultant high mortality.', 'PrimaryOutcomeTimeFrame': 'Three (3) year interval'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Effectiveness of CBE and Ultrasonography for Breast Cancer Detection', 'SecondaryOutcomeDescription': 'This study will examine the effectiveness of Clinical Breast Examination combined with Ultrasonography for breast cancer screening and detection in low resource settings where X-ray mammography proves not feasible in terms of cost, technology, and staff.', 'SecondaryOutcomeTimeFrame': 'Three (3) year interval'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nBreast Cancer: women age 35-64\nCervical Cancer: women age 30-59\nOvarian Cancer: symptomatic post menopausal women age 50-64\nEndometrial Cancer: symptomatic post menopausal women age 50-64\n\nExclusion Criteria:\n\nwomen under the age of 30', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Female', 'MinimumAge': '30 Years', 'MaximumAge': '64 Years', 'StdAgeList': {'StdAge': ['Adult']}, 'StudyPopulation': 'Brazil has two rural hospitals serving a population of roughly 46,000 people (Nova Andradina) inside Mato Grosso do Sul, which has a population of over 2 million. Cambodia has a population of over 1 million inside the Phnom Penh metropolitan area. India has a population of more than 1.3 million inside the state of Goa. According to the NFHS-2, nearly 30 percent of rural Goan women live 10 or more kilometers away from a primary health center.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Weiwei Yang, MD', 'OverallOfficialAffiliation': 'M.D. Anderson Cancer Center, University of Texas', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Diljeet K Singh, MD', 'OverallOfficialAffiliation': 'Northwestern University Feinberg School of Medicine', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Adhemar Longatto Filho, MD', 'OverallOfficialAffiliation': 'University of Sao Paolo', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Hospital de Cancer de Barretos', 'LocationCity': 'Sao Paolo', 'LocationCountry': 'Brazil', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Edmundo Mauad, MD, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '(17) 3321-6600', 'LocationContactEMail': 'ecmauad@hcancerbarretos.com.br'}, {'LocationContactName': 'Edmundo Mauad, MD, PhD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Sihanouk Hospital Center of Hope, Hope Worldwide Cambodia', 'LocationCity': 'Phnom Penh', 'LocationCountry': 'Cambodia', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Cornelia Haener, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '(855-23) 882-484', 'LocationContactEMail': 'corneliahaener@sihosp.org'}, {'LocationContactName': 'Shelly Malhotra', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'shellymalhotra@sihosp.org'}, {'LocationContactName': 'Cornelia Haener, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Manipal Healthcare Group', 'LocationCity': 'Goa', 'LocationCountry': 'India', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'R.G. Pinto, MD', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'rgwpinto@gmail.com'}, {'LocationContactName': 'Sharmila Sardesai, MD', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'R. G. Pinto, MD', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': "Eugene D'Silva, MD", 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '15755947', 'ReferenceType': 'background', 'ReferenceCitation': 'Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA. 2005 Mar 9;293(10):1245-56. doi: 10.1001/jama.293.10.1245.'}, {'ReferencePMID': '18477789', 'ReferenceType': 'background', 'ReferenceCitation': 'Kuhl CK. The "coming of age" of nonmammographic screening for breast cancer. JAMA. 2008 May 14;299(18):2203-5. doi: 10.1001/jama.299.18.2203. No abstract available.'}, {'ReferencePMID': '18477782', 'ReferenceType': 'background', 'ReferenceCitation': 'Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bohm-Velez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K; ACRIN 6666 Investigators. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008 May 14;299(18):2151-63. doi: 10.1001/jama.299.18.2151. Erratum In: JAMA. 2010 Apr 21;303(15):1482.'}, {'ReferencePMID': '12355001', 'ReferenceType': 'background', 'ReferenceCitation': 'Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2002 Oct;225(1):165-75. doi: 10.1148/radiol.2251011667.'}, {'ReferencePMID': '11719658', 'ReferenceType': 'background', 'ReferenceCitation': 'Kaplan SS. Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology. 2001 Dec;221(3):641-9. doi: 10.1148/radiol.2213010364.'}, {'ReferencePMID': '19009372', 'ReferenceType': 'background', 'ReferenceCitation': 'Tohno E, Ueno E, Watanabe H. Ultrasound screening of breast cancer. Breast Cancer. 2009;16(1):18-22. doi: 10.1007/s12282-008-0082-8. Epub 2008 Nov 14.'}, {'ReferencePMID': '19339719', 'ReferenceType': 'background', 'ReferenceCitation': 'Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. HPV screening for cervical cancer in rural India. N Engl J Med. 2009 Apr 2;360(14):1385-94. doi: 10.1056/NEJMoa0808516.'}, {'ReferencePMID': '19339726', 'ReferenceType': 'background', 'ReferenceCitation': 'Schiffman M, Wacholder S. From India to the world--a better way to prevent cervical cancer. N Engl J Med. 2009 Apr 2;360(14):1453-5. doi: 10.1056/NEJMe0901167. No abstract available.'}, {'ReferencePMID': '11427139', 'ReferenceType': 'background', 'ReferenceCitation': 'Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001 Jun 27;285(24):3107-15. doi: 10.1001/jama.285.24.3107. Erratum In: JAMA 2001 Sep 5;286(9):1026.'}, {'ReferencePMID': '17154394', 'ReferenceType': 'background', 'ReferenceCitation': 'Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007 Jan 15;109(2):221-7. doi: 10.1002/cncr.22371.'}, {'ReferencePMID': '15187051', 'ReferenceType': 'background', 'ReferenceCitation': 'Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004 Jun 9;291(22):2705-12. doi: 10.1001/jama.291.22.2705.'}, {'ReferencePMID': '19282241', 'ReferenceType': 'background', 'ReferenceCitation': 'Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.'}, {'ReferencePMID': '17373668', 'ReferenceType': 'background', 'ReferenceCitation': 'van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, Pavlik EJ, Kryscio RJ. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer. 2007 May 1;109(9):1887-96. doi: 10.1002/cncr.22594.'}, {'ReferencePMID': '17523157', 'ReferenceType': 'background', 'ReferenceCitation': 'Van den Bosch T, Van Schoubroeck D, Domali E, Vergote I, Moerman P, Amant F, Timmerman D. A thin and regular endometrium on ultrasound is very unlikely in patients with endometrial malignancy. Ultrasound Obstet Gynecol. 2007 Jun;29(6):674-9. doi: 10.1002/uog.4031.'}, {'ReferencePMID': '9809732', 'ReferenceType': 'background', 'ReferenceCitation': 'Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, Brand R, Grady D. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998 Nov 4;280(17):1510-7. doi: 10.1001/jama.280.17.1510.'}, {'ReferencePMID': '12039131', 'ReferenceType': 'background', 'ReferenceCitation': 'Tabor A, Watt HC, Wald NJ. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstet Gynecol. 2002 Apr;99(4):663-70. doi: 10.1016/s0029-7844(01)01771-9.'}, {'ReferencePMID': '16084259', 'ReferenceType': 'background', 'ReferenceCitation': 'Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005 Aug 6-12;366(9484):491-505. doi: 10.1016/S0140-6736(05)67063-8.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000009369', 'ConditionMeshTerm': 'Neoplasms'}, {'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}, {'ConditionMeshId': 'D000010051', 'ConditionMeshTerm': 'Ovarian Neoplasms'}, {'ConditionMeshId': 'D000002583', 'ConditionMeshTerm': 'Uterine Cervical Neoplasms'}, {'ConditionMeshId': 'D000016889', 'ConditionMeshTerm': 'Endometrial Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}, {'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000010049', 'ConditionAncestorTerm': 'Ovarian Diseases'}, {'ConditionAncestorId': 'D000000291', 'ConditionAncestorTerm': 'Adnexal Diseases'}, {'ConditionAncestorId': 'D000005833', 'ConditionAncestorTerm': 'Genital Neoplasms, Female'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000006058', 'ConditionAncestorTerm': 'Gonadal Disorders'}, {'ConditionAncestorId': 'D000014594', 'ConditionAncestorTerm': 'Uterine Neoplasms'}, {'ConditionAncestorId': 'D000002577', 'ConditionAncestorTerm': 'Uterine Cervical Diseases'}, {'ConditionAncestorId': 'D000014591', 'ConditionAncestorTerm': 'Uterine Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Neoplasms', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12126', 'ConditionBrowseLeafName': 'Ovarian Neoplasms', 'ConditionBrowseLeafAsFound': 'Ovarian Neoplasms', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4982', 'ConditionBrowseLeafName': 'Uterine Cervical Neoplasms', 'ConditionBrowseLeafAsFound': 'Uterine Cervical Neoplasms', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M18387', 'ConditionBrowseLeafName': 'Endometrial Neoplasms', 'ConditionBrowseLeafAsFound': 'Endometrial Neoplasms', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7015', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12124', 'ConditionBrowseLeafName': 'Ovarian Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2795', 'ConditionBrowseLeafName': 'Adnexal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8097', 'ConditionBrowseLeafName': 'Genital Neoplasms, Female', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7014', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8315', 'ConditionBrowseLeafName': 'Gonadal Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16494', 'ConditionBrowseLeafName': 'Uterine Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4977', 'ConditionBrowseLeafName': 'Uterine Cervical Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16491', 'ConditionBrowseLeafName': 'Uterine Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4352', 'ConditionBrowseLeafName': 'Ovarian Cancer', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M20472', 'InterventionBrowseLeafName': 'Acetic Acid', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M303191', 'InterventionBrowseLeafName': 'Retinol acetate', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T436', 'InterventionBrowseLeafName': 'Acetic Acid', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'Vi', 'InterventionBrowseBranchName': 'Vitamins'}]}}}}}, {'Rank': 24, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01130285', 'OrgStudyIdInfo': {'OrgStudyId': 'UTHSC - 11'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1RC2CA148572-01', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/1RC2CA148572-01'}]}, 'Organization': {'OrgFullName': 'University of Toledo', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Validation of a Multi-gene Test for Lung Cancer Risk', 'OfficialTitle': 'Validation of a Multi-gene Test for Lung Cancer Risk'}, 'StatusModule': {'StatusVerifiedDate': 'October 2020', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2011'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 24, 2010', 'StudyFirstSubmitQCDate': 'May 24, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 25, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 16, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 19, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of Toledo Health Science Campus', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to determine the validity of a multi-gene Lung Cancer Risk Test (LCRT). In the process, the investigators will establish a bank of NBEC samples and corresponding blood samples from individuals demographically at increased risk for lung cancer.', 'DetailedDescription': 'Because more than 160,000 individuals die of lung cancer/year in the United States alone, it is important to use the best possible methods to determine whether increased surveillance of individuals at highest risk for lung cancer will result in reduced lung cancer mortality. The Lung Cancer Risk Test (LCRT) proposed for evaluation promises to accurately identify the 10-15% of the population that is most susceptible to lung cancer based on genetic predisposition. More than 90 million individuals in the United States alone are demographically at high risk for lung cancer and potential candidates for increased surveillance.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Lung Cancer']}, 'KeywordList': {'Keyword': ['Lung Cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Normal bronchial epithelial cell (NBEC) RNA. NBEC samples were obtained by bronchoscopic brushing after informed consent to this project was obtained. RNA was extracted and frozen in aliquots then archived. Two aliquots, were prepared for most subjects. In most cases, there were more than 1 microgram of RNA per aliquot.'}, 'EnrollmentInfo': {'EnrollmentCount': '403', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Non-Lung Cancer, Heavy Smoker', 'ArmGroupDescription': 'Subjects will be ≥ 50 years of age and have a ≥ 20 pack year smoking history and will be either healthy volunteers or individuals undergoing diagnostic bronchoscopy, with absence of lung cancer documented at the time of enrollment.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: Lung Cancer Risk Test']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Genetic', 'InterventionName': 'Lung Cancer Risk Test', 'InterventionDescription': 'Measurement of gene expression in normal bronchial epithelial cells obtained at time of bronchoscopy.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Non-Lung Cancer, Heavy Smoker']}, 'InterventionOtherNameList': {'InterventionOtherName': ['LCRT']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Accuracy of LCRT to predict incidental lung cancer', 'PrimaryOutcomeDescription': 'Time of diagnosis of incidental lung cancer will be compared to value of the investigational device, the Lung Cancer Risk Test (LCRT).', 'PrimaryOutcomeTimeFrame': 'from time of enrollment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\n20 or more pack year smoking history\nclinical need for diagnostic bronchoscopy or consent to study driven bronchoscopy\n\nExclusion Criteria:\n\nLung Cancer within 3 months after the date of enrollment', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '50 Years', 'MaximumAge': '90 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'The study population will consist of subjects aged 50 to 90 and with 20 or more pack year smoking history, who are determined not to have lung cancer at the time of enrollment or within three months after the date of enrollment, and either a) volunteer for the study driven bronchoscopy, or b) have standard of care clinical need for diagnostic bronchoscopy (e.g. they may present with respiratory symptoms or abnormal test results consistent with the need for bronchoscopy).', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'James Willey, MD', 'OverallOfficialAffiliation': 'University of Toledo Health Science Campus', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'National Jewish Health', 'LocationCity': 'Denver', 'LocationState': 'Colorado', 'LocationZip': '80206', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Michigan', 'LocationCity': 'Ann Arbor', 'LocationState': 'Michigan', 'LocationZip': '48109', 'LocationCountry': 'United States'}, {'LocationFacility': 'Henry Ford', 'LocationCity': 'Detroit', 'LocationState': 'Michigan', 'LocationZip': '48202', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mayo Clinic', 'LocationCity': 'Rochester', 'LocationState': 'Minnesota', 'LocationZip': '55905', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cleveland Clinic Foundation', 'LocationCity': 'Cleveland', 'LocationState': 'Ohio', 'LocationZip': '44195', 'LocationCountry': 'United States'}, {'LocationFacility': 'Ohio State University', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43221', 'LocationCountry': 'United States'}, {'LocationFacility': 'The Toledo Hospital', 'LocationCity': 'Toledo', 'LocationState': 'Ohio', 'LocationZip': '43606', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mercy St. Vincent Medical Center', 'LocationCity': 'Toledo', 'LocationState': 'Ohio', 'LocationZip': '43608', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Toledo, Health Science Campus', 'LocationCity': 'Toledo', 'LocationState': 'Ohio', 'LocationZip': '43614', 'LocationCountry': 'United States'}, {'LocationFacility': 'Medical University of South Carolina', 'LocationCity': 'Charleston', 'LocationState': 'South Carolina', 'LocationZip': '29425', 'LocationCountry': 'United States'}, {'LocationFacility': 'Tennessee Valley Veterans Admin.', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37232', 'LocationCountry': 'United States'}, {'LocationFacility': 'Vanderbilt', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37232', 'LocationCountry': 'United States'}, {'LocationFacility': 'Inova Fairfax Hospital', 'LocationCity': 'Falls Church', 'LocationState': 'Virginia', 'LocationZip': '22042', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26801409', 'ReferenceType': 'derived', 'ReferenceCitation': 'Crawford EL, Levin A, Safi F, Lu M, Baugh A, Zhang X, Yeo J, Khuder SA, Boulos AM, Nana-Sinkam P, Massion PP, Arenberg DA, Midthun D, Mazzone PJ, Nathan SD, Wainz R, Silvestri G, Tita J, Willey JC. Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository. BMC Pulm Med. 2016 Jan 22;16:16. doi: 10.1186/s12890-016-0178-4.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000008175', 'ConditionMeshTerm': 'Lung Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000012142', 'ConditionAncestorTerm': 'Respiratory Tract Neoplasms'}, {'ConditionAncestorId': 'D000013899', 'ConditionAncestorTerm': 'Thoracic Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10324', 'ConditionBrowseLeafName': 'Lung Neoplasms', 'ConditionBrowseLeafAsFound': 'Lung Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14131', 'ConditionBrowseLeafName': 'Respiratory Tract Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15810', 'ConditionBrowseLeafName': 'Thoracic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10320', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14129', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 25, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05350059', 'OrgStudyIdInfo': {'OrgStudyId': '233756'}, 'Organization': {'OrgFullName': 'University of Oxford', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The HIFUB Study (HIFU in Breast Cancer)', 'OfficialTitle': 'Study of High Intensity Focused Ultrasound (HIFU) in the Treatment of Early Breast Cancer', 'Acronym': 'HIFUB'}, 'StatusModule': {'StatusVerifiedDate': 'April 2022', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 1, 2022', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 1, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'November 1, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 1, 2022', 'StudyFirstSubmitQCDate': 'April 26, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 27, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 26, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 27, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of Oxford', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'High Intensity Focused Ultrasound (HIFU) is a new method of treating solid tumours by thermally ablating them. It has been used in a number of different types of cancers but there is little information on its use in invasive breast cancer (IBC). The investigators aim to assess the efficacy and safety of HIFU in the treatment of IBC.\n\nIn this study, fifteen otherwise healthy women diagnosed with small, early stage IBC will be treated with HIFU prior to conventional surgical treatment. The effects of HIFU on the resected tumour will be analysed pathologically and correlated with radiological findings. Immune response and participant experience will also be evaluated'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['breast cancer', 'high intensity frequency ultrasound']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignInterventionModelDescription': 'High Intensity Focused Ultrasound (HIFU) treatment to breast cancer', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '15', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'High Intensity Focused Ultrasound (HIFU) treatment to breast cancer', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'High-Intensity Focused Ultrasound (HIFU) in the Treatment of Early Breast Cancer prior to surgical resection', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: High Intensity Focused Ultrasound (HIFU) to the Breast Cancer']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'High Intensity Focused Ultrasound (HIFU) to the Breast Cancer', 'InterventionDescription': 'Breast cancer will be ablated using high intensity frequency ultrasound prior to breast surgery', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['High Intensity Focused Ultrasound (HIFU) treatment to breast cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'To evaluate the efficacy of the HIFU treatment in achieving cancer ablation', 'PrimaryOutcomeDescription': 'Volume of tumour ablation on histological examination of the surgically excised specimen expressed as a percentage of pretreatment tumour volume on MRI scan.', 'PrimaryOutcomeTimeFrame': '1 month following intervention'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'To evaluate the sensitivity and specificity of post-HIFU MRI in assessing HIFU efficacy when compared with histological evaluation of the resected specimen', 'SecondaryOutcomeDescription': 'Volume of tumour ablation on histological examination of the surgically excised specimen and volume of tumour ablation on post-treatment MRI expressed as a percentages of pretreatment tumour volume on MRI scan.', 'SecondaryOutcomeTimeFrame': '1 month following intervention'}, {'SecondaryOutcomeMeasure': 'Assessment of the safety and toxicity of HIFU ablation', 'SecondaryOutcomeDescription': 'Using the Common Toxicity Criteria for Adverse Events (CTCAC) Grading Guideline (which scores any occurring adverse events with grades between 1 to 5, where higher grades indicate worse outcomes)', 'SecondaryOutcomeTimeFrame': '1 month following intervention'}, {'SecondaryOutcomeMeasure': 'To evaluate patient acceptance of HIFU treatment', 'SecondaryOutcomeDescription': 'Using 1 to 1 qualitative interviews with participants.', 'SecondaryOutcomeTimeFrame': '1 month following intervention'}]}}, 'EligibilityModule': {'EligibilityCriteria': "Inclusion Criteria:\n\nParticipant is willing and able to give informed consent for participation in the trial.\nFemale, aged 18 years or above.\nHistologically confirmed breast cancer (invasive ductal cancer) by core biopsy, which is suitable for surgical resection.\nParticipants must have one non-metastatic, clinically palpable, invasive breast cancer measuring ≤2cm in its largest dimension, which can be visualised using diagnostic ultrasound.\nAll participants must have an adequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.\nAdequate ECG, haematological, renal and hepatic function, as indicated, as would be required for imaging and surgery.\nIn the Investigator's opinion, is able and willing to comply with all trial requirements.\n\nExclusion Criteria:\n\nFemale participant who is pregnant.\nSignificant renal or hepatic impairment.\nAn inadequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.\nUnable to visualize lesion or tumour boundaries clearly on ultrasound.\nSubjects with tumours lying less than 5mm to overlying skin or less than 5mm to the underlying muscle on the diagnostic scan.\nAny uncontrolled illness or any other medical problem that would preclude surgery.\nThe presence of any contraindication for magnetic resonance imaging, e.g. the presence of a heart pacemaker, a metallic foreign body (metal sliver) in the eye, or an aneurysm clip in the brain or severe claustrophobia.", 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Female', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Gurdeep S Mannu, MRCSEd DPhil', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+44(0)1865 289452', 'CentralContactEMail': 'gurdeep.mannu@ndph.ox.ac.uk'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Gurdeep S Mannu, MRCSEd DPhil', 'OverallOfficialAffiliation': 'University of Oxford', 'OverallOfficialRole': 'Principal Investigator'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 26, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00948337', 'OrgStudyIdInfo': {'OrgStudyId': 'NCS-09-266'}, 'Organization': {'OrgFullName': 'National Cancer Center, Korea', 'OrgClass': 'OTHER_GOV'}, 'BriefTitle': 'A Study With Health Educational Material on Health Promotion in Cancer Survivors', 'OfficialTitle': 'A Randomized Controlled Trial on the Effect of Intervention With Health Educational Material on Knowledge, Attitude, and Behavior in Cancer Survivors'}, 'StatusModule': {'StatusVerifiedDate': 'September 2009', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2009', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2010', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 28, 2009', 'StudyFirstSubmitQCDate': 'July 28, 2009', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 29, 2009', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'February 25, 2010', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 26, 2010', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyOldNameTitle': 'National Cancer Center', 'ResponsiblePartyOldOrganization': 'National Cancer Center'}, 'LeadSponsor': {'LeadSponsorName': 'National Cancer Center, Korea', 'LeadSponsorClass': 'OTHER_GOV'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to provide educational material to promote screening for second primary cancer for the intervention group, or educational material to instruct appropriate use of dietary supplement for the control group.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stomach Cancer', 'Colon Cancer', 'Thyroid Cancer', 'Breast Cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '326', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Photonovella of Secondary Cancer Screening', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Brochure of Secondary Cancer Screening']}}, {'ArmGroupLabel': 'Photonovella of Dietary Suppelment of Cancer survivor', 'ArmGroupType': 'Active Comparator', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Brochure of Secondary Cancer Screening']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Brochure of Secondary Cancer Screening', 'InterventionDescription': 'One kind of printed educational material', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Photonovella of Dietary Suppelment of Cancer survivor', 'Photonovella of Secondary Cancer Screening']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Screening behavior for second primary cancer', 'PrimaryOutcomeTimeFrame': 'After 1 yr'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Knowledge and attitudes of Secondary cancer screening and dietary supplement', 'SecondaryOutcomeTimeFrame': 'In 2 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAge >=18, <80\nCancer survivors (pathologically confirmed)\nFinished primary treatment (surgery, radiotherapy, chemotherapy)\n>= 1 year from cancer diagnosis\nNo evidence of recurrence, metastasis, and second primary cancer\nNo evidence of hereditary cancer\nECOG 0,1,2\nAbility in reading Korean educational material\n\nExclusion Criteria:\n\nECOG 3,4\nDisagree with the investigators study purpose', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'National Cancer Center', 'LocationCity': 'Goyang', 'LocationState': 'Gyeonggi', 'LocationZip': '410-769', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Samsung Medical Center', 'LocationCity': 'Seoul', 'LocationZip': '135-710', 'LocationCountry': 'Korea, Republic of'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '22479375', 'ReferenceType': 'derived', 'ReferenceCitation': 'Shin DW, Cho J, Kim YW, Oh JH, Kim SW, Chung KW, Lee WY, Lee JE, Guallar E, Lee WC. Efficacy of an educational material on second primary cancer screening practice for cancer survivors: a randomized controlled trial. PLoS One. 2012;7(3):e33238. doi: 10.1371/journal.pone.0033238. Epub 2012 Mar 29.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000013274', 'ConditionMeshTerm': 'Stomach Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000013272', 'ConditionAncestorTerm': 'Stomach Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15875', 'ConditionBrowseLeafName': 'Thyroid Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15870', 'ConditionBrowseLeafName': 'Thyroid Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15216', 'ConditionBrowseLeafName': 'Stomach Neoplasms', 'ConditionBrowseLeafAsFound': 'Stomach Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15214', 'ConditionBrowseLeafName': 'Stomach Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T5486', 'ConditionBrowseLeafName': 'Stomach Cancer', 'ConditionBrowseLeafAsFound': 'Stomach Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 27, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05239325', 'OrgStudyIdInfo': {'OrgStudyId': 'Nigeria World Cancer Walk 2022'}, 'Organization': {'OrgFullName': 'AshtaYoga, LLC', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Step up to Health, Nigeria! Impact of 2022 World Cancer Day Walk on Health Behaviors Among Nigerians', 'OfficialTitle': "Step up to Health, Nigeria! Utilizing Information From Abuja's 2022 World Cancer Day Walk for Equity-based Cancer Prevention Interventions"}, 'StatusModule': {'StatusVerifiedDate': 'February 2022', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 5, 2022', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 5, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'February 5, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 3, 2022', 'StudyFirstSubmitQCDate': 'February 3, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 14, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 3, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 14, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'AshtaYoga, LLC', 'LeadSponsorClass': 'INDUSTRY'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Project PINKBLUE, Health and Psychological Trust Centre', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'University Of Nigeria Teaching Hospital', 'CollaboratorClass': 'NETWORK'}, {'CollaboratorName': 'Vaughn A. Lewis Institute for Research and Innovation', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Columbia University', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Cancer awareness is a critical element of cancer prevention and control. Creating public awareness on risk factors, preventative strategies, and the importance of early screening is the foundation upon which a cancer control program must be constructed. The purpose of this study is to describe the sociodemographic and risk factor distribution of the Abuja, Nigeria "World Cancer Day Walk" participants according to their motive for participating in the event (free cancer screening versus fun/activities), and secondarily, to investigate the impact of the event on educating attendees from the general population about cancer prevention and screening, in particular the importance of being physically active and maintaining a healthy body weight. Obesity is a known risk factor contributing to the development of cancer and NCD\'s.', 'DetailedDescription': 'Cancer awareness is a critical element of cancer prevention and control. Creating public awareness on risk factors, preventative strategies, and the importance of early screening is the foundation upon which a cancer control program must be constructed. Ideally, efforts should include knowledge of the problem and its solutions, a group of people who respect and care for the populations they want to serve, and importantly, resources.\n\nNigeria is the most populous black nation in the world with a population of over 196 million, more than 500 ethnic groups, 380 languages, and a diverse range of cultural, traditional and religious beliefs. Nigeria constitutes approximately 20% of the population of Africa and slightly more than 50% of the West African population. Cancer is a critical public health problem in this population. Nigeria is a major contributor to the overall cancer burden on the continent with 72,000 cancer deaths in 2012 and 115,950 new cases of cancer and 70,327 cancer deaths in 2018. Nigerians also have one of the world\'s poorest 5-year cancer survival rates.\n\nBreast cancer is the most frequently diagnosed cancer in Nigerian women and the leading cause of cancer death in Nigeria, with an estimated 26,310 new cases and 11,564 deaths in 2018 (44% death rate). Breast cancer incidence in this population historically has been low but is now increasing. By comparison, in the United States (population 329 million) there were 30,700 new breast cancer cases and 6,310 deaths in 2016. Another female cancer - cervical, is 99% preventable, however, it is the second leading cause of cancer death in Nigeria with over 26 deaths every day. By comparison, in the United States between 2013-2017, the average annual death rate of cervical cancer was 2.3% per 100,000 (age adjusted to the 2000 US standard population). Prostate cancer is the leading cause of cancer deaths in Nigerian men with 13,078 new cases (which is 29.1%) and 5,806 deaths in 2018. The age-standardized incidence rates (ASR) for prostate cancer was 32.8 new cases per 100,000 men and mortality rate was about 16.3 per 100,000 men in 2018. On a daily basis, at least 15 men die of prostate cancer in Nigeria. By comparison, in the United States prostate cancer death rates in men declined 52% from 1993 to 2017.\n\nStrategies for prevention and early detection are imperative in the reduction of cancer death rates globally; awareness campaigns (such as the annual "World Cancer Day Walk" in Abuja) are critical to educate the general population on cancer risk factors, the benefits of screening and early detection, and to offer free cancer screening to all populations.\n\nThis study "Step up to Health, Nigeria! Impact of the 2022 World Cancer Day Walk on Health Behaviors Among Nigerians" will describe the sociodemographic and risk factor distribution of the Abuja, Nigeria "World Cancer Day Walk" participants according to their motive for participation, and secondarily, to investigate the impact of the event on educating attendees from the general population about cancer prevention and screening, in particular the importance of being physically active and maintaining a healthy body weight. Obesity is a known risk factor contributing to the development of cancer and NCD\'s.\n\nThe study will take place in Abuja, Nigeria on Feb 5, 2022 during the 8th Annual "World Cancer Day Walk" sponsored by Project PINK BLUE, a registered Nigerian nonprofit cancer organization, viz. Health & Psychological Trust Centre (CAC/IT/NO 73960).\n\nThe purpose of the "World Cancer Day Walk" is to create awareness and advocate for better cancer care for Nigerians. The event offers free breast, cervical, and prostate cancer screenings; heath education and information about cancer risk reduction; and group physical activities that include a 5km Walk, 10km Race, 20km Ride, 5km Skate, 50km Cycle, and Marathon.\n\nOn the day of the event, the in-field research team will distribute a voluntary, one-page questionnaire to the anticipated 5,000 event participants to ascertain demographic information, cancer risk factors, motivations for attending the event, and lifestyle behaviors. Subjects will be recruited voluntarily onsite during the event following inclusion and exclusion criteria. Informed consent will be taken.\n\nThe questionnaire is 27 questions. Part one (eight questions) captures basic demographic information. Part two (six questions) captures personal and family history of cancer and cancer screening. Part three (six questions) captures information about the motivation for attending the event (free screening vs. fun/activities) and preferred ways to receive healthy lifestyle and cancer risk reduction / prevention information. Part four (five questions) captures lifestyle behaviors. Part five is the validated seven question International Physical Activity Questionnaire (IPAQ) instrument that measures physical activity and reduced sedentary behavior over the last seven days.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer Prevention']}, 'KeywordList': {'Keyword': ['Nigeria', 'Cancer Prevention', 'Cancer Screening', 'Physical Activity', 'Health Literacy', 'Health Behaviors']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '527', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention Group', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants having previously attended at least once in previous years the "World Cancer Day Walk" will be considered as the group exposed to the health education intervention (returning).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: World Cancer Day Walk']}}, {'ArmGroupLabel': 'Control Group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'The control/non-exposed group will be the participants who are attending the "World Cancer Day Walk" for the first time in 2022 (first timers) and have not yet received health education information.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'World Cancer Day Walk', 'InterventionDescription': 'Health literacy education (cancer prevention and healthy lifestyle) and free breast, prostate, cervical cancer screening', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention Group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Compare the sociodemographic and risk factor distribution of the "World Cancer Day Walk" participants who are attending the event for "free breast, cervical or prostate screening" with participants who are attending for "fun and activities".', 'PrimaryOutcomeDescription': 'The brief survey instrument captures participant sociodemographic characteristics. Participants are asked to provide known risk factors for cancer and to indicate if they are attending for "free cancer screening" or "fun/activities".', 'PrimaryOutcomeTimeFrame': 'Pre-intervention'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Compare physical activity metrics between those who are attending "World Cancer Day Walk" for the first time versus participants who have attended a previous "World Cancer Day Walk".', 'SecondaryOutcomeDescription': 'The International Physical Activity Questionnaire (IPAQ) measures self-reported time spent per week doing vigorous and moderate activity in the last 7 days; time spent walking in the last 7 days, and time spent sitting down in the last 7 days. It is a "fill in the blank" survey instrument.', 'SecondaryOutcomeTimeFrame': 'Pre-intervention'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nMale and Female age 18 and over\nWilling and able to converse and/or read and write in either English or Pidgin English.\n\nExclusion Criteria:\n\nParticipants who are unable to provide informed consent to the study due to cognitive or physical impairment, based on self-report.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Leigh Leibel, MSc', 'CentralContactRole': 'Contact', 'CentralContactPhone': '212-305-8029', 'CentralContactEMail': 'LL3125@cumc.columbia.edu'}, {'CentralContactName': 'Runcie CW Chidebe, MSc', 'CentralContactRole': 'Contact', 'CentralContactPhone': '2348036053866', 'CentralContactEMail': 'runcie.chidebe@projectpinkblue.org'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Leigh Leibel, MSc', 'OverallOfficialAffiliation': 'Columbia University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Project Pink Blue', 'LocationCity': 'Abuja', 'LocationCountry': 'Nigeria'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '10854470', 'ReferenceType': 'background', 'ReferenceCitation': 'Rimer BK, Glassman B. Is there a use for tailored print communications in cancer risk communication? J Natl Cancer Inst Monogr. 1999;(25):140-8. doi: 10.1093/oxfordjournals.jncimonographs.a024190.'}, {'ReferencePMID': '21416787', 'ReferenceType': 'background', 'ReferenceCitation': 'Oyetunde MO. Perception and management of cancer among the Yoruba in Ibadan, Nigeria. Afr J Med Med Sci. 2010 Sep;39(3):181-92.'}, {'ReferencePMID': '31552112', 'ReferenceType': 'result', 'ReferenceCitation': 'Jemal A, Brawley OW. Increasing cancer awareness and prevention in Africa. Ecancermedicalscience. 2019 Jul 25;13:939. doi: 10.3332/ecancer.2019.939. eCollection 2019.'}, {'ReferencePMID': '26284233', 'ReferenceType': 'result', 'ReferenceCitation': 'Jedy-Agba EE, Oga EA, Odutola M, Abdullahi YM, Popoola A, Achara P, Afolayan E, Banjo AA, Ekanem IO, Erinomo O, Ezeome E, Igbinoba F, Obiorah C, Ogunbiyi O, Omonisi A, Osime C, Ukah C, Osinubi P, Hassan R, Blattner W, Dakum P, Adebamowo CA. Developing National Cancer Registration in Developing Countries - Case Study of the Nigerian National System of Cancer Registries. Front Public Health. 2015 Jul 30;3:186. doi: 10.3389/fpubh.2015.00186. eCollection 2015.'}, {'ReferencePMID': '28759387', 'ReferenceType': 'result', 'ReferenceCitation': 'Brawley OW. The role of government and regulation in cancer prevention. Lancet Oncol. 2017 Aug;18(8):e483-e493. doi: 10.1016/S1470-2045(17)30374-1. Epub 2017 Jul 26.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}}}}, {'Rank': 28, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01428167', 'OrgStudyIdInfo': {'OrgStudyId': '11-112'}, 'Organization': {'OrgFullName': 'The University of Texas Medical Branch, Galveston', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Hashimotos Thyroiditis and Thyroid Cancer', 'OfficialTitle': 'Is There Any Association Between Thyroid Cancer and Hashimotos Thyroiditis?', 'Acronym': 'Thyroid Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'June 2012', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2011'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 2012', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 10, 2011', 'StudyFirstSubmitQCDate': 'September 1, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 2, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'June 5, 2012', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 6, 2012', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'The University of Texas Medical Branch, Galveston', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': "Thyroid cancer (TC) is the most common endocrine malignancy. The association between inflammation and cancer is well established but the association between thyroiditis (inflammation of thyroid gland) especially Hashimoto's thyroiditis (HT) and thyroid cancer remains controversial. Chronic inflammation leads to a repeated cycle of cellular damage and subsequent healing which contributes to inappropriate cell proliferation and subsequent neoplastic transformation. One of the most common forms of Thyroiditis is Hashimoto's thyroiditis which is a chronic autoimmune inflammatory disease affects almost 5% of the population and is more common in women. For the first time, Dailey and Lindsay reported in 1955 an increased association between Hashimoto's Thyroiditis (HT) and thyroid cancer. They reported 35 thyroid cancers in 278 patients with Hashimoto's Thyroiditis, a prevalence of 17.7% which they considered higher than the general population . Since then, various studies have been done, some studies have reported an increased risk of malignancy in Hashimoto's thyroiditis; others have failed to find an association. Most of the studies that have been done to identify the association between Hashimoto's thyroiditis and thyroid cancer are retrospective. The purpose of this pilot case-control study is to identify the association of Hashimoto's thyroiditis and thyroid cancer, to determine if the presence of Hashimoto's thyroiditis has any affect on the complication of thyroidectomy and prognostic factors of thyroid cancer.", 'DetailedDescription': "AIM1: To identify the association between Hashimoto's Thyroiditis and thyroid cancer by comparing the prevalence of thyroid cancer in patients with Hashimoto's Thyroiditis and patients without Hashimoto's Thyroiditis who undergoing Thyroidectomy for a variety of indications in UTMB in 12 months period of the study.\n\nAIM2: Compare Ultrasound (US) characteristics preoperatively in two groups of patients with thyroid cancer and Hashimoto's thyroiditis and patients with thyroid cancer but without Hashimoto's thyroiditis.\n\nAIM3: compare prognostic factors including tumor diameter, vascular and capsular invasion, extra thyroid invasion, lymph node metastasis, distant metastasis in two groups of patients including patients with thyroid cancer and Hashimoto's thyroiditis and patients with thyroid cancer but without Hashimoto's thyroiditis.\n\nAIM4: Compare the complication of surgery in patients with thyroid cancer and Hashimoto's Thyroiditis and patients with thyroid cancer but without Hashimoto's thyroiditis.\n\nAIM5: Compare inflammatory factors in two group of patient with thyroid cancer and Hashimoto's Thyroiditis and patients with thyroid cancer but without Hashimoto's thyroiditis.\n\nCoordinator in the ear, nose and throat (ENT) clinic will notify the assigned investigator about any patient admitted to UTMB for thyroidectomy. The investigator will meet and interview the patient to obtain the consent and fill out a data collection sheet which will include demographic data, history of thyroid disease, history of thyroid medications, history of radiotherapy of head and neck or radioactive iodine therapy, family history of thyroid disease or thyroid cancer. Patients meeting the inclusion criteria will be given the opportunity to participate in the study. All patients will have blood drawn. Blood samples will be stored in Endocrinology lab to measure Anti-TPO, Ca, PTH and inflammatory factors at the end of study. A chart review of all enrolled patients will be performed to obtain details of the preoperative thyroid U/S characteristics including echogenicity, texture, calcification, vascularity and TSH and Free T4 level. Postoperative histopathology evaluation will be done by a pathologist experienced in thyroid pathology. The diagnosis of Hashimoto's thyroiditis (HT ) will be made based on histopathology finding and AntiTPO level. The histopathology criteria for Hashimoto's thyroiditis (HT) must be seen in a normal region of the thyroid gland, distinct from the site of thyroid cancer. UTMB Subjects will be divided to two groups, subjects with Hashimoto's Thyroiditis and subjects without Hashimoto's Thyroiditis (control group).The prevalence of thyroid cancer will be compared in these two groups."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Thyroid Cancer', 'Hashimotos Thyroiditis']}, 'KeywordList': {'Keyword': ['Thyroid cancer', 'Hashimotos thyroiditis', 'Thyroidectomy', 'Anti-inflammatory factors']}}, 'DesignModule': {'StudyType': 'Observational', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'Plasma samples with be stored to measure anti inflammatory factors.'}, 'EnrollmentInfo': {'EnrollmentCount': '26', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Thyroidectomy', 'ArmGroupDescription': 'All patients undergoing thyroidectomy for a variety of indications.'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': "Number of Participants with thyroid cancer and Hashimoto's thyroiditis .", 'PrimaryOutcomeDescription': "To identify the association between Hashimoto's Thyroiditis and thyroid cancer by comparing the prevalence of thyroid cancer in patients with Hashimoto's Thyroiditis and patients without Hashimoto's Thyroiditis who undergoing Thyroidectomy for a variety of indications in UTMB in 12 months period of the study.", 'PrimaryOutcomeTimeFrame': 'one year'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Thyroid Ultrasound characteristics in participants with thyroid cancer in the setting of thyroid inflammation.', 'SecondaryOutcomeDescription': "Compare Ultrasound (US) characteristics preoperatively in two groups of patients with thyroid cancer and Hashimoto's thyroiditis and patients with thyroid cancer but without Hashimoto's thyroiditis.", 'SecondaryOutcomeTimeFrame': 'one year'}, {'SecondaryOutcomeMeasure': 'Prognostic factors of thyroid cancer', 'SecondaryOutcomeDescription': "compare prognostic factors including tumor diameter, vascular and capsular invasion, extra thyroid invasion, lymph node metastasis, distant metastasis in two groups of patients including patients with thyroid cancer and Hashimoto's thyroiditis and patients with thyroid cancer but without Hashimoto's thyroiditis.", 'SecondaryOutcomeTimeFrame': 'one year'}, {'SecondaryOutcomeMeasure': 'Complication of thyroidectomy( Thyroid surgery)', 'SecondaryOutcomeDescription': "Compare the complication of surgery in patients with thyroid cancer and Hashimoto's Thyroiditis and patients with thyroid cancer but without Hashimoto's thyroiditis.", 'SecondaryOutcomeTimeFrame': '2 weeks'}, {'SecondaryOutcomeMeasure': 'Inflammatory factors level in Plasma sample', 'SecondaryOutcomeDescription': "Compare inflammatory factors in two group of patient with thyroid cancer and Hashimoto's Thyroiditis and patients with thyroid cancer but without Hashimoto's thyroiditis.", 'SecondaryOutcomeTimeFrame': 'one year'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAll patients undergoing thyroidectomy for a variety of indications at University of Texas Medical Branch in Galveston between June 2011-May 2012\nAge 18-80 years old\n\nExclusion Criteria:\n\nHistory of previous radiotherapy to head and neck and History of radioactive iodine therapy', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'All patients undergoing thyroidectomy for a variety of indications at University of Texas Medical Branch in Galveston between June 2011-May 2012', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'LaDale St Clair, MD', 'OverallOfficialAffiliation': 'University of Texas', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Texas Medical Branch, Galveston , Endocrine Department', 'LocationCity': 'Galveston', 'LocationState': 'Texas', 'LocationZip': '77555', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000013964', 'ConditionMeshTerm': 'Thyroid Neoplasms'}, {'ConditionMeshId': 'D000013959', 'ConditionMeshTerm': 'Thyroid Diseases'}, {'ConditionMeshId': 'D000013966', 'ConditionMeshTerm': 'Thyroiditis'}, {'ConditionMeshId': 'D000050031', 'ConditionMeshTerm': 'Hashimoto Disease'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000006258', 'ConditionAncestorTerm': 'Head and Neck Neoplasms'}, {'ConditionAncestorId': 'D000013967', 'ConditionAncestorTerm': 'Thyroiditis, Autoimmune'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M15875', 'ConditionBrowseLeafName': 'Thyroid Neoplasms', 'ConditionBrowseLeafAsFound': 'Thyroid Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15870', 'ConditionBrowseLeafName': 'Thyroid Diseases', 'ConditionBrowseLeafAsFound': 'Thyroid', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M25309', 'ConditionBrowseLeafName': 'Hashimoto Disease', 'ConditionBrowseLeafAsFound': 'Hashimoto Thyroiditis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15877', 'ConditionBrowseLeafName': 'Thyroiditis', 'ConditionBrowseLeafAsFound': 'Thyroiditis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M7014', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7015', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8500', 'ConditionBrowseLeafName': 'Head and Neck Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15878', 'ConditionBrowseLeafName': 'Thyroiditis, Autoimmune', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T3542', 'ConditionBrowseLeafName': 'Lymphomatous Thyroiditis', 'ConditionBrowseLeafAsFound': 'Hashimoto Thyroiditis', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M3369', 'InterventionBrowseLeafName': 'Anti-Inflammatory Agents', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Infl', 'InterventionBrowseBranchName': 'Anti-Inflammatory Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 29, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00897832', 'OrgStudyIdInfo': {'OrgStudyId': 'VICC GI 0666'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'P30CA068485', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/P30CA068485'}, {'SecondaryId': 'VU-VICC-GI-0666'}, {'SecondaryId': 'VU-VICC-061225'}]}, 'Organization': {'OrgFullName': 'Vanderbilt-Ingram Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer', 'OfficialTitle': 'Developing Predictive Markers of Therapeutic Response in Pancreatic Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'March 2013', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2007'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2007', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2007', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 9, 2009', 'StudyFirstSubmitQCDate': 'May 9, 2009', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 12, 2009', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 2, 2013', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 5, 2013', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'A Bapsi Chakravarthy, MD', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor; Radiation Oncologist', 'ResponsiblePartyInvestigatorAffiliation': 'Vanderbilt-Ingram Cancer Center'}, 'LeadSponsor': {'LeadSponsorName': 'Vanderbilt-Ingram Cancer Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.\n\nPURPOSE: This laboratory study is looking at biomarkers in predicting response to treatment in patients who have undergone surgery for pancreatic cancer.', 'DetailedDescription': 'OBJECTIVES:\n\nTo determine if a method of extracting and identifying biomarkers (i.e., secreted cytokines and growth factors) from tissues of the quantity obtained from typical biopsy can now be applied in the setting of pancreatic cancer\nTo correlate pre-treatment biomarkers with recurrence, overall survival, and tumor response to radiotherapy and chemotherapy in patients with pancreatic cancer.\n\nOUTLINE: Tumor tissue specimens are obtained from the Vanderbilt Ingram Cancer Center Human Tissue Acquisition Core and analyzed for biomarkers (e.g., integrity of DNA repair pathways as analyzed by Rad51 and phosphorylated DNA-PK foci formation). The biomarkers are correlated with clinical outcomes (recurrence, overall survival, and tumor response to treatment).\n\nPatients are followed for recurrence, relapse, and death from disease.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Pancreatic Cancer']}, 'KeywordList': {'Keyword': ['pancreatic cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '50', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'pancreatic cancer', 'ArmGroupDescription': 'Patients with pancreatic cancer', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: laboratory biomarker analysis']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'laboratory biomarker analysis', 'InterventionDescription': 'Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), it will be determined if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['pancreatic cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Determination if a method of extracting and identifying biomarkers from tissues of the quantity obtained from typical biopsy can be applied in the setting of pancreatic cancer', 'PrimaryOutcomeTimeFrame': '1 year following final patient data'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria\n\nDiagnosis of pancreatic cancer\nExcess tissue collected at the time of routine surgery for pancreatic cancer must be available for analysis\n\nExclusion criteria\n\nNone known', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'Patients with pancreatic cancer', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'A. Bapsi Chakravarthy, MD', 'OverallOfficialAffiliation': 'Vanderbilt-Ingram Cancer Center', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Vanderbilt-Ingram Cancer Center - Cool Springs', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37064', 'LocationCountry': 'United States'}, {'LocationFacility': 'Vanderbilt-Ingram Cancer Center at Franklin', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37064', 'LocationCountry': 'United States'}, {'LocationFacility': 'Vanderbilt-Ingram Cancer Center', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37232-6838', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010190', 'ConditionMeshTerm': 'Pancreatic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010182', 'ConditionAncestorTerm': 'Pancreatic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12262', 'ConditionBrowseLeafName': 'Pancreatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7015', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12254', 'ConditionBrowseLeafName': 'Pancreatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7014', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4387', 'ConditionBrowseLeafName': 'Pancreatic Cancer', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 30, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05645471', 'OrgStudyIdInfo': {'OrgStudyId': '004181'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'AD-2020C3-21171', 'SecondaryIdType': 'Other Grant/Funding Number', 'SecondaryIdDomain': 'Patient-Centered Outcomes Research Institute (PCORI)'}]}, 'Organization': {'OrgFullName': 'University of South Florida', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Together After Cancer', 'OfficialTitle': 'Comparative Effectiveness of Together After Cancer Among Breast Cancer Survivors and Their Intimate Partners'}, 'StatusModule': {'StatusVerifiedDate': 'December 2022', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 1, 2023', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 1, 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'March 1, 2026', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'October 12, 2022', 'StudyFirstSubmitQCDate': 'December 1, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 9, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'December 1, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 9, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Dinorah Martinez Tyson, PhD, MPH, MA', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'University of South Florida'}, 'LeadSponsor': {'LeadSponsorName': 'University of South Florida', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'H. Lee Moffitt Cancer Center and Research Institute', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'University of Miami Sylvester Comprehensive Cancer Center', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'AdventHealth', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'University of Central Florida', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'To evaluate the impact of an adapted online, self-help relationship intervention (supplemented with brief coach calls) for survivors of breast cancer and their partners. Couples will be randomized to receive either the online intervention (Together after Cancer) or usual care (UC) and assessed at baseline, end of the program, and 3 months after randomization.', 'DetailedDescription': 'As the fastest-growing and largest ethnic minority group, projections indicate that 128 million Latinos will reside in the United States by 2050; with one in three Latinos receiving a diagnosis of cancer during his/her lifetime. Latino cancer survivors have a lower quality of life, experience distress due to strained spousal and family relationships, have poorer physical health, and have more depression, pain, and fatigue when compared to non-Latinos. In addition, emotional and mental well-being between Latino survivors and their partners is related, with partners also experiencing increased distress and physical symptoms. Research has shown that couples-based psychosocial programs improve the quality of life and emotional and physical health of cancer survivors and their partners. Yet, much of the in this area has focused on non-Hispanic Whites. Features of Latino culture may influence and interact with social, psychosocial, health care, and clinical factors that influence cancer-related outcomes. Our goal is to add to this literature and develop a program for Latina breast cancer survivors and their partners that is culturally meaningful and relevant and responds to their needs and concerns.\n\nSpecifically, investigators plan to culturally adapt a widely-available and effective online couple intervention, OurRelationship (ORI), for Latina breast cancer survivors and their intimate partners. The online OR program - which can be done on a smartphone, tablet, or computer - was developed to serve as an online tool to help couples solve a specific relationship problem they selected. Investigators will adapt the OR program to be useful for Latina breast cancer survivors and their intimate partners using feedback from focus groups with patients, community partners, and research advisors. Once investigators have completed our adaptation, the plan to test the impact of the adapted program, Together after Cancer, using a type of study called a randomized controlled trial where participants will be randomly allocated to either receive the culturally adapted intervention or usual care. Investigators are interested in learning if couples in the group that are assigned to the intervention program report changes in their relationship functioning, psychological functioning (depression, anxiety, and perceived stress), and cancer-related quality of life (pain, fatigue, body image, and quality of life) compared to couples who are assigned to the UC group.\n\nThrough this comparative study, investigators expect to establish effective strategies that can be implemented in clinic and community settings to improve psychological functioning, relationship functioning, and quality of life. Investigators are enthusiastic about the potential for the intervention program to easily reach cancer Latina survivors around the nation, due to the online format and ease of access from any location. Throughout the project, investigators will continue to engage our local partners to ensure that the study procedures and outcomes are meaningful to all stakeholders.\n\nInvestigators are using patient-centered approaches to offer a culturally relevant web-based program that cancer survivors and their partners can access from the comfort of their homes.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer', 'Quality of Life', 'Communication']}, 'KeywordList': {'Keyword': ['Breast Cancer, Latino, Couples,']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'The study aims to test the impact of the adapted Together After Cancer intervention using a cluster randomized controlled trial (cRCT), with individuals nested within couples and randomization occurring at the couple level to see if it is more effective than usual care (UC).', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '480', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Together After Cancer Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': "Couples randomized into the intervention will participate in the program which is approximately 8-10 hours of web-based online content to be delivered over the course of 5-8 weeks. The online program can be done on a smartphone, tablet, or computer. In this program, partners complete the majority of the program on their own (to make it more flexible) and come together for 2-3 key conversations with their partner. In addition to the online content, couples will receive up to 100 minutes of scheduled research check-in/coaching calls from a research assistant to check-in. These coach calls will occur via a video chat via Zoom or, if not possible given a couple's technology limitations, over the phone. The coach calls serve several purposes: a) helping couples stay accountable to staying on the recommended schedule of activity completion; b) addressing any technical or program questions the couple has; and c) collecting research data as couples move through the program.", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Together After Cancer']}}, {'ArmGroupLabel': 'Usual Care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Participants randomized into UC, will consist of primary referral sources for breast cancer survivorship. At AdventHealth, Moffitt, and Sylvester Cancer centers, usual care consists of screening items assessing relationship/intimacy issues as a practical need. If these items are endorsed, referrals are provided to supportive oncology. At Sylvester, the Cancer Support Services offers caregiver support groups, "mental well-being" services (i.e., individual therapy), and an online support community for patients, caregivers, and survivors. At Moffitt, Support Services offers psychotherapy, support groups for patients, support groups for family/caregivers of cancer patients, and a program to help patients talk with their children about their diagnosis. At AdventHealth, patients are offered referrals to social services and psychoeducational programs like HEAL. However, none of the sites have services designed to focus on issues specific to patients\' romantic relationships.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Together After Cancer', 'InterventionDescription': 'This is an online couples intervention for Latina breast cancer survivors and their intimate partners.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Together After Cancer Intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Evaluate the changes in the quality of life of the breast cancer survivor across the pre to post to follow-up measurement time points.', 'PrimaryOutcomeDescription': 'The FACT-B is a 37-item instrument designed to measure five domains of HRQOL in breast cancer patients which focuses on physical, social, emotional, functional well-being as well as a breast-cancer subscale. Each question is rated on a four-point scale from 0=Not at all to 4=Very Much. The scale has an internal consistency of an α=.90, with subscale alpha coefficients ranging from .63 to .86.', 'PrimaryOutcomeTimeFrame': 'Baseline, 2 and 5 month'}, {'PrimaryOutcomeMeasure': 'Evaluate the changes in the satisfaction of the relationship between couples who are married across the pre to post to follow-up measurement time points.', 'PrimaryOutcomeDescription': "The Couples Satisfaction Index (CSI) is a 32- item instrument assess one's satisfaction in a relationship which assess the presence of problems between individuals and the intensity of such problems. Each question is rated on a six-point scale from 0=Extremely Unhappy to 6=Perfect. The scale as an internal consistency α=0.92.", 'PrimaryOutcomeTimeFrame': 'Baseline, 2 and 5 month'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Evaluate the changes in the cancer-related body image of the breast cancer survivor across the pre to post to follow-up measurement time points.', 'SecondaryOutcomeDescription': "The Body Image Scale is a 10-item measure developed to measure cognitive, affective, and evaluative variables of an individual's concept of body image and reflects relatively time-stable physical aspects, rather than current physical conditions. Each question is rated on a four-point scale from 1=Not at all to 4=Very much. The scale has an internal consistency is α=.90.", 'SecondaryOutcomeTimeFrame': 'Baseline, 2 and 5 month'}, {'SecondaryOutcomeMeasure': 'Evaluate the changes in cancer-related fatigue of the breast cancer across the pre to post to follow-up measurement time points.', 'SecondaryOutcomeDescription': "The Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue is a 7-item scale that assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Each question is rated on a four-point scale from 1=Not at all to 4=Very much. The scale has an internal consistency is α=0.79.", 'SecondaryOutcomeTimeFrame': 'Baseline, 2 and 5 month'}, {'SecondaryOutcomeMeasure': 'Evaluate changes in the quality of life among the intimate partner across the pre to post to follow-up measurement time points.', 'SecondaryOutcomeDescription': 'The Functional Assessment of Cancer Therapy-General Pop. (FACT-GP) a shortened, 21-item that assess the perceived levels of health-related quality of life in the partner. Each question is rated on a five-point scale from 0=Not at all to 4=Very much. The scale has an internal consistency is α=0.89.', 'SecondaryOutcomeTimeFrame': 'Baseline, 2 and 5 month'}, {'SecondaryOutcomeMeasure': 'Evaluate changes in emotional distress-depression among breast cancer survivor and their intimate partner across the pre to post to follow-up measurement time points.', 'SecondaryOutcomeDescription': 'The PROMIS: Emotional Distress-Depression is an 8-item survey related to depressed mood in the past 7 days. Each question is rated on a five-point scale from 1=Never to 5=Always. The internal consistency is α=0.97.', 'SecondaryOutcomeTimeFrame': 'Baseline, 2, 5 month'}, {'SecondaryOutcomeMeasure': 'Evaluate changes in emotional distress-anxiety among breast cancer survivors and their intimate partner across the pre to post to follow-up measurement time points.', 'SecondaryOutcomeDescription': 'The PROMIS: Emotional Distress - Anxiety is a 6-item survey that assess self-reported fear, anxious misery, hyperarousal and somatic symptoms related to arousal. Each question is rated on a five-point scale from 1=Never to 5=Always. The internal consistency is α=0.96.', 'SecondaryOutcomeTimeFrame': 'Baseline, 2, 5 month'}, {'SecondaryOutcomeMeasure': 'Evaluate changes in stress among breast cancer survivors and their intimate partner across the pre to post to follow-up measurement time points.', 'SecondaryOutcomeDescription': "The Perceived Stress Scale (PSS) is a 10-item that measures the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. Each question is rated on a five-point scale from 0=never to 4 very often. The internal consistency is α=0.74.", 'SecondaryOutcomeTimeFrame': 'Baseline, 2, 5 month'}, {'SecondaryOutcomeMeasure': 'Evaluate changes in feeling cared and valued as a person among breast cancer survivors and their intimate partner across the pre to post to follow-up measurement time points.', 'SecondaryOutcomeDescription': 'The PROMIS: Emotional Support is a 4-item that assess perceived feelings of being cared and valued as a person; having confidant relationships. Each question is rated on a five-point scale from 1=Never to 5=Always. The internal consistency is α=0.98.', 'SecondaryOutcomeTimeFrame': 'Baseline, 2, 5 month'}, {'SecondaryOutcomeMeasure': 'Evaluate changes in supportive communication among breast cancer survivors and their intimate partner across the pre to post to follow-up measurement time points.', 'SecondaryOutcomeDescription': 'The Dyadic Coping Inventory is a 37-item instrument designed to measure perceived communication and dyadic coping (supportive, delegated, negative, and joint) that occurs in close relationships when one or both partners are stressed. The internal consistency is α=0.86.', 'SecondaryOutcomeTimeFrame': 'Baseline, 2, 5 month'}, {'SecondaryOutcomeMeasure': 'Evaluate changes in negative communication between the breast cancer survivor and their intimate partner across the pre to post to follow-up measurement time points.', 'SecondaryOutcomeDescription': 'The Conflictual Communication Index is a 7-item measure developed to assess negative communication. Participants were asked to report how often communication conflict occurred during the past month on a Likert-type scale from 1=Never to 4= Often. The internal consistency is α=0.89.', 'SecondaryOutcomeTimeFrame': 'Baseline, 2, 5 month'}, {'SecondaryOutcomeMeasure': 'Evaluate changes in intimacy between the breast cancer survivor and their intimate partner across the pre to post to follow-up measurement time points.', 'SecondaryOutcomeDescription': 'The Personal Assessment of Intimacy in Relationships (PAIR) is a 6-item measure of that assesses comfort, intimacy, and satisfaction with sexual relationship of a couple. Each question is rated on a five-point scale from 1=Very rarely to 5=Very often. The internal consistency is α=0.86.', 'SecondaryOutcomeTimeFrame': 'Baseline, 2, 5 month'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria for Latina Breast Cancer Survivors:\n\nBe 18 years of age and older\nSelf-identify as Latina/Hispanic\nSpanish speaker\nPrimary diagnosis of breast cancer in the last five years\nCompleted initial treatment\nBe married or in a committed relationship of six months duration or longer\nWillingness to be randomized and followed for approximately 5 months\nAccess to the internet or a smartphone, tablet, or computer\n\nInclusion criteria for Intimate Partners:\n\nBe 18 years of age or older\nBe married or in a committed relationship of six months duration or longer with a Latina Breast Cancer Survivor diagnosed who was diagnosed with breast cancer in the last five years\nWillingness to be randomized and followed for approximately 5 months\nAccess to the internet or a smartphone, tablet, or computer\n\nCouples will be eligible to participate if they also meet the following:\n\nMeet the inclusion criteria listed above for Latina Breast Cancer Survivors and Intimate Partners\nBoth partners are willing to participate in the study\nAdditionally, to be eligible, the Latina Breast Cancer Survivors must reside in Florida\n\nExclusion Criteria:\n\n-', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Dinorah Martinez Tyson, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '8139740723', 'CentralContactEMail': 'dmtyson@usf.edu'}, {'CentralContactName': 'Brian D. Doss, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '3052841101', 'CentralContactEMail': 'bdoss@miami.edu'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T6034', 'ConditionBrowseLeafName': 'Quality of Life', 'ConditionBrowseLeafAsFound': 'Quality of Life', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 31, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03573661', 'OrgStudyIdInfo': {'OrgStudyId': 'D16196'}, 'Organization': {'OrgFullName': 'Dartmouth-Hitchcock Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers', 'OfficialTitle': 'A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers', 'Acronym': 'BCL'}, 'StatusModule': {'StatusVerifiedDate': 'May 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 24, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 24, 2021', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 5, 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 19, 2018', 'StudyFirstSubmitQCDate': 'June 19, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 29, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 21, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 25, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Richard J. Barth,Jr.', 'ResponsiblePartyInvestigatorTitle': 'MD', 'ResponsiblePartyInvestigatorAffiliation': 'Dartmouth-Hitchcock Medical Center'}, 'LeadSponsor': {'LeadSponsorName': 'Dartmouth-Hitchcock Medical Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'Yes'}, 'DescriptionModule': {'BriefSummary': "The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer.", 'DetailedDescription': 'The primary purpose of the study is to determine whether a device called the Breast Cancer Locator (BCL) accurately identifies the location of cancer in the breast. The Breast Cancer Locator is a plastic bra-like form that gives the surgeon information about the location of the cancer in the breast. The location information is derived from an MRI which is obtained with the patient lying flat on their back (just as they are on an operating room table). The BCL is then custom-made for the patient using 3D printing technology.\n\nThe surgeon can feel the cancer, and the surgeon will remove the cancer by feeling the edges of it as the surgeon would normally. Since the cancer can be felt, the surgeon does not need an image guidance system such as the BCL to locate the cancer in the breast. Other women may have breast cancers that cannot be felt, but are only identified by mammography or MRI. If the BCL proves to accurately localize breast cancer, it may be a useful guide for the surgeon for these other women.\n\nAdditionally, the investigators want to determine whether this technology can be successfully employed at multiple sites and what, if any, complications occur during surgery as a result of using this device. The BCL has been used in 19 patients at Dartmouth with no complications.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Palpable Breast Cancer']}, 'KeywordList': {'Keyword': ['Breast Conserving Surgery', 'Breast Imaging', 'Breast Cancer Locator', 'Supine MRI']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Device Feasibility', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '18', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast Cancer Locator (BCL)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Breast Cancer Locator (BCL)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Breast Cancer Locator (BCL)', 'InterventionDescription': "This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Breast Cancer Locator (BCL)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The proportion of patients who had the localization wire placed within the cancer on the specimen mammogram', 'PrimaryOutcomeDescription': 'Yes/No answer from Radiologist. Final measure will be % of cases rated Yes (wire deployed within the cancer on specimen mammogram).', 'PrimaryOutcomeTimeFrame': 'Within approximately 60 Days post-surgery (all measures are collected by the time of patient follow-up visit within approximately 60 days after surgery, and recorded by the surgeon and radiologist in Case Report Forms (CRF forms).'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Whether the study Radiologist can accurately define boundaries of the tumor from the supine MRI images', 'SecondaryOutcomeDescription': 'Yes/No answer from Radiologist. Final measure will be % of cases rated Yes (tumor segregated accurately from supine MRI). The data is recorded by the radiologist on the CRF form.', 'SecondaryOutcomeTimeFrame': 'Within approximately 60 days following surgery'}, {'SecondaryOutcomeMeasure': 'Time from supine MRI to delivery of the Breast Cancer Locator (BCL) device to the surgeon', 'SecondaryOutcomeDescription': 'Unit of measure is in days. Final measure will be average days to delivery among all patients. The data is recorded by the surgeon on the CRF form.', 'SecondaryOutcomeTimeFrame': 'Within approximately 60 days following surgery'}, {'SecondaryOutcomeMeasure': 'Whether the BCL allowed the surgeon to successfully mark in/on the breast skin surface the items he or she needs to see during the surgery, including tumor edges and locations where wires will be placed', 'SecondaryOutcomeDescription': 'Yes/No answer from Surgeon. Final measure will be % of cases rated Yes (BCL enabled surgeon to successfully place all cues). The data is recorded by the surgeon on the CRF form.', 'SecondaryOutcomeTimeFrame': 'Within approximately 60 days following surgery'}, {'SecondaryOutcomeMeasure': 'Lumpectomy specimen volumes', 'SecondaryOutcomeDescription': 'Unit of measure is in mL, calculated by water displacement. Final measure will be average volume (mL) among all patients. The data is recorded by the study sponsor, Cairn Surgical, on the CRF form.', 'SecondaryOutcomeTimeFrame': 'Within approximately 60 days following surgery'}, {'SecondaryOutcomeMeasure': 'Operative times (Average time per operation)', 'SecondaryOutcomeDescription': 'Unit of measure is in minutes. Final measure will be average operative time (min.) among all patients. Data is collected by the surgeon from operative notes and placed in the CRF form.', 'SecondaryOutcomeTimeFrame': 'Within approximately 60 days following surgery'}, {'SecondaryOutcomeMeasure': 'The tumor margins, which the pathologist measures (as the distance from the tumor to the specimen edge)', 'SecondaryOutcomeDescription': 'Unit of measure is in cm. Final measure will be average margin (in cm) among all patients. Data is collected by the surgeon from the pathology report and reported in the CRF form.', 'SecondaryOutcomeTimeFrame': 'Within approximately 60 days following surgery'}, {'SecondaryOutcomeMeasure': 'Complications from surgery', 'SecondaryOutcomeDescription': "Surgeon to list any complications - which could include infections or bruising. Final measure will be % of patients with complications. Data is collected from the surgeon either post-operatively, if there were operative complications; or at the post-operative follow-up appointment with the patient, if she reports any complications then. It is also possible this data could be collected at any time between surgery and follow up appointment by the patient calling the surgeon's office to report it. The surgeon records this data in the CRF form.", 'SecondaryOutcomeTimeFrame': 'Within approximately 60 days following surgery'}, {'SecondaryOutcomeMeasure': 'Surgeon satisfaction with the technical aspects of surgery guided by the Breast Cancer Locator', 'SecondaryOutcomeDescription': 'Yes/No answer. Final measure will be % of surgeons who say Yes to satisfaction with the procedure. Data is collected from the surgeon and reported in the CRF form.', 'SecondaryOutcomeTimeFrame': 'Within approximately 60 days following surgery'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAge > 18 years.\nHistologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ.\nPatient desire to undergo breast surgery (lumpectomy or non-skin sparing mastectomy).\nAbility to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted.\nThe cancer enhances on prone breast MRI imaging\nThe cancer is visible on mammography.\n\nExclusion Criteria:\n\nAbsolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes.\nSevere claustrophobia.\nContraindication to use of gadolinium-based intravenous contrast, including life- threatening allergy or compromised renal function (creatinine > 2.0).\nHistory of median sternotomy.\nPregnancy. Patient attestation that they are not pregnant will be acceptable.\nPatients receiving neoadjuvant chemotherapy.', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Richard J Barth, Jr., MD', 'OverallOfficialAffiliation': 'Dartmouth-Hitchcock Medical Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Lahey Hospital & Medical Center (Lahey Clinic)', 'LocationCity': 'Burlington', 'LocationState': 'Massachusetts', 'LocationZip': '01805', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cheshire Medical Center', 'LocationCity': 'Keene', 'LocationState': 'New Hampshire', 'LocationZip': '03431', 'LocationCountry': 'United States'}, {'LocationFacility': 'Dartmouth Hitchcock Medical Center', 'LocationCity': 'Lebanon', 'LocationState': 'New Hampshire', 'LocationZip': '03756', 'LocationCountry': 'United States'}, {'LocationFacility': 'St. Joseph Hospital', 'LocationCity': 'Nashua', 'LocationState': 'New Hampshire', 'LocationZip': '03060', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 32, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03662633', 'OrgStudyIdInfo': {'OrgStudyId': '2018-TJ-BCD'}, 'Organization': {'OrgFullName': 'Tongji Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Diagnosis Value of SEMA4C in Breast Cancer', 'OfficialTitle': 'Diagnosis Value of SEMA4C in Breast Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'October 2022', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 1, 2023', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 1, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 1, 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'September 3, 2018', 'StudyFirstSubmitQCDate': 'September 5, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 7, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'October 18, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 20, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Qinglei Gao', 'ResponsiblePartyInvestigatorTitle': 'Clinical Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Tongji Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Tongji Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Hubei Cancer Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Qilu Hospital of Shandong University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Wuhan Central Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Xiangyang Central Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': "The First People's Hospital of Jingzhou", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The First Affiliated Hospital with Nanjing Medical University', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Breast cancer remains the most common cancer in women worldwide. Early diagnosis can greatly improve the prognosis. To date, imaging examination is still the most important diagnostic and grading tool for breast cancer. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The study is undertaken to evaluate the diagnostic efficiency of SEMA4C.', 'DetailedDescription': 'Breast cancer remains the most common cancer in women worldwide, with approximately 1.68 million new cases, and 0.52 million deaths, annually. Meanwhile the incidence of breast cancer continues to increase. Early diagnosis and access to optimum treatment are crucial to reduce mortality associated with breast cancer. Currently, mammography and breast ultrasonography are essential for the detection and diagnosis of disease, and breast magnetic resonance imaging is the choice to estimate the extent of disease and guide appropriate treatment. However, there is no robust biomarkers for early detection of breast cancer.\n\nSemaphorin4C (SEMA4C) has been previously identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs) using in situ laser capture microdissection of lymphatic vessels, followed by cDNA microarray analysis. Moreover, membrane-bound SEMA4C is cleaved by matrix metalloproteinase (MMPs) to release a soluble form of this protein. Therefore, this prospective project aims to assess the early diagnostic value of SEMA4C as a biomarker for breast cancer.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Neoplasm Female']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'serum'}, 'EnrollmentInfo': {'EnrollmentCount': '2300', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast cancer group', 'ArmGroupDescription': 'Patients who have histologically confirmed new diagnosis of breast cancer are recruited.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Breast cancer group']}}, {'ArmGroupLabel': 'Benign breast tumor group', 'ArmGroupDescription': 'Patients who have histologically confirmed new diagnosis of benign breast tumors are recruited.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Benign breast tumor group']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test', 'InterventionName': 'Breast cancer group', 'InterventionDescription': 'All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Breast cancer group']}}, {'InterventionType': 'Diagnostic Test', 'InterventionName': 'Benign breast tumor group', 'InterventionDescription': 'All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Benign breast tumor group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Diagnostic potential of SEMA4C as a biomarker for breast cancer', 'PrimaryOutcomeDescription': 'Analyzing the predictive value of SEMA4C in the diagnosis of breast cancer.', 'PrimaryOutcomeTimeFrame': 'At the time of inclusion'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Serum SEMA4C, Mammography, breast US and MRI in comparison and combination to distinguish breast cancer from benign breast tumor', 'SecondaryOutcomeDescription': 'Compare and combine the diagnostic performances of Serum SEMA4C, traditional mammography, ultrasonography, and contrast-enhanced MR imaging in the assessment of breast cancer', 'SecondaryOutcomeTimeFrame': 'At the time of inclusion'}]}}, 'EligibilityModule': {'EligibilityCriteria': "Inclusion Criteria:\n\nReceiving no treatment before diagnosis\nEstablishing Diagnosis according to biopsy or surgery\n\nExclusion Criteria:\n\nPatients who are not mentally capable of giving written informed consent\nClinical data missing\nSerum samples doesn't qualified\nPatients with a diagnosis of other severe acute or chronic medical conditions that may interfere with the interpretation of the study results", 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Participants including patients with benign breast tumors and patients with breast cancer. All cases were confirmed histopathologically according to the WHO Classification of Tumors.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Qinglei Gao, MD, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '13871127473', 'CentralContactEMail': 'qingleigao@hotmail.com'}, {'CentralContactName': 'Ding Ma, MD, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '13886090620', 'CentralContactEMail': 'dingma424@126.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Qinglei Gao, MD, PhD', 'OverallOfficialAffiliation': 'Tongji Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '27401250', 'ReferenceType': 'background', 'ReferenceCitation': 'Wei JC, Yang J, Liu D, Wu MF, Qiao L, Wang JN, Ma QF, Zeng Z, Ye SM, Guo ES, Jiang XF, You LY, Chen Y, Zhou L, Huang XY, Zhu T, Meng L, Zhou JF, Feng ZH, Ma D, Gao QL. Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis By Highly Expressing and Secreting SEMA4C. Clin Cancer Res. 2017 Jan 1;23(1):214-224. doi: 10.1158/1078-0432.CCR-16-0741. Epub 2016 Jul 8.'}, {'ReferencePMID': '29555978', 'ReferenceType': 'background', 'ReferenceCitation': 'Gurrapu S, Pupo E, Franzolin G, Lanzetti L, Tamagnone L. Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential. Cell Death Differ. 2018 Jul;25(7):1259-1275. doi: 10.1038/s41418-018-0097-4. Epub 2018 Mar 19.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Neoplasms', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M3377', 'InterventionBrowseLeafName': 'Antibodies', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M9336', 'InterventionBrowseLeafName': 'Immunoglobulins', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 33, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00900003', 'OrgStudyIdInfo': {'OrgStudyId': 'VICC GI 0717'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'P30CA068485', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/P30CA068485'}, {'SecondaryId': 'VU-VICC-GI-0717'}, {'SecondaryId': 'VU-VICC-070366'}]}, 'Organization': {'OrgFullName': 'Vanderbilt-Ingram Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Studying Biomarkers in Patients With Pancreatic Cancer', 'OfficialTitle': 'Developing Biomarkers in Pancreatic Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'December 2013', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2007'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2013', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 2013', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 9, 2009', 'StudyFirstSubmitQCDate': 'May 9, 2009', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 12, 2009', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'December 10, 2013', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 12, 2013', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'A Bapsi Chakravarthy, MD', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor; Radiation Oncologist', 'ResponsiblePartyInvestigatorAffiliation': 'Vanderbilt-Ingram Cancer Center'}, 'LeadSponsor': {'LeadSponsorName': 'Vanderbilt-Ingram Cancer Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'RATIONALE: Studying samples of tissue in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.\n\nPURPOSE: This research study is studying biomarkers in patients with pancreatic cancer.', 'DetailedDescription': 'OBJECTIVES:\n\nTo determine whether the cellular localization of BRCA1 can predict how patients with pancreatic cancer will respond to cytotoxic agents (e.g., fluorouracil or gemcitabine hydrochloride) or radiotherapy.\nTo identify pre-treatment markers that can be used to correlate with clinical outcomes of survival and recurrence.\nTo determine if a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue can now be applied to the pancreatic cancer population.\n\nOUTLINE: Tissue samples from biopsies performed during pancreatectomy are collected from the Vanderbilt Ingram Cancer Center Human Tissue Acquisition Core for laboratory biomarker studies. Proteins secreted by cancer cells and/or cancer-associated cells are studied by extracting and identifying secreted cytokines and growth factors from biopsy tissue. The integrity of the DNA repair pathway in pancreatic cancer is analyzed by Rad51 and phosphorylated DNA-PK foci formation. Markers are correlated with clinical outcome.\n\nPatients are followed for recurrence, relapse, and death from disease.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Pancreatic Cancer']}, 'KeywordList': {'Keyword': ['stage I pancreatic cancer', 'stage II pancreatic cancer', 'stage III pancreatic cancer', 'stage IV pancreatic cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '53', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'pancreatic cancer patients', 'ArmGroupDescription': 'pancreatic cancer patients with excess tissue collected at the time of standard of care surgery', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: protein analysis', 'Other: laboratory biomarker analysis']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Genetic', 'InterventionName': 'protein analysis', 'InterventionDescription': 'Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['pancreatic cancer patients']}}, {'InterventionType': 'Other', 'InterventionName': 'laboratory biomarker analysis', 'InterventionDescription': 'A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['pancreatic cancer patients']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy', 'PrimaryOutcomeDescription': 'Examine the location of BRCA1 in the cells and determine if this location predicts patient response to the chemotherapy drugs given', 'PrimaryOutcomeTimeFrame': 'following collection of all pancreatic tissue specimens and patient outcome data'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Correlation of pre-treatment markers with survival and recurrence', 'SecondaryOutcomeDescription': "Compare and contract of biomarkers in patient's tissue that are detected before treatment has a relationship to their survival and recurrence of their cancer", 'SecondaryOutcomeTimeFrame': 'at expiration date of final patient enrolled'}, {'SecondaryOutcomeMeasure': 'Application of a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue to the pancreatic cancer population', 'SecondaryOutcomeDescription': 'Researchers will determine if the methods they have developed for extracting and identifying cytokines in biopsy tissue can be applied to the pancreatic cancer tissue', 'SecondaryOutcomeTimeFrame': 'upon collection of pancreatic tissue for each patient'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria\n\nAny subject with excess tissue collected at time of routine surgery for pancreatic cancer is eligible.\nAll subjects participating in this protocol will be followed for recurrence, relapse and death from disease', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'patients with cancer of the pancreas', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'A. Bapsi Chakravarthy, MD', 'OverallOfficialAffiliation': 'Vanderbilt-Ingram Cancer Center', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Vanderbilt-Ingram Cancer Center - Cool Springs', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37064', 'LocationCountry': 'United States'}, {'LocationFacility': 'Vanderbilt-Ingram Cancer Center at Franklin', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37064', 'LocationCountry': 'United States'}, {'LocationFacility': 'Vanderbilt-Ingram Cancer Center', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37232-6838', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Vanderbilt-Ingram Cancer Center, Find a Clinical Trial', 'SeeAlsoLinkURL': 'http://www.vicc.org/ct/'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010190', 'ConditionMeshTerm': 'Pancreatic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010182', 'ConditionAncestorTerm': 'Pancreatic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12262', 'ConditionBrowseLeafName': 'Pancreatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7015', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12254', 'ConditionBrowseLeafName': 'Pancreatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7014', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4387', 'ConditionBrowseLeafName': 'Pancreatic Cancer', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M11052', 'InterventionBrowseLeafName': 'Mitogens', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 34, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05736367', 'OrgStudyIdInfo': {'OrgStudyId': '042210'}, 'Organization': {'OrgFullName': 'Rutgers, The State University of New Jersey', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer', 'OfficialTitle': 'Pilot Study to Investigate the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'February 2023', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 15, 2023', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 30, 2025', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 30, 2028', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 6, 2023', 'StudyFirstSubmitQCDate': 'February 16, 2023', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 21, 2023', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 16, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 21, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Coral Omene', 'ResponsiblePartyInvestigatorTitle': 'Assistant Professor, Medical Oncology, Rutgers Cancer Institute of New Jersey', 'ResponsiblePartyInvestigatorAffiliation': 'Rutgers, The State University of New Jersey'}, 'LeadSponsor': {'LeadSponsorName': 'Rutgers, The State University of New Jersey', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Ludwig Institute for Cancer Research', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'Yes', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.', 'DetailedDescription': 'Participants will be asked to receive a glucose infusion (U-13C- glucose intravenous) during routine breast cancer surgery at which time, tumor biopsy samples and blood samples will be collected to be used in research experiments to help provide insight into the metabolic activity of the tumor. The length of time on study for each patient will be three - four weeks including two to three hours for glucose infusion and breast cancer biopsy.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['Hormone Receptor Positive', 'Metabolic activity', 'Breast Cancer Surgery', '13C isotope glucose', 'Metabolomics']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Basic Science', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '16', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Administration of U-13C-glucose to participants with early-stage HR+/Her2- breast cancer fitting criteria, will be done intraoperatively at the time of resection, as well as blood sample collection.\n\nThis will allow for in depth evaluation of glycolysis as well as TCA cycle, lipid and amino acid metabolism and comprehensive genomic analyses to complement the metabolic assays that will be done by the Ludwig Institute of Cancer Research. HR+/Her2- breast cancer subtype is chosen for this feasibility pilot study given that metabolic studies have not been done in this subtype of breast cancer and it makes up the majority of breast cancer cases.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: U-13C-glucose']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'U-13C-glucose', 'InterventionDescription': 'Discover new insights into the glucose, TCA cycle, amino acid, and lipid metabolic dependencies of HR+/Her2- breast cancer, via liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo U-13C-glucose-labeled biopsy of tumor and benign adjacent tissue', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Measure glycolysis metabolism dependencies of hormone receptor positive/HER2 negative breast cancer using Liquid chromatography-mass spectrometry (LC-MS)', 'PrimaryOutcomeDescription': 'To analyze and describe the metabolism of these tumors in vivo uniformly-labeled (U-13C)-glucose-labeled biopsy of tumor and benign adjacent tissue. The participants will receive glucose infusion and their tumor specimens analyzed. Blood collection will allow for in depth evaluation of glycolysis metabolism.\n\nCompounds can range from low molecular mass analytes with m/z values < 1000 Da, to very high molecular mass proteins with m/z values > 100,000 Da\n\nU-13C-Glucose (study drug)', 'PrimaryOutcomeTimeFrame': 'Baseline to four weeks'}, {'PrimaryOutcomeMeasure': 'Measure glycolysis metabolism dependencies of hormone receptor positive/HER2 negative breast cancer using Nuclear Magnetic Resonance (NMR) spectroscopy in parts per million (ppm).', 'PrimaryOutcomeDescription': 'To analyze and describe the metabolism of these tumors in vivo uniformly-labeled (U-13C)-glucose-labeled biopsy of tumor and benign adjacent tissue. The participants will receive glucose infusion and their tumor specimens analyzed. Blood collection will allow for in depth evaluation of glycolysis metabolism.\n\nU-13C-Glucose (study drug)', 'PrimaryOutcomeTimeFrame': 'Baseline to four weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Measure lipid metabolic dependencies of hormone receptor positive/HER2 negative breast cancer using Liquid chromatography-mass spectrometry (LC-MS)', 'SecondaryOutcomeDescription': 'To analyze and describe the metabolism of these tumors in vivo uniformly-labeled (U-13C)-glucose-labeled biopsy of tumor and benign adjacent tissue. The participants will receive glucose infusion and their tumor specimens analyzed. Blood collection will allow for in depth evaluation of lipid metabolism.', 'SecondaryOutcomeTimeFrame': 'Baseline to four weeks'}, {'SecondaryOutcomeMeasure': 'Measure lipid metabolic dependencies of hormone receptor positive/HER2 negative breast cancer using Nuclear Magnetic Resonance (NMR) spectroscopy in parts per million (ppm)', 'SecondaryOutcomeDescription': 'To analyze and describe the metabolism of these tumors in vivo uniformly-labeled (U-13C)-glucose-labeled biopsy of tumor and benign adjacent tissue. The participants will receive glucose infusion and their tumor specimens analyzed. Blood collection will allow for in depth evaluation of lipid metabolism.', 'SecondaryOutcomeTimeFrame': 'Baseline to four weeks'}, {'SecondaryOutcomeMeasure': 'Measure amino acid metabolic dependencies of hormone receptor positive/HER2 negative breast cancer using Liquid chromatography-mass spectrometry (LC-MS).', 'SecondaryOutcomeDescription': 'To analyze and describe the metabolism of these tumors in vivo uniformly-labeled (U-13C)-glucose-labeled biopsy of tumor and benign adjacent tissue. The participants will receive glucose infusion and their tumor specimens analyzed. Blood collection will allow for in depth evaluation of amino acid metabolism.\n\nCompounds can range from low molecular mass analytes with m/z values < 1000 Da, to very high molecular mass proteins with m/z values > 100,000 Da', 'SecondaryOutcomeTimeFrame': 'Baseline to four weeks'}, {'SecondaryOutcomeMeasure': 'Measure amino acid metabolic dependencies of hormone receptor positive/HER2 negative breast cancer using Nuclear Magnetic Resonance (NMR) spectroscopy in parts per million (ppm)', 'SecondaryOutcomeDescription': 'To analyze and describe the metabolism of these tumors in vivo uniformly-labeled (U-13C)-glucose-labeled biopsy of tumor and benign adjacent tissue. The participants will receive glucose infusion and their tumor specimens analyzed. Blood collection will allow for in depth evaluation of amino acid metabolism.', 'SecondaryOutcomeTimeFrame': 'Baseline to four weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nHave hormone receptor (HR) positive [estrogen receptor( ER)+/progesterone receptor (PR)+, ER+/PR- or ER-/PR+)/Her2 negative breast cancer previously diagnosed by biopsy.\nHave early stage, clinical or anatomic stage I, II or III breast cancer (cT1cN0, cT1cN1, cT2N0, cT2N1, cT3N0)\nCandidates for intended curative primary resection who have not had neoadjuvant therapy (endocrine/hormonal therapy, chemotherapy with or without immunotherapy).\nWilling to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed surgical resection.\n\nExclusion Criteria:\n\nIs currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study.\nHas triple negative (ER-/PR-/Her2-) or HER2+ breast cancer.\nConcomitant active malignancy\nIs of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer)', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Coral Omene, MD, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '732-235-3374', 'CentralContactEMail': 'co273@cinj.rutgers.edu'}, {'CentralContactName': 'Shridar Ganesan, MD, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '732-235-3374', 'CentralContactEMail': 'ganesash@cinj.rutgers.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Coral Omene, MD, PhD', 'OverallOfficialAffiliation': 'Cancer Institute of New Jersey Rutgers', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Rutgers Cancer Institute of New Jersey', 'LocationCity': 'New Brunswick', 'LocationState': 'New Jersey', 'LocationZip': '08903', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Coral Omene, MD,PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '732-235-3374', 'LocationContactEMail': 'co273@cinj.rutgers.edu'}, {'LocationContactName': 'Shridar Ganesan, MD,PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '732-235-3374', 'LocationContactEMail': 'ganesash@cinj.rutgers.edu'}]}}, {'LocationFacility': 'RWJBarnabas Health', 'LocationCity': 'New Brunswick', 'LocationState': 'New Jersey', 'LocationZip': '08903', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Coral Omene, MD, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '732-235-3374', 'LocationContactEMail': 'co273@cinj.rutgers.edu'}, {'LocationContactName': 'Shridar Ganesan, MD,PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '732-235-3374', 'LocationContactEMail': 'ganesash@cinj.rutgers.edu'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M8941', 'InterventionBrowseLeafName': 'Hormones', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M5544', 'InterventionBrowseLeafName': 'Complement System Proteins', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 35, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01361035', 'OrgStudyIdInfo': {'OrgStudyId': 'RWJF-63523'}, 'Organization': {'OrgFullName': 'Tulane University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients', 'OfficialTitle': 'Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients'}, 'StatusModule': {'StatusVerifiedDate': 'March 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2008'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2012', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 24, 2011', 'StudyFirstSubmitQCDate': 'May 24, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 26, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 9, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 10, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Eboni Price-Haywood', 'ResponsiblePartyInvestigatorTitle': 'Adjunct Associate Professor of Clinical Medicine', 'ResponsiblePartyInvestigatorAffiliation': 'Tulane University School of Medicine'}, 'LeadSponsor': {'LeadSponsorName': 'Tulane University School of Medicine', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Robert Wood Johnson Foundation', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': "What's the purpose of this study? This 4-year study is designed: (1) to teach primary care physicians how to recognize low health literacy patients and effectively counsel them on cancer screening using risk communication and shared decision making and (2) to assess the impact of training on changes in physician communication behavior and changes in low health literacy patients' cancer screening behaviors. This study proposal is based on the hypothesis that physician training in cancer screening guidelines, health literacy, and communication skills will improve provider-patient interactions during encounters dealing with preventive health maintenance especially cancer screening.\n\nHow will the proposed study be implemented? Thirty-two physicians in the New Orleans metropolitan area will be recruited and randomly assigned to one of two groups. The unit of randomization will be the health care organization or clinic. The intervention group will receive training in health literacy, cancer screening, risk communication and shared decision-making. The control group will not receive communication training until the end of the study. Physicians in both groups will undergo three clinic visits with standardized patients (actors trained to portray real patients; mystery shoppers) but they will not be aware that they are conducting visits with actors. The visits will occur at study enrollment and at 6 and 12 months. At the end of each clinic visit, the standardized patients will rate the physicians' communication skills. Each physician assigned to the intervention group will receive verbal feedback on communication skills from the standardized patients and complete a web-based tutorial. Physicians in the control group will not have access to the web-based tutorial until the end of the study.\n\nFor each physician, 10-15 patients with limited health literacy will be recruited to the study. Each patient will rate his/her perceived involvement with care and global satisfaction with care at study enrollment and annually for three years. Age and gender-appropriate referral rates for breast, cervical and colorectal cancer screening and patients' receipt of such screening will be assessed annually for three years. All study physicians, regardless of group assignment, will receive performance feedback (report cards) on their cancer screening rates among low health literacy patients in their clinic."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cervical Cancer', 'Breast Cancer', 'Colorectal Cancer']}, 'KeywordList': {'Keyword': ['health literacy', 'cancer screening', 'doctor-patient communication', 'standardized patient', 'continuing medical education']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '168', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'No communication training', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Physicians enrolled in the control arm do not undergo training in health literacy, cancer screening and shared decision making'}, {'ArmGroupLabel': 'Cancer risk ommunication skills training', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Physicians enrolled in the intervention arm undergo training in health literacy, cancer screening and shared decision making', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Cancer risk communication skills training']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Cancer risk communication skills training', 'InterventionDescription': "Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer risk ommunication skills training']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in cervical, breast and colorectal cancer screening rates', 'PrimaryOutcomeDescription': 'Cervical/Breast/Colorectal cancer screening rates will be measured at baseline and annually for 2 years to assess whether screening rates improve over time', 'PrimaryOutcomeTimeFrame': '0, 12, 24 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in standardized patient ratings of physician communication behaviors', 'SecondaryOutcomeDescription': "The mystery shoppers (standardized patients) will rate the physicians' shared decision making and counseling about cancer screening prior to the intervention at baseline and then again at 6-month and 12-month follow up evaluations to assess whether communication behaviors improve over time", 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nPhysician\n\nPhysicians who practice at these clinic sites at least one half day per week are eligible to participate in this study.\n\nPatient\n\nEligible patients include men and women age 40 to 75, individuals enrolled in the clinic practice for at least one year, and individuals identified as having low or inadequate health literacy via the Rapid Estimate of Adult Literacy in Medicine.\n\nExclusion Criteria:\n\nPhysician\n\nAny provider planning to leave before the end of 12 months will be excluded.\n\nPatient\n\nPatients will be excluded if they plan to change primary care provider or site of health plan, have resided in the United States for less than five years, or do not speak English', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Eboni Price-Haywood, MD, MPH', 'OverallOfficialAffiliation': 'Tulane University School of Medicine', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Tulane Communty Health Center at Covenant House', 'LocationCity': 'New Orleans', 'LocationState': 'Louisiana', 'LocationZip': '70112', 'LocationCountry': 'United States'}, {'LocationFacility': 'Tulane Faculty Practice', 'LocationCity': 'New Orleans', 'LocationState': 'Louisiana', 'LocationZip': '70112', 'LocationCountry': 'United States'}, {'LocationFacility': 'EXCELth - Ida Hymel Community Health Center', 'LocationCity': 'New Orleans', 'LocationState': 'Louisiana', 'LocationZip': '70114', 'LocationCountry': 'United States'}, {'LocationFacility': 'DCSNO St Cecelia Medical Center', 'LocationCity': 'New Orleans', 'LocationState': 'Louisiana', 'LocationZip': '70117', 'LocationCountry': 'United States'}, {'LocationFacility': 'DCSNO Carrollton Medical Center', 'LocationCity': 'New Orleans', 'LocationState': 'Louisiana', 'LocationZip': '70118', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '20352506', 'ReferenceType': 'background', 'ReferenceCitation': 'Price-Haywood EG, Roth KG, Shelby K, Cooper LA. Cancer risk communication with low health literacy patients: a continuing medical education program. J Gen Intern Med. 2010 May;25 Suppl 2(Suppl 2):S126-9. doi: 10.1007/s11606-009-1211-6.'}, {'ReferencePMID': '24590734', 'ReferenceType': 'result', 'ReferenceCitation': 'Price-Haywood EG, Harden-Barrios J, Cooper LA. Comparative effectiveness of audit-feedback versus additional physician communication training to improve cancer screening for patients with limited health literacy. J Gen Intern Med. 2014 Aug;29(8):1113-21. doi: 10.1007/s11606-014-2782-4. Epub 2014 Feb 4.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000015179', 'ConditionMeshTerm': 'Colorectal Neoplasms'}, {'ConditionMeshId': 'D000002583', 'ConditionMeshTerm': 'Uterine Cervical Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000012002', 'ConditionAncestorTerm': 'Rectal Diseases'}, {'ConditionAncestorId': 'D000014594', 'ConditionAncestorTerm': 'Uterine Neoplasms'}, {'ConditionAncestorId': 'D000005833', 'ConditionAncestorTerm': 'Genital Neoplasms, Female'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000002577', 'ConditionAncestorTerm': 'Uterine Cervical Diseases'}, {'ConditionAncestorId': 'D000014591', 'ConditionAncestorTerm': 'Uterine Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4982', 'ConditionBrowseLeafName': 'Uterine Cervical Neoplasms', 'ConditionBrowseLeafAsFound': 'Cervical Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafAsFound': 'Colorectal Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13996', 'ConditionBrowseLeafName': 'Rectal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16494', 'ConditionBrowseLeafName': 'Uterine Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8097', 'ConditionBrowseLeafName': 'Genital Neoplasms, Female', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4977', 'ConditionBrowseLeafName': 'Uterine Cervical Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16491', 'ConditionBrowseLeafName': 'Uterine Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}]}}}}}, {'Rank': 36, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00084383', 'OrgStudyIdInfo': {'OrgStudyId': 'J9988'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01CA088058', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/R01CA088058'}, {'SecondaryId': 'P30CA006973', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/P30CA006973'}, {'SecondaryId': 'JHOC-J9988'}]}, 'Organization': {'OrgFullName': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas', 'OfficialTitle': 'A Safety and Efficacy Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene in Combination With Adjuvant Chemoradiotherapy for the Treatment of Adenocarcinoma of the Pancreas'}, 'StatusModule': {'StatusVerifiedDate': 'July 2013', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2002'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2005', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'July 2006', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 10, 2004', 'StudyFirstSubmitQCDate': 'June 10, 2004', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 11, 2004', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'March 1, 2013', 'ResultsFirstSubmitQCDate': 'June 10, 2013', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'July 15, 2013', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 17, 2013', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 22, 2013', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'RATIONALE: Vaccines made from gene-modified pancreatic cancer cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving vaccine therapy together with chemotherapy and radiation therapy after surgery may kill any remaining tumor cells.\n\nPURPOSE: This phase II trial is studying how well giving vaccine therapy together with adjuvant chemoradiotherapy works in treating patients with resected stage I or stage II adenocarcinoma (cancer) of the pancreas.', 'DetailedDescription': 'OBJECTIVES:\n\nPrimary\n\nDetermine overall and disease-free survival of patients with resected stage I or II adenocarcinoma of the pancreas treated with adjuvant chemoradiotherapy in combination with GVAX pancreatic cancer vaccine.\n\nSecondary\n\nCorrelate specific in vivo parameters of immune response (post-vaccination delayed-type hypersensitivity reactions to autologous tumor, mesothelin-specific T-cell response, and the degree of local eosinophil, macrophage, and T-cell infiltration at the vaccine site) with clinical responses in patients treated with this regimen.\nDetermine the toxic effects associated with intradermal injections of this vaccine in these patients.\n\nOUTLINE: This is an open-label study.\n\nPost surgery vaccination: Within 8-10 weeks after pancreaticoduodenectomy, patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 0.\nAdjuvant chemoradiotherapy: Within 16-28 days after the first vaccination, patients receive fluorouracil (5-FU) IV continuously for 3 weeks. Approximately 1-2 weeks after completion of 5-FU, patients receive chemoradiotherapy comprising radiotherapy daily and 5-FU IV continuously for 26-28 weeks. Approximately 3-5 weeks after completion of chemoradiotherapy, patients receive 5-FU IV continuously for 4 weeks. 5-FU repeats every 6 weeks for 2 courses.\nPost chemoradiotherapy vaccination: Within 4-8 weeks after the completion of chemoradiotherapy, patients receive GVAX pancreatic cancer vaccine ID on days 0, 28, 56, and 196.\n\nTreatment continues in the absence of unacceptable toxicity.\n\nPatients are followed every 3 months for 1 year and then every 6 months thereafter.\n\nPROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Pancreatic Cancer']}, 'KeywordList': {'Keyword': ['stage I pancreatic cancer', 'stage II pancreatic cancer', 'duct cell adenocarcinoma of the pancreas']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '60', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'GVAX pancreatic cancer vaccine', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': '5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth "booster" vaccination, six months following the fourth vaccination', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: GVAX pancreatic cancer vaccine']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Biological', 'InterventionName': 'GVAX pancreatic cancer vaccine', 'InterventionDescription': 'Patients will receive vaccinations consisting of 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth "booster" vaccination, six months following the fourth vaccination.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['GVAX pancreatic cancer vaccine']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Overall Survival', 'PrimaryOutcomeDescription': 'Overall survival in patients treated with adjuvant chemoradiotherapy in sequence with the irradiated allogeneic GM-CSF transfected pancreatic tumor cell lines. Overall survival is defined as time from surgery until death, regardless of cause.', 'PrimaryOutcomeTimeFrame': 'Participants were followed for the duration of the study, an average of 2 years'}, {'PrimaryOutcomeMeasure': 'Disease-free Survival', 'PrimaryOutcomeDescription': 'Disease-free Survival in Patients Treated With Adjuvant Chemoradiotherapy in Sequence With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines. DFS is defined as time from surgery until clinical evidence of disease (eg, CT scan) or death due to any cause.', 'PrimaryOutcomeTimeFrame': 'Participants were followed for the duration of the study, an average of 2 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'To Further Identify and Characterize Toxicities Associated With Intradermal Injections of the Vaccine That Were Initially Reported in the Phase 1 Trial.', 'SecondaryOutcomeTimeFrame': '4 years'}, {'SecondaryOutcomeMeasure': 'Estimate the Association of Specific in Vivo Parameters of Immune Response With Clinical Responses in Patients Treated With Combination Chemoradiotherapy Together With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines.', 'SecondaryOutcomeDescription': 'The specific immune parameters include: post-vaccination delayed type hypersensitivity reactions to autologous tumor and the degree of local eosinophil, macrophage, and T cell infiltration at the vaccine site, and mesothelin-specific T cell responses.', 'SecondaryOutcomeTimeFrame': 'Continuous'}]}}, 'EligibilityModule': {'EligibilityCriteria': "DISEASE CHARACTERISTICS:\n\nHistologically confirmed invasive ductal adenocarcinoma of the head, neck, and uncinate process of the pancreas\n\nMixed adenocarcinoma tumors allowed if the predominant invasive component of the tumor is adenocarcinoma\nStage I or II (clinical stage T1-3, N0-1, M0) disease\n\nHas undergone pancreaticoduodenectomy at the Johns Hopkins Hospital within the past 8-10 weeks\n\nCompletely resected (R0) or microscopic residual (R1) disease\n\nNo diagnosis other than ductal adenocarcinoma, including any of the following:\n\nAdenosquamous\nSquamous cell\nColloid\nIslet cell\nNon-invasive intraductal papillary mucinous neoplasms\nSerous or mucinous cystadenoma or cystadenocarcinoma\nCarcinoid\nSmall or large cell carcinoma\nIntraductal oncocytic papillary neoplasms\nOsteoclast-like giant cell tumors\nAcinar cell carcinoma\nPancreatoblastoma\nSolid pseudopapillary tumors\nUndifferentiated small cell carcinoma\nNon-epithelial tumors (sarcoma, gastrointestinal stromal tumor, or lymphoma)\nAdenocarcinoma of the ampulla\nAdenocarcinoma of the distal bile duct\nAdenocarcinoma of the duodenum\nNo recurrent disease\nNo metastatic disease, including peritoneal implants or liver and/or lung involvement\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n18 and over\n\nPerformance status\n\nECOG 0-1\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nAbsolute neutrophil count >/= 1,500/mm^3\nPlatelet count >/= 100,000/mm^3\nHemoglobin >/= 10 g/dL\n\nHepatic\n\nBilirubin </= 2 mg/dL\nAST/ALT </= 2 times upper limit of normal (ULN)\nAlkaline phosphatase </= 5 times ULN\n\nRenal\n\nCreatinine </= 2 mg/dL\n\nPulmonary\n\nNo asthma or chronic obstructive pulmonary disease requiring systemic corticosteroids\n\nImmunologic\n\nHIV negative\nNo active infection\n\nNo prior or concurrent autoimmune disease requiring treatment with systemic immunosuppressants, including any of the following:\n\nInflammatory bowel disease\nSystemic vasculitis\nScleroderma\nPsoriasis\nMultiple sclerosis\nHemolytic anemia or immune thrombocytopenia\nRheumatoid arthritis\nSystemic lupus erythematosus\nSjogren's syndrome\nSarcoidosis\nNegative results to viral delayed-type hypersensitivity serology testing if autologous tumor cells are available\n\nOther\n\nNo postoperative complications (e.g., inability to take oral nutrition >/= 1,500 calories/day, ongoing requirement for long-term biliary stenting, or persistence of wound infection)\nNo other malignancy within the past 5 years except nonmelanoma skin cancer\nNo uncontrolled medical conditions that would preclude study participation\nNo other major active medical or psychosocial problem that could be exacerbated by study treatment\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception during and for at least 4 weeks after study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nMore than 1 month since prior biologic therapy\nNo other concurrent biologic therapy, immunotherapy, or gene therapy for pancreatic cancer\n\nChemotherapy\n\nMore than 1 month since prior chemotherapy\nNo other concurrent chemotherapy for pancreatic cancer\n\nEndocrine therapy\n\nMore than 28 days since prior systemic steroids\nNo concurrent systemic corticosteroids\n\nRadiotherapy\n\nMore than 1 month since prior radiotherapy\nNo other concurrent radiotherapy for pancreatic cancer\n\nSurgery\n\nSee Disease Characteristics\nRecovered from prior surgery\n\nOther\n\nMore than 1 month since prior participation in an investigational new drug trial\nNo other concurrent investigational therapy for pancreatic cancer", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Daniel A. Laheru, MD', 'OverallOfficialAffiliation': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21231', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '21217520', 'ReferenceType': 'derived', 'ReferenceCitation': 'Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru D. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011 Feb;253(2):328-35. doi: 10.1097/SLA.0b013e3181fd271c.'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'GVAX Pancreatic Cancer Vaccine'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '60'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '13'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '47'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'GVAX Pancreatic Cancer Vaccine'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '60'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '33'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '27'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '62', 'BaselineMeasurementSpread': '9.375'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '23'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '37'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '60'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Overall Survival', 'OutcomeMeasureDescription': 'Overall survival in patients treated with adjuvant chemoradiotherapy in sequence with the irradiated allogeneic GM-CSF transfected pancreatic tumor cell lines. Overall survival is defined as time from surgery until death, regardless of cause.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'Months', 'OutcomeMeasureTimeFrame': 'Participants were followed for the duration of the study, an average of 2 years', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'GVAX Pancreatic Cancer Vaccine'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '24.8', 'OutcomeMeasurementLowerLimit': '21.2', 'OutcomeMeasurementUpperLimit': '31.6'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'To Further Identify and Characterize Toxicities Associated With Intradermal Injections of the Vaccine That Were Initially Reported in the Phase 1 Trial.', 'OutcomeMeasureReportingStatus': 'Not Posted', 'OutcomeMeasureTimeFrame': '4 years'}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Estimate the Association of Specific in Vivo Parameters of Immune Response With Clinical Responses in Patients Treated With Combination Chemoradiotherapy Together With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines.', 'OutcomeMeasureDescription': 'The specific immune parameters include: post-vaccination delayed type hypersensitivity reactions to autologous tumor and the degree of local eosinophil, macrophage, and T cell infiltration at the vaccine site, and mesothelin-specific T cell responses.', 'OutcomeMeasureReportingStatus': 'Not Posted', 'OutcomeMeasureTimeFrame': 'Continuous'}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Disease-free Survival', 'OutcomeMeasureDescription': 'Disease-free Survival in Patients Treated With Adjuvant Chemoradiotherapy in Sequence With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines. DFS is defined as time from surgery until clinical evidence of disease (eg, CT scan) or death due to any cause.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'Months', 'OutcomeMeasureTimeFrame': 'Participants were followed for the duration of the study, an average of 2 years', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'GVAX Pancreatic Cancer Vaccine'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '17.3', 'OutcomeMeasurementLowerLimit': '14.6', 'OutcomeMeasurementUpperLimit': '22.8'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '5', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'GVAX Pancreatic Cancer Vaccine', 'EventGroupSeriousNumAffected': '2', 'EventGroupSeriousNumAtRisk': '60', 'EventGroupOtherNumAffected': '60', 'EventGroupOtherNumAtRisk': '60'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Pain, Cancer related', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '1'}]}}, {'SeriousEventTerm': 'Biliary Obstruction, secondary to progessive disease', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '1'}]}}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Eosinophils, elevated', 'OtherEventOrganSystem': 'Blood and lymphatic system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '30', 'OtherEventStatsNumAffected': '17', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Chills', 'OtherEventOrganSystem': 'General disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '12', 'OtherEventStatsNumAffected': '11', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '11', 'OtherEventStatsNumAffected': '9', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Fever', 'OtherEventOrganSystem': 'General disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '19', 'OtherEventStatsNumAffected': '11', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Flu like symptoms', 'OtherEventOrganSystem': 'General disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Blister', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventNotes': 'Localized vaccine site reaction', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Erythema', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventNotes': 'Localized vaccine site reaction', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '172', 'OtherEventStatsNumAffected': '60', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Induration', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventNotes': 'Localized vaccine site reaction', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '171', 'OtherEventStatsNumAffected': '60', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Pruritis', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventNotes': 'Localized vaccine site reaction', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '152', 'OtherEventStatsNumAffected': '51', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Tenderness', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventNotes': 'Localized vaccine site reaction', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '142', 'OtherEventStatsNumAffected': '55', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Vaccine site flare', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventNotes': 'Localized vaccine site reaction', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '12', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Rash', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '8', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Myalgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '12', 'OtherEventStatsNumAffected': '10', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Dizziness', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '7', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Arthralgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '60'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Dr. Daniel Laheru', 'PointOfContactOrganization': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', 'PointOfContactEMail': 'laherda@jhmi.edu', 'PointOfContactPhone': '410-955-8974'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000000230', 'ConditionMeshTerm': 'Adenocarcinoma'}, {'ConditionMeshId': 'D000010190', 'ConditionMeshTerm': 'Pancreatic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002277', 'ConditionAncestorTerm': 'Carcinoma'}, {'ConditionAncestorId': 'D000009375', 'ConditionAncestorTerm': 'Neoplasms, Glandular and Epithelial'}, {'ConditionAncestorId': 'D000009370', 'ConditionAncestorTerm': 'Neoplasms by Histologic Type'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010182', 'ConditionAncestorTerm': 'Pancreatic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12262', 'ConditionBrowseLeafName': 'Pancreatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2737', 'ConditionBrowseLeafName': 'Adenocarcinoma', 'ConditionBrowseLeafAsFound': 'Adenocarcinoma', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4686', 'ConditionBrowseLeafName': 'Carcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11472', 'ConditionBrowseLeafName': 'Neoplasms, Glandular and Epithelial', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11467', 'ConditionBrowseLeafName': 'Neoplasms by Histologic Type', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7015', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12254', 'ConditionBrowseLeafName': 'Pancreatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7014', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4387', 'ConditionBrowseLeafName': 'Pancreatic Cancer', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16512', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M21707', 'InterventionBrowseLeafName': 'Pancrelipase', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M12266', 'InterventionBrowseLeafName': 'Pancreatin', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Gast', 'InterventionBrowseBranchName': 'Gastrointestinal Agents'}]}}}}}, {'Rank': 37, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04225741', 'OrgStudyIdInfo': {'OrgStudyId': 'gulcin'}, 'Organization': {'OrgFullName': 'Inonu University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Theory-based Training to Promote Breast Cancer Screening', 'OfficialTitle': 'Theory-based Training to Promote Breast Cancer Screening Among Women With Breast Cancer Worries: Randomized Controlled Trial', 'Acronym': 'cancer'}, 'StatusModule': {'StatusVerifiedDate': 'January 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 22, 2015', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 11, 2017', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'August 30, 2017', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 9, 2020', 'StudyFirstSubmitQCDate': 'January 9, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 13, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 10, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 14, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'gnacar', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Inonu University'}, 'LeadSponsor': {'LeadSponsorName': 'Inonu University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': "BACKGROUND: Breast cancer worries are important determinants in relation to behavior favoring breast cancer screening.\n\nOBJECTIVE: To determine the effect of theory-based training to promote breast cancer screening among women with high and low levels of breast cancer worries.\n\nDESIGN AND SETTING: Randomized controlled trial, conducted in two family health centers.\n\nMETHODS: In total, 285 women were recruited. Women with low levels of breast cancer worries were included in the first intervention group (112 women) and the first control group (112 women), while women with high levels of breast cancer worries were included in the second intervention group (37 women) and the second control group (43 women). Theory-based training to promote breast cancer screening was given to intervention groups. The women's willingness to undergo breast cancer screening and breast cancer worry scores were evaluated at 1, 3 and 6 months.", 'DetailedDescription': 'Breast cancer is the most frequent type of cancer and the most common cause of cancer death among gynecological cancers. One in every four women with cancer in the world has breast cancer. The International Cancer Agency reported that there were around 2,088,849 new cases and 626,679 deaths due to breast cancer worldwide in 2018. The incidence of breast cancer is higher in developed countries than in developing countries, but the numbers of deaths due to breast cancer are lower in developed countries than in developing countries.\n\nIt is known that breast self-examination, clinical breast examination and mammography play an important role in making an early diagnosis of breast cancer. The uptake rate for mammography performed on a regular basis is low because this is an expensive method, considering that not all individuals have health insurance and public funding is inadequate, especially in developing countries. Hence, breast self-examination (which has no cost) and clinical breast examination (which only has low cost) remain important diagnostic methods. Moreover, during clinical breast examination, healthcare professionals have the opportunity to advise on breast cancer, risk factors, prevention methods and screening methods.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer', 'Breast Cancer Female']}, 'KeywordList': {'Keyword': ['Mammography', 'Breast self-examination', 'Early diagnosis']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '285', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'training group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs.22,23 Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.22-24', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Training group']}}, {'ArmGroupLabel': 'Control Group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'None of the interventions described above were applied to the control group.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Training group', 'InterventionDescription': 'The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs. Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['training group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Breast Cancer Worry Scale', 'PrimaryOutcomeDescription': "Breast Cancer Worry Scale: Lerman et al. developed this three-item scale to measure breast cancer worry levels and their effect on daily activities and mood. Lerman subsequently modified the scale, such that it was extended from breast cancer to general cancer and its number of questions was increased to six. Lerman's six-item cancer worry scale was then modified by Timur Taşhan et al. to measure breast cancer worries alone, and a Turkish validity and reliability study on the BCWS was conducted. Thus, overall, the lowest score that can be obtained is 0, and the highest is 24. A total score of less than 12 denotes a low level of worry regarding cancer, and a total score ≥ 12 indicates a high level of worry.", 'PrimaryOutcomeTimeFrame': '6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nThe participants included did not have any diagnosis of breast cancer, had not been performing breast self-examination regularly (every month), had not previously had a mammogram, had not previously had a clinical breast examination, were not pregnant or breastfeeding and were literate.\n\nExclusion Criteria:\n\nMissing data collection forms.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Female', 'MinimumAge': '20 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Gülçin NACAR, Msc', 'OverallOfficialAffiliation': 'Inonu University', 'OverallOfficialRole': 'Study Director'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '30581784', 'ReferenceType': 'result', 'ReferenceCitation': 'Timur Tashan S, Ucar T, Aksoy Derya Y, Nacar G, Erci B. Validity and Reliability of the Turkish Version of the Modified Breast Cancer Worry Scale. Iran J Public Health. 2018 Nov;47(11):1681-1687.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Validity and Reliability of the Turkish Version of the Modified Breast Cancer Worry Scale.', 'SeeAlsoLinkURL': 'http://www.ncbi.nlm.nih.gov/pubmed/30581784'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 38, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00955773', 'OrgStudyIdInfo': {'OrgStudyId': '112110'}, 'Organization': {'OrgFullName': 'GlaxoSmithKline', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects', 'OfficialTitle': 'An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors', 'Acronym': 'Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'November 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 17, 2009', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 8, 2011', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 8, 2011', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 6, 2009', 'StudyFirstSubmitQCDate': 'August 6, 2009', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 10, 2009', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 7, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 9, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'GlaxoSmithKline', 'LeadSponsorClass': 'INDUSTRY'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with solid tumors. The escalation part of the study will determine the MTD. The combination will be further explored in the expansion part in subjects with metastatic pancreatic cancer. In addition, subjects with KRAS mutant non-small cell lung cancer will be enrolled.', 'DetailedDescription': 'MEK112110 is a dose-escalation, open-label study to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with solid tumors. This will be accomplished using a dose-escalation procedure starting at low doses of GSK1120212 and everolimus. Dose escalation will continue based on predefined parameters until the maximum tolerated dose is identified. The recommended doses and regimens will be selected based on the safety and pharmacokinetic profiles. The clinical activity of GSK1120212 dosed in combination with everolimus will be explored further in an expansion cohort consisting of 20 subjects with metastatic pancreatic cancer. In addition a substudy will be conducted in 40 subjects with KRAS-mutant non-small cell lung cancer.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer']}, 'KeywordList': {'Keyword': ['GSK1120212, everolimus, solid tumors, pancreatic cancer, non-small lung cancer, KRAS-mutant', 'cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '64', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Group I', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': '20 to 30 solid tumor subjects will be dosed with GSK1120212 in combination with everolimus to identify Maximum Tolerated Dose. Subjects will continue on study drug until disease progression or withdraw consent.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: GSK1120212 plus everolimus']}}, {'ArmGroupLabel': 'Group II', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': '20 subjects with pancreatic cancer will receive the recommended dose identified in group I. Subjects will remain on study drug until disease progression or withdrawal from consent.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: GSK1120212 plus everolimus']}}, {'ArmGroupLabel': 'Group III', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Approximately 40 lung cancer subjects will receive the recommended dose identified in group I. Subjects will remain on study until disease progression or withdrawal of consent.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: GSK1120212 plus everolimus']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'GSK1120212 plus everolimus', 'InterventionDescription': 'Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group I', 'Group II', 'Group III']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'AEs and changes in laboratory values and vital signs', 'PrimaryOutcomeTimeFrame': '6 months'}, {'PrimaryOutcomeMeasure': 'Response rate, CR + PR of GSK1120212 and everolimus in KRAS-mutant NSCLC.', 'PrimaryOutcomeTimeFrame': '6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'GSK1120212 and everolimus PK parameters following repeat-dose (Day 15) administration of GSK1120212 and everolimus, including AUC(0-tau), Ct, Cmax, tmax, and t1/2, data permitting', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Tumor response as defined by RECIST 1.1.', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'CA 19-9 levels compared to radiological response, per RECIST 1.1, over time for each pancreatic cancer subject', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Population PK parameters, oral clearance and oral volume of distribution of GSK1120212 and everolimus will be determined. Dependant upon the final compartmental model describing GSK1120212 + everolimus, add. PK may also be estimated.', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Clinical benefit response rate CR+PR+SD greater than 4mos', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Duration of response', 'SecondaryOutcomeTimeFrame': '6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': "Inclusion Criteria:\n\nCapable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\nAge 18 years old or older and able to swallow oral medication.\nPerformance Status score of 0 or 1 according to the Eastern Cooperative Oncology (ECOG) scale for Dose Escalation Cohort. Subjects with ECOG of 2 can be enrolled for expansion cohort.\nTumor Type criteria as listed in the protocol\nFasting glucose < 126mg/dL\nMale subjects must agree to use one of the contraception methods listed in the protocol.\nA female subject is eligible to participate if she is of non-childbearing potential, and if she is of childbearing potential she must use protocol defined contraception methods.\nCalcium phosphate product less than or equal to 4.0 mmol2/L2 (50 mg2/dL2)\nAdequate organ system function as defined below in the protocol.\n\nExclusion Criteria:\n\nMalignancies related to HIV or solid organ transplant.\nPrimary malignant brain tumors.\nChemotherapy, radiotherapy, or immunotherapy within 28 days (or 42 days for prior nitrosoureas or mitomycin C) prior to the first dose of GSK1120212. Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity are permitted with approval of a GSK Medical Monitor if dosing of that agent is terminated at least 14 days prior to the first dose of GSK1120212.\nUse of an investigational anti-cancer drug within 28 days or 5 half-lives, whichever is shorter preceding the first dose of GSK1120212 - as long as a minimum of 14 days has passed between the last dose of the prior investigational anti-cancer drug and the first dose of GSK1120212.\nPrevious treatment with an mTOR inhibitor unless approved by GSK Medical Monitor.\nPrevious treatment with GSK1120212.\nHistory of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.\nKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug, DMSO, or excipients. (To date there are no known FDA approved drugs chemically related to GSK1120212).\nUse of a prohibited medication (as defined in the protocol).\nCurrent use of anticoagulants (e.g. warfarin, heparin) at therapeutic levels within seven days prior to the first dose of GSK1120212. Low dose (prophylactic) low molecular weight heparin (LMWH) is permitted provided that subject's PT and PTT meet entry criteria. Subjects required therapeutic levels of LMWH must receive approval from GSK Medical Monitor and monitored appropriately as clinically indicated.\nGastrointestinal disease predicted to interfere with absorption of an oral drug, systemic disease, major surgery, or social/psychological issues that in the opinion of investigators would jeopardize compliance with protocol.\nHistory of retinal vein occlusion (RVO) or central serous retinopathy (CSR).\nPredisposing factors to RVO including uncontrolled hypertension, uncontrolled diabetes, uncontrolled hyperlipidemia, and coagulopathy.\nVisible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for RVO or CSR.\nIntraocular pressure > 21mm Hg as measured by tonography.\nGlaucoma diagnosed within 1 month prior to study Day 1.\nSymptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. Subjects previously treated for these conditions that are asymptomatic and off corticosteroids for at least two weeks are permitted. Subjects are not permitted to receive enzyme inducing anti-epileptic drugs (EIAEDs).\nUnresolved toxicity greater than common terminology criteria for adverse events (CTCAE) grade 1 from previous anti-cancer therapy except alopecia (if applicable) unless agreed to by a GSK Medical Monitor and the Investigator.\nHistory of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks.\nQTc interval ≥ 480 msecs.\nClass II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.\nPregnant or lactating female.\nHistory or active hepatitis B or C.\nHistory of HIV infection.\nSubjects on chronic antifungal therapy.\nUnwillingness or inability to follow the procedures outlined in the protocol.", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'GSK Clinical Trials', 'OverallOfficialAffiliation': 'GlaxoSmithKline', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37203', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78229', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Paris Cedex 20', 'LocationZip': '75970', 'LocationCountry': 'France'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25344362', 'ReferenceType': 'derived', 'ReferenceCitation': 'Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA 3rd, Patnaik A, Jones SF, Rasco D, Cox DS, Durante M, Bellew KM, Park J, Le NT, Infante JR. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann Oncol. 2015 Jan;26(1):58-64. doi: 10.1093/annonc/mdu482. Epub 2014 Oct 24.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10324', 'ConditionBrowseLeafName': 'Lung Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12262', 'ConditionBrowseLeafName': 'Pancreatic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4387', 'ConditionBrowseLeafName': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000068338', 'InterventionMeshTerm': 'Everolimus'}, {'InterventionMeshId': 'C000560077', 'InterventionMeshTerm': 'Trametinib'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000970', 'InterventionAncestorTerm': 'Antineoplastic Agents'}, {'InterventionAncestorId': 'D000007166', 'InterventionAncestorTerm': 'Immunosuppressive Agents'}, {'InterventionAncestorId': 'D000007155', 'InterventionAncestorTerm': 'Immunologic Factors'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000047428', 'InterventionAncestorTerm': 'Protein Kinase Inhibitors'}, {'InterventionAncestorId': 'D000004791', 'InterventionAncestorTerm': 'Enzyme Inhibitors'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M255', 'InterventionBrowseLeafName': 'Everolimus', 'InterventionBrowseLeafAsFound': 'Interval', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M218455', 'InterventionBrowseLeafName': 'Trametinib', 'InterventionBrowseLeafAsFound': 'Gefitinib', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M9364', 'InterventionBrowseLeafName': 'Immunosuppressive Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M9353', 'InterventionBrowseLeafName': 'Immunologic Factors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M24973', 'InterventionBrowseLeafName': 'Protein Kinase Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M7103', 'InterventionBrowseLeafName': 'Enzyme Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 39, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01723969', 'OrgStudyIdInfo': {'OrgStudyId': 'EORTC-40CRC'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '2012-003714-14', 'SecondaryIdType': 'EudraCT Number'}]}, 'Organization': {'OrgFullName': 'European Organisation for Research and Treatment of Cancer - EORTC', 'OrgClass': 'NETWORK'}, 'BriefTitle': 'Screening Platform for Clinical Trials in Advanced Colorectal Cancer', 'OfficialTitle': 'Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal Cancer "SPECTAcolor"', 'Acronym': 'SPECTAcolor'}, 'StatusModule': {'StatusVerifiedDate': 'July 2022', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2013', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 10, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 10, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 5, 2012', 'StudyFirstSubmitQCDate': 'November 6, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 8, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 1, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 7, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'European Organisation for Research and Treatment of Cancer - EORTC', 'LeadSponsorClass': 'NETWORK'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The EORTC GastroIntestinal Tract Cancer Group and the EORTC HeadQuarters wish to set up a European screening platform for advanced colo-rectal cancer (CRC) patients. The goal of this screening platform is to provide quick access to new drugs to patients by offering a new structure for clinical trials.\n\nCurrently some of the most challenging clinical questions arise from the molecular sub-division of CRC that would theoretically allow to inhibit the specific, altered pathways in the patients.\n\nA major problem for trials in this "personalized medicine" is that the low frequency of the different mutations requires a high effort for screening and identifying the patients.\n\nThe EORTC CRC screening platform will hopefully offer a feasible and efficient way to characterize the patients on the molecular basis of their tumors and allow to offer them rapid and preferential participation in clinical studies with new drugs targeted to their specific pathway alterations.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Colorectal Cancer', 'Advanced Colorectal Cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'FFPE blocks of tumour tissue'}, 'EnrollmentInfo': {'EnrollmentCount': '668', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Colo-rectal cancer', 'ArmGroupDescription': 'Tumour markers testing in patients with advanced or metastatic colo-rectal cancer', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: Tumour markers testing']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Genetic', 'InterventionName': 'Tumour markers testing', 'InterventionDescription': 'Tumour markers testing in patients advanced or metastatic colo-rectal cancer.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Colo-rectal cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Tumour markers assessment', 'PrimaryOutcomeDescription': 'Five basic tumour markers will be tested: Kras, nras, braf, MSI and PKI3', 'PrimaryOutcomeTimeFrame': 'Within 1 week after patient registration'}]}}, 'EligibilityModule': {'EligibilityCriteria': "Inclusion Criteria:\n\nColo-rectal cancer (advanced or metastatic)\nBefore patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.\n\nExclusion Criteria:\n\nAbsence of patient's consent", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients with advanced or metastatic colo-rectal cancer', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Gunnar Folprecht, MD', 'OverallOfficialAffiliation': 'Universitaetsklinikum Carl Gustav Carus, Dresden, DE', 'OverallOfficialRole': 'Study Chair'}, {'OverallOfficialName': 'Sabine Tejpar, MD, PhD', 'OverallOfficialAffiliation': 'U.Z. Leuven - Campus Gasthuisberg, Leuven, BE', 'OverallOfficialRole': 'Study Chair'}, {'OverallOfficialName': 'Daniela Aust, MD', 'OverallOfficialAffiliation': 'Universitaetsklinikum Carl Gustav Carus, Dresden, DE', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet', 'LocationCity': 'Brussels', 'LocationZip': '1000', 'LocationCountry': 'Belgium'}, {'LocationFacility': 'Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme', 'LocationCity': 'Brussels', 'LocationZip': '1070', 'LocationCountry': 'Belgium'}, {'LocationFacility': 'Cliniques Universitaires Saint-Luc', 'LocationCity': 'Brussels', 'LocationZip': '1200', 'LocationCountry': 'Belgium'}, {'LocationFacility': 'Universitair Ziekenhuis Antwerpen', 'LocationCity': 'Edegem', 'LocationZip': '2650', 'LocationCountry': 'Belgium'}, {'LocationFacility': 'U.Z. Leuven - Campus Gasthuisberg', 'LocationCity': 'Leuven', 'LocationZip': '3000', 'LocationCountry': 'Belgium'}, {'LocationFacility': 'Bank Of Cyprus Oncology Centre', 'LocationCity': 'Stróvolos', 'LocationZip': '2006', 'LocationCountry': 'Cyprus'}, {'LocationFacility': 'Gustave Roussy Cancer Campus', 'LocationCity': 'Villejuif', 'LocationZip': '94805', 'LocationCountry': 'France'}, {'LocationFacility': 'Universitaetsklinikum Carl Gustav Carus', 'LocationCity': 'Dresden', 'LocationZip': 'DE 01307', 'LocationCountry': 'Germany'}, {'LocationFacility': 'Universitaets-Krankenhaus Eppendorf', 'LocationCity': 'Hamburg', 'LocationZip': '20246', 'LocationCountry': 'Germany'}, {'LocationFacility': 'Universitaetsklinikum Leipzig', 'LocationCity': 'Leipzig', 'LocationZip': 'DE 04205', 'LocationCountry': 'Germany'}, {'LocationFacility': 'Ludwig-Maximilians-Universitaet Muenchen - Klinikum der Universitaet Muenchen - Campus Grosshadern', 'LocationCity': 'Muenchen', 'LocationZip': 'DE 81377', 'LocationCountry': 'Germany'}, {'LocationFacility': 'Kliniken Oldenburg', 'LocationCity': 'Oldenburg', 'LocationZip': 'DE 26133', 'LocationCountry': 'Germany'}, {'LocationFacility': 'University General Hospital Heraklion', 'LocationCity': 'Heraklion', 'LocationZip': 'GR 71110', 'LocationCountry': 'Greece'}, {'LocationFacility': 'IRCCS Azienda Ospedaliera Universitaria San Martino "IST" Istituto Nazionale per la Ricerca sul Cancro', 'LocationCity': 'Genova', 'LocationZip': '16132', 'LocationCountry': 'Italy'}, {'LocationFacility': 'Seconda Universita Degli Studi Di Napoli', 'LocationCity': 'Napoli', 'LocationZip': '80138', 'LocationCountry': 'Italy'}, {'LocationFacility': 'The Great Poland Cancer Centre', 'LocationCity': 'Poznan', 'LocationZip': 'PL 61 866', 'LocationCountry': 'Poland'}, {'LocationFacility': 'Maria Sklodowska-Curie Memorial Cancer Centre', 'LocationCity': 'Warsaw', 'LocationZip': 'PL 02 781', 'LocationCountry': 'Poland'}, {'LocationFacility': 'I.P.O. Francisco Gentil - Centro De Lisboa', 'LocationCity': 'Lisboa', 'LocationZip': 'PT 1099-023', 'LocationCountry': 'Portugal'}, {'LocationFacility': "Hospital General Vall D'Hebron", 'LocationCity': 'Barcelona', 'LocationZip': 'ES 08035', 'LocationCountry': 'Spain'}, {'LocationFacility': "Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals", 'LocationCity': "L'Hospitalet de Llobregat", 'LocationZip': 'ES 08907', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hospital Universitario San Carlos', 'LocationCity': 'Madrid', 'LocationZip': 'ES 28040', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hospital Universitario 12 De Octubre', 'LocationCity': 'Madrid', 'LocationZip': 'ES 28041', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Ostra Sjukhuset', 'LocationCity': 'Goteborg', 'LocationZip': 'SE 41685', 'LocationCountry': 'Sweden'}, {'LocationFacility': 'Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie', 'LocationCity': 'Geneva', 'LocationZip': 'CH-1211', 'LocationCountry': 'Switzerland'}, {'LocationFacility': 'Centre Hospitalier Universitaire Vaudois', 'LocationCity': 'Lausanne', 'LocationZip': 'CH-1011', 'LocationCountry': 'Switzerland'}, {'LocationFacility': 'Hopital du Valais - Hopital de Sion', 'LocationCity': 'Sion', 'LocationZip': 'CH 1951', 'LocationCountry': 'Switzerland'}, {'LocationFacility': 'UniversitaetsSpital Zurich', 'LocationCity': 'Zurich', 'LocationZip': 'CH 8091', 'LocationCountry': 'Switzerland'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000015179', 'ConditionMeshTerm': 'Colorectal Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000012002', 'ConditionAncestorTerm': 'Rectal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafAsFound': 'Colorectal Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13996', 'ConditionBrowseLeafName': 'Rectal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 40, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03240224', 'OrgStudyIdInfo': {'OrgStudyId': 'Bioinformation-breast'}, 'Organization': {'OrgFullName': 'Fuda Cancer Hospital, Guangzhou', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Bioinformation Therapy for Breast Cancer', 'OfficialTitle': 'Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Breast Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'August 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 2, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 1, 2017', 'StudyFirstSubmitQCDate': 'August 2, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 7, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 23, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 25, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Fuda Cancer Hospital, Guangzhou', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Shengxin Biotechnology Institute, Beijing', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable breast cancer.', 'DetailedDescription': 'By enrolling patients with unresectable breast cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Advanced Breast Cancer']}, 'KeywordList': {'Keyword': ['Cancer ablation', 'Life information rehabilitation therapy']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer ablation', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cancer ablation']}}, {'ArmGroupLabel': 'Life information rehabilitation therapy', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this group, the patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Life information rehabilitation therapy']}}, {'ArmGroupLabel': 'Combination therapy', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'In this group, the patients will receive combination therapy, including ablation and life information rehabilitation therapy. They will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm), then drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cancer ablation', 'Drug: Life information rehabilitation therapy']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Cancer ablation', 'InterventionDescription': 'Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer ablation', 'Combination therapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Cryoablation or irreversible electroporation']}}, {'InterventionType': 'Drug', 'InterventionName': 'Life information rehabilitation therapy', 'InterventionDescription': 'Each treatment: one bottle solution each day, consecutive 3 months, oral administration', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Combination therapy', 'Life information rehabilitation therapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['"Qilisheng" Immunoregulatory Oral Solution']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Relief degree of tumors', 'PrimaryOutcomeDescription': 'It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Progress free survival（PFS）', 'SecondaryOutcomeDescription': 'The duration between treatment and cancer recurrence', 'SecondaryOutcomeTimeFrame': '1 year'}, {'SecondaryOutcomeMeasure': 'Overall survival（OS）', 'SecondaryOutcomeDescription': 'The duration between treatment and patient pass away', 'SecondaryOutcomeTimeFrame': '3 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAll standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies\nBody tumor 1-6, with at least one tumor length > 2 cm\nKPS ≥ 70, lifespan > 6 months\nPlatelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L\n\nExclusion Criteria:\n\nPatients with cardiac pacemaker\nPatients with brain metastasis\nPatients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Fuda cancer institute of Fuda cancer hospital', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationZip': '510665', 'LocationCountry': 'China'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21013', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 41, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02217865', 'NCTIdAliasList': {'NCTIdAlias': ['NCT02321488']}, 'OrgStudyIdInfo': {'OrgStudyId': 'PA13-1002'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'CE13-04-6855', 'SecondaryIdType': 'Other Grant/Funding Number', 'SecondaryIdDomain': 'Patient-Centered Outcomes Research Institute'}]}, 'Organization': {'OrgFullName': 'M.D. Anderson Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Patient-Centered Risk Adjusted Surveillance After Curative Resection of Colorectal Cancer', 'OfficialTitle': 'Patient-Centered Risk Adjusted Surveillance After Curative Resection of Colorectal Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'February 2022', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 16, 2014', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 13, 2022', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'January 13, 2022', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 13, 2014', 'StudyFirstSubmitQCDate': 'August 13, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 15, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'February 11, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 15, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'M.D. Anderson Cancer Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Patient-Centered Outcomes Research Institute', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Alliance for Clinical Trials in Oncology', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No'}, 'DescriptionModule': {'BriefSummary': "The long-term goal of this research is to develop new tools to guide patients, caregivers, and clinicians in making individualized decisions regarding colorectal cancer (CRC) surveillance. As part of a Patient-Centered Outcomes Research Institute-funded contract, investigator will analyze surveillance data to determine the effectiveness of CRC surveillance and recurrence risk taking into account different patient and tumor characteristics; identify key issues about CRC surveillance important to patients, caregivers, and clinicians; and integrate the recurrence risk and patient priorities into a patient-centered, risk stratified surveillance strategy by creating an interactive decision aid for use by patients and clinicians.\n\nThis protocol addresses a formative step in the creation of the interactive decision aid where patients' information needs and preferences are assessed regarding decisions about surveillance.\n\nThe specific aims of this protocol are:\n\nPhase 1 - To interview patients and their caregivers to determine their concerns, preferences and key priorities regarding surveillance after curative resection of colorectal cancer, and\n\nPhase 2 - To refine the key priorities identified in phase 1 through focus groups and surveys with patients and caregivers.", 'DetailedDescription': 'You are being asked to take part in this research study which is conducted at The University of Texas MD Anderson ("MD Anderson") and the Harris Health System because you (or someone you act as a caregiver for) are undergoing follow-up after curative resection of colorectal cancer.\n\nThe goal of this study is to find out the key priorities for patients and their caregivers when it comes to surveillance after curative resection of colorectal cancer. Your responses will help develop decision aids to help future colorectal cancer patients make more informed decisions about surveillance.\n\nIf you agree to participate in this study, you will take part in an interview or focus group in person at MD Anderson, the Harris Health System, or the Alliance. The interview or focus group is expected to take between 30 minutes and 1 hour. The interview or focus group will be audiorecorded. Your name or other identifying information will not appear in the transcript. Adept Word Management, a transcription service that has been approved by the institution, may transcribe the interviews.\n\nYou will be asked questions about:\n\nyour priorities and concerns about colorectal cancer surveillance\nwhat you know about colorectal cancer and surveillance,\nyour cancer and treatment (or the patients\'),\nthe impact or inconvenience that surveillance causes,\nwho you think should make decisions about surveillance,\nyour thoughts about different surveillance scenarios,\nand general questions about your age, race, sex, education, and income level.\n\nInformation about you will be collected from the medical records and existing data in a database of colorectal patients that is used to organize existing information about colorectal patients to better understand the disease. Information collected will include things like age, gender, marital status, information about the tumor, type of surgery, and what treatment was done before and after surgery. There are no other plans to share your information with others outside the study.\n\nYour participation will be over when the interview is complete. If you are undergoing follow-up for colorectal cancer, research staff will look at your medical record after the interview for information about your cancer including tumor characteristics.\n\nYour participation is completely voluntary. Whether you say yes or no will not change your medical care.\n\nUp to 220 patients and their caregivers will participate in this multicenter study. Up to 190 patients and their caregivers will be enrolled at MD Anderson. Up to 10 patients and their caregivers will be enrolled at the Harris Health System.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Colorectal Cancer']}, 'KeywordList': {'Keyword': ['Colorectal Cancer', 'CRC', 'Curative resection of colorectal cancer', 'Caregivers', 'Interviews', 'Focus groups', 'Questionnaires', 'Surveys']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '32', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Colorectal Cancer Participants', 'ArmGroupDescription': 'Colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Interviews - Colorectal Cancer Participants', 'Behavioral: Questionnaire', 'Behavioral: Focus Groups']}}, {'ArmGroupLabel': 'Caregivers of Colorectal Cancer Participants', 'ArmGroupDescription': 'Caregivers of colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Interviews - Colorectal Cancer Participants', 'Behavioral: Focus Groups', 'Behavioral: Interviews - Caregivers of Colorectal Cancer Participants']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Interviews - Colorectal Cancer Participants', 'InterventionDescription': 'Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Caregivers of Colorectal Cancer Participants', 'Colorectal Cancer Participants']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Questionnaire', 'InterventionDescription': 'Questionnaire completion asking general health and demographic questions.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Colorectal Cancer Participants']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Survey']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Focus Groups', 'InterventionDescription': 'Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Caregivers of Colorectal Cancer Participants', 'Colorectal Cancer Participants']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Interviews - Caregivers of Colorectal Cancer Participants', 'InterventionDescription': 'Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Caregivers of Colorectal Cancer Participants']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Effectiveness of Colorectal Cancer (CRC) Surveillance', 'PrimaryOutcomeDescription': "Semi-structured interviews and focus groups reviewed to identify themes related to participants' and caregiver's priorities regarding surveillance of colorectal cancer.", 'PrimaryOutcomeTimeFrame': '1 day'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAge 21 or older\nAble to read and speak English\nAble to undergo a 30 to 60-minute interview or focus group\nFor phase 1: MD Anderson patient undergoing follow-up for curative resection of stage I-IV colon or rectal cancer OR caregiver of such a patient\nFor phase 2: Colon or rectal cancer patient\n\nExclusion Criteria:\n\nN/A', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '21 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients of MD Anderson Colorectal Center and their caregivers recruited by study staff.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'George J. Chang, MD,MS', 'OverallOfficialAffiliation': 'M.D. Anderson Cancer Center', 'OverallOfficialRole': 'Study Chair'}, {'OverallOfficialName': 'Robert Volk, PHD', 'OverallOfficialAffiliation': 'M.D. Anderson Cancer Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of California San Francisco', 'LocationCity': 'San Francisco', 'LocationState': 'California', 'LocationZip': '94143', 'LocationCountry': 'United States'}, {'LocationFacility': 'Lyndon B. Johnson General Hospital', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77026', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Texas MD Anderson Cancer Center', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '32080809', 'ReferenceType': 'derived', 'ReferenceCitation': 'Zafar SN, Hu CY, Snyder RA, Cuddy A, You YN, Lowenstein LM, Volk RJ, Chang GJ. Predicting Risk of Recurrence After Colorectal Cancer Surgery in the United States: An Analysis of a Special Commission on Cancer National Study. Ann Surg Oncol. 2020 Aug;27(8):2740-2749. doi: 10.1245/s10434-020-08238-7. Epub 2020 Feb 20.'}, {'ReferencePMID': '29800181', 'ReferenceType': 'derived', 'ReferenceCitation': 'Snyder RA, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, Van Loon K, You YN, Kozower BD, Greenberg CC, Schrag D, Venook A, McKellar D, Winchester DP, Chang GJ; Alliance for Clinical Trials in Oncology Network Cancer Surveillance Optimization Working Group. Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer. JAMA. 2018 May 22;319(20):2104-2115. doi: 10.1001/jama.2018.5816.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'University of Texas MD Anderson Cancer Center Website', 'SeeAlsoLinkURL': 'http://www.mdanderson.org'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000015179', 'ConditionMeshTerm': 'Colorectal Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000012002', 'ConditionAncestorTerm': 'Rectal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafAsFound': 'Colorectal Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13996', 'ConditionBrowseLeafName': 'Rectal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 42, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03797482', 'OrgStudyIdInfo': {'OrgStudyId': 'Protocol 254'}, 'Organization': {'OrgFullName': 'Tata Memorial Hospital', 'OrgClass': 'OTHER_GOV'}, 'BriefTitle': 'A Prospective Evaluation of the Peri-operative Hypoxia in Breast Cancer', 'OfficialTitle': 'A Prospective Evaluation of the Peri-operative Hypoxia in Breast Cancer', 'Acronym': 'Hypoxia'}, 'StatusModule': {'StatusVerifiedDate': 'April 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 27, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 30, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'November 30, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 28, 2018', 'StudyFirstSubmitQCDate': 'January 4, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 9, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 26, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 27, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Dr Rajendra A. Badwe', 'ResponsiblePartyInvestigatorTitle': 'Director, Tata Memorial Centre and Professor, Department of Surgical Oncology', 'ResponsiblePartyInvestigatorAffiliation': 'Tata Memorial Centre'}, 'LeadSponsor': {'LeadSponsorName': 'Tata Memorial Hospital', 'LeadSponsorClass': 'OTHER_GOV'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'To understand the effects induced by acute hypoxia that sets in during surgery in breast cancer. To study this, clinical samples (Tumor biopsies) will be obtained during the surgery after partial devascularisation (sample B) and stored for future genomic and proteonomic evaluations.', 'DetailedDescription': 'Three tumor samples will be obtained after the patient is under anaesthesia,\n\nPrior to starting surgery (Sample A)\nThe middle intra-operative sample, which will be collected when half the tumour has been devascularized (i.e., somewhere midway during the surgery). (Sample B)\nA third post excision (anoxic sample C). These tumour tissue samples will be stored as snap frozen, in RNA later and as paraffin sections.\n\nTo understand the effects induced by acute hypoxia that sets in during surgery in breast cancer. To study this, clinical samples (Tumor biopsies) will be obtained during and stored for future genomic and proteonomic evaluations.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer Female']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Breast cancer tumor tissue'}, 'EnrollmentInfo': {'EnrollmentCount': '500', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intra-operative tumour tissue biopsies', 'ArmGroupDescription': 'Intra-operative tumour tissue biopsies will be collected for all patients', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Intra-operative Tumor Tissue Biopsy']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'Intra-operative Tumor Tissue Biopsy', 'InterventionDescription': 'The changing pattern of gene expression during surgery has never been studied. This could be an effect of acute hypoxia that sets in the tumour during surgery or could be a surgical response. To study these changes happening in the tumour during surgery, we are taking serial biopsies during surgery, one at the beginning, one midway during surgery and one at the end of surgery. These samples will be snap frozen and stored at -80 deg celsius in biorepository for future analysis.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intra-operative tumour tissue biopsies']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Breast cancer surgery']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Gene expression changes', 'PrimaryOutcomeDescription': 'The primary outcome measured will be gene expression changes during surgical resection. Messenger ribonucleic acid (mRNA) transcripts will be quantitated and their levels evaluated during different time-points of surgical resection, using high throughput omics technologies (Next generation sequencing, nanostring ncounter, qRT-PCR array).', 'PrimaryOutcomeTimeFrame': 'The study aims to evaluate gene expression changes during surgical resection, which lasts for 30-90 minutes on an average. Thus, we have not planned a clinical follow-up or collection of data for the patients post sampling during surgical resection.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Immunohistochemistry for other markers', 'SecondaryOutcomeDescription': 'The secondary outcome measured will be protein expression changes during surgical resection. Protein levels will be quantitated, and their levels evaluated, during different time-points of surgical resection. Transcripts found to be de-regulated or changed at different time-points of surgical resection will be evaluated using IHC at protein level. We will also use high throughput omics technologies (SILAC, ITRAQ) for characterising these changes at protein levels.', 'SecondaryOutcomeTimeFrame': 'The study aims to evaluate gene expression changes during surgical resection, which lasts for 30-90 minutes on an average. Thus, we have not planned a clinical follow-up or collection of data for the patients post sampling during surgical resection.'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nClinically diagnosis of breast cancer (by FNAC or Biopsy)\nNot received any chemotherapy or surgical intervention except core biopsy.\nPlaned for Breast cancer surgery\nWilling to give consent for the study\n\nExclusion Criteria:\n\nClinically diagnosis of Metastatic breast cancer\nReceived any anticancer therapy', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'GenderBased': 'Yes', 'GenderDescription': 'Women diagnosed with breast cancer, undergoing surgery upfront', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Women diagnosed with breast cancer at outpatient clinic', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Shalaka Joshi, MS, MCh', 'CentralContactRole': 'Contact', 'CentralContactPhone': '9869089803', 'CentralContactPhoneExt': '4265', 'CentralContactEMail': 'drjoshishalaka@gmail.com'}, {'CentralContactName': 'Rohini A Hawaldar', 'CentralContactRole': 'Contact', 'CentralContactPhone': '09820432613', 'CentralContactEMail': 'rwhawaldar@gmail.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Rajendra Badwe', 'OverallOfficialAffiliation': 'Director, tata Memorial Centre', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Tata Memorial Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Mumbai', 'LocationState': 'Maharashtra', 'LocationZip': '400012', 'LocationCountry': 'India', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shalaka Joshi, MS, MCh', 'LocationContactRole': 'Contact', 'LocationContactPhone': '22241608601', 'LocationContactPhoneExt': '4265', 'LocationContactEMail': 'drjoshishalaka@gmail.com'}, {'LocationContactName': 'Rohini A Hawaldar, BSc', 'LocationContactRole': 'Contact', 'LocationContactPhone': '09820432613', 'LocationContactEMail': 'rwhawaldar@gmail.com'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '23222717', 'ReferenceType': 'background', 'ReferenceCitation': 'Semenza GL. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene. 2013 Aug 29;32(35):4057-63. doi: 10.1038/onc.2012.578. Epub 2012 Dec 10.'}, {'ReferencePMID': '11395851', 'ReferenceType': 'background', 'ReferenceCitation': 'Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol. 2001 Apr;28(2 Suppl 8):36-41.'}, {'ReferencePMID': '23915189', 'ReferenceType': 'background', 'ReferenceCitation': 'Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer. 2013 Aug 2;12:86. doi: 10.1186/1476-4598-12-86.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}, {'ConditionMeshId': 'D000000860', 'ConditionMeshTerm': 'Hypoxia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}, {'ConditionAncestorId': 'D000012818', 'ConditionAncestorTerm': 'Signs and Symptoms, Respiratory'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3337', 'ConditionBrowseLeafName': 'Hypoxia', 'ConditionBrowseLeafAsFound': 'Hypoxia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14775', 'ConditionBrowseLeafName': 'Signs and Symptoms, Respiratory', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 43, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03143140', 'OrgStudyIdInfo': {'OrgStudyId': 'Z151100004015186'}, 'Organization': {'OrgFullName': 'Peking University Cancer Hospital & Institute', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma', 'OfficialTitle': 'The Clinical Value of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma'}, 'StatusModule': {'StatusVerifiedDate': 'October 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 22, 2014', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 31, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 1, 2018', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 4, 2017', 'StudyFirstSubmitQCDate': 'May 4, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 8, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'October 16, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 17, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Kun Yan', 'ResponsiblePartyInvestigatorTitle': 'Director of ultrasonography department', 'ResponsiblePartyInvestigatorAffiliation': 'Peking University Cancer Hospital & Institute'}, 'LeadSponsor': {'LeadSponsorName': 'Peking University Cancer Hospital & Institute', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'To evaluate a novel technique-ultrasound guided percutaneous abaltion of tumor feeding artery before RFA for liver malignancy.', 'DetailedDescription': 'Hepatocellular carcinoma is one of the most common tumor in clinical practice. In recent years, various local therapies, especially radiofrequency ablation (RFA) has been proved safe and effective.The main limitation of RFA is that its therapeutic impact is significant compromised by blood flow cooling effect, especially in hypervascular HCC. Recent studies showed combined therapy of TACE and RFA can decrease the blood supply of tumor, increase ablated volume and therefore improve the outcome. However, TACE application is limited in patients who cannot tolerate this therapy due to the side effects of repeated TACE, poor liver function or previously legated hepatic artery. The present study is focus on "difficult-to-treat" HCC patients who are neither surgical candidates, nor TACE candidates. The investigators introduce the novel treatment mode that RFA followed ultrasound guided percutaneous ablation of tumur feeding arterial to treat these difficult cases and evaluate the clinical effect.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Liver Neoplasms']}, 'KeywordList': {'Keyword': ['Ablation Techniques']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'PAFA and tumor ablation', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'first percutaneous frequency ablation of tumor feeding artery and then ablation of tumor', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: PAFA', 'Other: tumor ablation']}}, {'ArmGroupLabel': 'tumor ablation', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'ablation of tumor directly', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: tumor ablation']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'PAFA', 'InterventionDescription': 'percutaneous ablation of tumor feeding artery', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['PAFA and tumor ablation']}, 'InterventionOtherNameList': {'InterventionOtherName': ['percutaneous ablation of tumor feeding artery']}}, {'InterventionType': 'Other', 'InterventionName': 'tumor ablation', 'InterventionDescription': 'ablation of tumor area directly', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['PAFA and tumor ablation', 'tumor ablation']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'completed tumor necrosis', 'PrimaryOutcomeDescription': 'Contrast enhanced CT or MRI was examed to evaluate tumor necrosis 1 month after ablation.', 'PrimaryOutcomeTimeFrame': '1 month'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'tumor recurrence', 'SecondaryOutcomeDescription': 'tumor recurrence around the ablation zone', 'SecondaryOutcomeTimeFrame': 'up to 36 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\ntumor number ≤3， maximum tumor size ≤5cm;\naccessibility of tumors via a percutaneous approach;\ntumor feeding artery can be detected by 3D contrast enhance ultrasound;\nplatelet count ≥ 50,000/ml and INR <1.6;\nlife expectancy more than 6 months\nChild grade A or B\n\nExclusion Criteria:\n\npatients who scheduled liver transplantation\nwith extrahepatic metastasis\nwomen during menstruation, pregnancy, child birth and baby nursing period\npatients with severe mental disorder\ncardiopulmonary failure', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kun Yan, master', 'OverallOfficialAffiliation': 'Peking University Cancer Hospital & Institute', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Beijing Cancer Hospital', 'LocationCity': 'Beijing', 'LocationState': 'Beijing', 'LocationZip': '100142', 'LocationCountry': 'China'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '29999436', 'ReferenceType': 'derived', 'ReferenceCitation': 'Zhang ZY, Lee JC, Yang W, Yan K, Wu W, Wang YJ, Chen MH. Percutaneous ablation of the tumor feeding artery for hypervascular hepatocellular carcinoma before tumor ablation. Int J Hyperthermia. 2018;35(1):133-139. doi: 10.1080/02656736.2018.1484525. Epub 2018 Jul 12. Erratum In: Int J Hyperthermia. 2018;35(1):140.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006528', 'ConditionMeshTerm': 'Carcinoma, Hepatocellular'}, {'ConditionMeshId': 'D000008113', 'ConditionMeshTerm': 'Liver Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002277', 'ConditionAncestorTerm': 'Carcinoma'}, {'ConditionAncestorId': 'D000009375', 'ConditionAncestorTerm': 'Neoplasms, Glandular and Epithelial'}, {'ConditionAncestorId': 'D000009370', 'ConditionAncestorTerm': 'Neoplasms by Histologic Type'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000000230', 'ConditionAncestorTerm': 'Adenocarcinoma'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000008107', 'ConditionAncestorTerm': 'Liver Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4686', 'ConditionBrowseLeafName': 'Carcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8765', 'ConditionBrowseLeafName': 'Carcinoma, Hepatocellular', 'ConditionBrowseLeafAsFound': 'Hepatocellular Carcinoma', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10265', 'ConditionBrowseLeafName': 'Liver Neoplasms', 'ConditionBrowseLeafAsFound': 'Liver Neoplasms', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11472', 'ConditionBrowseLeafName': 'Neoplasms, Glandular and Epithelial', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11467', 'ConditionBrowseLeafName': 'Neoplasms by Histologic Type', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2737', 'ConditionBrowseLeafName': 'Adenocarcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10259', 'ConditionBrowseLeafName': 'Liver Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}]}}}}}, {'Rank': 44, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05301296', 'OrgStudyIdInfo': {'OrgStudyId': 'IEC 05-05'}, 'Organization': {'OrgFullName': 'International Agency for Research on Cancer', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Trivandrum Breast Cancer Screening Trial', 'OfficialTitle': 'Evaluating of Clinical Early Detection of Breast Cancer in Trivandrum District, India', 'Acronym': 'TBCS'}, 'StatusModule': {'StatusVerifiedDate': 'March 2022', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 1, 2006', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2014', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 18, 2022', 'StudyFirstSubmitQCDate': 'March 18, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 29, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 18, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 29, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'International Agency for Research on Cancer', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Regional Cancer Centre, Trivandrum, India', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Cluster-randomized controlled trial in Trivandrum district, Kerala, India to evaluate the effect of triennial screening for breast cancer using clinical breast examination on breast cancer mortality.', 'DetailedDescription': 'The study population consisted of 274 administrative regions (clusters) in Trivandrum district, Kerala, southern Indian. 133 clusters were randomly assigned to the intervention arm (3 rounds of clinical breast examination conducted 3 years apart) and were compared to the remaining 141 clusters assigned to a control arm that received standard of care. The eligibility criteria were all healthy subjects aged 30 to 69, without a personal history of breast cancer. Informed consent was signed by each participant. The intervention arm consisted of 55,843 participants and the control group consisted of 59,447 participants.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'The control group received standard of care while the intervention group received 3 rounds of screening with clinical breast examination, each 3 years apart. After the 3 rounds of screening, the participants were followed up for an additional 4 years to accrue information on breast cancer incidence and mortality, and the vital status.', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)', 'DesignMaskingDescription': 'Cancer registry staff members blinded to study group assignments collected data on the date of diagnosis, stage, treatment and follow-up details of breast cancer patients by visiting hospitals and laboratories where breast cancer cases are diagnosed and treated. The cause of death was assessed by two independent experts blinded to group allocation after evaluation of data from hospital records, death certificates, house visits and interviews of relatives and friends.'}}, 'EnrollmentInfo': {'EnrollmentCount': '115290', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Control Arm', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Standard of Care.'}, {'ArmGroupLabel': 'Intervention Arm', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Clinical examination of the breast for early detection of Cancer.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Clinical examination of the breast for early detection of Cancer']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test', 'InterventionName': 'Clinical examination of the breast for early detection of Cancer', 'InterventionDescription': 'Participants were invited for 3 rounds of clinical breast examination, conducted 3-years apart. Screening was conducted by health workers trained to perform clinical breast examination for early detection of cancer. Women with abnormal referable lesions underwent CBE by a trained clinician and those women with a confirmed breast lump or any other breast abnormality warranting further investigations were evaluated by triple-testing involving expert physical examination, diagnostic mammography with or without ultrasonography and fine needle aspiration cytology (FNAC) or core biopsy or excision biopsy. Those with confirmed breast cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention Arm']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Breast Cancer Death Rate', 'PrimaryOutcomeDescription': 'Information on all deaths were collected from the municipal and district death registers, hospital medical records, death records of churches and mosques, hospital visits by the population cancer registry staff and by project health workers. Cancer cases were coded by the ICD-O 3rd edition codes and cause of death was coded using ICD-10 by the registry and project staff blinded to study group allocation. Deaths were attributed to breast cancer if the patient had histologically or clinically confirmed breast cancer, lymph nodes or distant metastasis at the time of death or had died due to complications of breast cancer treatment.', 'PrimaryOutcomeTimeFrame': '14 years'}, {'PrimaryOutcomeMeasure': 'Breast Cancer Incidence', 'PrimaryOutcomeDescription': 'Information on incident breast cancer cases were obtained from the Trivandrum population-based cancer registry, hospital cancer registry of the RCC and medical records departments of other hospitals treating breast cancer patients. Collection of information was blinded to study group assignment of cases. The staging of breast cancers was done according to the UICC TNM staging system.', 'PrimaryOutcomeTimeFrame': '14 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nResiding in 274 study clusters in Trivandrum City, Kerala\n\nExclusion Criteria:\n\nDiagnosis with breast cancer prior to study\nBedridden subjects\nSubjects suffering from open tuberculosis or other debilitating diseases', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '30 Years', 'MaximumAge': '69 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kunnambath Ramadas, MD. DNB. FAMS, PhD', 'OverallOfficialAffiliation': 'Regional Cancer Centre, Trivandrum, India', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Rengaswamy Sankaranarayanan, MD', 'OverallOfficialAffiliation': 'International Agency for Research on Cancer', 'OverallOfficialRole': 'Principal Investigator'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '21862730', 'ReferenceType': 'result', 'ReferenceCitation': 'Sankaranarayanan R, Ramadas K, Thara S, Muwonge R, Prabhakar J, Augustine P, Venugopal M, Anju G, Mathew BS. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst. 2011 Oct 5;103(19):1476-80. doi: 10.1093/jnci/djr304. Epub 2011 Aug 23.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 45, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04820868', 'OrgStudyIdInfo': {'OrgStudyId': 'RSCD2020003'}, 'Organization': {'OrgFullName': 'Shanghai Zhongshan Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Unintrusive Detection of EaRly-stage Cancers', 'OfficialTitle': 'A Blinded Prospective Study on Validation of the Performance of a cfDNA Methylation-based Model for Early Cancer Detection', 'Acronym': 'THUNDER'}, 'StatusModule': {'StatusVerifiedDate': 'April 2021', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 23, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 31, 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2021', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 26, 2021', 'StudyFirstSubmitQCDate': 'March 26, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 29, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 28, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 29, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Shanghai Zhongshan Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Guangzhou Burning Rock Dx Co., Ltd.', 'CollaboratorClass': 'INDUSTRY'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'According to a previous study, a cell-free DNA (cfDNA) methylation-based model showed high sensitivity and specificity (80.6% and 98.3%) in blood-based multi-cancer detection. In this way, a multi-center, prospective, single-blind study (THUNDER study) is designed to further validate the performance of the cfDNA methylation-based model for early cancer detection. Blood RNA markers will also be evaluated. The study will enroll approximately 2508 participants, including participants with malignancies and healthy participants.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer']}, 'KeywordList': {'Keyword': ['Cancer', 'Liquid biopsy', 'Cell-free DNA (cfDNA)', 'Early detection']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '2508', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer Arm', 'ArmGroupDescription': 'Participants with new diagnosis of cancer, from whom blood samples will be collected', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Multi-cancer early detection test']}}, {'ArmGroupLabel': 'Healthy Arm', 'ArmGroupDescription': 'Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Multi-cancer early detection test']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Multi-cancer early detection test', 'InterventionDescription': 'Blood collection and multi-cancer early detection test', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer Arm', 'Healthy Arm']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Sensitivity and specificity of early detection of 6 types of cancers and Tissue of origin (TOO) accuracy of a cfDNA methylation-based model', 'PrimaryOutcomeTimeFrame': '7 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Sensitivity, specificity and TOO accuracy of a cfDNA methylation-based model in different stages or pathological types of cancer', 'SecondaryOutcomeTimeFrame': '7 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria for All the Participants:\n\nAbility to provide a written informed consent\n40-75 years old\nAbility to comply with study procedures\n\nExclusion Criteria for All the Participants:\n\nPregnancy or lactating women\nRecipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant\nRecipients of blood transfusion within 7 days prior to study blood draw\nRecipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer\n\nInclusion Criteria for Cancer Arm Participants:\n\nConfirmed diagnosis or suspicious cases of cancer within 42 days prior to study blood draw.\nNo prior anti-cancer therapy (local or systematic) prior to study blood draw\n\nExclusion Criteria for Cancer Arm Participants:\n\nKnown prior or current diagnosis of other types of malignancies or multiple primary tumors\nDiagnosis of benign diseases by histopathological assessments\nNo confirmed diagnosis of cancer by histopathological or radiological assessments within 42 days of study blood draw, or inability to characterize whether the lesion is malignant or benign\nNon-small-cell lung cancer patients with ground-class nodularity by radiological examination\nDiagnosis of precancerous lesions\n\nInclusion Criteria for Healthy Arm Participants:\n\nNo cancer-related symptoms or discomfort within 30 days prior to study blood draw\nNo clinically significant finding by physical examinations, hematological assessment, urinalysis, LDCT or ultrasound\nNo clinically significant finding by breast ultrasound or Molybdenum Target Mammography Detection, or Thinprep cytologic test (TCT) detection for female participants\nNo active hepatitis B or hepatitis C infection\n\nExclusion Criteria for Healthy Arm Participants:\n\nPrior or ongoing treatment of cancer within 3 years prior to study blood draw\nClinically significant or uncontrolled comorbidities', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Eligible participants will be recruited from medical centers and assigned into two arms, including participants with new diagnosis of malignancies and healthy participants.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Qiang Gao, M.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+86-021-64041990', 'CentralContactEMail': 'gao.qiang@zs-hospital.sh.cn'}, {'CentralContactName': 'Shangli Cai, Ph.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+86-021-61631938', 'CentralContactEMail': 'shangli.cai@brbiotech.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Qiang Gao, M.D.', 'OverallOfficialAffiliation': 'Shanghai Zhongshan Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Zhongshan Hospital, Fudan University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Shanghai', 'LocationState': 'Shanghai', 'LocationZip': '200032', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Qiang Gao, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+86-021-64041990', 'LocationContactEMail': 'gao.qiang@zs-hospital.sh.cn'}]}}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Q. Gao, B. Li, S. Cai, et al. Early detection and localization of multiple cancers using a blood-based methylation assay (ELSA-seq). Annals of Oncology (2020) 31 (suppl_6): S1358.', 'SeeAlsoLinkURL': 'https://oncologypro.esmo.org/meeting-resources/esmo-asia-virtual-congress-2020/early-detection-and-localization-of-multiple-cancers-using-a-blood-based-methylation-assay-elsa-seq'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}}}}, {'Rank': 46, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01232881', 'OrgStudyIdInfo': {'OrgStudyId': 'HOG COE-03'}, 'Organization': {'OrgFullName': 'Hoosier Cancer Research Network', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer', 'OfficialTitle': 'Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study'}, 'StatusModule': {'StatusVerifiedDate': 'April 2011', 'OverallStatus': 'Terminated', 'WhyStopped': 'funding terminated', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2010', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 2010', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 1, 2010', 'StudyFirstSubmitQCDate': 'November 1, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 2, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'April 27, 2011', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 28, 2011', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyOldNameTitle': 'George Sledge, M.D.', 'ResponsiblePartyOldOrganization': 'Hoosier Oncology Group'}, 'LeadSponsor': {'LeadSponsorName': 'Hoosier Cancer Research Network', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'United States Department of Defense', 'CollaboratorClass': 'FED'}, {'CollaboratorName': 'Indiana University School of Medicine', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Emory University', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.', 'DetailedDescription': 'OUTLINE: This is a multi-center study.\n\nSample Collection:\n\nTumor sample\nSerum sample\n\nTreatment Regimen:\n\nAll registered patients must be planning treatment with lonafarnib'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'DesignInfo': {'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.\n\nSerum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.'}, 'EnrollmentInfo': {'EnrollmentCount': '27', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Tumor and Serum Collection', 'ArmGroupDescription': 'Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.\n\nSerum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Tumor Sample', 'Procedure: Serum Sample']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'Tumor Sample', 'InterventionDescription': 'Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Tumor and Serum Collection']}}, {'InterventionType': 'Procedure', 'InterventionName': 'Serum Sample', 'InterventionDescription': 'Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Tumor and Serum Collection']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'To correlate tumor gene expression (genomic profile) with response to lonafarnib in patients with advanced breast cancer', 'PrimaryOutcomeTimeFrame': '24 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'To correlate serum and tumor proteomic profiles with response to lonafarnib', 'SecondaryOutcomeTimeFrame': '24 months'}, {'SecondaryOutcomeMeasure': 'To compare serum and tissue proteomic analyses', 'SecondaryOutcomeTimeFrame': '24 months'}, {'SecondaryOutcomeMeasure': 'To compare genomic and proteomic profiles', 'SecondaryOutcomeTimeFrame': '24 months'}, {'SecondaryOutcomeMeasure': 'To correlate toxicity and /or response with drug-specific pharmacogenomic parameters', 'SecondaryOutcomeTimeFrame': '24 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nWritten informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\nAge > 18 years.\nPlanned treatment with lonafarnib for metastatic breast cancer.\nMust consent to have a biopsy performed to obtain fresh tissue or be able to identify a formalin fixed paraffin embedded (FFPE) tissue block in which tumor samples can be obtained to complete the testing for this study.\n\nExclusion Criteria:\n\nPlanned treatment with any other treatment regimen', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'The study population will be limited to patients with advanced breast cancer receiving treatment with lonafarnib.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'George Sledge, M.D.', 'OverallOfficialAffiliation': 'Hoosier Cancer Research Network', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Indiana University Melvin and Bren Simon Cancer Center', 'LocationCity': 'Indianapolis', 'LocationState': 'Indiana', 'LocationZip': '46202', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Hoosier Oncology Group Homepage', 'SeeAlsoLinkURL': 'http://www.hoosieroncologygroup.org'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M7833', 'InterventionBrowseLeafName': 'Formaldehyde', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M347274', 'InterventionBrowseLeafName': 'Lonafarnib', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 47, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03180086', 'OrgStudyIdInfo': {'OrgStudyId': '2017P000129'}, 'Organization': {'OrgFullName': 'Beth Israel Deaconess Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Breast Cancer Risk Assessment in Women Aged 40-49', 'OfficialTitle': 'Breast Cancer Risk Assessment in Women Aged 40-49'}, 'StatusModule': {'StatusVerifiedDate': 'December 2022', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 1, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 25, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'July 1, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 6, 2017', 'StudyFirstSubmitQCDate': 'June 6, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 8, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'December 13, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 14, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Mara Schonberg', 'ResponsiblePartyInvestigatorTitle': 'Principle Investigator - Staff Physician', 'ResponsiblePartyInvestigatorAffiliation': 'Beth Israel Deaconess Medical Center'}, 'LeadSponsor': {'LeadSponsorName': 'Beth Israel Deaconess Medical Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'In a randomized controlled trial, the investigators will test the effect of a novel strategy for breast cancer risk assessment and risk-based management of women in their 40s seen in primary care. The investigators anticipate that this approach will lead to more optimal use of mammography screening and breast cancer prevention interventions in women in their 40s and as a result will improve care of these women.', 'DetailedDescription': "There is currently no standardized practice for addressing breast cancer risk in primary care. While there are guidelines encouraging PCPs to assess patients' breast cancer risk, few PCPs assess patients' risk due to time constraints in primary care, lack of familiarity with risk calculators, and knowledge on how to incorporate risk into the care of women. Around 20% of PCPs have reported using a risk calculator but few routinely asses patients' risk. In HealthCare Associates (HCA), Beth Israel Deaconess Medical Center's primary-care based practice, the online medical record (OMR) has recently been edited to allow for PCPs to enter patients' breast cancer risk. However, it is not known whether PCPs are using this tab. To calculate patient's breast cancer risk, PCPs must go to web-based calculators, ask patients their risk factors, enter the information and then add the estimated risk to OMR. Previous studies suggest that leaving risk assessment to PCPs results in few women having their risk assessed. Instead, PCPs tend to simply use family history when deciding whether or not patients are at high risk. However, family history is only one risk factor for breast cancer. Therefore, the investigators will send women ages 40-49 participating in this study a questionnaire to complete before a visit to assess their risk factors for breast cancer. Using this information, the investigators will calculate patients' breast cancer risk using the available breast cancer risk assessment models and will present women with a personalized breast cancer risk report immediately before a visit with their PCP. After the visit, patients will be asked to complete a follow-up questionnaire about their experience and through their medical records will be followed to learn whether or not they are screened with mammography. The investigators will follow high-risk women to learn whether or not they receive a screening breast MRI, BRCA gene testing, and/or the option to take breast cancer prevention medications. The investigators aim to recruit 445 women 40-49 years seen at HCA into a single arm trial to learn the effect of our personalized risk based approach to breast cancer screening and prevention on women in their 40's intentions to be screened and knowledge of the pros and cons of screening.\n\nSpecific Aims: To determine the effect of a personalized risk based approach for breast cancer screening and prevention for women in their 40s seen in primary care on:\n\nwomen's intentions to be screened with mammography (primary outcome),\nknowledge of the pros and cons of mammography screening, and\ndecisional conflict around screening; and on\npatient report of PCP discussion of their breast cancer risk and of the pros and cons of mammography screening."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['Breast cancer risk', 'Primary Care', 'Women']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '338', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast cancer risk report', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Breast cancer risk report']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Breast cancer risk report', 'InterventionDescription': 'An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Breast cancer risk report']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Screening intentions', 'PrimaryOutcomeDescription': "Change in women's intentions to be screened with mammography after the intervention by 5-year breast cancer risk using a multivariable linear regression to examine the association between 5-year breast cancer risk and intentions to be screened after the intervention (as a continuous variable from 1 [not intending to be screened] to 15 [strongly intending to be screened]) adjusting for intentions to be screened at baseline as well as age, educational attainment, and race/ethnicity.", 'PrimaryOutcomeTimeFrame': '1 week'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Screening intentions within risk groups', 'SecondaryOutcomeDescription': 'The investigators will us the paired t-test (or Wilcoxon Signed Rank Test if data are not normal) to examine the differences in intentions to be screened with mammography after the intervention within each risk group.', 'SecondaryOutcomeTimeFrame': '1 week'}, {'SecondaryOutcomeMeasure': 'Knowledge of the pros and cons of mammography screening', 'SecondaryOutcomeDescription': "The investigators will use the paired t-test (or Wilcoxon Signed Rank Test when data are not normal) to examine the effect of the intervention on participants' knowledge of the benefits and risks of mammography screening (mean score on knowledge test)", 'SecondaryOutcomeTimeFrame': '1 week'}, {'SecondaryOutcomeMeasure': 'Decisional conflict scale', 'SecondaryOutcomeDescription': "The DCS is a validated 16 item scale to measure uncertainty around a decision, whether one feels informed, clear about their personal values, and supported in their decision-making (Cronbach's alpha=0.78 to 0.92); scores range 0-100 and lower scores indicate less conflict.", 'SecondaryOutcomeTimeFrame': '1 week'}, {'SecondaryOutcomeMeasure': 'Difference in PCP discussion of breast cancer risk', 'SecondaryOutcomeDescription': "The investigators will use McNemar's test to examine patient reports of PCP discussions of breast cancer risk [yes/no] before and after the intervention.", 'SecondaryOutcomeTimeFrame': '1 week'}, {'SecondaryOutcomeMeasure': 'Difference in PCP discussion of pros/cons of mammography screening', 'SecondaryOutcomeDescription': "The investigators will use McNemar's test to examine patient report of PCP discussion of the pros and cons of mammography screening [yes/no] before and after the intervention.", 'SecondaryOutcomeTimeFrame': '1 week'}, {'SecondaryOutcomeMeasure': 'PCP discussion of breast cancer prevention medications', 'SecondaryOutcomeDescription': 'The investigators will use descriptive statistics to examine the proportion of women with >1.7% 5-year breast cancer risk that report discussing breast cancer prevention medications with their PCP.', 'SecondaryOutcomeTimeFrame': '1 week'}, {'SecondaryOutcomeMeasure': 'PCP documentation of discussions of breast cancer medications', 'SecondaryOutcomeDescription': 'The investigators will use descriptive statistics to examine the proportion of women with >1.7% 5-year breast cancer whose PCPs document discussions about breast cancer prevention medications on the day of the visit.', 'SecondaryOutcomeTimeFrame': '1 week'}, {'SecondaryOutcomeMeasure': 'Prescription of breast cancer prevention medications', 'SecondaryOutcomeDescription': 'The investigators will use descriptive statistics to report proportion of women with >1.7% 5-year breast cancer risk who were prescribed breast cancer prevention medications through review of medication lists', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Time until breast screening MRI', 'SecondaryOutcomeDescription': 'The investigators will use the log-rank test to examine time until breast screening MRI among women with >20% lifetime breast cancer risk by lifetime breast cancer risk score as a continuous variable.', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Referral to genetic counseling', 'SecondaryOutcomeDescription': 'The investigators will examine the proportion of women who meet NCCN criteria for genetic counseling for a BRCA mutation that are referred for genetic counseling', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Attended genetic counseling', 'SecondaryOutcomeDescription': 'The investigators will examine the proportion of women who meet NCCN criteria for genetic counseling for a BRCA mutation that meet with a genetic counselor', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Time until next mammogram after intervention', 'SecondaryOutcomeDescription': "The investigators will examine the time until next mammogram after our intervention stratified by women's 5-year risk of breast cancer (based on the Breast Cancer Risk Assessment Tool [BCRAT]/Tice model [whichever is higher]) using the log-rank test.", 'SecondaryOutcomeTimeFrame': '21 months'}, {'SecondaryOutcomeMeasure': 'Date of mammogram(s) after intervention', 'SecondaryOutcomeDescription': "The investigators will document the date of mammogram performed on any women in the study during the study's follow-up time period.", 'SecondaryOutcomeTimeFrame': '21 months'}, {'SecondaryOutcomeMeasure': 'Type of mammogram(s) after intervention', 'SecondaryOutcomeDescription': "The investigators will document the type of mammogram performed on any women in the study during the study's follow-up time period.", 'SecondaryOutcomeTimeFrame': '21 months'}, {'SecondaryOutcomeMeasure': 'No mammogram after intervention', 'SecondaryOutcomeDescription': "The investigators will perform a chart review of women not identified as having had a mammogram during the study's follow-up time period to confirm that there is no mammogram noted in their screening sheet.", 'SecondaryOutcomeTimeFrame': '21 months'}, {'SecondaryOutcomeMeasure': 'Risk report acceptability', 'SecondaryOutcomeDescription': 'The investigators will ask whether patients and PCPs found our risk report acceptable and/or helpful.', 'SecondaryOutcomeTimeFrame': '1 week'}, {'SecondaryOutcomeMeasure': 'PCP facilitators and barriers', 'SecondaryOutcomeDescription': "The investigators will examine facilitators and/or barriers noted by PCPs when assessing women's breast cancer risk and managing women based on their risk.", 'SecondaryOutcomeTimeFrame': 'up to 24 months'}, {'SecondaryOutcomeMeasure': 'PCP risk of malpractice/litigation', 'SecondaryOutcomeDescription': 'The investigators will ask whether PCPs feel that our intervention would help lower their risk of malpractice litigation.', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': "Inclusion Criteria:\n\nwomen\naged 40-49 years\nread and speak English\nscheduled for a routine visit or physical examination with a non-resident PCP in the next 4-12 weeks at HealthCare Associates (HCA, BIDMC's outpatient primary care practice).\n\nExclusion Criteria:\n\nwomen scheduled for acute care\nwomen who had or will have a mammogram within 6 months of their PCP visit\nwomen with a history of breast cancer or a BRCA mutation\nwomen already receiving screening breast MRIs\nwomen who have been referred to genetic counseling\nwomen who have taken or are taking tamoxifen or aromatase inhibitors for breast cancer prevention\nwomen with a history of an abnormal mammogram in the past two years\nwomen with a history of breast enlargement or reduction.", 'HealthyVolunteers': 'No', 'Gender': 'Female', 'GenderBased': 'Yes', 'MinimumAge': '40 Years', 'MaximumAge': '49 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Mara Schonberg, MD, MPH', 'OverallOfficialAffiliation': 'Beth Israel Deaconess Medical Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Beth Israel Deaconess Medical Center', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02215', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '32828322', 'ReferenceType': 'derived', 'ReferenceCitation': 'Schonberg MA, Davis RB, Karamourtopoulos MC, Pinheiro A, Sternberg SB, Jacobson AR, Aliberti GM, Mehta TS, Cluett JL, Cohen ML, Atlas T, Tung NM. A Pre-Test-Post-Test Trial of a Breast Cancer Risk Report for Women in Their 40s. Am J Prev Med. 2020 Sep;59(3):343-354. doi: 10.1016/j.amepre.2020.04.014.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 48, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01977274', 'OrgStudyIdInfo': {'OrgStudyId': 'GC-BIO-IPC 2013-010'}, 'Organization': {'OrgFullName': 'Institut Paoli-Calmettes', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Predictive Clinical and Biological Parameters in Gynecological Cancer', 'OfficialTitle': 'Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010', 'Acronym': 'GC-BIO'}, 'StatusModule': {'StatusVerifiedDate': 'June 2020', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 2013'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2033', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'October 30, 2013', 'StudyFirstSubmitQCDate': 'October 30, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 6, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'June 30, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 2, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Institut Paoli-Calmettes', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Ovarian Cancer', 'Endometrium Cancer', 'Cervix Cancer']}, 'KeywordList': {'Keyword': ['ovarian, endometrium, cervix cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Basic Science', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '300', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'gynecological cancer', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'blood and tumor samples', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: gynecological cancer']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'gynecological cancer', 'InterventionDescription': 'blood and tumor samples', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['gynecological cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'molecular alteration in gynecological cancer', 'PrimaryOutcomeDescription': 'gene expression level', 'PrimaryOutcomeTimeFrame': 'average of 4 weeks after diagnosis'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'relation between molecular alteration and clinical and histological characteristics', 'SecondaryOutcomeDescription': 'hazard ratio between molecular alteration and clinico-histological characteristics', 'SecondaryOutcomeTimeFrame': 'up to 10 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\ngynecological cancer suspicion\nage > 18\nsigned informed consent\n\nExclusion Criteria:\n\n- emergency\n\nExclusion criteria after histological exam Any diagnosis that is not a gynecological cancer (ovarian, cervix, endometrium).', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Dominique GENRE, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '33491223778', 'CentralContactEMail': 'drci.up@ipc.unicancer.fr'}, {'CentralContactName': 'Margot BERLINE, MSc, MBA', 'CentralContactRole': 'Contact', 'CentralContactPhone': '33491223778', 'CentralContactEMail': 'drci.up@ipc.unicancer.fr'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Institut Paoli Calmettes', 'LocationStatus': 'Recruiting', 'LocationCity': 'Marseille', 'LocationZip': '13 009', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Dominique GENRE, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '33491223778', 'LocationContactEMail': 'drci.up@ipc.unicancer.fr'}, {'LocationContactName': 'Margot BERLINE, MSc, MBA', 'LocationContactRole': 'Contact', 'LocationContactPhone': '33491223778', 'LocationContactEMail': 'drci.up@ipc.unicancer.fr'}, {'LocationContactName': 'Eric LAMBAUDIE, MD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'official web site of the sponsor', 'SeeAlsoLinkURL': 'http://www.institutpaolicalmettes.fr'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000002583', 'ConditionMeshTerm': 'Uterine Cervical Neoplasms'}, {'ConditionMeshId': 'D000016889', 'ConditionMeshTerm': 'Endometrial Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000005833', 'ConditionAncestorTerm': 'Genital Neoplasms, Female'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000014594', 'ConditionAncestorTerm': 'Uterine Neoplasms'}, {'ConditionAncestorId': 'D000002577', 'ConditionAncestorTerm': 'Uterine Cervical Diseases'}, {'ConditionAncestorId': 'D000014591', 'ConditionAncestorTerm': 'Uterine Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12126', 'ConditionBrowseLeafName': 'Ovarian Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M1704', 'ConditionBrowseLeafName': 'Carcinoma, Ovarian Epithelial', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4982', 'ConditionBrowseLeafName': 'Uterine Cervical Neoplasms', 'ConditionBrowseLeafAsFound': 'Cervix Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M18387', 'ConditionBrowseLeafName': 'Endometrial Neoplasms', 'ConditionBrowseLeafAsFound': 'Endometrium Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8097', 'ConditionBrowseLeafName': 'Genital Neoplasms, Female', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16494', 'ConditionBrowseLeafName': 'Uterine Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4977', 'ConditionBrowseLeafName': 'Uterine Cervical Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16491', 'ConditionBrowseLeafName': 'Uterine Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4352', 'ConditionBrowseLeafName': 'Ovarian Cancer', 'ConditionBrowseLeafAsFound': 'Ovarian Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'T4354', 'ConditionBrowseLeafName': 'Ovarian Epithelial Cancer', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 49, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03350490', 'OrgStudyIdInfo': {'OrgStudyId': 'Bioinformation-intestinal'}, 'Organization': {'OrgFullName': 'Fuda Cancer Hospital, Guangzhou', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Bioinformation Therapy for Intestinal Cancer', 'OfficialTitle': 'Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Intestinal Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'November 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 30, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 30, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 30, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 19, 2017', 'StudyFirstSubmitQCDate': 'November 21, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 22, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 23, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 25, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Fuda Cancer Hospital, Guangzhou', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Shengxin Biotechnology Institute, Beijing', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable intestinal cancer.', 'DetailedDescription': 'By enrolling patients with unresectable intestinal cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Advanced Intestinal Cancer']}, 'KeywordList': {'Keyword': ['Cancer ablation', 'Life information rehabilitation therapy']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer ablation', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cancer ablation']}}, {'ArmGroupLabel': 'Life information rehabilitation therapy', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this group, the patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Life information rehabilitation therapy']}}, {'ArmGroupLabel': 'Combination therapy', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink "Qilisheng"Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cancer ablation', 'Drug: Life information rehabilitation therapy']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Cancer ablation', 'InterventionDescription': 'Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer ablation', 'Combination therapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Cryoablation or irreversible electroporation']}}, {'InterventionType': 'Drug', 'InterventionName': 'Life information rehabilitation therapy', 'InterventionDescription': 'Each treatment: one bottle solution each day, consecutive 3 months, oral administration', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Combination therapy', 'Life information rehabilitation therapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['"Qilisheng" Immunoregulatory Oral Solution']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Relief degree of tumors', 'PrimaryOutcomeDescription': 'It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Progress free survival（PFS）', 'SecondaryOutcomeDescription': 'The duration between treatment and cancer recurrence', 'SecondaryOutcomeTimeFrame': '1 year'}, {'SecondaryOutcomeMeasure': 'Overall survival（OS）', 'SecondaryOutcomeDescription': 'The duration between treatment and patient pass way', 'SecondaryOutcomeTimeFrame': '3 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAll standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies\nBody tumor 1-6, with at least one tumor length > 2 cm\nKPS ≥ 70, lifespan ：3 - 6 months\nPlatelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L\n\nExclusion Criteria:\n\nPatients with cardiac pacemaker\nPatients with brain metastasis\nPatients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Fuda cancer institute of Fuda cancer hospital', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationZip': '510665', 'LocationCountry': 'China'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000007414', 'ConditionMeshTerm': 'Intestinal Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafAsFound': 'Intestinal Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21013', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 50, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03350477', 'OrgStudyIdInfo': {'OrgStudyId': 'Bioinformation-gastric'}, 'Organization': {'OrgFullName': 'Fuda Cancer Hospital, Guangzhou', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Bioinformation Therapy for Gastric Cancer', 'OfficialTitle': 'Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresctable Gastric Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'November 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 30, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 30, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 30, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 19, 2017', 'StudyFirstSubmitQCDate': 'November 19, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 22, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 23, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 25, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Fuda Cancer Hospital, Guangzhou', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Shengxin Biotechnology Institute, Beijing', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable gastric cancer.', 'DetailedDescription': 'By enrolling patients with unresectable gastric cancer adapted to enrolled criteria,this study will document for the first time the synergistic effect of cancer according to local relief degree,progress free survival(PFS)and overall survival(OS).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Advanced Gastric Cancer']}, 'KeywordList': {'Keyword': ['Cancer ablation', 'Life information rehabilitation therapy']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer ablation', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this group,the patients will receive ablation therapy(e.g.cryosurgery or irrreversible electroporation) first for big tumors (>2cm).The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cancer ablation']}}, {'ArmGroupLabel': 'Life information rehabilitation therapy', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this group,the patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Life information rehabilitation therapy']}}, {'ArmGroupLabel': 'Combination therapy', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink "Qilisheng"Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cancer ablation', 'Drug: Life information rehabilitation therapy']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'In this group,the patients will recieve no special treatment and as a control group.The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Cancer ablation', 'InterventionDescription': 'Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer ablation', 'Combination therapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Cryoblation or irreversible electroporation']}}, {'InterventionType': 'Drug', 'InterventionName': 'Life information rehabilitation therapy', 'InterventionDescription': 'Each treatment: one bottle solution each day, consecutive 3 months, oral administration', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Combination therapy', 'Life information rehabilitation therapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['"Qilisheng" Immunoregulatory Oral Solution']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Relief degree of tumors', 'PrimaryOutcomeDescription': 'It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Progress free survival（PFS）', 'SecondaryOutcomeDescription': 'The duration between treament and cancer recurrence', 'SecondaryOutcomeTimeFrame': '1 year'}, {'SecondaryOutcomeMeasure': 'Overall survival', 'SecondaryOutcomeDescription': 'The duration between treament and patient pass way', 'SecondaryOutcomeTimeFrame': '3 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAll standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies\nBody tumor 1-6, with at least one tumor length > 2 cm\nKPS ≥ 70, lifespan：3-6 months\nPlatelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L\n\nExclusion Criteria:\n\nPatients with cardiac pacemaker\nPatients with brain metastasis\nPatients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Fuda cancer institute of Fuda cancer hospital', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationZip': '510665', 'LocationCountry': 'China'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000013274', 'ConditionMeshTerm': 'Stomach Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000013272', 'ConditionAncestorTerm': 'Stomach Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M15216', 'ConditionBrowseLeafName': 'Stomach Neoplasms', 'ConditionBrowseLeafAsFound': 'Gastric Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15214', 'ConditionBrowseLeafName': 'Stomach Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T5486', 'ConditionBrowseLeafName': 'Stomach Cancer', 'ConditionBrowseLeafAsFound': 'Gastric Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21013', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 51, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03239184', 'OrgStudyIdInfo': {'OrgStudyId': 'Bioinformation-panc'}, 'Organization': {'OrgFullName': 'Fuda Cancer Hospital, Guangzhou', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Bioinformation Therapy for Pancreatic Cancer', 'OfficialTitle': 'Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Pancreatic Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'August 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 1, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 1, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 1, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 1, 2017', 'StudyFirstSubmitQCDate': 'August 1, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 3, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 23, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 25, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Fuda Cancer Hospital, Guangzhou', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Shengxin Biotechnology Institute, Beijing', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': 'The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable pancreatic cancer.', 'DetailedDescription': 'By enrolling patients with unresectable pancreatic cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Unresectable Pancreatic Cancer']}, 'KeywordList': {'Keyword': ['Cancer ablation', 'Life information rehabilitation therapy']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer ablation', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cancer ablation']}}, {'ArmGroupLabel': 'Life information rehabilitation therapy', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this group, the patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Life information rehabilitation therapy']}}, {'ArmGroupLabel': 'Combination therapy', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then "Qilisheng" Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cancer ablation', 'Drug: Life information rehabilitation therapy']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Cancer ablation', 'InterventionDescription': 'Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer ablation', 'Combination therapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Cryoablation or irreversible electroporation']}}, {'InterventionType': 'Drug', 'InterventionName': 'Life information rehabilitation therapy', 'InterventionDescription': 'Each treatment: one bottle solution each day, consecutive 3 months, oral administration', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Combination therapy', 'Life information rehabilitation therapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['"Qilisheng" Immunoregulatory Oral Solution']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Relief degree of tumors', 'PrimaryOutcomeDescription': 'It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Progress free survival（PFS）', 'SecondaryOutcomeDescription': 'The duration between treatment and cancer recurrence', 'SecondaryOutcomeTimeFrame': '1 year'}, {'SecondaryOutcomeMeasure': 'Overall survival（OS）', 'SecondaryOutcomeDescription': 'The duration between treatment and patient pass away', 'SecondaryOutcomeTimeFrame': '3 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAll standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies\nBody tumor 1-6, with at least one tumor length > 2 cm\nKPS ≥ 70, lifespan > 6 months\nPlatelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L\n\nExclusion Criteria:\n\nPatients with cardiac pacemaker\nPatients with brain metastasis\nPatients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '30 Years', 'MaximumAge': '70 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Fuda cancer institute of Fuda cancer hospital', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationZip': '510665', 'LocationCountry': 'China'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010190', 'ConditionMeshTerm': 'Pancreatic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010182', 'ConditionAncestorTerm': 'Pancreatic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12262', 'ConditionBrowseLeafName': 'Pancreatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7015', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12254', 'ConditionBrowseLeafName': 'Pancreatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7014', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4387', 'ConditionBrowseLeafName': 'Pancreatic Cancer', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21013', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 52, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03239158', 'OrgStudyIdInfo': {'OrgStudyId': 'Bioinformation-liver'}, 'Organization': {'OrgFullName': 'Fuda Cancer Hospital, Guangzhou', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Bioinformation Therapy for Liver Cancer', 'OfficialTitle': 'Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Liver Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'August 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 2, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 1, 2017', 'StudyFirstSubmitQCDate': 'August 1, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 3, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 23, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 25, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Fuda Cancer Hospital, Guangzhou', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Shengxin Biotechnology Institute, Beijing', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable liver cancer.', 'DetailedDescription': 'By enrolling patients with unresectable liver cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Liver, Cancer of, Non-Resectable']}, 'KeywordList': {'Keyword': ['Cancer ablation', 'Life information rehabilitation therapy']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer ablation', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cancer ablation']}}, {'ArmGroupLabel': 'Life information rehabilitation therapy', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this group, the patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Life information rehabilitation therapy']}}, {'ArmGroupLabel': 'Combination therapy', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then "Qilisheng" Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cancer ablation', 'Drug: Life information rehabilitation therapy']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Cancer ablation', 'InterventionDescription': 'Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer ablation', 'Combination therapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Cryoablation or irreversible electroporation']}}, {'InterventionType': 'Drug', 'InterventionName': 'Life information rehabilitation therapy', 'InterventionDescription': 'Each treatment: one bottle solution each day, consecutive 3 months, oral administration', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Combination therapy', 'Life information rehabilitation therapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['"Qilisheng" Immunoregulatory Oral Solution']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Relief degree of tumors', 'PrimaryOutcomeDescription': 'It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Progress free survival（PFS）', 'SecondaryOutcomeDescription': 'The duration between treatment and cancer recurrence', 'SecondaryOutcomeTimeFrame': '1 year'}, {'SecondaryOutcomeMeasure': 'Overall survival（OS）', 'SecondaryOutcomeDescription': 'The duration between treatment and patient pass away', 'SecondaryOutcomeTimeFrame': '3 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAll standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies\nBody tumor 1-6, with at least one tumor length > 2 cm\nKPS ≥ 70, lifespan > 6 months\nPlatelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L\n\nExclusion Criteria:\n\nPatients with cardiac pacemaker\nPatients with brain metastasis\nPatients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '30 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Fuda cancer institute of Fuda cancer hospital', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationZip': '510665', 'LocationCountry': 'China'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000008113', 'ConditionMeshTerm': 'Liver Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000008107', 'ConditionAncestorTerm': 'Liver Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10265', 'ConditionBrowseLeafName': 'Liver Neoplasms', 'ConditionBrowseLeafAsFound': 'Liver, Cancer of', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10259', 'ConditionBrowseLeafName': 'Liver Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21013', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M10262', 'InterventionBrowseLeafName': 'Liver Extracts', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Hemat', 'InterventionBrowseBranchName': 'Hematinics'}]}}}}}, {'Rank': 53, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02493569', 'OrgStudyIdInfo': {'OrgStudyId': 'KYLLSL-2015-153-01'}, 'Organization': {'OrgFullName': "First Affiliated Hospital Xi'an Jiaotong University", 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China', 'OfficialTitle': 'A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China (Based on Hospital)'}, 'StatusModule': {'StatusVerifiedDate': 'August 2016', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 2016'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2017', 'PrimaryCompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 7, 2015', 'StudyFirstSubmitQCDate': 'July 7, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 9, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 9, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 10, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': "First Affiliated Hospital Xi'an Jiaotong University", 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'The purpose of the study is to study the epidemic features and diagnosis of female breast cancer, especially the diagnosis and treatment of breast cancer.The disease-free survival (DFS) and the total survival time(OS) of the breast cancer patients will also be studied.', 'DetailedDescription': 'The study is a multicentric, retrospective clinical study based on the hospital. The target number of cases are X patients who are eligible for breast cancer after radical mastectomy. To collect the clinicopathological data and treatment data of the breast cancer patients and do the follow-up visit of all the patients who are included in the study.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['Breast cancer, hospital, epidemiology, diagnosis, treatment']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Ecologic or Community']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Retrospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '3000', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Epidemiology breast cancer patients', 'ArmGroupDescription': 'Observe the features of clinical diagnosis and treatment for female breast cancer patients', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: The radical mastectomy of breast cancer']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'The radical mastectomy of breast cancer', 'InterventionDescription': 'The radical mastectomy of breast cancer could be used for the treatment of breast cancer during the observation.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Epidemiology breast cancer patients']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Overall five-year survival for the female breast cancer patients', 'PrimaryOutcomeTimeFrame': '5 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nFemale patients;\nThe hospitalized patients who are confirmed of the primary breast cancer histologically;\nThe date of the inpatients are within the month we chosen;\nPatients who are within the month we chosen have been received or under receiving the relevant treatment including surgical treatment, chemotherapy and radiotherapy.\n\nExclusion Criteria:\n\nMale breast cancer patients;\nPatients with breast cancer who are not under the chosen time;\nNon hospitalized patients.', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'The female breast cancer patients in Shaanxi Province of China, those study population shoud be the hospitalized patients who are confirmed of the primary breast cancer histologically, moreover, the date of the inpatients are within the month we chosen and those inpatients should have been received or under receiving the relevant treatment including surgical treatment, chemotherapy and radiotherapy.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Yu Ren, MD,PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '13700222161', 'CentralContactEMail': 'renyyyyy@126.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Yu Ren, MD,PhD', 'OverallOfficialAffiliation': "First Affiliated Hospital Xi'an Jiaotong University", 'OverallOfficialRole': 'Principal Investigator'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 54, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02550210', 'OrgStudyIdInfo': {'OrgStudyId': 'D15120'}, 'Organization': {'OrgFullName': 'Dartmouth-Hitchcock Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers', 'OfficialTitle': 'A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers'}, 'StatusModule': {'StatusVerifiedDate': 'April 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 2015'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'February 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 25, 2015', 'StudyFirstSubmitQCDate': 'September 14, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 15, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'April 8, 2019', 'ResultsFirstSubmitQCDate': 'April 8, 2019', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'April 30, 2019', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 8, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 30, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Richard J. Barth,Jr.', 'ResponsiblePartyInvestigatorTitle': 'MD', 'ResponsiblePartyInvestigatorAffiliation': 'Dartmouth-Hitchcock Medical Center'}, 'LeadSponsor': {'LeadSponsorName': 'Dartmouth-Hitchcock Medical Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'In this study, the investigators will enroll women with palpable cancers to assess the accuracy of the Breast Cancer Locator (BCL) and the concomitant procedure as a vehicle to optimize and validate the approach in such surgical cases. This approach of adopting palpable cancer patients before initiating an evaluative trial of the BCL in non-palpable breast cancer cases ensures that the BCL does not substantially alter or modify the standard-of-care procedure.', 'DetailedDescription': 'The investigators propose to test whether the Breast Cancer Locator (BCL) accurately defines the edges of the tumor. Twenty patients with palpable invasive breast cancer will undergo preoperative supine MRI, the creation of a BCL, and breast-conserving surgery using the BCL as an adjunct to palpation-guided tumor resection. Participants will also have the tumor position on their skin localized with the supine MR/optical scan/tracker method. The primary objective is to measure the distance from the center of the spots made by the BCL to the cancer edges.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['Breast Conserving Surgery', 'Breast Imaging', 'Breast Diagnostics']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '23', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast Cancer Locator (BCL)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Breast Cancer Locator (BCL)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Breast Cancer Locator (BCL)', 'InterventionDescription': "This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Breast Cancer Locator (BCL)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The Distance Measured by Pathology From the Tumor Edge to the Center of the Ink Spots, as Marked by the Black Inked Pins.', 'PrimaryOutcomeDescription': 'Five measurements will be made per patient and the mean difference in distance will be derived between the palpated and the co-registered supine MRI-optical scan image predicted tumor edges. The BCL will be considered accurate if all 5 measurements are > 0 cm from the tumor edge.', 'PrimaryOutcomeTimeFrame': '30 Days'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Positive Margin Rate', 'SecondaryOutcomeDescription': 'The positive margin rate as defined by standard pathologic evaluation of the entire specimen.', 'SecondaryOutcomeTimeFrame': '30 Days'}, {'SecondaryOutcomeMeasure': 'The Distances Between the Specimen Edges as Determined by the Breast Cancer Locator and by the Supine MRI/Optical Scan/ Tracker System', 'SecondaryOutcomeDescription': 'Distances will be measured and descriptive statistics will be employed.', 'SecondaryOutcomeTimeFrame': '30 days'}, {'SecondaryOutcomeMeasure': 'Mean Resection Specimen Volume', 'SecondaryOutcomeDescription': 'Volumes will be measured and descriptive statistics will be employed. The specimen volume is determined by recording the water displacement and specimen scanning.', 'SecondaryOutcomeTimeFrame': '30 days from surgery'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAge greater than or equal to 18 years\nHistologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ\nPatient desire to undergo breast surgery\nAbility to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted\nThe cancer enhances on breast MRI imaging.\n\nExclusion Criteria:\n\nAbsolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes\nSevere claustrophobia\nContraindication to use of gadolinium-based intravenous contrast, including life-threatening allergy or compromised renal function (creatinine > 2.0)\nHistory of median sternotomy\nPregnancy. Patient attestation that they are not pregnant will be acceptable as per standard policy for MRIs at DHMC.', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '99 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Dartmouth Hitchcock Medical Center', 'LocationCity': 'Lebanon', 'LocationState': 'New Hampshire', 'LocationZip': '03756', 'LocationCountry': 'United States'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Breast Cancer Locator (BCL)', 'FlowGroupDescription': "The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure.\n\nBreast Cancer Locator (BCL): This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin."}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '23'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '19'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '4'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Breast Cancer Locator (BCL)', 'BaselineGroupDescription': "The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.\n\nBreast Cancer Locator (BCL): This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin."}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '23'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Full Range', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '59', 'BaselineMeasurementLowerLimit': '44', 'BaselineMeasurementUpperLimit': '80'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '23'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '23'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '23'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'The Distance Measured by Pathology From the Tumor Edge to the Center of the Ink Spots, as Marked by the Black Inked Pins.', 'OutcomeMeasureDescription': 'Five measurements will be made per patient and the mean difference in distance will be derived between the palpated and the co-registered supine MRI-optical scan image predicted tumor edges. The BCL will be considered accurate if all 5 measurements are > 0 cm from the tumor edge.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'cm', 'OutcomeMeasureTimeFrame': '30 Days', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Breast Cancer Locator (BCL)', 'OutcomeGroupDescription': "The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure.\n\nBreast Cancer Locator (BCL): This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin."}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '18'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.7', 'OutcomeMeasurementSpread': '1.2'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Positive Margin Rate', 'OutcomeMeasureDescription': 'The positive margin rate as defined by standard pathologic evaluation of the entire specimen.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'percentage', 'OutcomeMeasureTimeFrame': '30 Days', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Breast Cancer Locator (BCL)', 'OutcomeGroupDescription': "The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure.\n\nBreast Cancer Locator (BCL): This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin."}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '19'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'The Distances Between the Specimen Edges as Determined by the Breast Cancer Locator and by the Supine MRI/Optical Scan/ Tracker System', 'OutcomeMeasureDescription': 'Distances will be measured and descriptive statistics will be employed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'cm', 'OutcomeMeasureTimeFrame': '30 days', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Breast Cancer Locator (BCL)', 'OutcomeGroupDescription': "The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure.\n\nBreast Cancer Locator (BCL): This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin."}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '19'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.33', 'OutcomeMeasurementSpread': '0.32'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Mean Resection Specimen Volume', 'OutcomeMeasureDescription': 'Volumes will be measured and descriptive statistics will be employed. The specimen volume is determined by recording the water displacement and specimen scanning.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'cm3', 'OutcomeMeasureTimeFrame': '30 days from surgery', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Breast Cancer Locator (BCL)', 'OutcomeGroupDescription': "The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure.\n\nBreast Cancer Locator (BCL): This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin."}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '19'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '116', 'OutcomeMeasurementSpread': '73'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': 'From the inception of baseline to end of intervention: 5 years', 'EventsDescription': 'Regular investigator assessment and regular laboratory testing', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Breast Cancer Locator (BCL)', 'EventGroupDescription': "The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure.\n\nBreast Cancer Locator (BCL): This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.", 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '23', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '23', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '23'}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Dr. Richard J. Barth Jr.', 'PointOfContactOrganization': 'Dartmouth Hitchcock Medical Center', 'PointOfContactEMail': 'Richard.J.Barth.Jr@hitchcock.org', 'PointOfContactPhone': '(603) 650-9479'}}}, 'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'Prot_SAP', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'Yes', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Study Protocol and Statistical Analysis Plan', 'LargeDocDate': 'December 4, 2015', 'LargeDocUploadDate': '03/12/2019 09:41', 'LargeDocFilename': 'Prot_SAP_000.pdf'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 55, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03146520', 'OrgStudyIdInfo': {'OrgStudyId': '1-2016-0068'}, 'Organization': {'OrgFullName': 'Genomictree, Inc.', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Clinical Validation of Stool DNA-based SDC2 Methylation Test for Colorectal Cancer Detection', 'OfficialTitle': 'Clinical Study for the Validation of Real Time qPCR for SDC2 Methylation in Stool DNA for Early Detection of Colorectal Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'April 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 13, 2016', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 18, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 30, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 7, 2017', 'StudyFirstSubmitQCDate': 'May 7, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 10, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 16, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 18, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Genomictree, Inc.', 'LeadSponsorClass': 'INDUSTRY'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Severance Hospital', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Pivotal trials of SDC2 methylation biomarker test in stool DNA to estimate clinical sensitivity and specificity in detection of colorectal cancer.', 'DetailedDescription': 'The purpose of this study is to validate the clinical performance of EarlyTect Colon Cancer test which is measuring Syndecan 2 methylation status in stool DNA to detect CRC. Syndecan 2 (SDC2) is a newly developed methylation biomarker for colorectal cancer diagnosis. Methylation status of SDC2 gene in stool DNA is determined by methylation specific qPCR. Sensitivity and specificity will be determined by comparing Stool DNA test from healthy subjects, CRC patients, and other group including polyps and other diseases.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Colorectal Cancer', 'Polyps', 'Other Cancers', 'Healthy']}, 'KeywordList': {'Keyword': ['Syndecan 2', 'Methylation biomarker', 'Colorectal cancer', 'EarlyTect Colon Cancer test']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Other']}}, 'EnrollmentInfo': {'EnrollmentCount': '634', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Colorectal (CRC)', 'ArmGroupDescription': 'stage I-IV CRC subjects', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: EarlyTect Colon Cancer']}}, {'ArmGroupLabel': 'Polyps', 'ArmGroupDescription': 'subjects with adenoma or polyps', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: EarlyTect Colon Cancer']}}, {'ArmGroupLabel': 'Other cancers', 'ArmGroupDescription': 'subjects with other cancers', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: EarlyTect Colon Cancer']}}, {'ArmGroupLabel': 'Healthy', 'ArmGroupDescription': 'subjects with no evidence of CRC', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: EarlyTect Colon Cancer']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'EarlyTect Colon Cancer', 'InterventionDescription': 'SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Colorectal (CRC)', 'Healthy', 'Other cancers', 'Polyps']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Clinical performance of EarlyTect Colon Cancer to detect colorectal cancer', 'PrimaryOutcomeDescription': 'Sensitivity and specificity of EarlyTect Colon Cancer to detect colorectal cancer (sensitivity: the ratio of positive cases in all CRC cases, specificity: the ratio of negative cases in all healthy controls)', 'PrimaryOutcomeTimeFrame': '1.5 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Positive ratio of SDC2 methylation in polyps', 'SecondaryOutcomeDescription': 'the ratio of SDC2 methylation positive in polyps', 'SecondaryOutcomeTimeFrame': '1.5 years'}, {'SecondaryOutcomeMeasure': 'Positive ratio of SDC2 methylation in other cancers', 'SecondaryOutcomeDescription': 'the ratio of SDC2 methylation positive in other cancers', 'SecondaryOutcomeTimeFrame': '1.5 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria:\n\nsample information is complete, including sample number, gender, family history, stage of cancer, treatment history, and other disease information\nthe CRC patient who has not any treatment (surgery, chemotherapy, or radiation)\nnon-CRC patient who has not received any treatment (surgery, chemotherapy, or radiation) within the last 6 months\nall of above conditions are satisfied, and any one of below can be applicable; 1) confirm to be CRC with colonoscopy and/or pathological examination, 2) confirm to be inflammatory or ulcerative bowel diseases or benign hyperplastic polyp, 3) confirm to be gastrointestinal or liver cancers who are not CRC, 4) schedule to receive colonoscopy and additional confirmation test for CRC with agreement to provide the test results.\n\nExclusion criteria: any one of below can be applicable;\n\nthe patient information is not complete and/or does not satisfy inclusion criteria\nthe sample information is not complete and/or does not satisfy inclusion criteria\nthe CRC patient who has history of colorectal cancer surgery, chemotherapy, or any other treatment\nnon-CRC patient who received any chemotherapy within the last 6 months\nthe patient who has limited ability or are vulnerable to accept clinical trial agreement\nthe patient who is judged as not suitable for clinical trial including a psychiatric disorder by a physician', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '30 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients who have colorectal cancer or pre-malignancy or benign polyp or other solid tumor, or healthy normal subjects, and confirmed by colonoscopy or pathological examination.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Severance Hospital', 'LocationCity': 'Seoul', 'LocationZip': '03722', 'LocationCountry': 'Korea, Republic of'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '23747112', 'ReferenceType': 'background', 'ReferenceCitation': 'Oh T, Kim N, Moon Y, Kim MS, Hoehn BD, Park CH, Kim TS, Kim NK, Chung HC, An S. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J Mol Diagn. 2013 Jul;15(4):498-507. doi: 10.1016/j.jmoldx.2013.03.004. Epub 2013 Jun 7.'}, {'ReferencePMID': '30876480', 'ReferenceType': 'derived', 'ReferenceCitation': 'Han YD, Oh TJ, Chung TH, Jang HW, Kim YN, An S, Kim NK. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin Epigenetics. 2019 Mar 15;11(1):51. doi: 10.1186/s13148-019-0642-0.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000015179', 'ConditionMeshTerm': 'Colorectal Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000012002', 'ConditionAncestorTerm': 'Rectal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M13163', 'ConditionBrowseLeafName': 'Polyps', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafAsFound': 'Colorectal Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13996', 'ConditionBrowseLeafName': 'Rectal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T120', 'InterventionBrowseLeafName': 'Cola', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 56, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02105545', 'OrgStudyIdInfo': {'OrgStudyId': 'INST 1306'}, 'Organization': {'OrgFullName': 'New Mexico Cancer Care Alliance', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Genome Sequencing of Human Cancer Tissues', 'OfficialTitle': 'Genome Sequencing of Human Cancer Tissues'}, 'StatusModule': {'StatusVerifiedDate': 'October 2022', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 1, 2015', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 13, 2014', 'StudyFirstSubmitQCDate': 'April 4, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 7, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 4, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 6, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'New Mexico Cancer Care Alliance', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The goal of this study is to develop a new, local system that will use special tests based on patients\' genetic makeup to better tailor cancer care at the University of New Mexico Cancer Center.\n\nThe Food and Drug Administration has already approved over forty (40) drugs to treat cancer patients based on specific genetic makeup, and more agents are in development that will support this new approach to treatment, often referred to as "personalized medicine."\n\nThe goal of performing specific tests on patients\' genetic material is to discover tumor-specific, single nucleotide variations (SNVs) and other forms of genetic changes (called epigenetic changes) that can be detected when comparing normal tissue and tumor tissue. This can help guide cancer care decisions that may be more effective for patients. These will be called clinically actionable findings, or CAF.\n\nAdditional health related findings may be made, not related to cancer but to other conditions, diseases or syndromes. These are called secondary findings (SF). In this study the investigators will also measure how often they find SF and will discuss their possible impact on other aspects of patients\' health. If patients want to know about these findings, they will be discussed with a panel of experts including genetic counselors.\n\nFinally, the investigators will compare how often CAF and SF differ from those identified in nationwide samples.', 'DetailedDescription': 'For brevity, the investigators include the approaches of whole genome sequencing, whole exome sequencing of just the protein-coding exons, enrichment and sequencing of methylated DNA and RNA or transcriptome-sequencing under the broad category term, Whole Genome Sequencing (WGS).\n\nThe development of rapid and low cost next-generation genome sequencing technologies brings the promise of a new era of precision therapeutics to clinical practice, but it is associated with significant challenges, including reproducible generation of high-quality sequence data and the need for comprehensive data analysis and interpretation that is translatable to clinical action. Equally critical are the ethical, legal, and social issues surrounding the introduction of WGS testing and its clinical application in multiethnic, multicultural populations, particularly those who have historically experienced discrimination or even unethical research practices. Of particular concern are issues surrounding the privacy, ownership, storage, and use of WGS data.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer']}, 'KeywordList': {'Keyword': ['cancer', 'oncology', 'malignant', 'malignancy', 'genetics', 'genomics', 'exome', 'DNA', 'RNA', 'sequencing', 'epigenetic', 'clinically actionable findings', 'CAF', 'secondary findings', 'SF', 'single nucleotide variants', 'SNV', 'bioinformatics', 'genotype', 'The American College of Medical Genetics and Genomics', 'ACMG']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Diagnostic', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '250', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer Treatment Options', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Blood samples and, for some patients, buccal (mouth cell) samples will be collected at diagnosis and/or relapse. Solid tumor samples will be collected in the normal course of treatment, from biopsy, blood or other specimens. For blood-based cancers such as leukemia, blood and bone marrow specimens will be collected before treatment begins, on day 29 and possibly at a later time point if relapse occurs.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Cancer Treatment Options']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Cancer Treatment Options', 'InterventionDescription': 'Patients may meet, depending on test results, with their physician and a genetic counselor to discuss possible changes in their treatment options and/or lifestyle changes.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer Treatment Options']}, 'InterventionOtherNameList': {'InterventionOtherName': ['treatment options', 'lifestyle changes', 'behavioral changes', 'genetics']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Number of patients with clinically actionable findings', 'PrimaryOutcomeDescription': 'The investigators will utilize new genomics technologies in to identify potentially Clinically Actionable Findings (CAF) in patient tumor and other samples. Based on individual patient data, alternative treatment options will be offered to patients.', 'PrimaryOutcomeTimeFrame': '3 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Frequency of findings (CAF) in cancer patients treated locally', 'SecondaryOutcomeDescription': 'The investigators will measure the frequency with which clinically actionable findings (CAF) that could impact current patient care decisions occur in tumor and other samples.', 'SecondaryOutcomeTimeFrame': '3 years'}, {'SecondaryOutcomeMeasure': 'Percentages and types of local patient CAF aligned with national genomics data sets', 'SecondaryOutcomeDescription': 'Determine whether CAF identified in the unique patient populations treated at the University of New Mexico Cancer Center differ from those identified in nationwide data sets such as The 1000 Genomes Project or The Cancer Genome Atlas (TCGA) data collections.', 'SecondaryOutcomeTimeFrame': '3 years'}, {'SecondaryOutcomeMeasure': 'Number of barriers limiting use of genomics information in local patient care', 'SecondaryOutcomeDescription': 'Identify the numbers and types technological, social, ethical and/or legal barriers that might limit the use of genomics information in patient care at the University of New Mexico Cancer Center and the University of New Mexico Health Sciences Center. The investigators will assess the frequency of use of CAF by local treating physicians. They will assess how often cancer treatment choice is altered as a result of providing CAF to physicians and patients. The investigators will assess how often identified CAF are entered into patient medical records. They will assess the frequency with which patients choose to receive information about potentially detrimental SF unrelated to their cancer care.', 'SecondaryOutcomeTimeFrame': '3 years'}, {'SecondaryOutcomeMeasure': 'Percentage of patients with secondary findings (SF)', 'SecondaryOutcomeDescription': "Identify other genomics-based findings in patient samples unrelated to cancer care, but which might impact other aspects of patients' health. These will be referred to as Secondary Findings, or SF. For example, if a SF is identified that suggests an increased risk of diabetes, this would be considered a secondary finding. This will be discussed by a panel of medical experts, and if patients wish to have this information returned to them, their doctor and genetic counselor will discuss the SF. Patients can choose not to have SF returned to them.", 'SecondaryOutcomeTimeFrame': '2 years'}, {'SecondaryOutcomeMeasure': 'Percentages and types of local patient Secondary Findings aligned with national genomics data sets', 'SecondaryOutcomeDescription': 'Determine whether SF identified in the unique patient populations treated at the University of New Mexico Cancer Center differ from those identified in nationwide samples such as The 1000 Genomes Project or The Cancer Genome Atlas (TCGA).', 'SecondaryOutcomeTimeFrame': '3 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAny patient with a malignant diagnosis at the time of diagnosis or relapse\nAny age (minimum 0 days old)\nMale or Female\nPregnant women are eligible for this study\nPatients may have existing, non-oncological genetic disorders\nPatients may have received any amount of prior treatment\nParticipants (or their parent/legal guardian in the case of minors) must have the ability to understand and the willingness to sign a written informed consent or assent form\n\nExclusion Criteria:\n\nSubjects for whom sufficient cancer tissues are not available to meet the objectives of the study.\nCognitively impaired adults are excluded from participation\nAdults not able to consent for themselves are excluded from participation\nPrisoners may not participate in this study', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Stuart S Winter, MD', 'OverallOfficialAffiliation': 'University of New Mexico Cancer Center', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of New Mexico Cancer Center', 'LocationCity': 'Albuquerque', 'LocationState': 'New Mexico', 'LocationZip': '87131', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'University of New Mexico Cancer Center', 'SeeAlsoLinkURL': 'http://www.cancer.unm.edu'}, {'SeeAlsoLinkLabel': 'New Mexico Cancer Care Alliance', 'SeeAlsoLinkURL': 'http://www.nmcca.org'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M11459', 'ConditionBrowseLeafName': 'Neoplasm Metastasis', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 57, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00949312', 'OrgStudyIdInfo': {'OrgStudyId': 'CDR0000649763'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'UCLA-0809064'}, {'SecondaryId': 'BILA-UECC-0107'}, {'SecondaryId': 'IRB# 08-09-064-02'}]}, 'Organization': {'OrgFullName': "Saint John's Cancer Institute", 'OrgClass': 'OTHER'}, 'BriefTitle': 'Studying Lymph Nodes in Patients With Stage II Colon Cancer', 'OfficialTitle': 'Ultrastaging of Early Colon Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'March 2022', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2009', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 29, 2009', 'StudyFirstSubmitQCDate': 'July 29, 2009', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 30, 2009', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 7, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 9, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': "Saint John's Cancer Institute", 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'RATIONALE: Diagnostic procedures that look for micrometastases in lymph nodes removed during surgery for colon cancer may help doctors learn the extent of disease.\n\nPURPOSE: This phase I trial is studying lymph nodes in patients with stage II colon cancer.', 'DetailedDescription': 'OBJECTIVES:\n\nDetermine whether the immunohistochemical and molecular presence of micrometastases in ≥ 12 lymph nodes removed during en-bloc resection in patients with stage II colon cancer correlates with 3-year disease-free survival.\nEvaluate the prognostic significance of molecular markers detected in the primary tumor and develop a microarray-based gene signature for stage II colon cancer.\n\nOUTLINE: This is a multicenter study.\n\nTumor tissue and regional lymph node samples are collected during surgery for analysis of micrometastases and molecular markers by immunohistochemistry, qRT-PCR, MM qRT-PCR, qRDNA-PCR, and microarray profiling.\n\nPatients are followed up periodically for 4 years after surgery.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Colorectal Cancer']}, 'KeywordList': {'Keyword': ['stage II colon cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Paraffin-embedded primary tumor and lymph node sections'}, 'EnrollmentInfo': {'EnrollmentCount': '26', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Stage II unresected Colon Cancer', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: RNA marker analysis of lymph node and primary tumors', 'Genetic: microarray profiling of primary tumors', 'Genetic: reverse transcriptase-polymerase chain reaction of lymph node specimens', 'Other: diagnostic laboratory RNA and DNA biomarker analysis of primary tumors', 'Procedure: regional lymph node dissection', 'Other: lymph node staining for H&E and pancytokeratin IHC']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Genetic', 'InterventionName': 'RNA marker analysis of lymph node and primary tumors', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stage II unresected Colon Cancer']}}, {'InterventionType': 'Genetic', 'InterventionName': 'microarray profiling of primary tumors', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stage II unresected Colon Cancer']}}, {'InterventionType': 'Genetic', 'InterventionName': 'reverse transcriptase-polymerase chain reaction of lymph node specimens', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stage II unresected Colon Cancer']}}, {'InterventionType': 'Other', 'InterventionName': 'diagnostic laboratory RNA and DNA biomarker analysis of primary tumors', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stage II unresected Colon Cancer']}}, {'InterventionType': 'Procedure', 'InterventionName': 'regional lymph node dissection', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stage II unresected Colon Cancer']}}, {'InterventionType': 'Other', 'InterventionName': 'lymph node staining for H&E and pancytokeratin IHC', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stage II unresected Colon Cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Disease-free survival (time to local or distant recurrence after resection)', 'PrimaryOutcomeDescription': 'The event to be used for DFS is time to recurrence (local or distant) after resection of colon cancer', 'PrimaryOutcomeTimeFrame': '48 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Overall survival (time to death from colorectal cancer)', 'SecondaryOutcomeDescription': 'The event to be used for DFS is time to death after resection of colon cancer', 'SecondaryOutcomeTimeFrame': '48 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': "Inclusion Criteria: All of the following inclusion criteria must be met in order for the subject to be eligible.\n\nSubjects must have CC detected by proctosigmoidoscopy, flexible endoscopy, or gastrograffin/barium enema, with no evidence of distant metastases within 8 weeks of enrollment.\nSubjects with CC must have a computerized tomography (CT; at a minimum - spiral (helical) CT with 5-mm contiguous reconstruction algorithms and adequate volume (based on site-specific protocols) of oral and intravenous contrast agents) of the abdomen and pelvis and a chest x-ray or CT of the chest per standard of care, within 8 weeks prior to enrollment to rule out distant metastases. Subjects with preoperative CT scans and testing showing non-specific or non-diagnostic (equivocal) abnormalities may be eligible pending intraoperative exploration.\nGreater than 18 years of age\nSubjects must have a performance status ≤ 2 on the ECOG/Zubrod scale.\nSubject is able to give informed consent, and must be willing to be followed clinically or by phone/email/mail correspondence\nSubject must have a life expectancy of greater than 5 years not including the disease/diagnosis of CC.\nSubject must have clinical assessment conducted by phone unless patients follow up are part of the regular clinical visits.\n\nExclusion Criteria: Any of the following criteria will exclude the subject from the study.\n\nSubjects requiring emergent surgery (within 2 hours of presentation) to prevent a life-threatening situation or death such as those with a perforated colon, metabolically significant complete bowel obstruction or massive GI bleeding will be excluded. Subjects who do not require emergent surgery, such as those with occult bleeding or early or partial bowel obstruction will be permitted to enter.\nSubjects with any history of Crohn's disease, chronic ulcerative colitis, or familial polyposis.\nDiscovery of distant metastases intra-operatively.\nSubjects with history of another malignancy over the last three years (except for completely resected cervical, skin cancers or in-situ cancers - see Appendix B for a list of exempt cancers).\nPregnant and/or lactating women. Potentially childbearing subjects (pre-menopausal women) should undergo a pregnancy test within 7 days prior to surgery and after signing consent. Subjects found to be pregnant will be ineligible and withdrawn from the study.\nSubjects should not be participating in another research protocol at the time of enrollment. Participation during follow-up is acceptable.\nSystemic chemotherapy for node negative colon cancer.\nComplete polypectomy by endoscopy\nLess than 12 lymph nodes", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'From the ambulatory cancer clinic, we will identify 300 stage II colon cancer patients eligible for the study.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Anton J. Bilchik, MD, PhD, FACS', 'OverallOfficialAffiliation': "Saint John's Cancer Institute", 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'John Wayne Cancer Institute', 'LocationCity': 'Santa Monica', 'LocationState': 'California', 'LocationZip': '90404', 'LocationCountry': 'United States'}, {'LocationFacility': 'Walter Reed Army Medical Center', 'LocationCity': 'Washington', 'LocationState': 'District of Columbia', 'LocationZip': '20307-5001', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26213360', 'ReferenceType': 'derived', 'ReferenceCitation': 'Protic M, Stojadinovic A, Nissan A, Wainberg Z, Steele SR, Chen DC, Avital I, Bilchik AJ. Prognostic Effect of Ultra-Staging Node-Negative Colon Cancer Without Adjuvant Chemotherapy: A Prospective National Cancer Institute-Sponsored Clinical Trial. J Am Coll Surg. 2015 Sep;221(3):643-51; quiz 783-5. doi: 10.1016/j.jamcollsurg.2015.05.007. Epub 2015 May 18.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003110', 'ConditionMeshTerm': 'Colonic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000015179', 'ConditionAncestorTerm': 'Colorectal Neoplasms'}, {'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5490', 'ConditionBrowseLeafName': 'Colonic Neoplasms', 'ConditionBrowseLeafAsFound': 'Colon Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T120', 'InterventionBrowseLeafName': 'Cola', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 58, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04817306', 'OrgStudyIdInfo': {'OrgStudyId': 'RSCD2020001'}, 'Organization': {'OrgFullName': 'Shanghai Zhongshan Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Pan-canceR Early DetectIon projeCT (PREDICT)', 'OfficialTitle': 'A Prospective, Multicenter Study on Development and Validation of the Performance of a cfDNA Methylation-based Model for Early Cancer Detection (Pan-canceR Early DetectIon projeCT, PREDICT Study)'}, 'StatusModule': {'StatusVerifiedDate': 'March 2021', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 29, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'March 31, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 23, 2021', 'StudyFirstSubmitQCDate': 'March 23, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 26, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 29, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 30, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Shanghai Zhongshan Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Guangzhou Burning Rock Dx Co., Ltd.', 'CollaboratorClass': 'INDUSTRY'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'PREDICT is a prospective, multicenter study for the early detection of pan-cancer through cell-free DNA (cfDNA) methylation-based model, in which approximately 14,000 participants will be enrolled. The development and validation of the model will be conducted in participants with cancers or benign diseases, along with non-tumor (healthy) individuals through a two-stage approach. The sensitivity and specificity of the model in cancer early detection will be evaluated, and the accuracy of the identification for tissue of origin will be obtained.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer']}, 'KeywordList': {'Keyword': ['Cancer', 'Cell-free DNA (cfDNA) methylation', 'Early detection']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '14026', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer Arm', 'ArmGroupDescription': 'Participants with new diagnosis of cancer, from whom blood samples will be collected', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Multi-cancer early detection test']}}, {'ArmGroupLabel': 'Benign Diseases Arm', 'ArmGroupDescription': 'Participants with benign diseases corresponding to the tumor types in the Cancer Arm, from whom blood samples will be collected', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Multi-cancer early detection test']}}, {'ArmGroupLabel': 'Non-tumor (Healthy) Arm', 'ArmGroupDescription': 'Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Multi-cancer early detection test']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Multi-cancer early detection test', 'InterventionDescription': 'Blood collection and multi-cancer early detection testing', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Benign Diseases Arm', 'Cancer Arm', 'Non-tumor (Healthy) Arm']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Sensitivity of early detection of cancer and Tissue of origin (TOO) accuracy of a cfDNA methylation-based model when specificity is 90%, 95% or 98% in healthy participants', 'PrimaryOutcomeTimeFrame': '24 months'}, {'PrimaryOutcomeMeasure': 'Sensitivity and specificity of early detection of cancer and TOO accuracy of a cfDNA methylation-based model', 'PrimaryOutcomeTimeFrame': '24 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Sensitivity, specificity and TOO accuracy of a cfDNA methylation-based model in various types of cancer', 'SecondaryOutcomeTimeFrame': '24 months'}, {'SecondaryOutcomeMeasure': 'Sensitivity, specificity and TOO accuracy of a cfDNA methylation-based model in different stages of cancer', 'SecondaryOutcomeTimeFrame': '24 months'}, {'SecondaryOutcomeMeasure': 'Sensitivity, specificity and TOO accuracy of a cfDNA methylation-based model, in combination with clinical characteristics and other biomarkers', 'SecondaryOutcomeTimeFrame': '24 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': "Inclusion Criteria for All the Participants:\n\nAbility to provide a written informed consent\n40-75 years old\n\nExclusion Criteria for All the Participants:\n\nInability to comply with study procedures\nPregnancy or lactating women\nRecipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant\nRecipients of blood transfusion within 7 days prior to study blood draw\nRecipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer\n\nInclusion Criteria for Cancer Arm Participants:\n\nConfirmed diagnosis of a cancer or highly suspicious cases of cancer within 42 days prior to study blood draw. Tumor types in this study include lung cancer, colorectal cancer, liver cancer, ovarian cancer, gastric cancer, esophageal cancer, pancreatic cancer, biliary tract cancer, squamous cell carcinoma of the head and neck (except nasopharyngeal carcinoma)\nNo prior or ongoing anti-cancer therapy (local or systematic) prior to study blood draw\n\nExclusion Criteria for Cancer Arm Participants:\n\nKnown prior diagnosis of malignancies\nOther current malignant diseases or multiple primary tumors\nNo confirmed diagnosis of cancer by histopathological or radiological assessments within 42 days of study blood draw, or diagnosis of a benign disease by histopathological assessments, or inability to characterize whether the lesion is malignant or benign\nNon-small-cell lung cancer patients with ground-class nodularity by radiological examination\n\nInclusion Criteria for Benign Diseases Arm Participants:\n\nHistopathologically confirmed or highly suspicious for benign diseases corresponding to the tumor types in the Cancer Arm within 90 days prior to study blood draw, or highly suspicious for benign diseases corresponding to the tumor types in Cancer Arm by radiological assessments or other clinical examinations\nNo prior treatment of benign disease prior to study blood draw\n\nExclusion Criteria for Benign Diseases Arm Participants:\n\nCurrent or history of malignancies or precancerous lesions\nNo confirmed diagnosis or inability to characterize a benign disease by radiological, endoscopic or histopathological assessments within 42 days of study blood draw\n\nInclusion Criteria for Non-tumor (Healthy) Arm Participants:\n\nNo cancer-related symptoms or discomfort within 30 days prior to study blood draw\nNo clinically significant finding by LDCT or abdominal ultrasound\nNo clinically significant finding by breast ultrasound or Molybdenum Target Mammography Detection, or cervical liquid-based cell (TCT) detection for female participants\nNo active hepatitis B or hepatitis C infection\n\nExclusion Criteria for Non-tumor (Healthy) Arm Participants:\n\nPrior or ongoing treatment of cancer within 3 years prior to study blood draw\nUnexplained weight loss\nPrior or current major diseases, including COPD, interstitial pneumonia, viral hepatitis, liver cirrhosis, inflammatory bowel disease\nPrior and current adenoma of the intestine and polyp of the intestine\nChanges in bowel habits, bowel abnormalities, hematochezia within 30 days prior to study blood draw\nUncontrolled hypertension and other cardiovascular diseases\nCurrently severe bleeding disorders\nMajor surgery within 24 weeks prior to study blood draw\nInfection requiring anti-microbial therapy within 24 weeks prior to study blood draw\nCurrent autoimmunity disease\nClinically significant or uncontrolled comorbidities which, in the investigator's opinion, should be excluded", 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Eligible participants will be recruited from medical centers and assigned into three arms, including participants with new diagnosis of cancer or corresponding benign diseases, and participants without the presence of malignancies or benign diseases.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Qiang Gao, M.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+86 021 64041990', 'CentralContactEMail': 'gao.qiang@zs-hospital.sh.cn'}, {'CentralContactName': 'Shangli Cai, Ph.D', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+86 021 61631938', 'CentralContactEMail': 'shangli.cai@brbiotech.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jia Fan, M.D., Ph.D', 'OverallOfficialAffiliation': 'Shanghai Zhongshan Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Cancer Hospital, Chinese Academy of Medical Sciences & China National Cancer Center', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Beijing', 'LocationState': 'Beijing', 'LocationZip': '100021', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zhijie Wang, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+86-010-67781331'}, {'LocationContactName': 'Jie Wang, M.D., Ph.D', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': "Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine", 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Shanghai', 'LocationState': 'Shanghai', 'LocationZip': '200011', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Xi Yang, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+86-021-23271699'}, {'LocationContactName': 'Chenping Zhang, M.D.', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Zhongshan Hospital, Fudan University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Shanghai', 'LocationState': 'Shanghai', 'LocationZip': '200032', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Qiang Gao, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+86-021 64041990', 'LocationContactEMail': 'gao.qiang@zs-hospital.sh.cn'}, {'LocationContactName': 'Jia Fan, M.D., Ph.D', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}}}}, {'Rank': 59, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01674959', 'OrgStudyIdInfo': {'OrgStudyId': '2011 CH-GI-024'}, 'Organization': {'OrgFullName': 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Postoperative IMRT Combined With Capecitabine for Advanced Gastric Cancer Patients', 'OfficialTitle': 'Phase II Study of Postoperative Intensity-modulated Radiotherapy (IMRT) Combined With Capecitabine for Stage II/III Gastric Cancer Patients'}, 'StatusModule': {'StatusVerifiedDate': 'February 2015', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 2011'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2015', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2017', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'August 26, 2012', 'StudyFirstSubmitQCDate': 'August 28, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 29, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'February 3, 2015', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 5, 2015', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Jing Jin, M.D.', 'ResponsiblePartyInvestigatorTitle': 'Attending doctor of Dept. radiation oncology, Cancer Hospital', 'ResponsiblePartyInvestigatorAffiliation': 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences'}, 'LeadSponsor': {'LeadSponsorName': 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Radiation therapy plus concurrent chemotherapy has been demonstrated a significant improvement in overall and disease-free survival according to Intergroup Trial 0116 in patients with gastric cancer after surgical complete resection. Advantage of application of IMRT has been shown in planning comparison studies for postoperative gastric patients. So the investigators designed the trial to see safety and efficacy of postoperative concurrent chemoradiotherapy of capecitabine combined with IMRT for stage II/II gastric cancer.', 'DetailedDescription': 'In Intergroup 0116, only 64% patients in concurrent chemoradiation group completed treatment as planed, but in recently reported ARTIST trial, capecitabine was admitted to concurrent with radiotherapy,patients who completed treatment as planed in concurrent group reach high as 80%. IMRT is an advanced radiotherapy technology which allows high conformal dose distribution to Planing Tumor Volume (PTV) and low dose to organ at risk. The purpose of this study is to evaluate feasibility and efficacy of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients after D1/2 surgery.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Gastric Cancer']}, 'KeywordList': {'Keyword': ['gastric cancer', 'radiation', 'chemotherapy']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '40', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'concurrent chemoradiation', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': '• Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.\n\nPostoperative current chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Radiation: concurrent chemoradiation']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Radiation', 'InterventionName': 'concurrent chemoradiation', 'InterventionDescription': 'postoperative Intensity-modulated radiotherapy (IMRT) combined with capecitabine for high risk gastric cancer patients Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.\n\nPostoperative chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['concurrent chemoradiation']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'feasibility of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients', 'PrimaryOutcomeDescription': 'feasibility of concurrent IMRT combined with capecitabine is defined as toxicities (CTC-AE 3.0) and rate of patients complete concurrent chemoradiation according to protocol.', 'PrimaryOutcomeTimeFrame': '3 months after concurrent chemoradiation'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'efficacy of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients', 'SecondaryOutcomeDescription': 'efficacy of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients in this trial is defined as 3-year overall survival and 3-year relapse free survival.', 'SecondaryOutcomeTimeFrame': '3 years after concurrent chemoradiation'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nPostoperative histologically confirmed advanced adenocarcinoma of the stomach or the gastroesophageal junction.\nAge of 18 to 75, Karnofsky score higher than 70.\nPostoperative histologically conformed metastasis in perigastric lymph nodes and/or tumor invasion to muscularis propria or subserosa, without positive incisal margin. Stage II/III(AJCC 7th).\nNo severe functional damage of major organ, normal blood cell, normal liver and kidney function.\nNo clinical findings of distant metastasis.\n\nPredictive survival time longer than 6 months.\n\n-\n\nExclusion Criteria:\n\nPeritoneal carcinomatosis, as diagnosed by mandatory laparoscopy or distant metastasis\nConcurrent treatment with other experimental drugs or other anti-cancer therapy, or treatment within a clinical trial within 30 days prior to trial entry\nSevere or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, no myocardial infarction within the last 12 months, unstable angina pectoris, or significant arrhythmia)\nActive or uncontrolled infection.\nDefinitive contraindications for the use of corticosteroids as premedication\nPrior systemic (chemo- or targeted) treatment. Prior radiotherapy to the upper abdomen\nAny contraindication to treatment with cetuximab, capecitabine or cisplatin\nPrevious malignancy within 5 years, with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer\nKnown hypersensitivity against any of the study drugs ( capecitabine)', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'jing jin', 'CentralContactRole': 'Contact', 'CentralContactPhone': '8610-87788280', 'CentralContactEMail': 'jingjin1025@163.com'}, {'CentralContactName': 'hua ren', 'CentralContactRole': 'Contact', 'CentralContactPhone': '8610-87788122', 'CentralContactEMail': 'renhua2009@hotmail.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'jing jin, professor', 'OverallOfficialAffiliation': 'Cancer Hospital, Chinese Academy of Medical Science', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Dept of Radiation oncology, Cancer Hospital , Chinese Academy of Medical Science', 'LocationStatus': 'Recruiting', 'LocationCity': 'Beijing', 'LocationState': 'Beijing', 'LocationZip': '100021', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'jing jin', 'LocationContactRole': 'Contact', 'LocationContactPhone': '8610-87788280', 'LocationContactEMail': 'jingjin1025@163.com'}, {'LocationContactName': 'hua ren', 'LocationContactRole': 'Contact', 'LocationContactPhone': '8610-87788122', 'LocationContactEMail': 'renhua2009@hotmail.com'}, {'LocationContactName': 'jing jin, professor', 'LocationContactRole': 'Principal Investigator'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000013274', 'ConditionMeshTerm': 'Stomach Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000013272', 'ConditionAncestorTerm': 'Stomach Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M15216', 'ConditionBrowseLeafName': 'Stomach Neoplasms', 'ConditionBrowseLeafAsFound': 'Gastric Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15214', 'ConditionBrowseLeafName': 'Stomach Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T5486', 'ConditionBrowseLeafName': 'Stomach Cancer', 'ConditionBrowseLeafAsFound': 'Gastric Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M377', 'InterventionBrowseLeafName': 'Capecitabine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M10262', 'InterventionBrowseLeafName': 'Liver Extracts', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Hemat', 'InterventionBrowseBranchName': 'Hematinics'}]}}}}}, {'Rank': 60, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03239171', 'OrgStudyIdInfo': {'OrgStudyId': 'Bioinformation-lung'}, 'Organization': {'OrgFullName': 'Fuda Cancer Hospital, Guangzhou', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Bioinformation Therapy for Lung Cancer', 'OfficialTitle': 'Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Lung Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'August 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 2, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 1, 2017', 'StudyFirstSubmitQCDate': 'August 1, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 3, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 23, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 25, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Fuda Cancer Hospital, Guangzhou', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Shengxin Biotechnology Institute, Beijing', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable lung cancer.', 'DetailedDescription': 'By enrolling patients with unresectable lung cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Small-cell Lung Cancer']}, 'KeywordList': {'Keyword': ['Cancer ablation', 'Life information rehabilitation therapy']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer ablation', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cancer ablation']}}, {'ArmGroupLabel': 'Life information rehabilitation therapy', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this group, the patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Life information rehabilitation therapy']}}, {'ArmGroupLabel': 'Combination therapy', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then "Qilisheng" Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cancer ablation', 'Drug: Life information rehabilitation therapy']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Cancer ablation', 'InterventionDescription': 'Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer ablation', 'Combination therapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Cryoablation or irreversible electroporation']}}, {'InterventionType': 'Drug', 'InterventionName': 'Life information rehabilitation therapy', 'InterventionDescription': 'Each treatment: one bottle solution each day, consecutive 3 months, oral administration', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Combination therapy', 'Life information rehabilitation therapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['"Qilisheng" Immunoregulatory Oral Solution']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Relief degree of tumors', 'PrimaryOutcomeDescription': 'It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Progress free survival（PFS）', 'SecondaryOutcomeDescription': 'The duration between treatment and cancer recurrence', 'SecondaryOutcomeTimeFrame': '1 year'}, {'SecondaryOutcomeMeasure': 'Overall survival（OS）', 'SecondaryOutcomeDescription': 'The duration between treatment and patient pass away', 'SecondaryOutcomeTimeFrame': '3 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAll standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies\nBody tumor 1-6, with at least one tumor length > 2 cm\nKPS ≥ 70, lifespan > 6 months\nPlatelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L\n\nExclusion Criteria:\n\nPatients with cardiac pacemaker\nPatients with brain metastasis\nPatients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Fuda cancer institute of Fuda cancer hospital', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationZip': '510665', 'LocationCountry': 'China'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000008175', 'ConditionMeshTerm': 'Lung Neoplasms'}, {'ConditionMeshId': 'D000055752', 'ConditionMeshTerm': 'Small Cell Lung Carcinoma'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000012142', 'ConditionAncestorTerm': 'Respiratory Tract Neoplasms'}, {'ConditionAncestorId': 'D000013899', 'ConditionAncestorTerm': 'Thoracic Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}, {'ConditionAncestorId': 'D000002283', 'ConditionAncestorTerm': 'Carcinoma, Bronchogenic'}, {'ConditionAncestorId': 'D000001984', 'ConditionAncestorTerm': 'Bronchial Neoplasms'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10324', 'ConditionBrowseLeafName': 'Lung Neoplasms', 'ConditionBrowseLeafAsFound': 'Lung Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M27476', 'ConditionBrowseLeafName': 'Small Cell Lung Carcinoma', 'ConditionBrowseLeafAsFound': 'Small Cell Lung Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4686', 'ConditionBrowseLeafName': 'Carcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14131', 'ConditionBrowseLeafName': 'Respiratory Tract Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15810', 'ConditionBrowseLeafName': 'Thoracic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10320', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14129', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4692', 'ConditionBrowseLeafName': 'Carcinoma, Bronchogenic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4412', 'ConditionBrowseLeafName': 'Bronchial Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T5271', 'ConditionBrowseLeafName': 'Small Cell Lung Cancer', 'ConditionBrowseLeafAsFound': 'Small Cell Lung Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21013', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 61, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04745754', 'OrgStudyIdInfo': {'OrgStudyId': 'R01CA249419', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://reporter.nih.gov/quickSearch/R01CA249419'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R01CA249419-01', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/1R01CA249419-01'}]}, 'Organization': {'OrgFullName': 'Kaiser Permanente', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Engaging Primary Care in Cancer Survivorship (EPICS) Study', 'OfficialTitle': 'The EPICS (Engaging Primary Care in Cancer Survivorship) Study: A Trial of Novel Models of Care for Cancer Survivors', 'Acronym': 'EPICS'}, 'StatusModule': {'StatusVerifiedDate': 'August 2022', 'OverallStatus': 'Enrolling by invitation', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 21, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 31, 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'May 31, 2025', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'January 25, 2021', 'StudyFirstSubmitQCDate': 'February 4, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 9, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 19, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 23, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Erin E. Hahn', 'ResponsiblePartyInvestigatorTitle': 'Research Scientist I', 'ResponsiblePartyInvestigatorAffiliation': 'Kaiser Permanente'}, 'LeadSponsor': {'LeadSponsorName': 'Kaiser Permanente', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'A quasi-experimental non-randomized pre/post with control group trial of two models of cancer survivorship care in early-stage colorectal and breast cancer survivors cared for in a community-based, integrated health care setting.', 'DetailedDescription': 'A quasi-experimental non-randomized pre/post with control group trial of two models of cancer survivorship care in early-stage colorectal and breast cancer survivors cared for in a community-based, integrated health care setting. The trial will test the efficacy of an embedded primary care provider (PCP) model (experimental condition) in which PCPs are embedded within an oncology practice and will care for low-risk survivors who will be transitioned at 6-36 months post-treatment for comprehensive survivorship care. We hypothesize that a) patients in the PCP model will have superior receipt of recommended care compared to usual care; b) patients in the PCP model will perceive significantly better care coordination, self-efficacy, and confidence in their PCP compared to usual care; and c) use of unplanned and non-recommended care will be less in the PCP model compared to usual care.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer', 'Colorectal Cancer']}, 'KeywordList': {'Keyword': ['Cancer survivorship', 'Models of care']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Embedded primary care providers (PCPs) will provide comprehensive care for survivors, including cancer surveillance services, preventive care, and management of long-term therapy and associated side effects (e.g., endocrine therapy in breast survivors). A comprehensive multilevel approach will prepare survivors and PCPs (physicians and/or advance practice providers). Eligible patients in the embedded PCP model will be provided with tailored education regarding the planned transition and, after cessation of active treatment, printed information on the planned course of care, expectations for embedded PCP care, transition timing, and reassurance that the oncology team will be available via telephone and email, and that PCPs will refer back to the oncologist for any concerning signs or symptoms. Tailored alerts will also be added to the electronic medical record (EMR) for recommended cancer surveillance and preventive care services that will fire for visits with embedded PCPs.', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '2450', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention Condition', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The trial will test the efficacy of an embedded primary care provider (PCP) model (experimental condition) in which PCPs are trained in survivorship and then embedded within an oncology practice to care for low-risk, early stage breast and colorectal cancer survivors who will be transitioned at 6-36 months post-treatment for comprehensive survivorship care.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Embedded primary care in cancer survivorship model']}}, {'ArmGroupLabel': 'Control Condition', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Usual care for breast and colorectal cancer survivors (oncology-led model).'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Embedded primary care in cancer survivorship model', 'InterventionDescription': 'Primacy care physicians will receive comprehensive training in cancer survivorship care for low-risk, early stage breast and colorectal patients. Training will include continuing medical education (CME) modules, webinars, and in-person discussion and clinical shadowing.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention Condition']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Cancer surveillance care services', 'PrimaryOutcomeDescription': 'Receipt of guideline-recommended cancer surveillance care services.', 'PrimaryOutcomeTimeFrame': '36 months'}, {'PrimaryOutcomeMeasure': 'Preventive care services', 'PrimaryOutcomeDescription': 'Receipt of guideline-recommended preventive care services.', 'PrimaryOutcomeTimeFrame': '36 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Non-recommended surveillance care/non-planned emergency and urgent care services', 'SecondaryOutcomeDescription': 'Receipt of non-recommended surveillance care based on current clinical guidelines, and use of non-planned hospitalization, emergency department, and urgent care services.', 'SecondaryOutcomeTimeFrame': '36 months'}, {'SecondaryOutcomeMeasure': 'Medical Expenditure Panel Survey (MEPS) 2016, Experiences with Cancer Supplement, Section 7, Medical Care for Cancer Module (Item #44)', 'SecondaryOutcomeDescription': 'Validated measures of cancer survivorship financial burden, access to medical care, employment and employment patterns, healthcare utilization and expenditures, and use of prescription drugs by cancer survivors (Item #44; response options: 4-item Likert scale)', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Patient-Centered Medical Home (PCMH) and Cancer Consumer Assessment of Healthcare Providers and Systems (CAHPS)', 'SecondaryOutcomeDescription': "The Patient-Centered Medical Home (PCMH) Item Set is a set of supplemental questions that can be added to the adult and child versions of the CAHPS Clinician & Group Survey (CG-CAHPS) to gather more information on patient experience with the domains of primary care that define a medical home. However, use of this item set is not limited to practices that explicitly function as medical homes. Any primary care practice that is interested in a more comprehensive assessment of their patients' experiences may add the PCMH items to the survey (6 questions; response options: 3-item, 4-item or 6-item Likert scale).", 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale v1.2 (answer responses using a Likert Scale)', 'SecondaryOutcomeDescription': 'As part of the Patient-Reported Outcomes Measurement Information System (PROMIS) created in 2004, The PROMIS Global-10 is a publically available global health assessment tool that allows measurements of symptoms, functioning, and healthcare-related quality of life (HRQoL) for a wide variety of chronic diseases and conditions (10 questions; response options: 5-item Likert scale).', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy for Managing Chronic Conditions Symptoms Scale (Self-efficacy for managing symptoms short form 8a (8 questions; 5-item Likert scale)', 'SecondaryOutcomeDescription': 'The PROMIS adult Self-Efficacy for Managing Chronic Conditions Symptoms Scale assesses self-reported current level of confidence in managing symptoms from chronic health conditions (8 questions; response options: 5-item Likert scale).', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'The European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (version 3)', 'SecondaryOutcomeDescription': 'Questionnaire developed to assess the quality of life of cancer patients (30 questions; response options: 4-item or 7-item Likert scale)', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Receipt of Treatment Summary from Health Information and National Trends Survey (HINTS 4, Cycle 2)', 'SecondaryOutcomeDescription': "The Health Information National Trends Survey (HINTS) regularly collects nationally representative data about the American public's knowledge of, attitudes toward, and use of cancer- and health-related information (1 question; response option: yes/no).", 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Primary Care Delivery of Survivorship Care Scale', 'SecondaryOutcomeDescription': 'Self-reported measure of perceived survivorship care (6 questions; response options: 5-item Likert scale)', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Patient-Reported Bother from Side Effects of Cancer Therapy (Validated Single-Item Measure)', 'SecondaryOutcomeDescription': 'The single item "I am bothered by side effects of treatment" (GP5), rated on a 5-point Likert scale, is part of the Functional Assessment of Cancer Therapy-General (FACT-G) version (1 question; response option: 5-item Likert scale)', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'The Satisfaction with Decision Scale', 'SecondaryOutcomeDescription': '(6 questions; response options: 4-item Likert Scale)', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Confidence in Managing Survivorship Care', 'SecondaryOutcomeDescription': 'Questionnaire assessing self-reported receipt of survivorship care planning, expectations of their providers, and confidence in managing their survivorship care (5 questions; response options: 4-item Likert scales).', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Cancer recurrence', 'SecondaryOutcomeDescription': 'Single item, question: Did a doctor or other health professional ever tell you that your cancer had come back? (response option: yes/no). 1a. If yes, what was the most recent year a doctor or other health professional told you that your cancer had come back? _______________', 'SecondaryOutcomeTimeFrame': '12 months'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Self-reported patient demographics', 'OtherOutcomeDescription': 'gender, race/ethnicity; insurance type; highest level education; school/employment status; total household income', 'OtherOutcomeTimeFrame': '12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nPatients: Adult (21+) Kaiser Permanente Southern California members diagnosed and treated for pathologically confirmed first primary early-stage breast (stage 0, I, II) or colorectal (stage I, II) cancer within Kaiser Permanente Southern California. Completed active cancer treatment within the past 6-36 months; active treatment includes cancer-directed surgery, chemotherapy (includes Herceptin (Trastuzumab)), radiation therapy, and ovarian suppression therapy (e.g., Goserelin (Zoladex)). Completed at least one office visit within Kaiser Permanente Southern California medical oncology. At low-risk for cancer recurrence and treatment-related toxicities based on state of disease and treatment modalities. For our Aim 2 survey: Primary language of English or Spanish (although we will assess our Aim 1 participants for recorded preferred spoken language and adjust translations as needed). Ability to complete surveys of patient-reported outcomes.\nPhysicians: For centers assigned to the embedded primary care physician (PCP) model, PCPs selected to participate must be Board Certified in a relevant primary care specialty; hold a valid and current MD or advanced practitioner license; and be employed by the Southern California Permanente Medical Group.\n\nExclusion criteria:\n\nPatients less than 21 years of age\nPatients at high risk for recurrence and treatment-related toxicities based on stage of disease and treatment modalities', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '21 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Erin E. Hahn, PhD, MPH', 'OverallOfficialAffiliation': 'Kaiser Permanente Southern California, Department of Research & Evaluation', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Kaiser Permanente Orange County Anaheim/Irvine Medical Center Oncology Clinics', 'LocationCity': 'Anaheim', 'LocationState': 'California', 'LocationZip': '92806', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente Baldwin Park Medical Center Oncology Clinic', 'LocationCity': 'Baldwin Park', 'LocationState': 'California', 'LocationZip': '91706', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente Downey/Bellflower Medical Center Oncology Clinics', 'LocationCity': 'Downey', 'LocationState': 'California', 'LocationZip': '90242', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente Fontana Medical Center Oncology Clinic', 'LocationCity': 'Fontana', 'LocationState': 'California', 'LocationZip': '92335', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente South Bay Medical Center Oncology Clinic', 'LocationCity': 'Harbor City', 'LocationState': 'California', 'LocationZip': '90710', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente Kern County Medical Facilities Oncology Clinic', 'LocationCity': 'Kern', 'LocationState': 'California', 'LocationZip': '93306', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente Antelope Valley Medical Center Oncology Clinic', 'LocationCity': 'Lancaster', 'LocationState': 'California', 'LocationZip': '93534', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente Los Angeles Medical Center Oncology Clinic', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90027', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente West Lost Angeles Medical Center Oncology Clinic', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90034', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente Panorama City Medical Center Oncology Clinic', 'LocationCity': 'Panorama City', 'LocationState': 'California', 'LocationZip': '91402', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente Riverside/Palm Springs Medical Center Oncology Clinics', 'LocationCity': 'Riverside', 'LocationState': 'California', 'LocationZip': '92505', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente San Diego Medical Center Oncology Clinics', 'LocationCity': 'San Diego', 'LocationState': 'California', 'LocationZip': '92123', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente Woodland Hills Medical Center Oncology Clinic', 'LocationCity': 'Woodland Hills', 'LocationState': 'California', 'LocationZip': '91367', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'Prot_SAP', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'Yes', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Study Protocol and Statistical Analysis Plan', 'LargeDocDate': 'July 12, 2022', 'LargeDocUploadDate': '08/19/2022 12:59', 'LargeDocFilename': 'Prot_SAP_002.pdf'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000015179', 'ConditionMeshTerm': 'Colorectal Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000012002', 'ConditionAncestorTerm': 'Rectal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafAsFound': 'Colorectal Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13996', 'ConditionBrowseLeafName': 'Rectal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}]}}}}}, {'Rank': 62, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02203136', 'OrgStudyIdInfo': {'OrgStudyId': 'PA13-0942'}, 'Organization': {'OrgFullName': 'M.D. Anderson Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging', 'OfficialTitle': 'Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging'}, 'StatusModule': {'StatusVerifiedDate': 'May 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 25, 2014', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 16, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 16, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 25, 2014', 'StudyFirstSubmitQCDate': 'July 28, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 29, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'May 20, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 22, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'M.D. Anderson Cancer Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The goal of this research study is to improve detection of cancer outside of the bladder through genetic testing and improved imaging.', 'DetailedDescription': 'If participant agrees to take part in the study, a piece of the tumor that is removed during the biopsy will be collected for research purposes. The tissue will be sent to the laboratory for genetic testing.\n\nIf they have had a computed tomography scan (CT scan) or magnetic resonance imaging scan (MRI) recently, information collected from the scan will be collected. If they have not had one recently, they will have an MRI with contrast as part of this study. They will receive a separate consent form for this MRI scan.\n\nThe results of the test will be given to their doctor, but the results will not be used to decide their treatment.\n\nAfter they have surgery, information will be collected from their medical records, such as their diagnosis.\n\nLength of Study:\n\nTheir participation on this study will be over once their surgery is completed.\nThis is an investigational study.\n\nUp to 100 participants will take part in this study. All will be enrolled at MD Anderson.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Bladder Cancer']}, 'KeywordList': {'Keyword': ['Bladder cancer', 'Muscle invasive bladder cancer', 'MIBC', 'Biopsy specimen molecular profiling', 'Bladder surgery', 'Magnetic resonance imaging', 'MRI', 'Trans urethral resection of bladder']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'At the time of biopsy, a portion of the fresh human tumor biopsy samples utilized for DNA and RNA extraction.'}, 'EnrollmentInfo': {'EnrollmentCount': '16', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Muscle Invasive Bladder Cancer (MIBC)', 'ArmGroupDescription': 'During bladder cancer surgery, whole genome gene expression array assays obtained on tumor biopsy specimens. Analysis to determine biologic subtypes which will then be correlated with final pathology, identifying the subtype(s) associated with noc-MIBC. 3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Tissue Biopsy', 'Procedure: Magnetic Resonance Imaging (MRI)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'Tissue Biopsy', 'InterventionDescription': 'During bladder cancer surgery, tissue specimen taken for molecular profiling.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Muscle Invasive Bladder Cancer (MIBC)']}}, {'InterventionType': 'Procedure', 'InterventionName': 'Magnetic Resonance Imaging (MRI)', 'InterventionDescription': '3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Muscle Invasive Bladder Cancer (MIBC)']}, 'InterventionOtherNameList': {'InterventionOtherName': ['MRI']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Detection Improvement of Cancer Outside of the Bladder', 'PrimaryOutcomeDescription': 'Improved cross sectional imaging with pelvic MRI, and biopsy specimen molecular profiling used to identify muscle invasive bladder cancer (noc-MIBC). Analysis to determine biologic subtypes which will then be correlated with final pathology, identifying the subtype(s) associated with noc-MIBC.', 'PrimaryOutcomeTimeFrame': '4 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\n1. Patients with biopsy proven bladder cancer of any age will be eligible for enrollment.\n\nExclusion Criteria:\n\nContraindication to pelvic MRI (metallic implants/hardware, claustrophobia)\nParticipants who have previously received chemotherapy as part of multimodal therapy.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'Participants scheduled for bladder cancer surgery and biopsy from the Department of Urology at MD Anderson Cancer Center in Houston, Texas.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Neema Navai, MD', 'OverallOfficialAffiliation': 'M.D. Anderson Cancer Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Texas MD Anderson Cancer Center', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'University of Texas MD Anderson Cancer Center Website', 'SeeAlsoLinkURL': 'http://www.mdanderson.org'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001749', 'ConditionMeshTerm': 'Urinary Bladder Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000014571', 'ConditionAncestorTerm': 'Urologic Neoplasms'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001745', 'ConditionAncestorTerm': 'Urinary Bladder Diseases'}, {'ConditionAncestorId': 'D000014570', 'ConditionAncestorTerm': 'Urologic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4182', 'ConditionBrowseLeafName': 'Urinary Bladder Neoplasms', 'ConditionBrowseLeafAsFound': 'Bladder Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16472', 'ConditionBrowseLeafName': 'Urologic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4178', 'ConditionBrowseLeafName': 'Urinary Bladder Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16471', 'ConditionBrowseLeafName': 'Urologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 63, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04022616', 'OrgStudyIdInfo': {'OrgStudyId': 'OSU-09142'}, 'Organization': {'OrgFullName': 'Ohio State University Comprehensive Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients', 'OfficialTitle': 'Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients'}, 'StatusModule': {'StatusVerifiedDate': 'January 2023', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 4, 2010', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 15, 2019', 'StudyFirstSubmitQCDate': 'July 13, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 17, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 26, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 30, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'William Carson', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Ohio State University Comprehensive Cancer Center'}, 'LeadSponsor': {'LeadSponsorName': 'Ohio State University Comprehensive Cancer Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '99', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Immediate Surgery', 'ArmGroupDescription': 'Adult patients with breast malignancy.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Specimen collection']}}, {'ArmGroupLabel': 'Neo-adjuvant Chemotherapy', 'ArmGroupDescription': 'Adult patients with biopsy proven operable breast cancer who in the opinion of treating physician are suited to receive neo-adjuvant chemotherapy.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Specimen collection']}}, {'ArmGroupLabel': 'Lymph Node Tissue', 'ArmGroupDescription': 'Adult patients with breast malignancy who will be having a primary lymph node removed during breast surgery.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Specimen collection']}}, {'ArmGroupLabel': 'Metastatic Breast Cancer', 'ArmGroupDescription': 'Adult patients with biopsy proven stage IV breast cancer who are starting a new line palliative systemic therapy. A palliative systemic therapy will be defined in this trial as any chemotherapy regimen or combination of endocrine therapy with targeted agents such as cyclin dependent kinase 4/6 (CDK 4/6) inhibitors, HER2 targeting agents or inhibitors of mammalian target of rapamycin (mTOR).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Specimen collection']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Specimen collection', 'InterventionDescription': 'Specimens are obtained from patients who are being treated for breast malignancies.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Immediate Surgery', 'Lymph Node Tissue', 'Metastatic Breast Cancer', 'Neo-adjuvant Chemotherapy']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Isolate unfavorable immune cells MDSC from the peripheral blood or tumors of study subjects and test how strongly they inhibit function of favorable immune cells called Natural Killer Cells.', 'PrimaryOutcomeDescription': 'Function of Natural Killer Cells will be studied by measuring their ability to kill target cancer cells coated with monoclonal antibodies.\n\nisolate unfavorable immune cells called Myeloid Derived Suppressor Cells (MDSC) from the peripheral blood or the tumors of study subjects and test how strongly they inhibit function of favorable immune cells called Natural Killer Cells. Function of Natural Killer Cells will be studied by measuring their ability to kill target cancer cells coated with monoclonal antibodies.', 'PrimaryOutcomeTimeFrame': 'up to 1 year'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Isolate unfavorable immune cells called Myeloid Derived Suppressor Cells (MDSC) from the peripheral blood of study subjects who plan to start pre-operative chemotherapy for breast cancer to see if MDSC levels can predict who will respond to treatment. W', 'SecondaryOutcomeDescription': 'Percentage of MDSC at baseline and whether there is an association of baseline MDSC percent with response to chemotherapy.', 'SecondaryOutcomeTimeFrame': 'up to 1 year'}, {'SecondaryOutcomeMeasure': 'Isolate unfavorable immune cells MDSC from peripheral blood of study subjects who receive pre-operative chemotherapy for breast cancer to identify changes in MDSC levels during treatment can predict who will respond to treatment.', 'SecondaryOutcomeDescription': 'Changes will be reported in percentage of MDSC and associations of such changes with response to chemotherapy.', 'SecondaryOutcomeTimeFrame': 'up to 1 year'}, {'SecondaryOutcomeMeasure': 'Isolate lymph nodes from patients with breast cancer undergoing breast surgery to study what types of Natural Killer Cells are present.', 'SecondaryOutcomeDescription': 'Isolate a lymph nodes from patients with breast cancer undergoing breast surgery to study what types of Natural Killer Cells are present. Natural Killer cells are immune cells that are capable of killing cancer cells.', 'SecondaryOutcomeTimeFrame': 'up to 1 year'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\n18 years of age or older\nAbility to give informed consent\nStage I-III breast malignancy\n\nExclusion Criteria:\n\nUnable to tolerate venipuncture', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients who are being treated at the Ohio State Comprehensive Cancer Center and Stefanie Spielman Comprehensive Breast Center', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Ohio State Comprehensive Cancer Center', 'CentralContactRole': 'Contact', 'CentralContactPhone': '1-800-293-5066', 'CentralContactEMail': 'OSUCCCClinicaltrials@osumc.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'William Carson, MD', 'OverallOfficialAffiliation': 'Ohio State Comprehensive Cancer Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Ohio State University Comprehensive Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43210', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '32429929', 'ReferenceType': 'derived', 'ReferenceCitation': 'Wesolowski R, Stiff A, Quiroga D, McQuinn C, Li Z, Nitta H, Savardekar H, Benner B, Ramaswamy B, Lustberg M, Layman RM, Macrae E, Kassem M, Williams N, Sardesai S, VanDeusen J, Stover D, Cherian M, Mace TA, Yu L, Duggan M, Carson WE 3rd. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. BMC Cancer. 2020 May 19;20(1):445. doi: 10.1186/s12885-020-06949-4.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'The Jamesline', 'SeeAlsoLinkURL': 'http://cancer.osu.edu'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21113', 'InterventionBrowseLeafName': 'Sirolimus', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 64, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03039595', 'OrgStudyIdInfo': {'OrgStudyId': '11846'}, 'Organization': {'OrgFullName': 'Oxford University Hospitals NHS Trust', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Ploidy and Stroma in Early Rectal Cancer', 'OfficialTitle': 'An Observational Study to Correlate the Results of Ploidy and Stroma Analysis With Prognosis in Early Rectal Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'March 2022', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 29, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 31, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'July 31, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 30, 2017', 'StudyFirstSubmitQCDate': 'January 30, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 1, 2017', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'January 10, 2022', 'ResultsFirstSubmitQCDate': 'March 9, 2022', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'June 9, 2022', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 9, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 9, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Chris Cunningham', 'ResponsiblePartyInvestigatorTitle': 'Consultant colorectal surgeon', 'ResponsiblePartyInvestigatorAffiliation': 'Oxford University Hospitals NHS Trust'}, 'LeadSponsor': {'LeadSponsorName': 'Oxford University Hospitals NHS Trust', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Oslo University Hospital', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Early rectal cancer can be removed by minimally-invasive surgery, and the standard pathological assessment of the removed tumour gives valuable information about how advanced the tumour is. This gives an indication of how likely the cancer is to recur, so doctors and patient can decide on the most appropriate further treatment and follow-up. However there is still much uncertainty in these predictions about recurrence. This study will assess two further pathology tests, ploidy and stroma ratio in the tumour, by correlating the results with outcome. This will determine whether these two tests provide additional value in predicting outcome. If so, clinicians would be better able to advise patients with early rectal cancer about their prognosis and further management.', 'DetailedDescription': 'Early rectal cancer can be removed by minimally-invasive surgery, and the standard pathological assessment of the removed tumour gives valuable information about how advanced the tumour is. This information is very important in indicating whether the cancer is likely to recur, and therefore in advising the patient after surgery whether further treatment is advisable, and if not, what is the most appropriate follow-up regime. However there is still a lot of uncertainty in these predictions about recurrence of the cancer, and better tests are being sought. This study aims to look at two further pathology tests, ploidy and stroma ratio in the tumour, and correlate these test results with outcome in patients who have had an early rectal cancer removed. This will allow the investigators to assess whether these two tests provide additional value in predicting outcome. If so, clinicians would be better able to advise patients with early rectal cancer about their prognosis and further management.\n\nRoutine histopathology analysis of a rectal cancer specimen removed at surgery includes assessment of tumour size, depth of invasion, vascular, lymphatic and perineural invasion, tumour involvement of resection margins and nodal involvement. This information is valuable in predicting outcome. For example, predicted rates of local recurrence at 36 months following local excision of rectal cancer by transanal endoscopic microsurgery (TEM) based on tumour size, depth of invasion and lymphatic invasion have been tabulated. However such models are not perfect, and leave room for improvement. Ploidy and stroma ratio are two further tests which have shown some promise in predicting outcome.\n\nPloidy refers to the number of sets of chromosomes in a cell nucleus. Most human cells are normally diploid, with two sets of 23 chromosomes. Abnormal tumour cells may have a different number of sets of chromosomes, or be aneuploid, having some replicated or deleted chromosomes. In general, aneuploidy in cancer cells is associated with a worse prognosis. An early study of DNA ploidy in rectal cancer using flow cytometry showed an independent but small predictive effective of aneuploidy on survival. Technological advances now allow more accurate and detailed assessment of ploidy. The DNA ploidy status of tumour cells in early ovarian cancer has been found to predict which patients will benefit from adjuvant chemotherapy after surgery to remove the ovarian tumour and is used routinely in some centres to aid in decision-making.\n\nStroma ratio refers to the tumour: stroma ratio. A lower proportion of tumour cells or, conversely, a higher percentage of stroma, in a cancer tends to be associated with a poorer prognosis. This ratio has been found to be strongly associated with tumour growth and invasion in colorectal cancers, and to independently predict survival in patients undergoing surgery to removal colorectal tumours. However previous studies have looked mainly at more advanced colon cancers, rather than early rectal cancers, and have used only cancer-related death as the endpoint, rather than looking at local recurrence and response to adjuvant treatments.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Rectal Cancer']}, 'KeywordList': {'Keyword': ['Early rectal cancer', 'Ploidy', 'Tumour:stroma ratio']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Other']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'Specimens of early rectal cancer removed by transanal endoscopic microsurgery, which are routinely retained, will be further analysed.'}, 'EnrollmentInfo': {'EnrollmentCount': '150', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Ploidy and tumour:stromal ratio measurements', 'InterventionDescription': 'Ploidy and tumour:stromal ratio measurements will be made on specimens of early rectal cancer removed by transanal endoscopic microsurgery (TEM)'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Correlation Between Ploidy Status With Local Recurrence of Cancer', 'PrimaryOutcomeDescription': 'Results of ploidy status will be correlated with patient follow-up information for between 6 months and 9 years following surgery, to look for any correlation with local recurrence of the rectal cancer', 'PrimaryOutcomeTimeFrame': 'a minimum of 6 months after surgery'}, {'PrimaryOutcomeMeasure': 'Correlation Between Tumour: Stroma Ratio With Local Recurrence of Cancer', 'PrimaryOutcomeDescription': 'Results of tumour:stromal ratio (TSR) will be correlated with patient follow-up information for between 6 months and 9 years following surgery, to look for any correlation with local recurrence of the rectal cancer. A 50% cut-off is used to define high TSR.', 'PrimaryOutcomeTimeFrame': 'a minimum of 6 months after surgery'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Correlation Between Ploidy Status and Overall Survival After TEM Surgery to Remove Rectal Cancer', 'SecondaryOutcomeDescription': 'Results of ploidy status will be correlated with patient follow-up information for between 6 months and 9 years following surgery, to look for any correlation between the test results and overall survival', 'SecondaryOutcomeTimeFrame': 'a minimum of 6 months after surgery'}, {'SecondaryOutcomeMeasure': 'Correlation Between Tumour:Stroma Ratio and Overall Survival After TEM Surgery to Remove Rectal Cancer', 'SecondaryOutcomeDescription': 'Results of tumour:stromal ratio (TSR) will be correlated with patient follow-up information for between 6 months and 9 years following surgery, to look for any correlation between the test results and overall survival. High TSR is defined using a 50% cut-off.', 'SecondaryOutcomeTimeFrame': 'a minimum of 6 months after surgery'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nParticipant is willing and able to give informed consent (in English) for participation in the study, or gave informed consent for donation of tissue for research at the time of surgery\nMale or Female, aged 18 years or above\nDiagnosed with operable rectal cancer\nDue to undergo, or has already undergone, TEM surgery to remove rectal cancer\nA useable tissue sample has already been, or will be, taken as part of routine surgery\n\nExclusion Criteria:\n\nAge less than 18\nAdults who are not able to give consent or who are deemed vulnerable\nParticipants who do not have a useable tissue sample will be excluded', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Participants diagnosed with rectal cancer that is operable and patients who have already had rectal cancer removed by transanal endoscopic microsurgery (TEM) in Oxford since 2007.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Chris Cunningham, MD', 'OverallOfficialAffiliation': 'Employee', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Churchill Hospital', 'LocationCity': 'Oxford', 'LocationZip': 'OX3 7LE', 'LocationCountry': 'United Kingdom'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '19224520', 'ReferenceType': 'background', 'ReferenceCitation': 'Bach SP, Hill J, Monson JR, Simson JN, Lane L, Merrie A, Warren B, Mortensen NJ; Association of Coloproctology of Great Britain and Ireland Transanal Endoscopic Microsurgery (TEM) Collaboration. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg. 2009 Mar;96(3):280-90. doi: 10.1002/bjs.6456.'}, {'ReferencePMID': '3598327', 'ReferenceType': 'background', 'ReferenceCitation': 'Goh HS, Jass JR, Atkin WS, Cuzick J, Northover JM. Value of flow cytometric determination of ploidy as a guide to prognosis in operable rectal cancer: a multivariate analysis. Int J Colorectal Dis. 1987 Feb;2(1):17-21. doi: 10.1007/BF01648992.'}, {'ReferencePMID': '14504048', 'ReferenceType': 'background', 'ReferenceCitation': 'Kristensen GB, Kildal W, Abeler VM, Kaern J, Vergote I, Trope CG, Danielsen HE. Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Ann Oncol. 2003 Oct;14(10):1494-500. doi: 10.1093/annonc/mdg403.'}, {'ReferencePMID': '24458470', 'ReferenceType': 'background', 'ReferenceCitation': 'Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CSD. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol. 2014 Mar;25(3):644-651. doi: 10.1093/annonc/mdt593. Epub 2014 Jan 23.'}, {'ReferencePMID': '24548861', 'ReferenceType': 'background', 'ReferenceCitation': 'Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jordan LB, Kulka J, Pollock S, Rajan SS, Thygesen HH, Hanby AM, Speirs V. The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer. Br J Cancer. 2014 Apr 2;110(7):1744-7. doi: 10.1038/bjc.2014.69. Epub 2014 Feb 18.'}, {'ReferencePMID': '20407439', 'ReferenceType': 'background', 'ReferenceCitation': 'West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, Treanor D, Quirke P, Grabsch H. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br J Cancer. 2010 May 11;102(10):1519-23. doi: 10.1038/sj.bjc.6605674. Epub 2010 Apr 20.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': 'No individual data will be made available'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Patients', 'FlowGroupDescription': 'All patients. This is an observational study; no interventions were used.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '150'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '143'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '7'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Patients', 'BaselineGroupDescription': 'All patients'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '143'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Median', 'BaselineMeasureDispersionType': 'Full Range', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '143'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '69', 'BaselineMeasurementLowerLimit': '38', 'BaselineMeasurementUpperLimit': '94'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '143'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '56'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '87'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race and Ethnicity Not Collected', 'BaselineMeasurePopulationDescription': 'Race and Ethnicity were not collected from any participant.', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United Kingdom', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '143'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '143'}]}}]}}]}}, {'BaselineMeasureTitle': 'Tumour stage', 'BaselineMeasureDescription': 'Tumour component of the TNM (Tumour, Node, Metastasis) staging system determined by histopathological analysis of the resected tumour.', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '143'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'pT1 (tumour confined to the inner layer of the bowel)', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '76'}]}}, {'BaselineCategoryTitle': 'pT2 (tumour extends into the muscle layer of the bowel wall)', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '58'}]}}, {'BaselineCategoryTitle': 'pT3 (tumour has reached the outer lining of the bowel wall)', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '9'}]}}]}}]}}, {'BaselineMeasureTitle': 'Post-TEM management', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '143'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Surveillance', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '88'}]}}, {'BaselineCategoryTitle': 'Completion radical surgery', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '13'}]}}, {'BaselineCategoryTitle': 'Adjuvant radiotherapy', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '42'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Correlation Between Ploidy Status With Local Recurrence of Cancer', 'OutcomeMeasureDescription': 'Results of ploidy status will be correlated with patient follow-up information for between 6 months and 9 years following surgery, to look for any correlation with local recurrence of the rectal cancer', 'OutcomeMeasurePopulationDescription': 'Only patients for whom ploidy status was available were included in the analysis (ploidy assessment failed in 3 patients for technical reasons)', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'a minimum of 6 months after surgery', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Patients', 'OutcomeGroupDescription': 'All patients'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '140'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': 'Diploid - Local recurrence', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3'}]}}, {'OutcomeCategoryTitle': 'Diploid - No local recurrence', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '31'}]}}, {'OutcomeCategoryTitle': 'Non-diploid - Local recurrence', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '14'}]}}, {'OutcomeCategoryTitle': 'Non-diploid - No local recurrence', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '92'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Correlation Between Tumour: Stroma Ratio With Local Recurrence of Cancer', 'OutcomeMeasureDescription': 'Results of tumour:stromal ratio (TSR) will be correlated with patient follow-up information for between 6 months and 9 years following surgery, to look for any correlation with local recurrence of the rectal cancer. A 50% cut-off is used to define high TSR.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'a minimum of 6 months after surgery', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Patients', 'OutcomeGroupDescription': 'All patients'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '143'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': 'High TSR - Local recurrence', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2'}]}}, {'OutcomeCategoryTitle': 'High TSR - No local recurrence', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '9'}]}}, {'OutcomeCategoryTitle': 'Low TSR - Local recurrence', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '17'}]}}, {'OutcomeCategoryTitle': 'Low TSR - No local recurrence', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '115'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Correlation Between Ploidy Status and Overall Survival After TEM Surgery to Remove Rectal Cancer', 'OutcomeMeasureDescription': 'Results of ploidy status will be correlated with patient follow-up information for between 6 months and 9 years following surgery, to look for any correlation between the test results and overall survival', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'a minimum of 6 months after surgery', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Patients', 'OutcomeGroupDescription': 'All patients'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '140'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': 'Diploid - Alive', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '27'}]}}, {'OutcomeCategoryTitle': 'Diploid - Deceased', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '7'}]}}, {'OutcomeCategoryTitle': 'Non-diploid - Alive', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '86'}]}}, {'OutcomeCategoryTitle': 'Non-diploid - Deceased', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '20'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Correlation Between Tumour:Stroma Ratio and Overall Survival After TEM Surgery to Remove Rectal Cancer', 'OutcomeMeasureDescription': 'Results of tumour:stromal ratio (TSR) will be correlated with patient follow-up information for between 6 months and 9 years following surgery, to look for any correlation between the test results and overall survival. High TSR is defined using a 50% cut-off.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'a minimum of 6 months after surgery', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Patients', 'OutcomeGroupDescription': 'All patients'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '143'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': 'High TSR - Alive', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6'}]}}, {'OutcomeCategoryTitle': 'High TSR - Deceased', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5'}]}}, {'OutcomeCategoryTitle': 'Low TSR - Alive', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '110'}]}}, {'OutcomeCategoryTitle': 'Low TSR - Deceased', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '22'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': 'Up to 12 years following surgery', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Patients', 'EventGroupDescription': 'All patients', 'EventGroupDeathsNumAffected': '27', 'EventGroupDeathsNumAtRisk': '143', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '143', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '143'}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Dr Helen Jones', 'PointOfContactOrganization': 'Oxford Univeristy Hospitals NHS Foundation Trust', 'PointOfContactEMail': 'helen.jones3@ouh.nhs.uk', 'PointOfContactPhone': '01865 235657'}}}, 'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'Prot_SAP', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'Yes', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Study Protocol and Statistical Analysis Plan', 'LargeDocDate': 'October 21, 2016', 'LargeDocUploadDate': '01/07/2022 06:58', 'LargeDocFilename': 'Prot_SAP_000.pdf'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000012004', 'ConditionMeshTerm': 'Rectal Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000015179', 'ConditionAncestorTerm': 'Colorectal Neoplasms'}, {'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000012002', 'ConditionAncestorTerm': 'Rectal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M13998', 'ConditionBrowseLeafName': 'Rectal Neoplasms', 'ConditionBrowseLeafAsFound': 'Rectal Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13996', 'ConditionBrowseLeafName': 'Rectal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 65, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05140252', 'OrgStudyIdInfo': {'OrgStudyId': 'UMCC 2021.087'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'HUM00195321', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'University of Michigan'}]}, 'Organization': {'OrgFullName': 'University of Michigan Rogel Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid', 'OfficialTitle': 'Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid'}, 'StatusModule': {'StatusVerifiedDate': 'August 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 12, 2022', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'May 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 17, 2021', 'StudyFirstSubmitQCDate': 'November 17, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 1, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 31, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 1, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of Michigan Rogel Cancer Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The aim of this study is to learn whether participants find a patient guide to breast cancer treatment decisions acceptable and appropriate for use.', 'DetailedDescription': 'This study seeks to adapt and pilot test de-implementation strategies targeting low-value breast cancer treatments which have persisted despite national recommendations. Breast cancer is an ideal setting in which to study de-implementation given it is common, well-studied, typically presents at an early-stage, and care is provided primarily in a community setting.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['de-implementation strategies']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '40', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast cancer decision aid', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants receive a breast cancer decision aid.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Breast cancer decision aid']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Breast cancer decision aid', 'InterventionDescription': "The decision aid is tailored from a previously published aid, specific to women ≥70 with early-stage breast cancer. The aid will be delivered via mail or electronically per patient preference before the patient's initial appointment with a surgeon.", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Breast cancer decision aid']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Acceptability of Intervention (AIM) Survey', 'PrimaryOutcomeDescription': 'AIM is a validated, 4-item survey with all items measured on a 5-point Likert scale (Completely Disagree [1] - Completely Agree [5]), scored as a mean. The median score across all participants will be reported.', 'PrimaryOutcomeTimeFrame': '1 week after receiving decision aid'}, {'PrimaryOutcomeMeasure': 'Intervention Appropriateness Measure (IAM)', 'PrimaryOutcomeDescription': 'IAM is a validated, 4-item survey with all items measured on a 5-point Likert scale (Completely Disagree [1] - Completely Agree [5]), scored as a mean. The median score across all participants will be reported.', 'PrimaryOutcomeTimeFrame': '1 week after receiving decision aid'}, {'PrimaryOutcomeMeasure': 'Engagement with the patient decision aid', 'PrimaryOutcomeDescription': 'To determine feasibility, participants will be asked whether they engaged with the patient decision aid (1=thoroughly, 2=somewhat or 3=not at all), scored as a mean. The median score across all participants will be reported.', 'PrimaryOutcomeTimeFrame': '1 week after receiving decision aid'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Satisfaction with decision (SWD)', 'SecondaryOutcomeDescription': 'The SWD survey will be administered by telephone between 60- and 120-days following surgery. SWD is a validated, 6-item survey with all items measured on a 5-point Likert scale (Completely Disagree [1] - Completely Agree [5]), scored as a mean. The median score across all participants will be reported.', 'SecondaryOutcomeTimeFrame': 'up to 120-days following surgery'}, {'SecondaryOutcomeMeasure': 'Treatment choice', 'SecondaryOutcomeDescription': 'The research team will access participants electronic medical records to determine the number of participants who underwent SLNB, radiation treatment, both or neither after surgery. This will be reported in 4 categories: Only SLNB, Only Radiation, Both or Neither.', 'SecondaryOutcomeTimeFrame': '90 days after surgery'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria\n\nEarly stage breast cancer that is hormone receptor positive (HR+) and human epidermal growth factor negative (HER2-)\nMeet criteria for omission of sentinel lymph node biopsy (SLNB)\nReceiving care at Michigan Medicine\n\nExclusion Criteria\n\nNon-English speaking\nMale patients (current data does not support omission of SLNB in men)', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '70 Years', 'StdAgeList': {'StdAge': ['Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Lesly A Dossett, MD, MPH', 'OverallOfficialAffiliation': 'University of Michigan Rogel Cancer Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Michigan Rogel Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Ann Arbor', 'LocationState': 'Michigan', 'LocationZip': '48109', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Cancer AnswerLine', 'LocationContactRole': 'Contact', 'LocationContactPhone': '800-865-1125', 'LocationContactEMail': 'CancerAnswerLine@med.umich.edu'}, {'LocationContactName': 'Lesly A Dossett, MD, MPH', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31130442', 'ReferenceType': 'background', 'ReferenceCitation': 'Schonberg MA, Freedman RA, Recht AR, Jacobson AR, Aliberti GM, Karamourtopoulos M, Nakhlis F, McCarthy EP, Pories SE, Sharma R, Dominici LS. Developing a patient decision aid for women aged 70 and older with early stage, estrogen receptor positive, HER2 negative, breast cancer. J Geriatr Oncol. 2019 Nov;10(6):980-986. doi: 10.1016/j.jgo.2019.05.004. Epub 2019 May 24.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 66, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00665899', 'OrgStudyIdInfo': {'OrgStudyId': '04-0977'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R01CA107477-01', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/1R01CA107477-01'}, {'SecondaryId': 'LCC 0402', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'UNC'}]}, 'Organization': {'OrgFullName': 'University of North Carolina, Chapel Hill', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Couples Approach to Enhance Breast Cancer Survivorship', 'OfficialTitle': 'A Couples Approach to Enhance Breast Cancer Survivorship', 'Acronym': 'CanThrive'}, 'StatusModule': {'StatusVerifiedDate': 'October 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2004'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2010', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 2010', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 22, 2008', 'StudyFirstSubmitQCDate': 'April 23, 2008', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 24, 2008', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 25, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 27, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of North Carolina, Chapel Hill', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Duke University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': "The purpose of the proposed study is to evaluate the efficacy of a new couple-based intervention for women with recently diagnosed, early stage breast cancer and their spouses or male partners. This cancer-focused relationship enhancement intervention adapts well-validated cognitive-behavioral interventions to teach patients and partners specific relationship skills, such as problem-solving skills, communication, and maximizing positive interactions, that they can use in addressing breast cancer. This project's major goals are to improve the patient's individual functioning and specific aspects of the couple's relationship affected by breast cancer (e.g., mood, role functioning, sexual functioning, and social support). In the current investigation, cancer-focused relationship enhancement will be compared to (a) a couple-based Cancer Education intervention and (b) a Treatment-as-Usual condition."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Early-Stage Breast Cancer']}, 'KeywordList': {'Keyword': ['breast cancer', 'couples', 'cognitive behavioral therapy', 'Women with early stage breast cancer and their partners.']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '163', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cancer-Focused Relationship Enhancement', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Cancer-Focused Relationship Enhancement', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cancer-Focused Relationship Enhancement']}}, {'ArmGroupLabel': "Couple's Cancer Education", 'ArmGroupType': 'Experimental', 'ArmGroupDescription': "Couple's Cancer Education", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ["Behavioral: Couple's Cancer Education"]}}, {'ArmGroupLabel': 'Usual Care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Cancer-Related Community and Internet Resources'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Cancer-Focused Relationship Enhancement', 'InterventionDescription': 'Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cancer-Focused Relationship Enhancement']}}, {'InterventionType': 'Behavioral', 'InterventionName': "Couple's Cancer Education", 'InterventionDescription': 'Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ["Couple's Cancer Education"]}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Relationship Functioning, Individual Functioning, Cancer Related Physical Functioning', 'PrimaryOutcomeTimeFrame': 'Pre, post, 6 month follow-up, 12 month follow-up'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Observational coding of couples social support and decision making conversations', 'SecondaryOutcomeTimeFrame': 'pre, post, 6 month follow-up, 12 month follow-up'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nDiagnosed with early stage breast cancer within last year\nNo history of breast cancer, or other cancers in last 5 years (except skin cancer)\nLiving together in a committed heterosexual relationship\nread and speak English\nAgree to participate\n\nExclusion Criteria:\n\nStage 3b and above breast cancer\nNotable psychopathology, including severe depression with suicidality', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Donald H Baucom, Ph.D.', 'OverallOfficialAffiliation': 'University of North Carolina, Chapel Hill', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Laura S Porter, Ph.D.', 'OverallOfficialAffiliation': 'Duke University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of North Carolina at Chapel Hill', 'LocationCity': 'Chapel Hill', 'LocationState': 'North Carolina', 'LocationZip': '27599', 'LocationCountry': 'United States'}, {'LocationFacility': 'Duke University Medical Center', 'LocationCity': 'Durham', 'LocationState': 'North Carolina', 'LocationZip': '27708', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '18020933', 'ReferenceType': 'background', 'ReferenceCitation': 'Zimmermann T, Heinrichs N, Baucom DH. "Does one size fit all?" moderators in psychosocial interventions for breast cancer patients: a meta-analysis. Ann Behav Med. 2007 Nov-Dec;34(3):225-39. doi: 10.1007/BF02874548.'}, {'ReferencePMID': '16823173', 'ReferenceType': 'background', 'ReferenceCitation': 'Baucom DH, Porter LS, Kirby JS, Gremore TM, Keefe FJ. Psychosocial issues confronting young women with breast cancer. Breast Dis. 2005-2006;23:103-13. doi: 10.3233/bd-2006-23114.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'CanThrive Website', 'SeeAlsoLinkURL': 'http://www.canthrive.org'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 67, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00003432', 'OrgStudyIdInfo': {'OrgStudyId': '2030'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'IRB 2030', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'DUMC'}, {'SecondaryId': 'CDR0000066458', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'NCI'}]}, 'Organization': {'OrgFullName': 'Duke University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Immunotherapy in Treating Patients With Metastatic Breast Cancer', 'OfficialTitle': 'A Phase I/II Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous Cultured Dendritic Cells for Patients With Breast Cancer Who Achieve a Complete Response After High Dose Chemotherapy and Stem Cell Support'}, 'StatusModule': {'StatusVerifiedDate': 'November 2013', 'OverallStatus': 'Terminated', 'WhyStopped': 'low accrual', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 1998'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2002', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 2002', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 1, 1999', 'StudyFirstSubmitQCDate': 'April 24, 2003', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 25, 2003', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 5, 2013', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 6, 2013', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Duke University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': "RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to and kill their tumor cells.\n\nPURPOSE: Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with metastatic breast cancer who have achieved a partial or complete response after chemotherapy and peripheral stem cell transplantation.", 'DetailedDescription': 'OBJECTIVES:\n\nEvaluate the ability of active immunotherapy with carcinoembryonic antigen (CEA) RNA pulsed dendritic cells to induce CEA specific T cells in patients with metastatic breast cancer in complete remission following peripheral blood stem cell transplant.\nDetermine the clinical efficacy in terms of overall and recurrence free survival of immunotherapy with CEA RNA pulsed dendritic cells in this patients population.\n\nOUTLINE: Dendritic cells are taken from the leukapheresis product obtained during the peripheral blood stem cell transplant procedure performed prior to treatment on this study. The dendritic cells are pulsed with carcinoembryonic antigen (CEA) RNA. Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses. Patients undergo a second leukopheresis after the last dose of immunotherapy to obtain specimens for immunologic tests.\n\nPatients are followed every 3 months for the first year and annually thereafter.\n\nPROJECTED ACCRUAL: A total of 14-26 patients will be accrued for this study within 2 years.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['stage IV breast cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1', 'Phase 2']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '4', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'carcinoembryonic antigen RNA-pulsed DC cancer vaccine', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'carcinoembryonic antigen RNA-pulsed DC cancer vaccine', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Biological', 'InterventionName': 'carcinoembryonic antigen RNA-pulsed DC cancer vaccine', 'InterventionDescription': 'Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['carcinoembryonic antigen RNA-pulsed DC cancer vaccine']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Evaluate the ability of active immunotherapy with carcinoembryonic antigen (CEA) RNA pulsed dendritic cells to induce CEA specific T cells in patients with metastatic breast cancer in complete remission following peripheral blood stem cell transplant.', 'PrimaryOutcomeTimeFrame': 'Following administration of 4 IV vaccine doses (1 vaccine administered every 3 weeks)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Determine the clinical efficacy in terms of overall and recurrence free survival of immunotherapy with CEA RNA pulsed dendritic cells in this patients population.', 'SecondaryOutcomeTimeFrame': 'Following administration of 4 IV vaccine doses (1 vaccine administered every 3 weeks)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'DISEASE CHARACTERISTICS:\n\nHistologically confirmed metastatic breast cancer that expresses carcinoembryonic antigen (CEA)\n\nAt least 25% of the tumor cells must stain positive for CEA with at least moderate intensity\nMust have achieved either partial response or complete response after high dose chemotherapy and peripheral blood stem cell transplant\n\nHormone receptor status:\n\nNot specified\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n18 and over\n\nMenopausal status:\n\nNot specified\n\nPerformance status:\n\nKarnofsky 70-100%\n\nLife expectancy:\n\nGreater than 6 months\n\nHematopoietic:\n\nAbsolute neutrophil count at least 1000/mm^3\nAbsolute lymphocyte count at least 1000/mm^3\nHemoglobin at least 9 mg/dL\nPlatelet count at least 100,000/mm^3\n\nHepatic:\n\nBilirubin less than 2.0 mg/dL\nNo serious ongoing chronic or acute hepatic disease\n\nRenal:\n\nCreatinine less than 2.5 mg/dL\n\nCardiovascular:\n\nNo serious ongoing chronic or acute cardiac disease (New York Heart Association class III or IV)\n\nPulmonary:\n\nNo serious ongoing chronic or acute pulmonary illness such as asthma, chronic obstructive pulmonary disease, or radiation or drug induced pneumonitis\n\nOther:\n\nNo other prior or concurrent malignancy except nonmelanoma skin cancer or controlled superficial bladder cancer within the past 5 years\nNo history of autoimmune disease such as inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, scleroderma, or multiple sclerosis\nNo inflammatory bowel condition such as active infectious enteritis or eosinophilic enteritis\nNo active acute or chronic infection such as urinary tract infection, HIV, or viral hepatitis\nNot pregnant or nursing\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\nSee Disease Characteristics\nNo concurrent immunotherapy\n\nChemotherapy:\n\nSee Disease Characteristics\nNo concurrent chemotherapy\n\nEndocrine therapy:\n\nAt least 4 weeks since steroids\nNo concurrent steroid therapy\n\nRadiotherapy:\n\nNo concurrent radiotherapy\n\nSurgery:\n\nNot specified\n\nOther:\n\nNo concurrent immunosuppressive agents such as azathioprine or cyclosporine A', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Herbert K. Lyerly, MD', 'OverallOfficialAffiliation': 'Duke University', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Duke Comprehensive Cancer Center', 'LocationCity': 'Durham', 'LocationState': 'North Carolina', 'LocationZip': '27710', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16512', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 68, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04516330', 'OrgStudyIdInfo': {'OrgStudyId': 'MCBC-MIR'}, 'Organization': {'OrgFullName': 'Bezmialem Vakif University', 'OrgClass': 'OTHER'}, 'BriefTitle': "Can MicroRNA's Predict Multicentricity in Breast Cancer?", 'OfficialTitle': "Can MicroRNA's Predict Multicentricity in Breast Cancer?"}, 'StatusModule': {'StatusVerifiedDate': 'August 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'December 10, 2013', 'StudyFirstSubmitQCDate': 'August 14, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 18, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 14, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 18, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Yeliz Emine Ersoy', 'ResponsiblePartyInvestigatorTitle': 'Assoc. Prof.', 'ResponsiblePartyInvestigatorAffiliation': 'Bezmialem Vakif University'}, 'LeadSponsor': {'LeadSponsorName': 'Bezmialem Vakif University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': "The aim of this study is to determine if microRNA's have role in predicting multicentricity in breast cancer. If a specific microRNA will be found to be related with multicentricity, it will help us to make appropriate decisions on the treatment of patients with multicentric breast cancer.", 'DetailedDescription': "In the study that will be held at Bezmialem Vakif University Medical Faculty, General Surgery Department, 20 unifocal and 20 multifocal breast cancer patients will be included. Tissues will be taken from both tumoral and normal breast tissues and they will be saved in microRNA later solution under -80°C. Then, 84 microRNA's will be studied in these tissues to see if they express any of these microRNA's."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Multicentric Breast Cancer']}, 'KeywordList': {'Keyword': ['multicentric', 'breast', 'cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Diagnostic', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '57', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'unifocal breast cancer', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'patients having unifocal breast cancer', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: miRNA']}}, {'ArmGroupLabel': 'multicentric breast cancer', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'patients having multicentric breast cancer', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: miRNA']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Genetic', 'InterventionName': 'miRNA', 'InterventionDescription': "miRNA's expressed in breast cancer", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['multicentric breast cancer', 'unifocal breast cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': "MicroRNA's in multicentric breast cancer", 'PrimaryOutcomeDescription': "Evaluation of 84 microRNA's in patients with multicentric breast cancer", 'PrimaryOutcomeTimeFrame': 'April 2014'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Treatment plan according to the detected microRNA in patients with multicentric breast cancer', 'SecondaryOutcomeDescription': 'If a specific microRNA will be detected in patients with multicentric breast cancer, treatment plan will be individualized according to the detected microRNA', 'SecondaryOutcomeTimeFrame': 'April 2014'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nHaving breast cancer\nHaving no other malignancy\nFemale patient\n\nExclusion Criteria:\n\nHaving other malignancy\nUnder 18 years old\nMale patient', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '70 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Bezmialem Vakif University', 'LocationCity': 'Istanbul', 'LocationZip': '34306', 'LocationCountry': 'Turkey'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 69, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05129605', 'OrgStudyIdInfo': {'OrgStudyId': '2020P000081'}, 'Organization': {'OrgFullName': 'Massachusetts General Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Prostate Cancer Genetic Risk Evaluation and Screening Study', 'OfficialTitle': 'Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)', 'Acronym': 'PROGRESS'}, 'StatusModule': {'StatusVerifiedDate': 'November 2021', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 12, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2030', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2040', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 2, 2021', 'StudyFirstSubmitQCDate': 'November 9, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 22, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'November 30, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 15, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Keyan Salari, MD, PhD', 'ResponsiblePartyInvestigatorTitle': 'Urologic Oncology', 'ResponsiblePartyInvestigatorAffiliation': 'Massachusetts General Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Massachusetts General Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations or a positive family history and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.', 'DetailedDescription': 'Prostate cancer is the most common malignancy and the second leading cause of cancer-related deaths in American men. Prostate cancer has substantial inherited predisposition and men harboring specific genetic variants or a positive family history have been associated with an increased risk of developing prostate cancer. Men with specific genetic variants, such as pathogenic BRCA2 mutations, are at particularly greater risk of developing aggressive forms of prostate cancer and thus warrant undergoing careful screening for prostate cancer. However, the penetrance of many mutations in prostate cancer risk genes is unknown, and some men have no identifiable mutations in known risk genes despite a strong family history of prostate cancer. Prospectively collected clinical data along with biospecimens from unaffected individuals at high genetic risk for developing prostate cancer will advance the understanding of how specific mutations contribute to the development of prostate cancer and how these prostate cancers might be best detected. The purpose of this study is to prospectively screen men at high risk genetic risk for prostate cancer by prostate exam, PSA, and prostate MRI to characterize the penetrance and cancer-related outcomes of specific mutations, identify potentially novel genetic risk mutations and/or markers for early detection.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Prostatic Neoplasm', 'Prostate Cancer', 'BRCA2 Mutation', 'BRCA1 Mutation', 'ATM Gene Mutation', 'MMR Mutation', 'Lynch Syndrome', 'Genetic Predisposition to Disease']}, 'KeywordList': {'Keyword': ['BRCA2', 'BRCA1', 'Mismatch Repair Deficiency', 'Lynch Syndrome', 'HOXB13', 'Family History of Prostate Cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'Yes', 'TargetDuration': '20 Years', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Saliva, blood, and urine on all subjects\nTumor tissue on subjects who develop prostate cancer'}, 'EnrollmentInfo': {'EnrollmentCount': '200', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cohort 1', 'ArmGroupDescription': 'Documented germline known pathogenic or likely pathogenic mutation in a prostate cancer related risk gene', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Prostate cancer screening']}}, {'ArmGroupLabel': 'Cohort 2', 'ArmGroupDescription': 'Family history suggestive of high genetic risk for prostate cancer with clinical genetic testing negative for known pathogenic or likely pathogenic mutations in prostate cancer-related risk genes', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Prostate cancer screening']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test', 'InterventionName': 'Prostate cancer screening', 'InterventionDescription': 'Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cohort 1', 'Cohort 2']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Diagnosis of prostate cancer', 'PrimaryOutcomeDescription': 'Diagnosis of prostate cancer stratified by NCCN clinical risk category incorporating clinical stage, grade, and PSA at diagnosis.', 'PrimaryOutcomeTimeFrame': 'From date of enrollment until date of diagnosis of prostate cancer or age of 75 reached, which ever came first, assessed up to 20 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Positive predictive value of multiparametric MRI for detection of prostate cancer', 'SecondaryOutcomeDescription': 'Positive predictive value of multiparametric prostate MRI for detecting clinically significant prostate cancer in men at high genetic risk for prostate cancer with a positive MRI (PI-RADS score of 3 or higher)', 'SecondaryOutcomeTimeFrame': 'From date of enrollment until date of diagnosis of prostate cancer or age of 75 reached, which ever came first, assessed up to 20 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nMen 35-74 years old\nNo known diagnosis of prostate cancer\nLife expectancy >10 years\nMeet either cohort 1 or 2 criteria\nCohort 1: Documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a CLIA-certified laboratory (ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53)\nCohort 2: A strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing\n\nExclusion Criteria:\n\nPrior diagnosis or treatment of prostate cancer\nInability to undergo prostate MRI\nInability to receive MRI contrast agent', 'HealthyVolunteers': 'No', 'Gender': 'Male', 'MinimumAge': '35 Years', 'MaximumAge': '74 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Men ages 35-74 years old at high genetic risk for prostate cancer on the basis of a specific germline genetic mutation or a strong family history.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Felicia Mett', 'CentralContactRole': 'Contact', 'CentralContactPhone': '857-238-3838', 'CentralContactEMail': 'fmett@partners.org'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Keyan Salari, MD, PhD', 'OverallOfficialAffiliation': 'Massachusetts General Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Massachusetts General Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02114', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000011471', 'ConditionMeshTerm': 'Prostatic Neoplasms'}, {'ConditionMeshId': 'D000003123', 'ConditionMeshTerm': 'Colorectal Neoplasms, Hereditary Nonpolyposis'}, {'ConditionMeshId': 'D000004198', 'ConditionMeshTerm': 'Disease Susceptibility'}, {'ConditionMeshId': 'D000020022', 'ConditionMeshTerm': 'Genetic Predisposition to Disease'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000005834', 'ConditionAncestorTerm': 'Genital Neoplasms, Male'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000011469', 'ConditionAncestorTerm': 'Prostatic Diseases'}, {'ConditionAncestorId': 'D000020969', 'ConditionAncestorTerm': 'Disease Attributes'}, {'ConditionAncestorId': 'D000015179', 'ConditionAncestorTerm': 'Colorectal Neoplasms'}, {'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009386', 'ConditionAncestorTerm': 'Neoplastic Syndromes, Hereditary'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000030342', 'ConditionAncestorTerm': 'Genetic Diseases, Inborn'}, {'ConditionAncestorId': 'D000049914', 'ConditionAncestorTerm': 'DNA Repair-Deficiency Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M15507', 'ConditionBrowseLeafName': 'Syndrome', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13487', 'ConditionBrowseLeafName': 'Prostatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Prostate Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6532', 'ConditionBrowseLeafName': 'Disease Susceptibility', 'ConditionBrowseLeafAsFound': 'Predisposition', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21028', 'ConditionBrowseLeafName': 'Genetic Predisposition to Disease', 'ConditionBrowseLeafAsFound': 'Genetic Predisposition to Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5503', 'ConditionBrowseLeafName': 'Colorectal Neoplasms, Hereditary Nonpolyposis', 'ConditionBrowseLeafAsFound': 'Lynch Syndrome', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8098', 'ConditionBrowseLeafName': 'Genital Neoplasms, Male', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13485', 'ConditionBrowseLeafName': 'Prostatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21853', 'ConditionBrowseLeafName': 'Disease Attributes', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11483', 'ConditionBrowseLeafName': 'Neoplastic Syndromes, Hereditary', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22839', 'ConditionBrowseLeafName': 'Genetic Diseases, Inborn', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25284', 'ConditionBrowseLeafName': 'DNA Repair-Deficiency Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10791', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T5764', 'ConditionBrowseLeafName': 'Turcot Syndrome', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC16', 'ConditionBrowseBranchName': 'Diseases and Abnormalities at or Before Birth'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 70, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04257786', 'OrgStudyIdInfo': {'OrgStudyId': 'epithelial ovarian cancer'}, 'Organization': {'OrgFullName': 'Assiut University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Primary Cyto-reductive Surgery Vs Neo-adjuvant Chemotherapy (NAC) in Epithelial Ovarian Cancer', 'OfficialTitle': 'Primary Cyto-reductive Surgery Vs Neo-adjuvant Chemotherapy (NAC) Followed by Surgery in Patients With Advanced Primary Epithelial Ovarian Cancer: A Pilot Randomized Study', 'Acronym': 'ovarian cancer'}, 'StatusModule': {'StatusVerifiedDate': 'February 2020', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 1, 2020', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 30, 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'April 1, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 4, 2020', 'StudyFirstSubmitQCDate': 'February 4, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 6, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 4, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 6, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Ali hussien ali sayed', 'ResponsiblePartyInvestigatorTitle': 'Specialist', 'ResponsiblePartyInvestigatorAffiliation': 'Assiut University'}, 'LeadSponsor': {'LeadSponsorName': 'Assiut University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Assessment of efficacy of primary cyto-reductive surgery in patients with advanced primary epithelial ovarian cancer in Comparison to patients receiving neo-adjuvant chemotherapy (NAC) followed by surgery in complete excision of the tumor reaching R0 without significant morbidity.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Advanced Cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '80', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Group 1', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': '1ry surgery', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: 1ry cyto-reductive surgery']}}, {'ArmGroupLabel': 'Group 2', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Neoadjuvant Chemotherapy followed by surgery', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Combination Product: Neoadjuvant chemotherapy followed by surgery']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': '1ry cyto-reductive surgery', 'InterventionDescription': '1ry surgery then chemotherapy', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group 1']}, 'InterventionOtherNameList': {'InterventionOtherName': ['1ry surgery']}}, {'InterventionType': 'Combination Product', 'InterventionName': 'Neoadjuvant chemotherapy followed by surgery', 'InterventionDescription': 'chemotherapy then surgery', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group 2']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Neoadjuvant chemotherapy']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Percentage of patient where complete resection of the tumor can be achieved', 'PrimaryOutcomeDescription': 'complete resection of the tumor', 'PrimaryOutcomeTimeFrame': '3 month postoperative'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nFemale patients diagnosed with epithelial ovarian cancer (By histopathology)\n\nAge ≥ 18 years old\n\nAdvanced defined as (stage 2D or more ) by surgical staging.\n\nPerformance status (PS) according to Eastern Cooperative Oncology Group (ECOG) ≤ 2\n\nChemotherapy naïve\n\nInformed consent\n\nExclusion Criteria:\n\nPatients previously received chemotherapy or radiotherapy to any part of the abdomen or pelvis.\n\nPatients with uncontrolled infection.\n\nPatients with active bleeding or conditions associated with high risk of bleeding.\n\ncontraindications for surgery\n\ncontraindications To chemotherapy - bevacizumab', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Ali H Ali Sayed, M.Sc', 'CentralContactRole': 'Contact', 'CentralContactPhone': '02 01061830890', 'CentralContactEMail': 'lolf372@gmail.com'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Ali hussien Ali sayed', 'LocationStatus': 'Recruiting', 'LocationCity': 'Assiut', 'LocationZip': '71111', 'LocationCountry': 'Egypt'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000077216', 'ConditionMeshTerm': 'Carcinoma, Ovarian Epithelial'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010051', 'ConditionAncestorTerm': 'Ovarian Neoplasms'}, {'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000010049', 'ConditionAncestorTerm': 'Ovarian Diseases'}, {'ConditionAncestorId': 'D000000291', 'ConditionAncestorTerm': 'Adnexal Diseases'}, {'ConditionAncestorId': 'D000005833', 'ConditionAncestorTerm': 'Genital Neoplasms, Female'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000006058', 'ConditionAncestorTerm': 'Gonadal Disorders'}, {'ConditionAncestorId': 'D000002277', 'ConditionAncestorTerm': 'Carcinoma'}, {'ConditionAncestorId': 'D000009375', 'ConditionAncestorTerm': 'Neoplasms, Glandular and Epithelial'}, {'ConditionAncestorId': 'D000009370', 'ConditionAncestorTerm': 'Neoplasms by Histologic Type'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12126', 'ConditionBrowseLeafName': 'Ovarian Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M1704', 'ConditionBrowseLeafName': 'Carcinoma, Ovarian Epithelial', 'ConditionBrowseLeafAsFound': 'Epithelial Ovarian Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4686', 'ConditionBrowseLeafName': 'Carcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7015', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12124', 'ConditionBrowseLeafName': 'Ovarian Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2795', 'ConditionBrowseLeafName': 'Adnexal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8097', 'ConditionBrowseLeafName': 'Genital Neoplasms, Female', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7014', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8315', 'ConditionBrowseLeafName': 'Gonadal Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11472', 'ConditionBrowseLeafName': 'Neoplasms, Glandular and Epithelial', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11467', 'ConditionBrowseLeafName': 'Neoplasms by Histologic Type', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4352', 'ConditionBrowseLeafName': 'Ovarian Cancer', 'ConditionBrowseLeafAsFound': 'Ovarian Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'T4354', 'ConditionBrowseLeafName': 'Ovarian Epithelial Cancer', 'ConditionBrowseLeafAsFound': 'Epithelial Ovarian Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 71, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04495244', 'OrgStudyIdInfo': {'OrgStudyId': '241391'}, 'Organization': {'OrgFullName': 'Syantra Inc.', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'A Study to Identify Breast Cancer (IDBC)', 'OfficialTitle': 'Investigation of a Novel Blood Test to Identify Breast Cancer (IDBC)', 'Acronym': 'IDBC'}, 'StatusModule': {'StatusVerifiedDate': 'July 2020', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 24, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 7, 2020', 'StudyFirstSubmitQCDate': 'July 28, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 31, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 28, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 31, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Syantra Inc.', 'LeadSponsorClass': 'INDUSTRY'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed.\n\nThe primary objective of this study is to validate Syantra DX Breast Cancer methodology and biomarker panel using prospective samples, well categorized by diagnostic imaging scores, pathology outcomes, and subject characteristics.', 'DetailedDescription': "The current project is aimed at validating Syantra DX Breast Cancer in a UK population. Results of the UK study will be combined with those from additional sites, including those in Canada, with additional samples expected from the United States and South Korea. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed, and is described below.\n\nThe study seeks to evaluate performance of Syantra DX Breast Cancer in prospective samples and to optimize test methodology and biomarkers. Key to performance of the study is recruitment of women who have received an abnormal mammography report, and have been classified under the UK Royal College of Radiologists Breast Group (RCRBG) scoring system in categories 3 - 5. This will support the ability to employ the test for breast cancer detection in a screening/call-back environment. To complete the study cohort, additional women will be recruited from the population who have normal or benign mammography results (RCRBG category 1 and 2), and/or a recent normal physical breast exam, with no history of breast cancer. Blood samples will be acquired from all women following completion of an informed consent procedure.\n\nFor those with an abnormal mammogram, blood will be drawn before a biopsy is performed. All sample information will be de-identified, and the samples will be processed and analysed according to Syantra DX Breast Cancer standard operating procedures. These procedures include extracting sample RNA and aliquoting for storage in a manner that maintains sample anonymity. All processing and analysis will be conducted in a blind environment without knowing the associated RCRBG or pathology outcomes for any samples. Only after testing is complete will sample classifications be revealed. Syantra DX Breast Cancer results will then be compared to RCRBG, biopsy and pathology data to determine concordance, and statistics will be calculated. If or when biomarker panel or test methodology is modified during the performance of the study, samples will be reanalysed with updated test parameters. This reanalysis will make use of a de-identified aliquot of sample RNA to ensure that testing is maintained in a blind environment.\n\nThere is an optional part of the study procedure that is included as 'additional research'. A specific question seeking approval for the additional research is included on the study consent form. For individuals who agree to participate in the additional research, material extracted from their blood sample will be stored for additional investigations."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer Female']}, 'KeywordList': {'Keyword': ['Detection, blood test, clinical assay']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'Yes', 'TargetDuration': '1 Year', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'Whole blood'}, 'EnrollmentInfo': {'EnrollmentCount': '600', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Investigational Population', 'ArmGroupDescription': 'Suspected Invasive Breast Cancer (any size) or DCIS (pre-invasive) are of particular interest. Women with abnormal screening mammograms (R3-5) recalled for further investigation.\n\nInclusion criteria\n\nWomen with suspected Invasive Breast Cancer (tumours of any size and/or DCIS).\nIndividuals with an abnormal or suspicious screening mammogram recalled for further evaluation.\nSuspected Invasive Breast Cancer (tumours of any size and/or DCIS).\nWilling to give written Informed Consent and provide whole blood samples\nAge 30-75 years\n\nExclusion criteria\n\nBreast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)\nInoperable (T4 category) or inflammatory breast cancer\nPrevious history of cancer previously at any site\nPrevious history of breast cancer\nConcomitant or other concurrent anti-cancer therapy\nMale\nNo histopathological diagnosis', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Syantra DX Breast Cancer']}}, {'ArmGroupLabel': 'Borderline (Atypica and LCIS) Population', 'ArmGroupDescription': 'Women with borderline pathological B3 lesions (suspected atypia Ductal or Lobular and benign proliferative disease without DCIS or invasion) Inclusion criteria\n\nAbnormal screening mammogram with suspected benign breast disease or proliferative changes\nWilling to give Written Informed Consent and provide whole blood samples\nAged 30-75 years\n\nExclusion criteria\n\nExisting cancer diagnosis\nMale\nBreast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)\nPrevious history of any cancer\nPrevious history of breast cancer\nConcomitant or other concurrent anti-cancer therapy', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Syantra DX Breast Cancer']}}, {'ArmGroupLabel': 'Control Population', 'ArmGroupDescription': 'Healthy Controls Inclusion criteria\n\nNormal breast examination - No cancer detected/suspected by physical exam, diagnostic radiology or screening mammography\nWilling to give Written Informed Consent and provide whole blood samples\nAged 30-75 years\n\nExclusion criteria\n\nCancer diagnosis\nMale\nBreast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)\nPrevious history of any cancer\nConcomitant or other concurrent anti-cancer therapy', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Syantra DX Breast Cancer']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test', 'InterventionName': 'Syantra DX Breast Cancer', 'InterventionDescription': 'Blood test for detecting the presence of breast cancer.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Borderline (Atypica and LCIS) Population', 'Control Population', 'Investigational Population']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Performance of the Syantra DX Breast Cancer test as assessed by sensitivity and specificity', 'PrimaryOutcomeDescription': 'The number of participants that test positive or negative for breast cancer with the Syantra DX Breast Cancer test and their breast cancer status as assessed by mammography or pathology.', 'PrimaryOutcomeTimeFrame': 'through completion of the study, approximately eighteen months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Modulate test methodology to account for differences between retrospective and prospective samples', 'SecondaryOutcomeDescription': 'Determine the sensitivity and specificity of the assay with biomarker panel modifications.', 'SecondaryOutcomeTimeFrame': 'through completion of the study, approximately eighteen months'}, {'SecondaryOutcomeMeasure': 'Performance of the Syantra DX Breast Cancer test in prediction of molecular subtype of breast cancer as assessed by pathology', 'SecondaryOutcomeDescription': 'Correlate the performance of the test to molecular characterizations of identified cancers as assessed by pathology of tissue from biopsy or resection.', 'SecondaryOutcomeTimeFrame': 'through completion of the study, approximately eighteen months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria\n\nAged 30-75 years\nNormal breast examination - No cancer detected/suspected by physical exam, diagnostic radiology or screening mammography\nWomen with suspected Invasive Breast Cancer\nIndividuals with an abnormal or suspicious mammogram\nAbnormal screening mammogram with suspected benign breast disease or proliferative changes\n\nExclusion criteria\n\nCancer diagnosis\nMale\nBreast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)\nPrevious history of any cancer\nConcomitant or other concurrent anti-cancer therapy\nInoperable or inflammatory breast cancer', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Female', 'GenderBased': 'Yes', 'GenderDescription': 'Self-identified', 'MinimumAge': '30 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Populations will be selected from women visiting the Nightingale Centre at Wythenshaw Hospital for breast cancer imaging.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Hayley Brooks', 'CentralContactRole': 'Contact', 'CentralContactPhone': '0161 291 4045', 'CentralContactEMail': 'Hayley.brooks@mft.nhs.uk'}, {'CentralContactName': 'Linda Bailey', 'CentralContactRole': 'Contact', 'CentralContactPhone': '0161 291 4492', 'CentralContactEMail': 'linda.bailey3@mft.nhs.uk'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Nigel Bundred, MD', 'OverallOfficialAffiliation': 'Manchester University NHS Foundation Trust', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Cliona Kirwin, MD', 'OverallOfficialAffiliation': 'Manchester University NHS Foundation Trust', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Wythenshawe Hospital, Southmoor Road', 'LocationStatus': 'Recruiting', 'LocationCity': 'Manchester', 'LocationZip': 'M23 9LT', 'LocationCountry': 'United Kingdom', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hayley Brooks', 'LocationContactRole': 'Contact'}, {'LocationContactName': 'Nigel Bundred, MD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 72, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01064349', 'OrgStudyIdInfo': {'OrgStudyId': '113349'}, 'Organization': {'OrgFullName': 'GlaxoSmithKline', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Breast Cancer With Over-expression of erbB2-BRAINSTORM', 'OfficialTitle': 'Breast Cancer With Over-expression of erbB2 Study of the Treatment Paradigm in Metastasis to BRAIN (BRAINSTORM)'}, 'StatusModule': {'StatusVerifiedDate': 'May 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 6, 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 3, 2011', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 3, 2011', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 21, 2010', 'StudyFirstSubmitQCDate': 'February 4, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 8, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 13, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 14, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'GlaxoSmithKline', 'LeadSponsorClass': 'INDUSTRY'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region. We aim to identify approximately 300 erbB2+ breast cancer patients with brain metastases diagnosed between 2006-2008 in 6 countries. Medical records will be analyzed to determine the treatment pattern for brain metastases, including anti-erbB2 therapy. Additional objectives are to understand the impact of anti-erbB2 therapy on survival after brain metastases and to investigate the relationship between anti-erbB2 therapy for brain metastases and: 1) the time interval between diagnosis of erb2+ breast cancer and brain metastasis, and 2) the occurrence of brain metastasis as the first site of disease progression.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer']}, 'KeywordList': {'Keyword': ['ErbB2+ breast cancer', 'ErbB2 treatment', 'brain metastases']}}, 'DesignModule': {'StudyType': 'Observational', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Retrospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '144', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast cancer patients with brain metastases', 'ArmGroupDescription': 'Female Erb2+ breast cancer patients with brain metastases diagnosed between January 2006 and December 2008 in 6 Asian countries (Indonesia, Korea, Malaysia, Philippines, Singapore, and Thailand).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer', 'InterventionDescription': 'Trastuzumab or Lapatinib', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Breast cancer patients with brain metastases']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'To describe the treatment pattern of brain metastasis in ErbB2 over-expressing breast cancer in Asia Pacific countries.', 'PrimaryOutcomeTimeFrame': 'Time (in months) from date of first diagnosis of brain metastasis through to death or end of study period'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'To describe the survival of ErbB2 over-expressing breast cancer patients with brain metastasis after diagnosis of brain metastasis in relation to the receipt of anti-erbB2 therapy.', 'SecondaryOutcomeTimeFrame': 'Time (in months) from date of first diagnosis of brain metastasis through to death or end of study period'}, {'SecondaryOutcomeMeasure': 'Describe association between usage of anti-erbB2 therapy (before brain metastasis) & 1) time interval from diagnosis of erbB2+ breast cancer to occurrence of brain metastasis and 2) occurrence of brain metastasis as the first site of disease progression', 'SecondaryOutcomeTimeFrame': 'Time (in month) between the date of diagnosis of erbB2+ breast cancer and date of first diagnosis of brain metastasis'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nFemale patients diagnosed with erbB2+ breast cancer. ErbB2 positivity will be as determined by respective institutional standards, and will be based on medical history only.\nBrain metastasis diagnosis made between January 2006 - December 2008.\n\nExclusion Criteria:\n\nWomen who have another primary cancer diagnosed between the time of breast cancer diagnosis and brain metastasis..\nPatient has leptomeningeal metastases only without parenchymal brain involvement (since this pattern of the disease requires a different treatment approach.)', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'This study aims to enrol approximately 300 Erb2+ breast cancer cases with brain metastases in 6 Asian countries (Indonesia, Korea, Malaysia, Philippines, Singapore, and Thailand).', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'GSK Clinical Trials', 'OverallOfficialAffiliation': 'GlaxoSmithKline', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Pasay City', 'LocationZip': '1300', 'LocationCountry': 'Philippines'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Quezon City', 'LocationZip': '1101', 'LocationCountry': 'Philippines'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Quezon City', 'LocationZip': '1102', 'LocationCountry': 'Philippines'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Singapore', 'LocationZip': '119074', 'LocationCountry': 'Singapore'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Bangkok', 'LocationZip': '10110', 'LocationCountry': 'Thailand'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Bangkok', 'LocationZip': '10310', 'LocationCountry': 'Thailand'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Bangkok', 'LocationZip': '10330', 'LocationCountry': 'Thailand'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Bangkok', 'LocationZip': '10400', 'LocationCountry': 'Thailand'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Bangkok', 'LocationZip': '10700', 'LocationCountry': 'Thailand'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Chiangmai', 'LocationZip': '50200', 'LocationCountry': 'Thailand'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '22918394', 'ReferenceType': 'background', 'ReferenceCitation': 'Yap YS, Cornelio GH, Devi BC, Khorprasert C, Kim SB, Kim TY, Lee SC, Park YH, Sohn JH, Sutandyo N, Wong DW, Kobayashi M, Landis SH, Yeoh EM, Moon H, Ro J. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer. 2012 Sep 25;107(7):1075-82. doi: 10.1038/bjc.2012.346. Epub 2012 Aug 23.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11459', 'ConditionBrowseLeafName': 'Neoplasm Metastasis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000068878', 'InterventionMeshTerm': 'Trastuzumab'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000074322', 'InterventionAncestorTerm': 'Antineoplastic Agents, Immunological'}, {'InterventionAncestorId': 'D000000970', 'InterventionAncestorTerm': 'Antineoplastic Agents'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M325', 'InterventionBrowseLeafName': 'Trastuzumab', 'InterventionBrowseLeafAsFound': 'Tenofovir Alafenamide', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M1778', 'InterventionBrowseLeafName': 'Lapatinib', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M1346', 'InterventionBrowseLeafName': 'Antineoplastic Agents, Immunological', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 73, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02230462', 'OrgStudyIdInfo': {'OrgStudyId': 'H13-02922'}, 'Organization': {'OrgFullName': 'University of British Columbia', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Patient Satisfaction After Facial Reconstruction', 'OfficialTitle': 'Effects of Visualization of Pre-operative Defects on Patient Satisfaction After Facial Reconstruction for Skin Cancer Resection.'}, 'StatusModule': {'StatusVerifiedDate': 'October 2014', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2015', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 2015', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 16, 2014', 'StudyFirstSubmitQCDate': 'August 28, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 3, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 2, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 6, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of British Columbia', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to assess the effects of visualization of skin cancer resection defects on the face on the post-operative satisfaction of patients after their reconstruction. To achieve this aim, patients invited to participate in this study will be randomized to either seeing or not seeing their skin cancer excision defect prior to reconstruction. After reconstruction, patient satisfaction will be assessed in both groups to determine if visualization of the defect prior to reconstruction has any effect on patient satisfaction and if any detected effect has durability over time.', 'DetailedDescription': 'Purpose:\n\nThe purpose of this study is to assess patient satisfaction after reconstruction of Mohs skin cancer resection defects in the face, with the resection defect either seen or unseen by the patient. In this way, the investigators will determine the effects of visualization of the pre-operative defects on patient satisfaction after facial reconstruction. Any effects on patient satisfaction that are identified will then be tracked over time.\n\nHypothesis:\n\nThe null hypothesis for this study is that patient satisfaction after reconstruction of Mohs defects on the face is unaffected by the opportunity to visualize the defect prior to reconstruction, and that this observation persists over time. Furthermore, patients are able to recall the size of their cancer resection defect as accurately from a detailed description as from seeing the defect in a mirror.\n\nJustification:\n\nThis study will address whether visualization of a defect prior to its reconstruction affects patient satisfaction. Visualization of a defect prior to reconstruction is not standardized and is occasionally, but by no means necessarily, a portion of their consent for the reconstruction procedure. For the excision and reconstruction procedure in this study, all patients will be receiving the gold standard treatment for skin cancer. This includes a Mohs excision of their cancer and subsequent reconstruction of the excision defect using either primary closure or local flaps. Alternative treatments to this approach include various forms of excision and reconstruction where cancer free margins cannot be immediately determined.\n\nObjectives:\n\nThe objectives of this study are to determine whether visualization of a cancer excision defect on the face, prior to its reconstruction, improves post-reconstruction patient satisfaction. The satisfaction measures sought will primarily be satisfaction with the cosmetic result but will also include measures pertaining to symptomatic scarring, skin related quality of life and ability to recall defect size will also be collected.\n\nResearch Method:\n\nPatients meeting research criteria will be recruited to this study. These patients will all undergo cancer excision and reconstruction of the skin cancer defect during the same clinic visit. After their cancer excision is complete, they will be and randomized to either viewing or not-viewing their skin cancer excision defect prior to its reconstruction. After reconstruction they will be provided a series of surveys that assess the research questions posed by this study. Surveys will be distributed in the clinic on the day of surgery and at routine follow-up appointments at one week and two to three months.\n\nStatistical Analysis:\n\nThe planned sample size for this study is eighty patients randomized to two groups of forty. Study end points will be sought from patient answers to three sets of surveys that determine patient satisfaction with the cosmetic appearance of their reconstruction, ranked on an ordinal scale, as a primary end-point. Secondary end points using ordinal and binary measures will also be sought and include skin related quality of life (as measured by the Skindex 16), scarring, and the ability to accurately recall the size of the skin cancer excision defect. A chi-squared analysis of the data will be performed.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Skin Neoplasms']}, 'KeywordList': {'Keyword': ['patient satisfaction', 'Mohs surgery']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '80', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Viewing of cancer excision defect', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients in this arm of the study will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Viewing of cancer excision defect']}}, {'ArmGroupLabel': 'No viewing of cancer excision defect', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Patients in this arm of the study will not be invited to view their cancer excision defect prior to its reconstruction.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Viewing of cancer excision defect', 'InterventionDescription': 'Patients will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Viewing of cancer excision defect']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Patient satisfaction with the cosmetic appearance of their skin cancer reconstruction.', 'PrimaryOutcomeDescription': 'Patient satisfaction with the cosmetic appearance of their skin cancer reconstruction site will be assessed on a ten point scale on the day of surgery.', 'PrimaryOutcomeTimeFrame': 'The day of reconstruction.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Ability to recall cancer excision defect size.', 'SecondaryOutcomeDescription': 'Patients will be asked to draw what they recall to be the size of their cancer excision defect prior to its reconstruction. This will be done at the final routine surgical follow up appointment (3 months after surgery).', 'SecondaryOutcomeTimeFrame': '3 months after reconstruction'}, {'SecondaryOutcomeMeasure': 'Symptomatic scarring', 'SecondaryOutcomeDescription': 'Patients will complete survey questions to determine whether they are bothered by their scar appearance, texture or any neuropathic symptoms.', 'SecondaryOutcomeTimeFrame': '3 months after reconstruction'}, {'SecondaryOutcomeMeasure': 'Persistence of patient satisfaction with the cosmetic appearance of their skin cancer reconstruction.', 'SecondaryOutcomeDescription': 'Patient satisfaction with the cosmetic appearance of their skin cancer reconstruction site will be reassessed on a ten point scale at the two week and 3 month routine followup appointments.', 'SecondaryOutcomeTimeFrame': '2 weeks, and 3 months after reconstruction.'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Skindex -16', 'OtherOutcomeDescription': 'Patient quality of life relating to their skin cancer will be assessed using the Skindex-16 (a validated tool for this purpose).', 'OtherOutcomeTimeFrame': 'The day of reconstruction, 2 weeks, and 3 months after reconstruction.'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nPatients recruited for this study must undergo Mohs resection of skin cancer of the face with negative margins at the completion of their cancer resection.\nPatients recruited for this study must have a post cancer resection defect on the face at least 1.5 centimeters in size in the greatest dimension.\nPatients recruited for this study must undergo single stage repair of their post cancer resection defect with primary closure or local flaps.\nPatients must be from the Greater Vancouver area.\n\nExclusion Criteria:\n\nPatients with insufficient visual acuity to be able to appreciate wound and scarring changes to their face post-operatively will be excluded.\nPatients lacking the cognitive capacity to complete the data collection forms utilized in this study will be excluded.\nPatients suffering from significant psychiatric conditions will be excluded.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Bryce J Cowan, MD, PhD', 'OverallOfficialAffiliation': 'University of British Columbia', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Dermatology & Skin Science (UBC), The Skin Care Centre', 'LocationCity': 'Vancouver', 'LocationState': 'British Columbia', 'LocationZip': 'V5Z 4E8', 'LocationCountry': 'Canada', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Bryce J Cowan, MD, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '604-875-4888', 'LocationContactEMail': 'skinsurg@gmail.com'}, {'LocationContactName': 'Jorga Zabojova, MD, PhD', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'jorga.zabojova@gmail.com'}, {'LocationContactName': 'Bryce J Cowan, MD, PhD', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Jorga Zabojova, MD, PhD', 'LocationContactRole': 'Sub-Investigator'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000012878', 'ConditionMeshTerm': 'Skin Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M14833', 'ConditionBrowseLeafName': 'Skin Neoplasms', 'ConditionBrowseLeafAsFound': 'Skin Neoplasms', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M20242', 'ConditionBrowseLeafName': 'Facies', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 74, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03871816', 'OrgStudyIdInfo': {'OrgStudyId': 'CR108591'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '64091742PCR0002', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Janssen Research & Development, LLC'}]}, 'Organization': {'OrgFullName': 'Janssen Research & Development, LLC', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer', 'OfficialTitle': 'Biomarker Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'January 2023', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 22, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 30, 2022', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 29, 2022', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 11, 2019', 'StudyFirstSubmitQCDate': 'March 11, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 12, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 17, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 18, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Janssen Research & Development, LLC', 'LeadSponsorClass': 'INDUSTRY'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair gene defects in a population of men with metastatic Prostate Cancer (PC) and to use the reported DNA-repair gene defects to assess biomarker eligibility for niraparib interventional studies.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Metastatic Prostate Cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '14532', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Participants with Metastatic Prostate Cancer', 'ArmGroupDescription': 'Participants with metastatic prostate Cancer (PC) will be evaluated for the prevalence of DNA-repair gene defects (DRDs) and will be assessed for biomarker eligibility status for niraparib interventional studies. Participants will be consented to saliva, blood, and/or archival tumor tissue testing for the presence or absence of DNA-repair gene defects.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis', 'InterventionDescription': 'Saliva, blood, and/or archival tumor tissue will be collected from the participants with metastatic PC for genomic testing to confirm DRD status.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Participants with Metastatic Prostate Cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Percentage of Participants with 4 or more DNA-repair Gene Defects with Metastatic Prostate Cancer as an Estimate for Prevalence', 'PrimaryOutcomeDescription': 'Percentage of participants with 4 or more Deoxyribonucleic acid (DNA)-repair gene defects with metastatic Prostate Cancer (PC) as an estimate for prevalence will be assessed. A saliva, blood, and/or archival tumor tissue sample will be collected for genomic testing to confirm DNA-repair gene defect (DRD) status.', 'PrimaryOutcomeTimeFrame': 'Approximately 2.4 years'}, {'PrimaryOutcomeMeasure': 'Percentage of Participants who Meet Biomarker Eligibility Criteria for Other Niraparib Interventional Studies', 'PrimaryOutcomeDescription': 'Percentage of participants who meet biomarker eligibility criteria for other niraparib interventional studies will be assessed.', 'PrimaryOutcomeTimeFrame': 'Approximately 2.4 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Percentage of Participants with 4 or more DNA-repair Gene Defects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and with Metastatic Hormone Sensitive PC (HSPC) as an Estimate for Prevalence', 'SecondaryOutcomeDescription': 'Percentage of participants with 4 or more DRDs with mCRPC and HSPC as an estimate for prevalence will be assessed. A saliva, blood, and/or archival tumor tissue sample will be collected for genomic testing to confirm DRD status.', 'SecondaryOutcomeTimeFrame': 'Approximately 2.4 years'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants with 1 or more DNA-repair gene defects with Metastatic Prostate Cancer as an Estimate for Prevalence', 'SecondaryOutcomeDescription': 'Percentage of participants with 1 or more DRDs with metastatic PC as an estimate for prevalence will be assessed. Saliva, blood, and/or archival tumor tissue sample will be collected for genomic testing to confirm DRD status.', 'SecondaryOutcomeTimeFrame': 'Approximately 2.4 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nDiagnosis of metastatic (Stage IV) prostate cancer (PC), confirmed by either biopsy of a metastatic tumor site or history of localized disease supported by metastatic disease on imaging studies (that is [i.e.], clearly noted in hospital/clinical records)\nSigned Informed consent form (ICF)\nNo condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example [e.g.], compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments\nWilling to provide a saliva, blood, and/or archival tumor tissue sample for genomic analysis\nNo prior poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitor (PARPi) for the treatment of prostate cancer\nNo prior DNA-repair gene defect test results from a Janssen sponsored interventional trial', 'HealthyVolunteers': 'No', 'Gender': 'Male', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Study population consists of male participants diagnosed with metastatic prostate cancer who will be evaluated for the prevalence for DNA-repair gene defects.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Janssen Research & Development, LLC Clinical Trial', 'OverallOfficialAffiliation': 'Janssen Research & Development, LLC', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Urology Centers Of Alabama', 'LocationCity': 'Homewood', 'LocationState': 'Alabama', 'LocationZip': '35209', 'LocationCountry': 'United States'}, {'LocationFacility': 'Southern Cancer Center, PC', 'LocationCity': 'Mobile', 'LocationState': 'Alabama', 'LocationZip': '36608', 'LocationCountry': 'United States'}, {'LocationFacility': 'Arizona Oncology Associates, PC - HAL', 'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationZip': '85016', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mayo Clinic', 'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationZip': '85054', 'LocationCountry': 'United States'}, {'LocationFacility': 'Urological Associates of Southern Arizona, P.C.', 'LocationCity': 'Tucson', 'LocationState': 'Arizona', 'LocationZip': '85741', 'LocationCountry': 'United States'}, {'LocationFacility': 'Yuma Regional Medical Center', 'LocationCity': 'Yuma', 'LocationState': 'Arizona', 'LocationZip': '85364', 'LocationCountry': 'United States'}, {'LocationFacility': 'Arkansas Urology', 'LocationCity': 'Little Rock', 'LocationState': 'Arkansas', 'LocationZip': '72211', 'LocationCountry': 'United States'}, {'LocationFacility': "MemorialCare Research Miller Children's and Women's Hospital Long Beach", 'LocationCity': 'Long Beach', 'LocationState': 'California', 'LocationZip': '90806', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente', 'LocationCity': 'Riverside', 'LocationState': 'California', 'LocationZip': '92505', 'LocationCountry': 'United States'}, {'LocationFacility': 'San Bernardino Urological Associates', 'LocationCity': 'San Bernardino', 'LocationState': 'California', 'LocationZip': '92506', 'LocationCountry': 'United States'}, {'LocationFacility': 'Sansum Clinic Pharm', 'LocationCity': 'Santa Barbara', 'LocationState': 'California', 'LocationZip': '93105', 'LocationCountry': 'United States'}, {'LocationFacility': 'Rocky Mountain Cancer Centers', 'LocationCity': 'Aurora', 'LocationState': 'Colorado', 'LocationZip': '80012', 'LocationCountry': 'United States'}, {'LocationFacility': 'The Urology Center of Colorado', 'LocationCity': 'Denver', 'LocationState': 'Colorado', 'LocationZip': '80211', 'LocationCountry': 'United States'}, {'LocationFacility': 'Foothills Urology - Golden Off', 'LocationCity': 'Golden', 'LocationState': 'Colorado', 'LocationZip': '80401', 'LocationCountry': 'United States'}, {'LocationFacility': 'Eastern Connecticut Hematology & Oncology Assoc.', 'LocationCity': 'Norwich', 'LocationState': 'Connecticut', 'LocationZip': '06360', 'LocationCountry': 'United States'}, {'LocationFacility': 'Advanced Urology Institute', 'LocationCity': 'Daytona Beach', 'LocationState': 'Florida', 'LocationZip': '32114', 'LocationCountry': 'United States'}, {'LocationFacility': 'Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center', 'LocationCity': 'Fort Lauderdale', 'LocationState': 'Florida', 'LocationZip': '33308-4668', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cancer Specialists of North Florida', 'LocationCity': 'Jacksonville', 'LocationState': 'Florida', 'LocationZip': '32256', 'LocationCountry': 'United States'}, {'LocationFacility': 'Miami Cancer Institute at Baptist Health / Baptist Health Medical Group', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33176', 'LocationCountry': 'United States'}, {'LocationFacility': 'Ocala Oncology Center', 'LocationCity': 'Ocala', 'LocationState': 'Florida', 'LocationZip': '34474', 'LocationCountry': 'United States'}, {'LocationFacility': 'Woodlands Medical Specialists, PA', 'LocationCity': 'Pensacola', 'LocationState': 'Florida', 'LocationZip': '32503', 'LocationCountry': 'United States'}, {'LocationFacility': 'University Cancer & Blood Center, LLC', 'LocationCity': 'Athens', 'LocationState': 'Georgia', 'LocationZip': '30607', 'LocationCountry': 'United States'}, {'LocationFacility': 'Hawaii Cancer Care', 'LocationCity': 'Honolulu', 'LocationState': 'Hawaii', 'LocationZip': '96813', 'LocationCountry': 'United States'}, {'LocationFacility': 'Affiliated Oncologists, LLC', 'LocationCity': 'Chicago Ridge', 'LocationState': 'Illinois', 'LocationZip': '60415', 'LocationCountry': 'United States'}, {'LocationFacility': 'Illinois Cancer Care', 'LocationCity': 'Peoria', 'LocationState': 'Illinois', 'LocationZip': '61615', 'LocationCountry': 'United States'}, {'LocationFacility': 'Fort Wayne Medical Oncology and Hematology, Inc.', 'LocationCity': 'Fort Wayne', 'LocationState': 'Indiana', 'LocationZip': '46804', 'LocationCountry': 'United States'}, {'LocationFacility': 'First Urology', 'LocationCity': 'Jeffersonville', 'LocationState': 'Indiana', 'LocationZip': '47130', 'LocationCountry': 'United States'}, {'LocationFacility': 'Beacon Medical Group Clinical Research', 'LocationCity': 'South Bend', 'LocationState': 'Indiana', 'LocationZip': '46601', 'LocationCountry': 'United States'}, {'LocationFacility': 'Norton Healthcare', 'LocationCity': 'Louisville', 'LocationState': 'Kentucky', 'LocationZip': '40202', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pontchartrain Cancer Center', 'LocationCity': 'Covington', 'LocationState': 'Louisiana', 'LocationZip': '70433', 'LocationCountry': 'United States'}, {'LocationFacility': 'Ochsner Clinic Foundation', 'LocationCity': 'New Orleans', 'LocationState': 'Louisiana', 'LocationZip': '70121', 'LocationCountry': 'United States'}, {'LocationFacility': 'Maryland Oncology Hematology, PA', 'LocationCity': 'Columbia', 'LocationState': 'Maryland', 'LocationZip': '21044', 'LocationCountry': 'United States'}, {'LocationFacility': 'Frederick Health Hospital - James M Stockman Cancer Institute', 'LocationCity': 'Frederick', 'LocationState': 'Maryland', 'LocationZip': '21702-4337', 'LocationCountry': 'United States'}, {'LocationFacility': 'Chesapeake Urology Associates', 'LocationCity': 'Towson', 'LocationState': 'Maryland', 'LocationZip': '21204', 'LocationCountry': 'United States'}, {'LocationFacility': 'Beth Israel Deaconess Hospital Plymouth, Jordan Club Cancer Center', 'LocationCity': 'Plymouth', 'LocationState': 'Massachusetts', 'LocationZip': '02360', 'LocationCountry': 'United States'}, {'LocationFacility': 'Barbara Ann Karmanos Cancer Institute', 'LocationCity': 'Detroit', 'LocationState': 'Michigan', 'LocationZip': '48201', 'LocationCountry': 'United States'}, {'LocationFacility': 'Edward W Sparrow Hospital', 'LocationCity': 'Lansing', 'LocationState': 'Michigan', 'LocationZip': '48219', 'LocationCountry': 'United States'}, {'LocationFacility': 'Michigan Institute of Urology', 'LocationCity': 'Troy', 'LocationState': 'Michigan', 'LocationZip': '48084', 'LocationCountry': 'United States'}, {'LocationFacility': 'Minnesota Oncology Hematology, P.A.', 'LocationCity': 'Minneapolis', 'LocationState': 'Minnesota', 'LocationZip': '55404', 'LocationCountry': 'United States'}, {'LocationFacility': 'Central Care Cancer Center', 'LocationCity': 'Bolivar', 'LocationState': 'Missouri', 'LocationZip': '65613', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mosaic Life Care', 'LocationCity': 'Saint Joseph', 'LocationState': 'Missouri', 'LocationZip': '64507', 'LocationCountry': 'United States'}, {'LocationFacility': 'Adult Pediatric Urology & Urogynecology, P.C', 'LocationCity': 'Omaha', 'LocationState': 'Nebraska', 'LocationZip': '68114', 'LocationCountry': 'United States'}, {'LocationFacility': 'GU Research Network', 'LocationCity': 'Omaha', 'LocationState': 'Nebraska', 'LocationZip': '68130', 'LocationCountry': 'United States'}, {'LocationFacility': 'Nebraska Cancer Specialists', 'LocationCity': 'Omaha', 'LocationState': 'Nebraska', 'LocationZip': '68130', 'LocationCountry': 'United States'}, {'LocationFacility': 'New York Oncology Hematology', 'LocationCity': 'Albany', 'LocationState': 'New York', 'LocationZip': '12208', 'LocationCountry': 'United States'}, {'LocationFacility': 'Montefiore Medical Center', 'LocationCity': 'Bronx', 'LocationState': 'New York', 'LocationZip': '10461', 'LocationCountry': 'United States'}, {'LocationFacility': 'Tisch Cancer Institution', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10029', 'LocationCountry': 'United States'}, {'LocationFacility': 'Associated Medical Professionals', 'LocationCity': 'Syracuse', 'LocationState': 'New York', 'LocationZip': '13210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Upstate Cancer Center', 'LocationCity': 'Syracuse', 'LocationState': 'New York', 'LocationZip': '13210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Southeastern Medical Oncology Center', 'LocationCity': 'Goldsboro', 'LocationState': 'North Carolina', 'LocationZip': '27534', 'LocationCountry': 'United States'}, {'LocationFacility': 'Oklahoma Cancer Specialists and Research Institute, LLC', 'LocationCity': 'Tulsa', 'LocationState': 'Oklahoma', 'LocationZip': '74146', 'LocationCountry': 'United States'}, {'LocationFacility': 'Willamette Valley Cancer Institute and Research Center', 'LocationCity': 'Eugene', 'LocationState': 'Oregon', 'LocationZip': '97401', 'LocationCountry': 'United States'}, {'LocationFacility': 'Northwest Cancer Specialists PC', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97213-2982', 'LocationCountry': 'United States'}, {'LocationFacility': 'Oregon Oncology Specialists', 'LocationCity': 'Salem', 'LocationState': 'Oregon', 'LocationZip': '97301', 'LocationCountry': 'United States'}, {'LocationFacility': 'Oregon Urology Institute', 'LocationCity': 'Springfield', 'LocationState': 'Oregon', 'LocationZip': '97477', 'LocationCountry': 'United States'}, {'LocationFacility': 'Centers for Advanced Urology, LLC; d/b/a MidLantic Urology', 'LocationCity': 'Bala-Cynwyd', 'LocationState': 'Pennsylvania', 'LocationZip': '19004', 'LocationCountry': 'United States'}, {'LocationFacility': 'Gettysburg Cancer Center', 'LocationCity': 'Gettysburg', 'LocationState': 'Pennsylvania', 'LocationZip': '17325', 'LocationCountry': 'United States'}, {'LocationFacility': 'Consultants in Medical Oncology and Hematology, P.C. - Abington', 'LocationCity': 'Horsham', 'LocationState': 'Pennsylvania', 'LocationZip': '19044', 'LocationCountry': 'United States'}, {'LocationFacility': 'Lancaster Urology', 'LocationCity': 'Lancaster', 'LocationState': 'Pennsylvania', 'LocationZip': '17601', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Pittsburgh Medical Center (UPMC)', 'LocationCity': 'Pittsburgh', 'LocationState': 'Pennsylvania', 'LocationZip': '15232', 'LocationCountry': 'United States'}, {'LocationFacility': 'Prisma Health', 'LocationCity': 'Greenville', 'LocationState': 'South Carolina', 'LocationZip': '29615', 'LocationCountry': 'United States'}, {'LocationFacility': 'Atlantic Urology Clinics', 'LocationCity': 'Myrtle Beach', 'LocationState': 'South Carolina', 'LocationZip': '29572', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Onc.', 'LocationCity': 'Abilene', 'LocationState': 'Texas', 'LocationZip': '79606', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology-Amarillo', 'LocationCity': 'Amarillo', 'LocationState': 'Texas', 'LocationZip': '79106', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology-Austin', 'LocationCity': 'Austin', 'LocationState': 'Texas', 'LocationZip': '78731', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center', 'LocationCity': 'Beaumont', 'LocationState': 'Texas', 'LocationZip': '77702-1449', 'LocationCountry': 'United States'}, {'LocationFacility': 'Methodist Dallas Medical Center', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75203', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology-Denton South', 'LocationCity': 'Denton', 'LocationState': 'Texas', 'LocationZip': '76201', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology, P.A. - Flower Mound', 'LocationCity': 'Flower Mound', 'LocationState': 'Texas', 'LocationZip': '75028', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology-Fort Worth Cancer Center', 'LocationCity': 'Fort Worth', 'LocationState': 'Texas', 'LocationZip': '76104', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology-Memorial City', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77024', 'LocationCountry': 'United States'}, {'LocationFacility': 'Houston Metro Urology', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77027', 'LocationCountry': 'United States'}, {'LocationFacility': 'MD Anderson Cancer Center', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology - Willowbrook', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77070', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology P.A.', 'LocationCity': 'Longview', 'LocationState': 'Texas', 'LocationZip': '75601', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology P.A.', 'LocationCity': 'McAllen', 'LocationState': 'Texas', 'LocationZip': '78503', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology-Mesquite', 'LocationCity': 'Mesquite', 'LocationState': 'Texas', 'LocationZip': '75150', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology-Midland Allison Cancer Center', 'LocationCity': 'Midland', 'LocationState': 'Texas', 'LocationZip': '79701', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology, P.A. - Paris', 'LocationCity': 'Paris', 'LocationState': 'Texas', 'LocationZip': '75460', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology P A', 'LocationCity': 'Plano', 'LocationState': 'Texas', 'LocationZip': '75075', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology P.A.', 'LocationCity': 'Plano', 'LocationState': 'Texas', 'LocationZip': '75093', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Texas at San Antonio', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78217', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology -Waco', 'LocationCity': 'Waco', 'LocationState': 'Texas', 'LocationZip': '76712', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology Deke Slayton Cancer Center', 'LocationCity': 'Webster', 'LocationState': 'Texas', 'LocationZip': '77598', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Oncology P.A.', 'LocationCity': 'Wichita Falls', 'LocationState': 'Texas', 'LocationZip': '76310', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Virginia', 'LocationCity': 'Charlottesville', 'LocationState': 'Virginia', 'LocationZip': '22908', 'LocationCountry': 'United States'}, {'LocationFacility': 'INOVA', 'LocationCity': 'Fairfax', 'LocationState': 'Virginia', 'LocationZip': '22031', 'LocationCountry': 'United States'}, {'LocationFacility': 'Virginia Cancer Specialists', 'LocationCity': 'Leesburg', 'LocationState': 'Virginia', 'LocationZip': '20176', 'LocationCountry': 'United States'}, {'LocationFacility': 'Virginia Oncology Asc', 'LocationCity': 'Norfolk', 'LocationState': 'Virginia', 'LocationZip': '23502', 'LocationCountry': 'United States'}, {'LocationFacility': 'Urology of Virginia, PLCC', 'LocationCity': 'Virginia Beach', 'LocationState': 'Virginia', 'LocationZip': '23462', 'LocationCountry': 'United States'}, {'LocationFacility': 'Northwest Medical Specialists', 'LocationCity': 'Tacoma', 'LocationState': 'Washington', 'LocationZip': '98405', 'LocationCountry': 'United States'}, {'LocationFacility': 'Building Oncology Research', 'LocationCity': 'Janesville', 'LocationState': 'Wisconsin', 'LocationZip': '53548', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Wisconsin Carbone Cancer Center', 'LocationCity': 'Madison', 'LocationState': 'Wisconsin', 'LocationZip': '53792', 'LocationCountry': 'United States'}, {'LocationFacility': 'Hospital Aleman', 'LocationCity': 'Buenos Aires', 'LocationZip': 'C1118AAT', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Sociedade Beneficente de Senhoras - Hospital Sírio Libanês', 'LocationCity': 'Buenos Aires', 'LocationZip': 'C1419AHN', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Centro de Urologia (CDU)', 'LocationCity': 'Ciudad Automoma Buenos Aires', 'LocationZip': 'C1120AAT', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'CINME - Centro de Investigaciones Metabolicas', 'LocationCity': 'Ciudad Autonoma de Buenos Aires', 'LocationZip': 'C1027AAP', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'CEMIC Saavedra', 'LocationCity': 'Ciudad Autonoma de Buenos Aires', 'LocationZip': 'C1431FWN', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Hospital Italiano de Buenos Aires', 'LocationCity': 'Ciudad Autonoma de', 'LocationZip': 'C1199ABB', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Centro Oncológico Korben', 'LocationCity': 'Ciudad Autónoma de Buenos Aires', 'LocationZip': 'C1426AGE', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Clínica Adventista Belgrano', 'LocationCity': 'Ciudad De Buenos Aires', 'LocationZip': 'C1430EGF', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica', 'LocationCity': 'Cordoba', 'LocationZip': '5000', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Centro Urologico Profesor Bengio', 'LocationCity': 'Cordoba', 'LocationZip': 'X5000KPH', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Hospital Privado - Centro Medico de Cordoba', 'LocationCity': 'Cordoba', 'LocationZip': 'X5016KEH', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Hospital Privado de Comunidad', 'LocationCity': 'Mar Del Plata', 'LocationZip': 'B7602CBM', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Centro de Investigacion Pergamino SA', 'LocationCity': 'Pergamino', 'LocationZip': 'B2700CPM', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Sanatorio Parque', 'LocationCity': 'Rosario', 'LocationZip': 'S2000SDV', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'ARS Médica', 'LocationCity': 'San Salvador De Jujuy', 'LocationZip': 'Y4600AFW', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Pindara Private Hospital', 'LocationCity': 'Benowa', 'LocationZip': '4217', 'LocationCountry': 'Australia'}, {'LocationFacility': 'Sunshine Coast University Hospital', 'LocationCity': 'Birtinya', 'LocationZip': '4575', 'LocationCountry': 'Australia'}, {'LocationFacility': "Chris O'Brien Lifehouse", 'LocationCity': 'Camperdown', 'LocationZip': '2050', 'LocationCountry': 'Australia'}, {'LocationFacility': "St Vincent's hospital", 'LocationCity': 'Darlinghurst', 'LocationZip': '2010', 'LocationCountry': 'Australia'}, {'LocationFacility': 'Border Medical Oncology', 'LocationCity': 'East Albury', 'LocationZip': '2640', 'LocationCountry': 'Australia'}, {'LocationFacility': 'Royal Hobart Hospital', 'LocationCity': 'Hobart', 'LocationZip': '7000', 'LocationCountry': 'Australia'}, {'LocationFacility': 'Ashford Cancer Centre', 'LocationCity': 'Kurralta Park', 'LocationZip': '5037', 'LocationCountry': 'Australia'}, {'LocationFacility': 'Liverpool Hospital', 'LocationCity': 'Liverpool', 'LocationZip': '2170', 'LocationCountry': 'Australia'}, {'LocationFacility': 'Macquarie University Hospital', 'LocationCity': 'Macquarie University', 'LocationZip': '2109', 'LocationCountry': 'Australia'}, {'LocationFacility': 'Peter MacCallum Cancer Centre', 'LocationCity': 'Melbourne', 'LocationZip': '3000', 'LocationCountry': 'Australia'}, {'LocationFacility': 'Fiona Stanley Hospital', 'LocationCity': 'Murdoch', 'LocationZip': '6150', 'LocationCountry': 'Australia'}, {'LocationFacility': 'Prince Of Wales Hospital', 'LocationCity': 'Randwick', 'LocationZip': '2031', 'LocationCountry': 'Australia'}, {'LocationFacility': 'Sydney Adventist Hospital', 'LocationCity': 'Wahroonga', 'LocationZip': '2076', 'LocationCountry': 'Australia'}, {'LocationFacility': 'Bobruisk Interregional Oncological Dispensary', 'LocationCity': 'Bobruisk', 'LocationZip': '213825', 'LocationCountry': 'Belarus'}, {'LocationFacility': 'Brest Regional Oncology Dispensary', 'LocationCity': 'Brest', 'LocationZip': '224027', 'LocationCountry': 'Belarus'}, {'LocationFacility': 'Gomel Regional Clinical Oncology Dispensary', 'LocationCity': 'Gomel', 'LocationZip': '246012', 'LocationCountry': 'Belarus'}, {'LocationFacility': 'Grodno University Hospital', 'LocationCity': 'Grodno', 'LocationZip': '230017', 'LocationCountry': 'Belarus'}, {'LocationFacility': 'State Institution N.N. Alexandrov Republican Scientific and', 'LocationCity': 'Lesnoy', 'LocationZip': '223040', 'LocationCountry': 'Belarus'}, {'LocationFacility': 'Minsk city Clinical Oncological Dispensary', 'LocationCity': 'Minsk', 'LocationZip': '220013', 'LocationCountry': 'Belarus'}, {'LocationFacility': 'Mogilev Regional Hospital', 'LocationCity': 'Mogilev', 'LocationZip': '212018', 'LocationCountry': 'Belarus'}, {'LocationFacility': 'Vitebsk Regional Clinical Hospital', 'LocationCity': 'Vitebsk', 'LocationZip': '210603', 'LocationCountry': 'Belarus'}, {'LocationFacility': 'Clinique Notre Dame de Grâce', 'LocationCity': 'Charleroi', 'LocationZip': '6000', 'LocationCountry': 'Belgium'}, {'LocationFacility': 'Jolimont', 'LocationCity': 'Haine-Saint-Paul, La Louviere', 'LocationZip': '7100', 'LocationCountry': 'Belgium'}, {'LocationFacility': 'Clinique Saint Pierre', 'LocationCity': 'Ottignies', 'LocationZip': '1340', 'LocationCountry': 'Belgium'}, {'LocationFacility': 'Algemeen Ziekenhuis Delta', 'LocationCity': 'Roeselare', 'LocationZip': '8800', 'LocationCountry': 'Belgium'}, {'LocationFacility': 'Fundacao Pio XII', 'LocationCity': 'Barretos', 'LocationZip': '14784-400', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Cetus Oncologia', 'LocationCity': 'Belo Horizonte', 'LocationZip': '30110-022', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'PERSONAL - Oncologia de Precisão e Personalizada', 'LocationCity': 'Belo Horizonte', 'LocationZip': '30130-090', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia', 'LocationCity': 'Brasilia', 'LocationZip': '7020-730', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'CIONC - Centro Integrado de Oncologia de Curitiba', 'LocationCity': 'Curitiba', 'LocationZip': '80810-050', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Liga Paranaense de Combate ao Cancer', 'LocationCity': 'Curitiba', 'LocationZip': '81520-060', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Centro de Pesquisa e Ensino em Oncologia de Santa Catarina - CEPEN', 'LocationCity': 'Florianopolis', 'LocationZip': '88034-000', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Suporte Nutricional e Quimioterapia Ltda - Pronutrir', 'LocationCity': 'Fortaleza', 'LocationZip': '60 810180', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge', 'LocationCity': 'Goiania', 'LocationZip': '74605-070', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda', 'LocationCity': 'Ijui', 'LocationZip': '98700-000', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Fundação São Francisco Xavier', 'LocationCity': 'Ipatinga', 'LocationZip': '35162 189', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Clínica de Neoplasias Litoral Ltda.', 'LocationCity': 'Itajai', 'LocationZip': '88301-220', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Instituto Joinvilense de Hematologia e Oncologia Ltda - Centro de Hematologia e Oncologia', 'LocationCity': 'Joinville', 'LocationZip': '89201-260', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Medradius Clinica de Medicina Nuclear e Radiologia de Maceio Ltda.', 'LocationCity': 'Maceio', 'LocationZip': '57052-765', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Liga Norte Riograndense Contra O Cancer', 'LocationCity': 'Natal', 'LocationZip': '59062-000', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Irmandade Santa Casa de Misericordia de Porto Alegre', 'LocationCity': 'Porto Alegre', 'LocationZip': '90020-090', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Hospital Ernesto Dornelles', 'LocationCity': 'Porto Alegre', 'LocationZip': '90160-093', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'MultiHemo Servicos Medicos S.A', 'LocationCity': 'Recife', 'LocationZip': 'CEP: 50070-460', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Universidade do Estado do Rio de Janeiro - UERJ', 'LocationCity': 'Rio de Janeiro', 'LocationZip': '20551-030', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Oncoclínicas Rio de Janeiro S.A.', 'LocationCity': 'Rio de Janeiro', 'LocationZip': '22250-905', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)', 'LocationCity': 'Rio de Janeiro', 'LocationZip': '22775-001', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Núcleo de Oncologia da Bahia', 'LocationCity': 'Salvador', 'LocationZip': '40170-110', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Hospital Sao Rafael', 'LocationCity': 'Salvador', 'LocationZip': '41253-190', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia', 'LocationCity': 'Santo André', 'LocationZip': '09060-650', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Irmandade Santa Casa de Misericordia de Sao Paulo', 'LocationCity': 'Sao Paulo', 'LocationZip': '01221-020', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Instituto de Ensino e Pesquisa São Lucas', 'LocationCity': 'Sao Paulo', 'LocationZip': '01236-030', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo', 'LocationCity': 'Sao Paulo', 'LocationZip': '01246-000', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Fundação Antônio Prudente - A.C. Camargo Cancer Center', 'LocationCity': 'Sao Paulo', 'LocationZip': '01509900', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Instituto de Assistencia Medica ao Servidor Publico Estadual - IAMSPE', 'LocationCity': 'Sao Paulo', 'LocationZip': '04039-004', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado', 'LocationCity': 'Sorocaba', 'LocationZip': '18030-075', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Instituto do Cancer Arnaldo Vieira de Carvalho', 'LocationCity': 'São Paulo', 'LocationZip': '01221-020', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Real e Benemérita Associação Portuguesa de Beneficência', 'LocationCity': 'São Paulo', 'LocationZip': '01323-900', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Núcleo de Pesquisa São Camilo', 'LocationCity': 'São Paulo', 'LocationZip': '04014-002', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'Instituto do Cancer De Tres Lagoas', 'LocationCity': 'Três Lagoas', 'LocationZip': '79601-001', 'LocationCountry': 'Brazil'}, {'LocationFacility': 'MHAT Deva Maria', 'LocationCity': 'Burgas', 'LocationZip': '8001', 'LocationCountry': 'Bulgaria'}, {'LocationFacility': "UMHAT 'Dr. Georgi Stranski', EAD", 'LocationCity': 'Pleven', 'LocationZip': '5800', 'LocationCountry': 'Bulgaria'}, {'LocationFacility': 'District Oncology Dispensary with In-Patient Stationary - Plovdiv', 'LocationCity': 'Plovdiv', 'LocationZip': '4004', 'LocationCountry': 'Bulgaria'}, {'LocationFacility': 'Comprehensive Cancer Center', 'LocationCity': 'Vratsa', 'LocationZip': '3001', 'LocationCountry': 'Bulgaria'}, {'LocationFacility': 'Southern Alberta Institute of Urology / Prostate Cancer Centre', 'LocationCity': 'Calgary', 'LocationState': 'Alberta', 'LocationZip': 'T2V 1P9', 'LocationCountry': 'Canada'}, {'LocationFacility': 'British Columbia Cancer Agency (BCCA) - Vancouver Centre', 'LocationCity': 'Vancouver', 'LocationState': 'British Columbia', 'LocationZip': 'V5Z 4E6', 'LocationCountry': 'Canada'}, {'LocationFacility': 'British Columbia Cancer Agency - Vancouver Island Centre', 'LocationCity': 'Victoria', 'LocationState': 'British Columbia', 'LocationZip': 'V8R 6V5', 'LocationCountry': 'Canada'}, {'LocationFacility': 'McMaster Institute of Urology', 'LocationCity': 'Hamilton', 'LocationState': 'Ontario', 'LocationZip': 'L8N 4A6', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Cancer Centre of Southeastern Ontario (Kingston Regional Cancer Centre)', 'LocationCity': 'Kingston', 'LocationState': 'Ontario', 'LocationZip': 'K7L 3N6', 'LocationCountry': 'Canada'}, {'LocationFacility': 'University Health Network (UHN) Princess Margaret Cancer Centre', 'LocationCity': 'Toronto', 'LocationState': 'Ontario', 'LocationZip': 'M5G 2M9', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Centre de Recherche du CHUM', 'LocationCity': 'Montreal', 'LocationState': 'Quebec', 'LocationZip': 'H2X 0A9', 'LocationCountry': 'Canada'}, {'LocationFacility': "Centre hospitalier universitaire de Québec (CHUQ), L'Hotel-Dieu de Quebéc", 'LocationCity': 'Quebec', 'LocationZip': 'G1R2J6', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Copenhagen University Hospital', 'LocationCity': 'Copenhagen', 'LocationZip': '2100', 'LocationCountry': 'Denmark'}, {'LocationFacility': 'Næstved Hospital', 'LocationCity': 'Naestved', 'LocationZip': '4700', 'LocationCountry': 'Denmark'}, {'LocationFacility': 'Institut Sainte Catherine', 'LocationCity': 'Avignon', 'LocationZip': '84918', 'LocationCountry': 'France'}, {'LocationFacility': 'Centre Hospitalier Regional Universitaire Besancon', 'LocationCity': 'Besançon', 'LocationZip': '25030', 'LocationCountry': 'France'}, {'LocationFacility': 'Institut Bergonié', 'LocationCity': 'Bordeaux', 'LocationZip': '33000', 'LocationCountry': 'France'}, {'LocationFacility': 'Centre Jean Perrin', 'LocationCity': 'Clermont Ferrand', 'LocationZip': '63011', 'LocationCountry': 'France'}, {'LocationFacility': 'Centre Oscar Lambret', 'LocationCity': 'Lille', 'LocationZip': '59020', 'LocationCountry': 'France'}, {'LocationFacility': 'Centre Leon Bérard', 'LocationCity': 'Lyon', 'LocationZip': '69008', 'LocationCountry': 'France'}, {'LocationFacility': 'Polyclinique de Gentilly', 'LocationCity': 'Nancy', 'LocationZip': '54100', 'LocationCountry': 'France'}, {'LocationFacility': 'Centre Antoine Lacassagne', 'LocationCity': 'Nice', 'LocationZip': '6189', 'LocationCountry': 'France'}, {'LocationFacility': 'Hopital Europeen Georges-Pompidou', 'LocationCity': 'Paris Cedex 15', 'LocationZip': '75908', 'LocationCountry': 'France'}, {'LocationFacility': "Institut de Cancérologie de l'Ouest (ICO)", 'LocationCity': 'Saint Herblain', 'LocationZip': '44805', 'LocationCountry': 'France'}, {'LocationFacility': 'HIA Begin', 'LocationCity': 'Saint Mande', 'LocationZip': '94163', 'LocationCountry': 'France'}, {'LocationFacility': 'Institut de Cancérologie de Loire', 'LocationCity': 'Saint-Priest-en-Jarez', 'LocationZip': '42271', 'LocationCountry': 'France'}, {'LocationFacility': 'Clinique Sainte Anne', 'LocationCity': 'Strasbourg', 'LocationZip': '67000', 'LocationCountry': 'France'}, {'LocationFacility': 'Hôpitaux Universitaire de Strasbourg -CHU', 'LocationCity': 'Strasbourg', 'LocationZip': '67091', 'LocationCountry': 'France'}, {'LocationFacility': 'Hopital Foch', 'LocationCity': 'Suresnes', 'LocationZip': '32151', 'LocationCountry': 'France'}, {'LocationFacility': 'CHRU de Tours', 'LocationCity': 'Tours', 'LocationZip': '37044', 'LocationCountry': 'France'}, {'LocationFacility': 'Institut Gustave Roussy', 'LocationCity': 'Villejuif', 'LocationZip': '94805', 'LocationCountry': 'France'}, {'LocationFacility': 'Urologisches Zentrum Bonn', 'LocationCity': 'Bonn', 'LocationZip': '53111', 'LocationCountry': 'Germany'}, {'LocationFacility': 'Urologie im Schlosscarree Schreier/Eichler/Junius - Germany', 'LocationCity': 'Braunschweig', 'LocationZip': '38100', 'LocationCountry': 'Germany'}, {'LocationFacility': 'Zeisigwaldkliniken Bethanien Chemnitz', 'LocationCity': 'Chemnitz', 'LocationZip': '09130', 'LocationCountry': 'Germany'}, {'LocationFacility': 'Urologische Gemeinschaftspraxis Böhm/Linne - Germany', 'LocationCity': 'Dresden', 'LocationZip': '01307', 'LocationCountry': 'Germany'}, {'LocationFacility': 'uro Eimsbüttel - Gemeinschaftspraxis Bath/Weinzierl', 'LocationCity': 'Hamburg', 'LocationZip': '20255', 'LocationCountry': 'Germany'}, {'LocationFacility': 'Klinikum Region Hannover Klinikum Siloah', 'LocationCity': 'Hannover', 'LocationZip': '30459', 'LocationCountry': 'Germany'}, {'LocationFacility': 'Matthias Schulze - Germany', 'LocationCity': 'Markkleeberg', 'LocationZip': '04416', 'LocationCountry': 'Germany'}, {'LocationFacility': 'CUROS - Uberörtliche urologische Gemeinschaftspraxis', 'LocationCity': 'Wesseling', 'LocationZip': '50389', 'LocationCountry': 'Germany'}, {'LocationFacility': 'Soroka Hospital', 'LocationCity': 'Beer-Sheva', 'LocationZip': '85101', 'LocationCountry': 'Israel'}, {'LocationFacility': 'Rambam Hospital', 'LocationCity': 'Haifa', 'LocationZip': '31096', 'LocationCountry': 'Israel'}, {'LocationFacility': 'Rabin Medical Center', 'LocationCity': 'Petah Tikva', 'LocationZip': '49100', 'LocationCountry': 'Israel'}, {'LocationFacility': 'Sheba Medical Center', 'LocationCity': 'Ramat Gan', 'LocationZip': '74047', 'LocationCountry': 'Israel'}, {'LocationFacility': 'Asaf Harofe Medical Center', 'LocationCity': 'Zrifin', 'LocationZip': '60930', 'LocationCountry': 'Israel'}, {'LocationFacility': 'Ospedale Cardinal Massaia', 'LocationCity': 'Asti', 'LocationZip': '14100', 'LocationCountry': 'Italy'}, {'LocationFacility': 'Ospedale Sacro Cuore Di Gesu', 'LocationCity': 'Benevento', 'LocationZip': '82100', 'LocationCountry': 'Italy'}, {'LocationFacility': 'Azienda Ospedaliera Papa Giovanni XXIII', 'LocationCity': 'Bergamo', 'LocationZip': '24127', 'LocationCountry': 'Italy'}, {'LocationFacility': 'Ospedale di Bolzano', 'LocationCity': 'Bolzano', 'LocationZip': '39100', 'LocationCountry': 'Italy'}, {'LocationFacility': 'oncologia medica - Oncology', 'LocationCity': 'Brindisi', 'LocationZip': '72100', 'LocationCountry': 'Italy'}, {'LocationFacility': 'Azienda Ulss 6 Euganea- Ospedale Di Camposampiero', 'LocationCity': 'Camposampiero', 'LocationZip': '35012', 'LocationCountry': 'Italy'}, {'LocationFacility': 'Ospedale Di Carrara', 'LocationCity': 'Carrara', 'LocationZip': '54033', 'LocationCountry': 'Italy'}, {'LocationFacility': "AORN Sant'anna e San Sebastiano", 'LocationCity': 'Caserta', 'LocationZip': '81100', 'LocationCountry': 'Italy'}, {'LocationFacility': 'ASST -Ospedale Maggiore di Crema', 'LocationCity': 'Crema', 'LocationZip': '26013', 'LocationCountry': 'Italy'}, {'LocationFacility': 'Azienda ULSS 3 Serenissima, presidio di Mirano', 'LocationCity': 'Mirano', 'LocationZip': '30035', 'LocationCountry': 'Italy'}, {'LocationFacility': 'PP.OO. di Piombino e Portoferraio Azienda USL Toscana nord ovest', 'LocationCity': 'Piombino', 'LocationZip': '57025', 'LocationCountry': 'Italy'}, {'LocationFacility': 'Ospedale degli Infermi', 'LocationCity': 'Ponderano', 'LocationZip': '13875', 'LocationCountry': 'Italy'}, {'LocationFacility': 'Ospedale del Mare ASL Napoli 1 centro', 'LocationCity': 'Ponticelli', 'LocationZip': '80147', 'LocationCountry': 'Italy'}, {'LocationFacility': 'Azienda ULSS5 Polesana di Rovigo - Ospedale Santa Maria della Misericordia', 'LocationCity': 'Rovigo', 'LocationZip': '45100', 'LocationCountry': 'Italy'}, {'LocationFacility': 'PO Ospedale S.Anna, ASST Lariana', 'LocationCity': 'San Fermo della Battaglia', 'LocationZip': '22042', 'LocationCountry': 'Italy'}, {'LocationFacility': 'Pusan National University Hospital', 'LocationCity': 'Busan', 'LocationZip': '49241', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Kyungpook National University Chilgok Hospital', 'LocationCity': 'Daegu', 'LocationZip': '41404', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Keimyung University Dongsan Hospital', 'LocationCity': 'Daegu', 'LocationZip': '42601', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Chungnam National University Hospital', 'LocationCity': 'Daejeon', 'LocationZip': '35015', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'National Cancer Center', 'LocationCity': 'Goyang-Si', 'LocationZip': '10408', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Chonnam National University Hospital', 'LocationCity': 'Gwangju', 'LocationZip': '61469', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Seoul National University Bundang Hospital', 'LocationCity': 'Gyeonggi-do', 'LocationZip': '13620', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Ajou University Hospital', 'LocationCity': 'Gyeonggi-do', 'LocationZip': '16499', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Seoul National University Hospital', 'LocationCity': 'Seoul', 'LocationZip': '03080', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Severance Hospital, Yonsei University Health System', 'LocationCity': 'Seoul', 'LocationZip': '03722', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Asan Medical Center', 'LocationCity': 'Seoul', 'LocationZip': '05505', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Gangnam Severance Hospital', 'LocationCity': 'Seoul', 'LocationZip': '06273', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Samsung Medical Center', 'LocationCity': 'Seoul', 'LocationZip': '06351', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': "The Catholic University of Korea, Seoul St. Mary's Hospital", 'LocationCity': 'Seoul', 'LocationZip': '06591', 'LocationCountry': 'Korea, Republic of'}, {'LocationFacility': 'Hospital Pulau Pinang', 'LocationCity': 'George Town', 'LocationZip': '10990', 'LocationCountry': 'Malaysia'}, {'LocationFacility': 'Hospital Kuala Lumpur', 'LocationCity': 'Kuala Lumpur', 'LocationZip': '50586', 'LocationCountry': 'Malaysia'}, {'LocationFacility': 'University Malaya Medical Centre', 'LocationCity': 'Kuala Lumpur', 'LocationZip': '59100', 'LocationCountry': 'Malaysia'}, {'LocationFacility': 'Sarawak General Hospital', 'LocationCity': 'Kuching', 'LocationZip': '93586', 'LocationCountry': 'Malaysia'}, {'LocationFacility': 'Renier de Graaf', 'LocationCity': 'Delft', 'LocationZip': '2625 AD', 'LocationCountry': 'Netherlands'}, {'LocationFacility': 'Canisius-Wilhelmina Ziekenhuis', 'LocationCity': 'Nijmegen', 'LocationZip': '6524 KD', 'LocationCountry': 'Netherlands'}, {'LocationFacility': 'Elisabeth-TweeSteden Ziekenhuis', 'LocationCity': 'Tilburg', 'LocationZip': '5022 GC', 'LocationCountry': 'Netherlands'}, {'LocationFacility': 'Centrum Onkologii im. Prof. F. Lukaszczyka', 'LocationCity': 'Bydgoszcz', 'LocationZip': '85-796', 'LocationCountry': 'Poland'}, {'LocationFacility': 'Uniwersyteckie Centrum Kliniczne', 'LocationCity': 'Gdańsk', 'LocationZip': '80-214', 'LocationCountry': 'Poland'}, {'LocationFacility': 'Szpitale Pomorskie Sp. z o.o.', 'LocationCity': 'Gdynia', 'LocationZip': '81-519', 'LocationCountry': 'Poland'}, {'LocationFacility': 'Przychodnia Lekarska KOMED Roman Karaszewski', 'LocationCity': 'Konin', 'LocationZip': '62-500', 'LocationCountry': 'Poland'}, {'LocationFacility': 'Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi', 'LocationCity': 'Lodz', 'LocationZip': '93-513', 'LocationCountry': 'Poland'}, {'LocationFacility': 'Urologica Praktyka Lekarska Adam Marcheluk', 'LocationCity': 'Siedlce', 'LocationZip': '08-110', 'LocationCountry': 'Poland'}, {'LocationFacility': 'Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy', 'LocationCity': 'Warszawa', 'LocationZip': '02-781', 'LocationCountry': 'Poland'}, {'LocationFacility': 'Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o.', 'LocationCity': 'Warszawa', 'LocationZip': '04-073', 'LocationCountry': 'Poland'}, {'LocationFacility': 'Specjalistyczna przychodnia lekarska POLIMED', 'LocationCity': 'Wroclaw', 'LocationZip': '53-329', 'LocationCountry': 'Poland'}, {'LocationFacility': 'Altai Regional Oncology Dispensary', 'LocationCity': 'Barnaul', 'LocationZip': '656045', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine', 'LocationCity': 'Chelyabinsk', 'LocationZip': '454087', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Ivanovo Regional Oncology Dispensary', 'LocationCity': 'Ivanovo', 'LocationZip': '153040', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Russian Scientific Center of Roentgenoradiology', 'LocationCity': 'Moscow', 'LocationZip': '117997', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Moscow City Clinical Hospital # 62', 'LocationCity': 'Moscow', 'LocationZip': '125130', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Hertzen Oncology Research Institute', 'LocationCity': 'Moscow', 'LocationZip': '125284', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Privolzhsky District Medical Centre', 'LocationCity': 'Nizhny Novgorod', 'LocationZip': '603074', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Clinical Oncology Dispensary', 'LocationCity': 'Omsk', 'LocationZip': '644013', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Pyatigorsk Regional Oncology Dispensary', 'LocationCity': 'Pyatigorsk', 'LocationZip': '357502', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Leningrad Regional Oncology Dispensary', 'LocationCity': 'Saint-Petersburg', 'LocationZip': '191104', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Republican Oncology Dispensary', 'LocationCity': 'Saransk', 'LocationZip': '430032', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': "Multifunctional clinical medical center 'Medical city'", 'LocationCity': 'Tyumen', 'LocationZip': '625041', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Bashkir State Medical University', 'LocationCity': 'Ufa', 'LocationZip': '450008', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Hosp. Univ. A Coruña', 'LocationCity': 'A Coruña', 'LocationZip': '15006', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. de la Santa Creu i Sant Pau', 'LocationCity': 'Barcelona', 'LocationZip': '08025', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Clinic I Provincial De Barcelona', 'LocationCity': 'Barcelona', 'LocationZip': '08036', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Gral. Univ. de Castellon', 'LocationCity': 'Castellon', 'LocationZip': '12004', 'LocationCountry': 'Spain'}, {'LocationFacility': "Institut Català D'Oncologia Girona", 'LocationCity': 'Girona', 'LocationZip': '17007', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Univ. de Jaen', 'LocationCity': 'Jaén', 'LocationZip': '23007', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. De Jerez De La Frontera', 'LocationCity': 'Jerez de la Frontera', 'LocationZip': '11407', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Univ. Arnau de Vilanova de Lleida', 'LocationCity': 'Lleida', 'LocationZip': '25198', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Univ. de La Princesa', 'LocationCity': 'Madrid', 'LocationZip': '28006', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Univ. Infanta Leonor', 'LocationCity': 'Madrid', 'LocationZip': '28031', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Univ. Ramon Y Cajal', 'LocationCity': 'Madrid', 'LocationZip': '28034', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Univ. 12 de Octubre', 'LocationCity': 'Madrid', 'LocationZip': '28041', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Univ. La Paz', 'LocationCity': 'Madrid', 'LocationZip': '28046', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Univ. Hm Monteprincipe', 'LocationCity': 'Madrid', 'LocationZip': '28660', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Univ. Del Henares', 'LocationCity': 'Madrid', 'LocationZip': '28822', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Virgen de La Victoria', 'LocationCity': 'Málaga', 'LocationZip': '29010', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Complexo Hosp. Univ. de Ourense', 'LocationCity': 'Ourense', 'LocationZip': '32005', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Univ. Infanta Cristina', 'LocationCity': 'Parla, Madrid', 'LocationZip': '28981', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Puerto Real', 'LocationCity': 'Puerto Real, Cádiz', 'LocationZip': '11510', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Corporacio Sanitari Parc Tauli', 'LocationCity': 'Sabadell', 'LocationZip': '08208', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Univ. Marques de Valdecilla', 'LocationCity': 'Santander', 'LocationZip': '39008', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Virgen Del Rocio', 'LocationCity': 'Sevilla', 'LocationZip': '41013', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. de Sant Pau I Santa Tecla', 'LocationCity': 'Tarragona', 'LocationZip': '43003', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. de Terrassa', 'LocationCity': 'Terrassa', 'LocationZip': '08227', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hosp. Clinico Univ. de Valencia', 'LocationCity': 'Valencia', 'LocationZip': '46010', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Skanes universitetssjukhus', 'LocationCity': 'Malmö', 'LocationZip': '20502', 'LocationCountry': 'Sweden'}, {'LocationFacility': 'Södersjukhuset', 'LocationCity': 'Stockholm', 'LocationZip': '11883', 'LocationCountry': 'Sweden'}, {'LocationFacility': 'Kaohsiung Medical University Chung-Ho Memorial Hospital', 'LocationCity': 'Kaohsiung', 'LocationZip': '807', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'Kaohsiung Chang Gung Memorial Hospital', 'LocationCity': 'Kaohsiung', 'LocationZip': '88301', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'China Medical University Hospital', 'LocationCity': 'Taichung', 'LocationZip': '40447', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'Taichung Veterans General Hospital', 'LocationCity': 'Taichung', 'LocationZip': '40705', 'LocationCountry': 'Taiwan'}, {'LocationFacility': "Tungs' Taichung MetroHarbor Hospital", 'LocationCity': 'Taichung', 'LocationZip': '435', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'National Cheng Kung University Hospital', 'LocationCity': 'Tainan', 'LocationZip': '70403', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'Chi Mei Medical Center - Yong Kang', 'LocationCity': 'Tainan', 'LocationZip': '710', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'National Taiwan University Hospital', 'LocationCity': 'Taipei', 'LocationZip': '10002', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'Tri-Service General Hospital', 'LocationCity': 'Taipei', 'LocationZip': '11490', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'Chang Gung Memorial Hospital', 'LocationCity': 'Taoyuan', 'LocationZip': '33305', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'Ramathibodi Hospital', 'LocationCity': 'Bangkok', 'LocationZip': '10400', 'LocationCountry': 'Thailand'}, {'LocationFacility': 'King Chulalongkorn Memorial Hospital', 'LocationCity': 'Bangkok', 'LocationZip': '10500', 'LocationCountry': 'Thailand'}, {'LocationFacility': 'Siriraj Hospital', 'LocationCity': 'Bangkok', 'LocationZip': '10700', 'LocationCountry': 'Thailand'}, {'LocationFacility': 'Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital', 'LocationCity': 'Ankara', 'LocationZip': '06200', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Memorial Ankara Hastanesi', 'LocationCity': 'Ankara', 'LocationZip': '06520', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Ankara Bilkent City Hospital', 'LocationCity': 'Ankara', 'LocationZip': '06800', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Akdeniz University Medical Faculty', 'LocationCity': 'Antalya', 'LocationZip': '07070', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Bursa Yuksek lhtisas EAH Medikal Onkoloji Klinigi', 'LocationCity': 'Bursa', 'LocationZip': '16310', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Trakya University Medical Faculty', 'LocationCity': 'Edirne', 'LocationZip': '22030', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Istanbul University Istanbul Medical Faculty', 'LocationCity': 'Istanbul', 'LocationZip': '34000', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd', 'LocationCity': 'Istanbul', 'LocationZip': '34098', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'T.C. Saglik Bakanlıgi Goztepe Prof. Dr. Suleyman Yalcın Sehir Hastanesi', 'LocationCity': 'Istanbul', 'LocationZip': '34722', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Izmir Medical Park Hospital', 'LocationCity': 'Izmir', 'LocationZip': '35580', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Sakarya University Training and Research Hospital', 'LocationCity': 'Sakarya', 'LocationZip': '54100', 'LocationCountry': 'Turkey'}, {'LocationFacility': "Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council'", 'LocationCity': 'Cherkasy', 'LocationZip': '18009', 'LocationCountry': 'Ukraine'}, {'LocationFacility': "Ce 'Dnipropetrovsk Regional Clinical Hospital N.A. Mechnikov' of Dnipropetrovsk Rc", 'LocationCity': 'Dnipo', 'LocationZip': '49005', 'LocationCountry': 'Ukraine'}, {'LocationFacility': "Municipal Institution 'Clinical Oncology Dispensary' Under Dnipropetrovsk Regional Council", 'LocationCity': 'Dnipro', 'LocationZip': '49100', 'LocationCountry': 'Ukraine'}, {'LocationFacility': 'Ivano-Frankivsk Regional Clinical Hospital', 'LocationCity': 'Ivano-Frankivsk', 'LocationZip': '76008', 'LocationCountry': 'Ukraine'}, {'LocationFacility': "Communal Institution 'City hospital №7 of Kamianske' of Dnepropetrov'sk Regional Council", 'LocationCity': 'Kamianske', 'LocationZip': '51900', 'LocationCountry': 'Ukraine'}, {'LocationFacility': "Municipal non-profit enterprise 'Regional Center of Oncology'", 'LocationCity': 'Khakhiv', 'LocationZip': '61070', 'LocationCountry': 'Ukraine'}, {'LocationFacility': 'Regional Medical Clinical Center for Urology and Nephrology named after V.I. Shapoval', 'LocationCity': 'Kharkiv', 'LocationZip': '61037', 'LocationCountry': 'Ukraine'}, {'LocationFacility': 'Khmelnitckiy regional hospital', 'LocationCity': 'Khmelnytsky', 'LocationZip': '29000', 'LocationCountry': 'Ukraine'}, {'LocationFacility': "Communal Nonprofit Enterprise 'Regional Clinical Oncology Center of Kirovohrad Regional Council'", 'LocationCity': 'Kropyvnytskyi', 'LocationZip': '25011', 'LocationCountry': 'Ukraine'}, {'LocationFacility': 'National Cancer Institute', 'LocationCity': 'Kyiv', 'LocationZip': '03022', 'LocationCountry': 'Ukraine'}, {'LocationFacility': 'State Institution Institute of Urology NAMS of Ukraine based on Kyiv City Clinical Oncology Center', 'LocationCity': 'Kyiv', 'LocationZip': '03115', 'LocationCountry': 'Ukraine'}, {'LocationFacility': 'Lviv Clinical Regional Hospital', 'LocationCity': 'Lviv', 'LocationZip': '79031', 'LocationCountry': 'Ukraine'}, {'LocationFacility': "ME 'Poltava Regional Clinical Hospital n.a. M.V. Sklifosovsky of the Poltava Regional Council'", 'LocationCity': 'Poltava', 'LocationZip': '36024', 'LocationCountry': 'Ukraine'}, {'LocationFacility': 'Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal', 'LocationCity': 'Uzhgorod', 'LocationZip': '88000', 'LocationCountry': 'Ukraine'}, {'LocationFacility': "Communal Institution 'Regional Oncology Dispensary' of Zhytomyr Region Council", 'LocationCity': 'Zhytomyr', 'LocationZip': '10002', 'LocationCountry': 'Ukraine'}, {'LocationFacility': 'Royal Blackburn Hospital', 'LocationCity': 'Blackburn', 'LocationZip': 'BB2 3HH', 'LocationCountry': 'United Kingdom'}, {'LocationFacility': 'Royal Marsden Hospital', 'LocationCity': 'London', 'LocationZip': 'SW7 3RP', 'LocationCountry': 'United Kingdom'}, {'LocationFacility': 'University College London Hospitals', 'LocationCity': 'London', 'LocationZip': 'WC1E 6BT', 'LocationCountry': 'United Kingdom'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023', 'RemovedCountryList': {'RemovedCountry': ['New Zealand']}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000011471', 'ConditionMeshTerm': 'Prostatic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000005834', 'ConditionAncestorTerm': 'Genital Neoplasms, Male'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000011469', 'ConditionAncestorTerm': 'Prostatic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M13487', 'ConditionBrowseLeafName': 'Prostatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Prostate Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8098', 'ConditionBrowseLeafName': 'Genital Neoplasms, Male', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13485', 'ConditionBrowseLeafName': 'Prostatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M289473', 'InterventionBrowseLeafName': 'Niraparib', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 75, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03715660', 'OrgStudyIdInfo': {'OrgStudyId': 'AE 2395'}, 'Organization': {'OrgFullName': 'Mansoura University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study', 'OfficialTitle': 'Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study'}, 'StatusModule': {'StatusVerifiedDate': 'November 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 1, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 1, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 1, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'October 17, 2018', 'StudyFirstSubmitQCDate': 'October 21, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 23, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'November 20, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 21, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Amr Abdel-Lateif El-Sawy', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Mansoura University'}, 'LeadSponsor': {'LeadSponsorName': 'Mansoura University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Cepheid', 'CollaboratorClass': 'INDUSTRY'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The primary objective of this prospective, single-centre study is to establish the clinical performance characteristics of Xpert Bladder Cancer Monitor on the GeneXpert Instrument Systems in comparison to the methods currently used at the site for detecting recurrent bladder cancer.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Bladder Cancer']}, 'KeywordList': {'Keyword': ['Non muscle invasive bladder cancer, recurrence, progression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Diagnostic', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '198', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Xpert monitor- evaluated patients', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Xpert Bladder Cancer Monitor performance shall be established in recurrence patients relative to cystoscopy (for disease negative patients) or histology (for disease positive patients)and relative to a currently used diagnostic assay (urine cytology)which is the standard of care used for detecting recurrent bladder cancer at the site. In this study, clinical sensitivity shall be established in patients who have been previously diagnosed with bladder cancer and are scheduled for a standard of care (SOC) surveillance cystoscopy.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Xpert bladder cancer monitor']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test', 'InterventionName': 'Xpert bladder cancer monitor', 'InterventionDescription': 'Xpert Bladder Cancer Monitor, is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.The test utilizes a voided urine specimen and measures the levels of five targetmRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR). The Xpert Bladder Cancer Monitor is indicated as an aid to standard clinical evaluation in monitoring for bladder cancer recurrence in patients previously diagnosed with bladder cancer and should be used in conjunction with other clinical measures to assess disease recurrence.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Xpert monitor- evaluated patients']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Accuracy of Xpert Bladder Cancer Monitor in monitoring of non muscle invasive bladder cancer by comparing its results to the results of the standard tool of monitoring of bladder cancer (diagnostic cystoscopy)', 'PrimaryOutcomeDescription': 'Xpert Bladder Cancer Monitor performance shall be established in recurrence patients relative to cystoscopy (for disease negative patients) or histology (for disease positive patients)and relative to a currently used diagnostic assay (urine cytology)which is the standard of care used for detecting recurrent bladder cancer at the site. In this study, clinical sensitivity shall be established in patients who have been previously diagnosed with bladder cancer and are scheduled for a standard of care (SOC) surveillance cystoscopy', 'PrimaryOutcomeTimeFrame': 'within 1 month after test assessment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nThe patient shall meet all of the following criteria in order to be considered eligible for enrollment:\n\nPatient has been diagnosed with NMIBC within 24 months of enrollment\nAt the time of the enrollment visit, the patient is scheduled for a cystoscopy within the next 6 weeks of enrollment\n\nExclusion Criteria:\n\nPatient has had an excision procedure or BCG treatment within six weeks (42 days) before enrollment.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Urology and Nephrology Center', 'LocationCity': 'Mansourah', 'LocationZip': '35516', 'LocationCountry': 'Egypt'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001749', 'ConditionMeshTerm': 'Urinary Bladder Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000014571', 'ConditionAncestorTerm': 'Urologic Neoplasms'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001745', 'ConditionAncestorTerm': 'Urinary Bladder Diseases'}, {'ConditionAncestorId': 'D000014570', 'ConditionAncestorTerm': 'Urologic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M19712', 'ConditionBrowseLeafName': 'Disease Progression', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4182', 'ConditionBrowseLeafName': 'Urinary Bladder Neoplasms', 'ConditionBrowseLeafAsFound': 'Bladder Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14002', 'ConditionBrowseLeafName': 'Recurrence', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16472', 'ConditionBrowseLeafName': 'Urologic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4178', 'ConditionBrowseLeafName': 'Urinary Bladder Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16471', 'ConditionBrowseLeafName': 'Urologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}}}}, {'Rank': 76, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03423303', 'OrgStudyIdInfo': {'OrgStudyId': '2910/2017'}, 'Organization': {'OrgFullName': 'Tampere University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)', 'OfficialTitle': 'Prostate Cancer Screening Trial', 'Acronym': 'ProScreen'}, 'StatusModule': {'StatusVerifiedDate': 'December 2022', 'OverallStatus': 'Enrolling by invitation', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 23, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2032', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2032', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'January 15, 2018', 'StudyFirstSubmitQCDate': 'January 30, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 6, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'December 6, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 9, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Anssi Auvinen', 'ResponsiblePartyInvestigatorTitle': 'Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Tampere University'}, 'LeadSponsor': {'LeadSponsorName': 'Tampere University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Helsinki University Hospital, Finland', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Tampere University Hospital, Finland', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Finnish Cancer Registry, Finland', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'University of Turku, Finland', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Lund University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Fimlab Laboratories, Finland', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Laboratory HUSLAB, Finland', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'University of Helsinki', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Hospital District of Helsinki and Uusimaa', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Clinical Research Institute HUCH Ltd, Finland', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'A population-based randomised trial of prostate cancer screening will be carried out. A total of approximately 117,200 men aged 50-63 in Helsinki and Tampere are randomised to intervention (screening) or control arm. A reduction in harms of screening in the form of overdiagnosis is sought, while retaining as much as possible of the mortality benefit (reduction in prostate cancer mortality). Novel methods that have been shown to increase specificity for clinically relevant prostate cancer but never tested in a randomised setting will be employed in screening and diagnostics. The main end-point is prostate cancer mortality at 10 and 15 years of follow-up.', 'DetailedDescription': 'Frequent adverse effects have so far tipped the balance of benefits and harms against prostate cancer screening, and therefore the investigators will focus on employing the best possible means for reducing them. The project introduces a novel concept for PC screening that minimises overdiagnosis and overtreatment, while retaining the mortality benefit to shift the balance of screening benefits and harms to a favourable net effect. The strategy for implementation as a randomised screening trial utilises three levels of risk assessment (PSA, kallikrein panel and MRI) before the diagnostic procedure (prostate biopsy), each aimed at eliminating detection of indolent disease. The study hypothesis is that by virtue of the novel three-tiered screening algorithm, the beneficial screening effect (prostate cancer mortality reduction) can be retained, while the overdiagnosis can be largely eliminated. The impact of an integrative approach has never been evaluated - each of the methods has only been assessed in isolation. The breakthrough potential of the proposal lies in combining the three novel approaches and taking them to the forefront of applied research through a randomised trial. The key impact of the study is in defining whether the overall balance of benefits and harms of prostate cancer screening can be reversed by applying the best possible methods to detect only clinically important disease. If the study hypothesis is affirmed, it opens the way to introduction of prostate cancer screening. If the balance of harms and benefits is still unfavourable, the problem of overdiagnosis in prostate cancer may be intractable.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Prostate Cancer']}, 'KeywordList': {'Keyword': ['Prostate cancer', 'Screening', 'Randomised trial', 'Kallikrein', 'Magnetic resonance imaging', 'Prostate-specific antigen']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Of the approximately 117,200 men aged 50-63 years resident in Helsinki and Tampere regions, a fourth will be randomised to screening and the rest to control arm (after exclusion of prevalent cases).', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '17400', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Screening arm', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Invitation to prostate cancer screening and questionnaires.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: Prostate cancer screening']}}, {'ArmGroupLabel': 'Control arm', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Registry-based follow-up and a questionnaire.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test', 'InterventionName': 'Prostate cancer screening', 'InterventionDescription': 'Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Screening arm']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Prostate cancer (PrCa) mortality', 'PrimaryOutcomeDescription': 'An intention to screen analysis will be performed, with all men in the groups defined by random allocation, regardless of compliance. Follow-up starts at randomisation, and ends at death. Cox regression will be used with prostate cancer death as the outcome.', 'PrimaryOutcomeTimeFrame': 'At 10 years of follow-up.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Prostate cancer (PrCa) mortality - secondary analysis', 'SecondaryOutcomeDescription': 'A secondary analysis of prostate cancer mortality will be performed using the Cuzick method with correction for contamination and selection bias due to non-compliance.', 'SecondaryOutcomeTimeFrame': 'At 10 years of follow-up.'}, {'SecondaryOutcomeMeasure': 'Cumulative incidence of advanced (T3-T4 or M1) prostate cancer', 'SecondaryOutcomeDescription': 'Intermediate outcomes include cumulative incidence of advanced (T3-T4 or M1) prostate cancer (number of cases relative to population size, not using incidence density to avoid the lead-time bias due to early detection by screening).', 'SecondaryOutcomeTimeFrame': 'At approximately 5 years of follow-up.'}, {'SecondaryOutcomeMeasure': 'Cumulative incidence of low-risk cancer (Gleason<7)', 'SecondaryOutcomeDescription': 'Intermediate outcomes include cumulative incidence of low-risk cancer (Gleason<7) as an indicator of overdiagnosis.', 'SecondaryOutcomeTimeFrame': 'At approximately 5 years of follow-up.'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Analysis of screening test performance - 4Kscore', 'OtherOutcomeDescription': 'Diagnostic performance of 4Kscore among men with PSA>3 in terms of predictive values, sensitivity, and specificity for clinically significant PrCa (defined as Gleason 7+ cancers - including those diagnosed within the next four years for test-negative non-biopsied men i.e. false negatives).', 'OtherOutcomeTimeFrame': 'At 2, 4, and 6 years.'}, {'OtherOutcomeMeasure': 'Analysis of screening test performance - MRI', 'OtherOutcomeDescription': 'Diagnostic performance of MRI based on PI-RADS v2 scores among men with PSA>3 and positive 4Kscore in terms of predictive values, sensitivity, and specificity for clinically significant PrCa (defined as Gleason 7+ cancers - including those diagnosed within the next four years for test-negative non-biopsied men i.e. false negatives).', 'OtherOutcomeTimeFrame': 'At 2, 4, and 6 years.'}, {'OtherOutcomeMeasure': 'Assessment of health-related quality of life in men with prostate cancer', 'OtherOutcomeDescription': 'Health-related quality of life among men diagnosed with prostate cancer will be assessed using the EPIC 26 instrument enrolling screen-detected and interval cases, as well as those diagnosed among non-participants and in the control arm.', 'OtherOutcomeTimeFrame': 'At 4 years.'}, {'OtherOutcomeMeasure': 'Assessment of short-term prostate cancer (PrCa)-specific anxiety', 'OtherOutcomeDescription': 'Anxiety among men diagnosed with prostate cancer will be assessed using the Memorial Anxiety Scale for Prostate Cancer (MAX-PC), enrolling screen-detected and interval cases, as well as those diagnosed among non-participants and in the control arm.', 'OtherOutcomeTimeFrame': 'At 4 years.'}, {'OtherOutcomeMeasure': 'Adverse effects of prostate biopsy immediately after the biopsy', 'OtherOutcomeDescription': 'Adverse effects of biopsy are evaluated using a questionnaire on complications including assessment of bleeding, lower urinary tract symptoms (LUTS), erectile dysfunction (ED), pain, and antibiotic treatment immediately after the biopsy.', 'OtherOutcomeTimeFrame': 'During the first year.'}, {'OtherOutcomeMeasure': 'Adverse effects of prostate biopsy 30 days after the biopsy', 'OtherOutcomeDescription': 'Adverse effects of biopsy are evaluated with a questionnaire on complications, including assessment of bleeding, lower urinary tract symptoms (LUTS), erectile dysfunction (ED), pain, and antibiotic treatment 30 days after the biopsy.', 'OtherOutcomeTimeFrame': 'During the first year.'}, {'OtherOutcomeMeasure': 'Cost analysis (incremental cost effectiveness ratio)', 'OtherOutcomeDescription': 'Economic evaluation will commence with cost analysis, and the final analysis of incremental cost effectiveness ratio (with a decision analysis) will be conducted once data on both long-term cost and real outcome data on both utilities (quality-adjusted life-years) and mortality are available.', 'OtherOutcomeTimeFrame': 'At 5 (cost analysis) and 10-15 (final analysis) years of follow-up.'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\n50-63-year-old men (age in 2018) residing in Tampere or Helsinki\n\nExclusion Criteria:\n\nPrevalent prostate cancer', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Male', 'GenderBased': 'Yes', 'GenderDescription': 'Trial participants will be identified by the Finnish Population Register Centre.', 'MinimumAge': '50 Years', 'MaximumAge': '63 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Anssi Auvinen, MD, PhD', 'OverallOfficialAffiliation': 'Tampere University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Helsinki University and Helsinki University Hospital', 'LocationCity': 'Helsinki', 'LocationCountry': 'Finland'}, {'LocationFacility': 'University of Tampere', 'LocationCity': 'Tampere', 'LocationCountry': 'Finland'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Website of the study.', 'SeeAlsoLinkURL': 'https://seulontatutkimus.fi/'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Yes', 'IPDSharingDescription': 'The data will be managed and made openly available with Finnish Social Science Data Archive (FSD) and publisher websites. The type of data includes numerical data, mainly counts, and continuous variables classified as categorical. The data will be uploaded in tabular form (as a data matrix). The data will be deidentified and supplied only as frequencies. The released data will be available under CC license for research purposes (accessible for registered users of FSD database). Citation of the original research is needed whenever used by third parties.', 'IPDSharingInfoTypeList': {'IPDSharingInfoType': ['Study Protocol', 'Informed Consent Form (ICF)']}, 'IPDSharingTimeFrame': 'The data wil be released after publication of the results (approximately 2032-).', 'IPDSharingAccessCriteria': 'CC license, FSD database registered users'}}, 'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'Prot_SAP', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'Yes', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Study Protocol and Statistical Analysis Plan', 'LargeDocDate': 'September 5, 2017', 'LargeDocUploadDate': '01/15/2018 08:22', 'LargeDocFilename': 'Prot_SAP_000.pdf'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000011471', 'ConditionMeshTerm': 'Prostatic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000005834', 'ConditionAncestorTerm': 'Genital Neoplasms, Male'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000011469', 'ConditionAncestorTerm': 'Prostatic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M13487', 'ConditionBrowseLeafName': 'Prostatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Prostate Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8098', 'ConditionBrowseLeafName': 'Genital Neoplasms, Male', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13485', 'ConditionBrowseLeafName': 'Prostatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M9790', 'InterventionBrowseLeafName': 'Kallikreins', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Coag', 'InterventionBrowseBranchName': 'Coagulants'}, {'InterventionBrowseBranchAbbrev': 'Repr', 'InterventionBrowseBranchName': 'Reproductive Control Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 77, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03598660', 'OrgStudyIdInfo': {'OrgStudyId': 'Breast cancer'}, 'Organization': {'OrgFullName': 'Assiut University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Role of Sorcin and Annexin A3 in Breast Cancer Patients', 'OfficialTitle': 'Role of Sorcin and Annexin A3 in Breast Cancer Patients'}, 'StatusModule': {'StatusVerifiedDate': 'January 2019', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 20, 2019', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 1, 2019', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 30, 2019', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 8, 2018', 'StudyFirstSubmitQCDate': 'July 23, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 26, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 8, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 9, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Reham I El-mahdy', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Assiut University'}, 'LeadSponsor': {'LeadSponsorName': 'Assiut University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Breast cancer (BC) is the most common female malignancy worldwide and the second leading cause of cancer death in women. One in eight women in the United States will develop the illness in their lifetimes. In Egypt, 37.7% of total cancer cases among women is breast cancer. A locally advanced disease is very common and total mastectomy is the most commonly performed surgery. Screening methods and adjuvant therapy following surgery led to a remarkable decrease in mortality.\n\nReliable prognostic and predictive markers are needed to guide the selection of the most appropriate adjuvant therapies for individual patients with breast cancer. In fact, a shift from defining the cancer patients who should receive chemotherapy on the basis of their prognostic characteristics to defining the patients who are likely to benefit most from this modality of adjuvant treatment is currently taking place. Understanding the molecular mechanisms underlying the spread of cancer cells to distant organs, therefore, is a prerequisite for the development of novel cancer therapies.', 'DetailedDescription': 'Breast cancer is the most common female malignancy worldwide. Despite advances in cancer diagnosis and treatment in recent years, traditional treatments (radiotherapy, chemotherapy, and hormone therapy) are always limited by the resistance of some tumor cells, thus forcing researchers to continue to look for new therapeutic approaches and targets. Soluble resistance-related Calcium-binding protein (Sorcin) is a penta-EF hand calcium binding protein, which participates in the regulation of calcium homeostasis in cells and has molecular mass of 22 kDa. The EF-hand is a common helix-loop-helix structural motif used by proteins to bind calcium. Most proteins are endowed with an even number of EF-hands, which are usually structurally and functionally paired. The penta-EF hand (PEF) family includes sorcin, calpains, programmed cell death protein 6 (PDCD6), peflin and grancalcin.\n\nHigh sorcin regulates the calcium channels and exchangers located at the plasma membrane and at the endo/sarcoplasmic reticulum (ER/SR) and allows high levels of calcium in the ER to be maintained, preventing ER stress and the unfolded protein response, and increases escape from apoptosis. The 18-kDa variant of sorcin is regulated by Tumor necrosis factor receptor-associated protein 1 (TRAP1), a mitochondrial anti-apoptotic protein upregulated in several human tumors which controls sorcin folding and expression. Conversely, sorcin silencing activates apoptotic proteases as caspase-3 and caspase-12 results in major defects in mitosis and cytokinesis, blocks cell cycle progression in mitosis, increases the number of rounded polynucleated cells and induces apoptosis and cell death shifting the equilibrium between cell life and cell death towards proliferation in MDR cancer cells overexpressing sorcin.\n\nSorcin is highly expressed in the heart, brain and breast and overexpressed in many cancer cells. The gene for sorcin (SRI) spans about 21.9 kb of human genomic DNA. The gene is located in chromosome 7q21. Sorcin gene is in the same amplicon as other genes involved in the resistance to chemotherapeutics in cancer cells (multi-drug resistance, MDR) such as the ATP-binding cassette (ABC) transporters ABCB4 and ABCB1 (Mdr1, or P-glycoprotein 1).\n\nAnnexins are a family of intracellular proteins that bind membrane phospholipids in a Calcium concentration-dependent manner. The human genome encodes for 12 different annexins varying in expression and distribution within the tissues. Some of these are ubiquitously expressed (A1, A2, A5, A6, and A7), while some are selective (A3, A8, A9, A10, and A13). Several annexins play important roles during tumor progression. However, little is known about the clinical implications and biological functions of Annexin A3 (ANXA3) in breast cancer. ANXA3 has a role in cell differentiation, cell migration, immune regulation.\n\nThe ANXA3 gene is located on human chromosome 4q13-q22 and encodes a protein of 323 amino acid residues. Annexin A3 participates in various tumor-associated biological processes, including tumor initiation, progression, metastasis and is associated with chemotherapy resistance.\n\nANXA3 is expressed and secreted by neoplastic mammary cells, and its inhibition halts migration in breast cancer cells. The expression of Annexin A3 in human breast carcinoma closely correlated with tumor size and axillary lymph node metastasis. Elevated serum levels of ANXA3 protein were due to its increased secretion from neoplastic breast cells into the systemic circulation. There is inverse correlation between Annexin A3 expression and overall breast cancer patient survival. Moreover, Annexin A3 might be a novel and potential prognostic marker for patients with breast cancer and is involved in regulating apoptosis by affecting the Bcl-2/Bax balance. It promote the transcription of the anti-apoptotic gene Bcl-2 and downregulate the proapoptotic gene BAX.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['Breast cancer, SORCIN, Annexin A3']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'EnrollmentInfo': {'EnrollmentCount': '80', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast cancer patients', 'ArmGroupDescription': 'The present study will be carried on 50 breast cancer patients before surgery.\n\nThe followings markers must be estimated:\n\nSorcin gene expression using real time PCR and Annexin A3 serum mesurement using enzyme linked immuno sorbent assay (ELISA).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: Sorcin gene expression', 'Other: Annexin A3 serum mesurement']}}, {'ArmGroupLabel': 'Healthy controls', 'ArmGroupDescription': 'The present study will be carried on 15 age and sex matched controls.\n\nThe followings markers must be estimated:\n\nSorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: Sorcin gene expression', 'Other: Annexin A3 serum mesurement']}}, {'ArmGroupLabel': 'Benign breast diseases', 'ArmGroupDescription': 'The present study will be carried on 15 patients with benign breast diseases.\n\nThe followings markers must be estimated:\n\nSorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: Sorcin gene expression', 'Other: Annexin A3 serum mesurement']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Genetic', 'InterventionName': 'Sorcin gene expression', 'InterventionDescription': 'Sorcin gene expression Will be measured by real time PCR', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Benign breast diseases', 'Breast cancer patients', 'Healthy controls']}}, {'InterventionType': 'Other', 'InterventionName': 'Annexin A3 serum mesurement', 'InterventionDescription': 'serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Benign breast diseases', 'Breast cancer patients', 'Healthy controls']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Role of SORCIN in patients with breast cancer', 'PrimaryOutcomeDescription': 'genetic expression of SORCIN new biomarker in breast cancer patients', 'PrimaryOutcomeTimeFrame': '1 year'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Role of annexin A3 biomarker in with breast cancer patients', 'SecondaryOutcomeDescription': 'serum measurement of annexin A3 in breast cancer patients', 'SecondaryOutcomeTimeFrame': '1 year'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nbreast cancer patients before surgery who are admitted to the South Egypt Cancer Institute, Surgery Department, Assiut University\n\nExclusion Criteria:\n\n• Patients with malignancies elsewhere in the body.\n\nPatients with chronic cardiac diseases.\nGetting neoadjuvant chemotherapy.\nRenal disease.\nNeurodegenerative disease.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Female', 'MinimumAge': '20 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'breast cancer patients', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'reham elmahdy', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+201002714637', 'CentralContactEMail': 'reham.elmahdy@yahoo.com'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24207092', 'ReferenceType': 'background', 'ReferenceCitation': 'Zeeneldin AA, Ramadan M, Elmashad N, Fakhr I, Diaa A, Mosaad E. Breast cancer laterality among Egyptian patients and its association with treatments and survival. J Egypt Natl Canc Inst. 2013 Dec;25(4):199-207. doi: 10.1016/j.jnci.2013.09.003. Epub 2013 Oct 25.'}, {'ReferencePMID': '28797046', 'ReferenceType': 'background', 'ReferenceCitation': 'Cubasch H, Joffe M, Ruff P, Dietz D, Rosenbaum E, Murugan N, Chih MT, Ayeni O, Dickens C, Crew K, Jacobson JS, Neugut A. Breast conservation surgery versus total mastectomy among women with localized breast cancer in Soweto, South Africa. PLoS One. 2017 Aug 10;12(8):e0182125. doi: 10.1371/journal.pone.0182125. eCollection 2017.'}, {'ReferencePMID': '25197934', 'ReferenceType': 'background', 'ReferenceCitation': 'Colotti G, Poser E, Fiorillo A, Genovese I, Chiarini V, Ilari A. Sorcin, a calcium binding protein involved in the multidrug resistance mechanisms in cancer cells. Molecules. 2014 Sep 5;19(9):13976-89. doi: 10.3390/molecules190913976.'}, {'ReferencePMID': '29217453', 'ReferenceType': 'background', 'ReferenceCitation': 'Kim JY, Jung EJ, Park HJ, Lee JH, Song EJ, Kwag SJ, Park JH, Park T, Jeong SH, Jeong CY, Ju YT, Lee YJ, Hong SC. Tumor-Suppressing Effect of Silencing of Annexin A3 Expression in Breast Cancer. Clin Breast Cancer. 2018 Aug;18(4):e713-e719. doi: 10.1016/j.clbc.2017.11.009. Epub 2017 Nov 21.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 78, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03357276', 'OrgStudyIdInfo': {'OrgStudyId': 'colorectal cancer MV'}, 'Organization': {'OrgFullName': 'Fuda Cancer Hospital, Guangzhou', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Mix Vaccine for Metastatic Colorectal Cancer', 'OfficialTitle': 'Safety and Efficacy Study of Mix Vaccine in Colorectal Cancer Patient'}, 'StatusModule': {'StatusVerifiedDate': 'November 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 30, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 30, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'August 30, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 23, 2017', 'StudyFirstSubmitQCDate': 'November 23, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 29, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'September 10, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 12, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Fuda Cancer Hospital, Guangzhou', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Jinan University Guangzhou', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The aim of this study is the safety and efficacy of mix vaccine to small metastases of colorectal cancer.', 'DetailedDescription': 'By enrolling patients with small metastases of colorectal cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of mix vaccine.\n\nThe safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Metastatic Colorectal Cancer', 'Reaction - Mixed Vaccine']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1', 'Phase 2']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '30', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Mix vaccine', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Mix vaccine']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Biological', 'InterventionName': 'Mix vaccine', 'InterventionDescription': 'Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Mix vaccine']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Active immunotherapy for cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Relief degree of tumors', 'PrimaryOutcomeDescription': 'It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Progress free survival（PFS）', 'SecondaryOutcomeDescription': 'The duration from the beginning of treatment to cancer recurrence or progression', 'SecondaryOutcomeTimeFrame': '1 year'}, {'SecondaryOutcomeMeasure': 'Overall survival（OS）', 'SecondaryOutcomeDescription': 'The duration from the beginning of treatment to patient death', 'SecondaryOutcomeTimeFrame': '3 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAll standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence\nBody tumor 1-6, the maximum tumor length < 2 cm\nKPS ≥ 70, lifespan > 6 months\nPlatelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L\n\nExclusion Criteria:\n\nPatients with cardiac pacemaker\nPatients with brain metastasis\nPatients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '70 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Fuda cancer institute of Fuda cancer hospital', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationZip': '510665', 'LocationCountry': 'China'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000015179', 'ConditionMeshTerm': 'Colorectal Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000012002', 'ConditionAncestorTerm': 'Rectal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafAsFound': 'Colorectal Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13996', 'ConditionBrowseLeafName': 'Rectal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16512', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 79, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04427761', 'OrgStudyIdInfo': {'OrgStudyId': '20-038'}, 'Organization': {'OrgFullName': 'Memorial Sloan Kettering Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Study of the Life Changes Experienced by Patients With Pancreatic Cancer', 'OfficialTitle': 'Health-Illness Transition Experiences Among Patients With Pancreatic Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'February 2023', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 5, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 8, 2020', 'StudyFirstSubmitQCDate': 'June 10, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 11, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 2, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 3, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Memorial Sloan Kettering Cancer Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Hunter College School of Nursing', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': "The purpose of this study is to better understand what types of transitions people with pancreatic cancer face when they receive chemotherapy. Again, this study defines transition as a change in a life situation or a status that causes a change in a person's identity, role, behavior, or personal relationships. Examples of transitions include changes in sleeping habits, anxiety, employment, relationship with a higher power, and treatment goals."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Pancreatic Cancer']}, 'KeywordList': {'Keyword': ['Quality of Life', 'Health-Illness Transition', '20-038']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '55', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'pancreatic cancer health-illness transition', 'ArmGroupDescription': 'In this prospective longitudinal correlational study, a convenience sample of patients with pancreatic cancer receiving chemotherapy will be asked to report on their health-illness transition experiences and their level of distress.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Measurement of Transitions in Cancer Scale (MOT-CA) Survey', 'Behavioral: Distress Thermometer Survey']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Measurement of Transitions in Cancer Scale (MOT-CA) Survey', 'InterventionDescription': 'These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit) The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['pancreatic cancer health-illness transition']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Distress Thermometer Survey', 'InterventionDescription': 'These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit).The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['pancreatic cancer health-illness transition']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Extent of the change experienced by patients with pancreatic cancer', 'PrimaryOutcomeDescription': 'Descriptive statistics will be calculated at both time points using (part A on the MOT-CA) for each of the seven transition domains (physical, emotional, social, spiritual, cancer status, treatment, and approach) at both time points (Time 0 and Time 1).', 'PrimaryOutcomeTimeFrame': '4 to 6 weeks after baseline'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nadult patients 18 years of age and older\nprimary language listed as English in electronic medical record\nbiopsy proven diagnosis of pancreatic cancer\nwithin three months after initiating a chemotherapy regimen at the Rockefeller Outpatient Pavilion at MSKCC (patient may have previously received chemotherapy at an outside institution or may have received previous chemotherapy regimens at MSKCC).\n\nExclusion Criteria:\n\nprevious history of cancer within the past five years, except for non-melanoma skin cancer, ductal carcinoma in situ breast cancer, and thyroid cancer.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Medical oncology clinic', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jessica Goldberg, RN, MSN, AGPCNP-BC, ACHPN', 'OverallOfficialAffiliation': 'Memorial Sloan Kettering Cancer Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Memorial Sloan Kettering Cancer Center (All Protocol Activities)', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10065', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Memorial Sloan Kettering Cancer Center', 'SeeAlsoLinkURL': 'http://www.mskcc.org/mskcc/html/44.cfm'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Yes', 'IPDSharingDescription': 'Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010190', 'ConditionMeshTerm': 'Pancreatic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010182', 'ConditionAncestorTerm': 'Pancreatic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12262', 'ConditionBrowseLeafName': 'Pancreatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7015', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12254', 'ConditionBrowseLeafName': 'Pancreatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7014', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T6034', 'ConditionBrowseLeafName': 'Quality of Life', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T6036', 'ConditionBrowseLeafName': 'Menopause', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4387', 'ConditionBrowseLeafName': 'Pancreatic Cancer', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 80, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00385866', 'OrgStudyIdInfo': {'OrgStudyId': '0120060236'}, 'Organization': {'OrgFullName': 'Rutgers, The State University of New Jersey', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Addressing Disparities in Cancer Care for Latino Medicare Beneficiaries', 'OfficialTitle': 'Addressing Disparities in Cancer Care for Latino Medicare Beneficiaries'}, 'StatusModule': {'StatusVerifiedDate': 'April 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 2006'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2010', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2010', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'October 10, 2006', 'StudyFirstSubmitQCDate': 'October 10, 2006', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 11, 2006', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'April 19, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 20, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of Medicine and Dentistry of New Jersey', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Centers for Medicare and Medicaid Services', 'CollaboratorClass': 'FED'}]}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'To reduce Cancer health care disparities that exists among minority Medicare beneficiaries and to demonstrate cost effectiveness of patient navigation in reducing the burden of cancer.', 'DetailedDescription': 'The Latino population is the fastest growing minority population in the United States . Cancer ranks as the second leading cause of death among Latinos in the United States (24%), second only to heart disease . This project will evaluate whether an innovative facilitation program (targeting cancers of the prostate, colon/rectum, breast, and cervix) will improve cancer outcomes among Latino Medicare beneficiaries in the city of Newark, New Jersey.\n\nThe overall aim of this project is to institute an innovative cancer care facilitation program for elderly Latinos in the city of Newark, NJ. The goal is to reduce the disparities observed in screening, time to diagnosis and treatment services, by utilizing a multidisciplinary team approach to health care, incorporating systems thinking methodology. Using the Multilevel Approach to Community Health (MATCH) planning model , the program will incorporate community outreach, education, and access to screening, and patient assistance in all aspects of the health care continuum. It will also include cultural and linguistic competency training for all those involved in the facilitation process. To accomplish this goal, we propose four objectives:\n\nTo establish a multidisciplinary team that will utilize a systems thinking approach to design and structure the delivery of cancer screening, diagnosis and treatment facilitation services.\nTo build a collaborative consortium between program partners to improve screening outcomes, that will encourage the utilization of services in the community.\nTo improve the delivery of cancer prevention and treatment facilitation by providing cultural and linguistic competency training to the multidisciplinary team, providers, and the community.\nTo demonstrate the effectiveness of the intervention in reducing the burden of cancer, by increasing screening rates, improving time to diagnosis and delivery of treatment services, patient satisfaction, and appropriate use of Medicare services.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer']}, 'KeywordList': {'Keyword': ['Patient Navigator', 'Community health', 'Communication']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '1272', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Comparison Group', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'The control or lesser intervention group, will receive cancer screening information on a quarterly basis, with no facilitation of services.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: cancer screening and health education']}}, {'ArmGroupLabel': 'Intervention group', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'The intervention group are those participants who were randomly assigned to receive facilitation of services in the form of patient navigation for the duration of the study.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: cancer screening and health education', 'Behavioral: facilitation of Services to improve cancer screening']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'cancer screening and health education', 'InterventionDescription': 'The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Comparison Group', 'Intervention group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['patient navigation', 'cancer screening and education']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'facilitation of Services to improve cancer screening', 'InterventionDescription': 'The intervention group will receive cancer education and faciliation of services in the form of patient navigation', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['patient navigation', 'faciliation of services', 'screening']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Reduce the disparities observed in utilization of cancer screening services', 'PrimaryOutcomeTimeFrame': '2-4 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Improve the time to diagnosis and treatment services (resulting in reduced cost of cancer care', 'SecondaryOutcomeTimeFrame': '4 years'}, {'SecondaryOutcomeMeasure': 'Improve patient satisfaction and informed decision making.', 'SecondaryOutcomeTimeFrame': '4 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nCancer-Negative Group\n\nBe of Hispanic/Latino Origin\nFluent in English and/or Spanish\nRecipient of, Medicare Part A & B, or combined Medicare/Medicaid\nNot having a previous diagnosis of cancer\nBe capable of giving written informed consent prior to any study related procedures.\nBe available and willing to complete all study assessments as specified.\n\nCancer-Positive Group\n\nBe of Hispanic/Latino Origin\nFluent in English and/or Spanish\nRecipient of, Medicare Part A & B, or combined Medicare/Medicaid\nHaving a previous diagnosis of cancer of the breast, cervix, colon and/or rectum, prostate, or lung.\nBe capable of giving written informed consent prior to any study related procedures.\nBe available and willing to complete all study assessments as specified.\n\nExclusion Criteria:\n\nMember of the Medicare Advantage Plan, any Medicare managed care plan (Those who join the Medicare Advantage plan or a managed care plan during the course of the study will become ineligible to continue.)\nMedicaid only beneficiaries\nInstitutionalized\nUnable to provide written informed consent', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Ana Natale-Pereira, MD, MPH', 'OverallOfficialAffiliation': 'Rutgers, The State University of New Jersey', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'UMDNJ', 'LocationCity': 'Newark', 'LocationState': 'New Jersey', 'LocationZip': '07107', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}}}}, {'Rank': 81, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04818125', 'OrgStudyIdInfo': {'OrgStudyId': '21 SEIN 01'}, 'Organization': {'OrgFullName': 'Institut Claudius Regaud', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.', 'OfficialTitle': 'Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.', 'Acronym': 'CARMMYC'}, 'StatusModule': {'StatusVerifiedDate': 'September 2022', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 31, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 29, 2022', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'July 29, 2022', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 24, 2021', 'StudyFirstSubmitQCDate': 'March 24, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 26, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'September 27, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 28, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Institut Claudius Regaud', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating cancer cell/macrophage hybrid cells in the peripheral blood.\n\nThe study will be conducted on a population of patients with breast cancer (regardless of stage of the disease and the immunohistochemical subtype).\n\nFor each included patient, blood samples will be taken and tumor specimens will be collected for the study.\n\nAt the end of the blood collection, the patient will have completed his participation in the study.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['Breast Cancer', 'Cancer cell/macrophage hybrid cells', 'Hybrid cells']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Other', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '61', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Patients with breast cancer', 'ArmGroupType': 'Other', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Patients with breast cancer (stage I, II III or IV)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Patients with breast cancer (stage I, II III or IV)', 'InterventionDescription': 'Blood samples will be collected at different times:\n\nat Baseline for all patients with breast cancer: before initiation of treatment (i.e. before initiation of planned treatment for stage I to III patients and before any new line of treatment for stage IV patients);\nat the time of disease progression (or at 12 months in absence of progression) for patients with metastatic breast cancer (stage IV)\n\nFor each patient a tumor sample from the initial diagnosis of the disease (i.e. primary tumor +/- biopsy of a metastasis) will be collected (archived tumor block) for the study.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Patients with breast cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Rate of patients with cancer cell / macrophage hybrid cells in peripheral blood defined as the ratio of the number of patients with hybrid cells to the total number of patients.', 'PrimaryOutcomeTimeFrame': '20 months after the study start'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quantification of circulating hybrid cells in peripheral blood by automatic measurement (Cell Counter Corning) and expressed in number of cells / millilitre of blood.', 'SecondaryOutcomeTimeFrame': '20 months after the study start'}, {'SecondaryOutcomeMeasure': 'Progression-free survival (PFS) defined as the time from the date of inclusion to the date of progression or death from any cause.', 'SecondaryOutcomeTimeFrame': '20 months after the study start'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nPatient with breast cancer of any stage (stage I, II, III or IV) and any immunohistochemical subtype (triple-negative, HR+/HER2-negative or HER2-positive).\nPatient not yet initiated on specific treatment for the stage of breast cancer at inclusion.\nAvailable tumor sample (archived tumor block) : initial tumor or metastasis depending on the stage of the disease and availability.\nAge ≥ 18 years old.\nPatient affiliated to a Social Health Insurance in France.\nPatient having signed informed consent prior to inclusion in the study and prior to any specific study procedure.\n\nExclusion Criteria:\n\nAssociated pathology(ies) that may prevent the proper conduct of the procedure under consideration.\nPregnant or breastfeeding woman.\nAny psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures of the study protocol.\nPatient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship protection of justice).\nPatient who has presented another solid tumor (except breast or cervix carcinoma in situ) within 5 years.', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Institut Universitaire du Cancer de Toulouse - Oncopole', 'LocationCity': 'Toulouse', 'LocationCountry': 'France'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 82, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03807102', 'OrgStudyIdInfo': {'OrgStudyId': 'TVATLC01'}, 'Organization': {'OrgFullName': 'Hunan Province Tumor Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Trail of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer', 'OfficialTitle': 'Phase I/II Trial of Tumor Vaccine in Post Radical Operation Patients With Lung Cancer', 'Acronym': 'TVATLC01'}, 'StatusModule': {'StatusVerifiedDate': 'January 2019', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 16, 2019', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 31, 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'January 31, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'January 4, 2019', 'StudyFirstSubmitQCDate': 'January 12, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 16, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 12, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 16, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator', 'ResponsiblePartyInvestigatorFullName': 'Wenxiang Wang', 'ResponsiblePartyInvestigatorTitle': 'MD, pHD, Director of Thoracic Surgery Department II', 'ResponsiblePartyInvestigatorAffiliation': 'Hunan Province Tumor Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Wenxiang Wang', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Shanghai Houchao Biotechnology Co., Ltd', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Tumor vaccines may make the body build an immune response to kill tumor cells. This research study is evaluating a new type of tumor vaccine termed as "Neoantigen Tumor Vaccine". The purpose of this phase I/II trial study is to assess the safety and effectiveness of neoantigentumor vaccine in post radical operation patients with stage IIIA lung cancer.', 'DetailedDescription': 'Outline: After successful vaccine manufacturing, patients receive neoantigen tumor vaccine hypodermically (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years). Treatment continues in the absence of disease recurrence and metastasis or unacceptable toxicity.\n\nPatients are followed for 2 years or up to the absence of disease recurrence and metastasis.\n\nProjected accrual: A total of 30 patients will be accrued for this study.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Lung Cancer']}, 'KeywordList': {'Keyword': ['Lung Cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1', 'Phase 2']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '30', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Tumor Vaccine', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Injection of NeoAntigen Tumor Vaccine', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Tumor Vaccine']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Biological', 'InterventionName': 'Tumor Vaccine', 'InterventionDescription': 'NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Tumor Vaccine']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Disease-free Survival (DFS)', 'PrimaryOutcomeDescription': 'The time that participants stay free of cancer after surgery following administration of tumor vaccine', 'PrimaryOutcomeTimeFrame': 'Approximately 2 years'}, {'PrimaryOutcomeMeasure': 'Adverse Events (AEs)', 'PrimaryOutcomeDescription': 'Number of participants experiencing clinical and laboratory adverse events', 'PrimaryOutcomeTimeFrame': '30 days from first study vaccine administration'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAge: 18 to 70 years, Male or Female\nHistological or cytologically diagnosis of lung adenocarcinoma\nAfter surgical treatment (lobectomy and systematic lymph node dissection)\nPathological stage IIIA (According to the IASLC Lung Cancer Staging (eight Edition))\nPostoperative standard treatment (platinum-based double-drug adjuvant treatment with or without chemotherapy) or no adjuvant treatment\nHave potential dynamic tumor biomarkers\nAble and willing to give witnessed, written informed consent form prior to receiving any study related procedure, agree to participate in long-term follow-up for up to 3 years\n\nExclusion Criteria:\n\nAge < 18 or< 70 years\nLung squamous cell carcinoma, small cell lung cancer, large cell lung cancer\nWithout surgical treatment\nPathological stage I、II、IIIB、IIIC or IV (According to the IASLC Lung Cancer Staging (eight Edition))\nParticipation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study vaccine\nDrug or alcohol abusers\nPregnant or breast-feeding patients\nHistory of immunodeficiency disease or autoimmune disease\nPatients with chronic disease which is undergoing immune reagents or hormone therapy\nConcurrent other medical condition that would prevent the patient from undergoing protocol-based therapy\nLack of availability of a patient for immunological and clinical follow-up', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '70 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Nong Yang, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+86 731 89762323', 'CentralContactEMail': 'yangnong0217@163.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Wenxiang Wang, MD, PhD', 'OverallOfficialAffiliation': 'Hunan Provincal Tumor Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Hunan Provincal Tumor Hospital', 'LocationCity': 'Changsha', 'LocationState': 'Hunan', 'LocationZip': '410013', 'LocationCountry': 'China'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000008175', 'ConditionMeshTerm': 'Lung Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000012142', 'ConditionAncestorTerm': 'Respiratory Tract Neoplasms'}, {'ConditionAncestorId': 'D000013899', 'ConditionAncestorTerm': 'Thoracic Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10324', 'ConditionBrowseLeafName': 'Lung Neoplasms', 'ConditionBrowseLeafAsFound': 'Lung Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14131', 'ConditionBrowseLeafName': 'Respiratory Tract Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15810', 'ConditionBrowseLeafName': 'Thoracic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10320', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14129', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16512', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 83, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03387527', 'OrgStudyIdInfo': {'OrgStudyId': 'CASE7817'}, 'Organization': {'OrgFullName': 'Case Comprehensive Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Using Decision Analysis to Enhance Decision-Making Regarding Prostate Cancer Screening', 'OfficialTitle': 'Using Decision Analysis to Enhance Decision-Making Regarding Prostate Cancer Screening'}, 'StatusModule': {'StatusVerifiedDate': 'October 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 1, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 3, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 3, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'December 22, 2017', 'StudyFirstSubmitQCDate': 'December 22, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 2, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'October 23, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 24, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Case Comprehensive Cancer Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to evaluate a new counseling tool for patients deciding whether or not to undergo prostate cancer screening. This screening decision aid is a computer program that provides individual patients estimates of their risks of prostate cancer diagnosis, prostate cancer related death, or death from any cause. The researchers are evaluating whether or not patients find this screening decision aid helpful. As part of this study, participants will be asked for their response on questionnaires.\n\nIf patients find the screening decision aid helpful, the researchers will make it available at other clinic locations.', 'DetailedDescription': "To conduct a feasibility study on implementing the computer-based screening decision aid for prostate cancer screening in a primary care setting during a 60-minute interview. To aid in informed decision making, the screening decision aid will include a graphical representation of predicted probabilities of prostate cancer diagnosis, prostate cancer-specific mortality, death from competing causes based on a man's unique demographic information. The study team will provide standardized counseling followed by individualized counseling with the screening decision aid. It will assess the quality of the decision making process (patient feels knowledgeable, informed of the risks/benefits, feels clear about their values, is involved in the decision), and quality of the decision."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Prostate Cancer']}, 'KeywordList': {'Keyword': ['Decision Aid']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '50', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Prostate Cancer Decision Aid', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The research intervention will be exposure to the screening decision aid. Patients will receive standardized counseling including population based risks and benefits of prostate cancer screening. Then, patients will be given opportunity to review the screening decision aid prior to offering a decision on whether or not to undergo prostate cancer screening. The patient decision aid will be a computer application that generates predicted risks associated with prostate cancer.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Prostate cancer decision aid']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Prostate cancer decision aid', 'InterventionDescription': 'Patients will undergo standardized counseling and individualized counseling with the screening decision aid. The screening decision aid is a computer program that provides individual patients estimates of their risks of prostate cancer diagnosis, prostate cancer related death, or death from any cause', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Prostate Cancer Decision Aid']}, 'InterventionOtherNameList': {'InterventionOtherName': ['screening decision aid']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Number of initial interviews completed in 60 minutes', 'PrimaryOutcomeDescription': 'To be considered feasible in a busy clinical setting, researchers anticipate 80% of the initial interviews to be completed within the allotted 60-minute interview time.', 'PrimaryOutcomeTimeFrame': '60 minutes from beginning of interview'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Health Literacy', 'SecondaryOutcomeDescription': 'Five item scale measuring attitudes towards screening', 'SecondaryOutcomeTimeFrame': '1 month after clinical visit'}, {'SecondaryOutcomeMeasure': 'Patient decisional control preferences', 'SecondaryOutcomeDescription': '4 item scale where lower scores indicate more positive outcomes from screening', 'SecondaryOutcomeTimeFrame': '1 month after clinical visit'}, {'SecondaryOutcomeMeasure': 'Decisional conflict Scale', 'SecondaryOutcomeDescription': '16 item scale ranging in a score from 0-4 where higher scores indicate more disagreement', 'SecondaryOutcomeTimeFrame': '1 month after clinical visit'}, {'SecondaryOutcomeMeasure': 'Multidimensional measure of informed choice', 'SecondaryOutcomeDescription': '10 item true/false scale', 'SecondaryOutcomeTimeFrame': '1 month after clinical visit'}, {'SecondaryOutcomeMeasure': 'Decisional regret scale', 'SecondaryOutcomeDescription': '5 item questionnaire using 5 point Likert scales where higher scores indicate more disagreement', 'SecondaryOutcomeTimeFrame': '1 month after clinical visit'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nLife expectancy > 10 years\nAbility to read English\n\nExclusion Criteria:\n\nPersonal history of prostate cancer\nPersonal history of prostate biopsy or prostate surgery\nPrior prostate specific antigen screening in the past year leading up to their scheduled clinic visit\nCognitive impairment', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Male', 'MinimumAge': '55 Years', 'MaximumAge': '69 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Michael A Brooks, MD', 'OverallOfficialAffiliation': 'Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center', 'LocationCity': 'Cleveland', 'LocationState': 'Ohio', 'LocationZip': '44195', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000011471', 'ConditionMeshTerm': 'Prostatic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000005834', 'ConditionAncestorTerm': 'Genital Neoplasms, Male'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000011469', 'ConditionAncestorTerm': 'Prostatic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M13487', 'ConditionBrowseLeafName': 'Prostatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Prostate Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8098', 'ConditionBrowseLeafName': 'Genital Neoplasms, Male', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13485', 'ConditionBrowseLeafName': 'Prostatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 84, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02195076', 'OrgStudyIdInfo': {'OrgStudyId': '0695-13-SMC'}, 'Organization': {'OrgFullName': 'BioSense Medical LTD', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Non Invasive Detection of Lung and Breast Cancer by Odor Signature', 'OfficialTitle': 'A Clinical Study Design to Evaluate the Specificity and Sensitivity of Our Novel System for Detection of Breast and Lung Cancer by Odor Signature'}, 'StatusModule': {'StatusVerifiedDate': 'July 2014', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2017', 'PrimaryCompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 16, 2014', 'StudyFirstSubmitQCDate': 'July 17, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 21, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 17, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 21, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'BioSense Medical LTD', 'LeadSponsorClass': 'INDUSTRY'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Sheba Medical Center', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'The investigators have developed an early detection solution for lung and breast cancer. A system which can distinguish between different medical odors based on biosensors. Our product is user-friendly noninvasive, nonradioactive and nontoxic to the patients. The technology enables a high level of sensitivity and provides users with a quick lab response and a simple yes or no answer.\n\nThe aim of this study is to contribute and detect the patient at the earliest possible stage, in a noninvasive, nonradioactive and nontoxic way. Exhaled breath and urine samples are a promising approach towards future possible lung and breast cancer screening method.', 'DetailedDescription': 'Early detection of cancer can dramatically improve the survival chances. to date, there is no efficient diagnostic tool for detection of lung cancer in early stages. Regarding breast cancer, the common screening tool us mammography, which suffer from low sensitivity and high false positive. Thus, there is an urgent need for developing a screening tool for early stages lung and breast cancer.\n\nThe sense of smell depends on the ability of specialized sensory cells of the nose to perceive volatile compounds (VOCs). Diseases such as infections and malignancies can be associated with changes in host metabolism, accompanied by production of different VOCs, and thus a different odor. Several studies have shown that different cancers secrete different VOCs, thus produce different smell.\n\nWe have developed a system which uses biosensors that can scent the VOCs that lung and breast cancer cell produce, thus distinguish between healthy control and lung or breast cancer. These biosensors can detect low stages lung and breast cancer.\n\nPatients will supply urine samples and exhaled breath samples using a kit that we will supply. The samples will be shipped to our lab, where they will be processed and the VOCs will be separated from the head space of the samples. The biosensors will be exposed to the VOCs samples and will report whether the specific sample id cancerous (lung or breast) or not.\n\nThe Data will be collected from all samples and statistical analysis will be calculated, in order to test the specificity and sensitivity of our biosensors to detect cancerous samples.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Lung Cancer', 'Breast Cancer']}, 'KeywordList': {'Keyword': ['Lung cancer', 'Breast Cancer', 'Biosensors', 'Volatile Organic Compounds', 'Odor', 'Urine Sample', 'Exhaled Breath Samples']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'Yes', 'TargetDuration': '3 Years', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'urine samples and exhaled breath samples'}, 'EnrollmentInfo': {'EnrollmentCount': '400', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast Cancer patients', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: non-invasive detection of cancer odor']}}, {'ArmGroupLabel': 'Lung cancer patients', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: non-invasive detection of cancer odor']}}, {'ArmGroupLabel': 'Healthy controls', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: non-invasive detection of cancer odor']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'non-invasive detection of cancer odor', 'InterventionDescription': 'The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Breast Cancer patients', 'Healthy controls', 'Lung cancer patients']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The sensitivity and specificity of our biosensors in lung and breast cancer detection', 'PrimaryOutcomeDescription': 'We will measure the ability of our biosensors to detect lung and breast cancer in urine samples from patients. Each urine sample will be subjected to 5 biosensors. If 3 out of 5 will report positively, the sample will be marked as cancerous. Each type of cancer (lung or breast) will be detected by different groups of biosensors, trained specifically to detect the specific cancer type.\n\nAfter the data of the detections will be collected, statistical analysis will be calculated in order to evaluate the sensitivity and specificity of our biosensor in cancer detection.', 'PrimaryOutcomeTimeFrame': '3 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Testing the ability of our biosensors to distinguish between different sub- types of breast and lung cancer.', 'SecondaryOutcomeDescription': 'After the collection of the detection data (primary outcome measure), we will compare it to the patients data records (in terms of staging, CT, pathology, biological markers etc.) and evaluate whether our biosensors can detect different sub- types of lung and breast cancer in different sensitivity and specifity.', 'SecondaryOutcomeTimeFrame': '3 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nDiagnosed Lung Cancer patients\nDiagnosed Breast Cancer patients\n\nExclusion Criteria:\n\nCancer patients who were treated using chemotherapy\nCancer patients who were treated using radiation\nCancer patients who were treated using biological treatments\nCancer patients who were treated with chemotherapy\nCancer patients who were treated with any anti- cancer therapies\nCancer patients who use drugs that affect the immune system', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '30 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Breast Cancer patient after diagnosis. Lung Cancer patients after diagnosis. Healthy controls, matching gender and age.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Michal Mark Danieli, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+972-4-7706816', 'CentralContactEMail': 'Michal@biosensem.com'}, {'CentralContactName': 'Asher Castiel, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+972-4-7706816', 'CentralContactEMail': 'asher.castiel@biosensem.com'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Sheba Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Tel Hashomer, Ramat- Gan', 'LocationZip': '52621', 'LocationCountry': 'Israel', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Einav Gal-Yam, MD PhD', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'Einav.NiliGal-Yam@sheba.health.gov.il'}, {'LocationContactName': 'Yair Bar, MD', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'Yair.bar@sheba.health.gov.il'}, {'LocationContactName': 'Einav Gal- Yam, M.D Ph.D', 'LocationContactRole': 'Principal Investigator'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}, {'ConditionMeshId': 'D000008175', 'ConditionMeshTerm': 'Lung Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}, {'ConditionAncestorId': 'D000012142', 'ConditionAncestorTerm': 'Respiratory Tract Neoplasms'}, {'ConditionAncestorId': 'D000013899', 'ConditionAncestorTerm': 'Thoracic Neoplasms'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M9170', 'ConditionBrowseLeafName': 'Hypersensitivity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10324', 'ConditionBrowseLeafName': 'Lung Neoplasms', 'ConditionBrowseLeafAsFound': 'Lung Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14131', 'ConditionBrowseLeafName': 'Respiratory Tract Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15810', 'ConditionBrowseLeafName': 'Thoracic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10320', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14129', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}]}}}}}, {'Rank': 85, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05645328', 'OrgStudyIdInfo': {'OrgStudyId': '202202104'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01CA254628', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/R01CA254628'}]}, 'Organization': {'OrgFullName': 'University of Iowa', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Implementation of a Health System Intervention to Improve Quality of Cancer Care for Rural Patients', 'OfficialTitle': 'Effectiveness and Implementation of a Health System Intervention to Improve Quality of Cancer Care for Rural, Underserved Patients'}, 'StatusModule': {'StatusVerifiedDate': 'February 2023', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 20, 2023', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2026', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2026', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 1, 2022', 'StudyFirstSubmitQCDate': 'December 1, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 9, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 24, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 28, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator', 'ResponsiblePartyInvestigatorFullName': 'Mary Charlton', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'University of Iowa'}, 'LeadSponsor': {'LeadSponsorName': 'Mary Charlton', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': "The purpose of this study is to implement and evaluate the recently developed Iowa Cancer Affiliate Network (ICAN) intervention.\n\nThe ICAN intervention will consist of members of the research team providing ongoing support to participating hospitals in achieving the quality standards outlined by the American College of Surgeons Commission on Cancer (CoC). Support will be offered in the form of education and training regarding the standards and provision of cancer services, regular in-person and zoom check-ins with hospital stakeholders to evaluate progress, and provision of documentation and educational resources regarding standard requirements.\n\nImplementation approach:1) Engage implementation teams and develop and execute implementation plans based on hospital needs assessments; and 2) Conduct interviews with key ICAN stakeholders to assess acceptability, adoption, appropriateness and cost (based on Proctor's implementation outcomes framework) and determinants of these outcomes (e.g., hospital structure, culture, resources, capacity, readiness) based on the Consolidated Framework for Implementation Research.\n\nEvaluation approach: Using Iowa Cancer Registry data routinely collected for surveillance purposes, the investigators will compare rates of compliance with pre- and post-intervention treatment-related quality measures in target and control hospitals. The rural hospitals in Iowa that serve the most rural cancer patients and have never been accredited by the CoC were chosen for intervention targets, and all committed to participating in the study (letters of support provided). The remainder of rural hospitals that care for >100 newly diagnosed cancer patients per year (n=5) were chosen as a comparison group. The investigators will use data routinely collected by the Iowa Cancer Registry to compare aggregate compliance with quality measures for cancer care between the hospitals included in the intervention and comparison group hospitals using a difference-in-difference estimator. In addition, the investigators will conduct interviews with representatives from intervention hospitals to assess the extent to which ICAN hospitals implemented the CoC standards of cancer care.", 'DetailedDescription': 'Intervention: The investigators received letters of support from hospitals, and those who direct the cancer center staff have expressed their willingness to participate on behalf of their staff. This is a health-system-level intervention, designed as single-arm intervention trial, where five participating hospitals will be offered support in the areas of training and education, cancer data collection and reporting, quality improvement and clinical peer-to-peer support.\n\nThe ICAN intervention was developed through implementation science processes as an adaptation of the Markey Cancer Center Affiliate Network (MCCAN) with retention of identified core functions. Each hospital in the intervention arm has undergone interviews about their current cancer program needs and offerings. From the information gathered through these meetings, the investigators established baseline understandings of cancer centers and their services. Through these meetings, the investigators elicited program goals, challenges, and readiness for change within their cancer services. Prior to starting the ICAN intervention, the cancer centers will be provided a documentation specifying current status for meeting CoC accreditation standards, gaps identified, suggestions and resources for the next steps to meet goals, and progress toward fulfilling CoC accreditation standards. Through the intervention, each of the five hospitals will be offered support, expertise, and resources necessary to facilitate hospitals in achieving the standards set forth by the American College of Surgeons Commission on Cancer. Support will be offered in the form of education and training regarding the standards and provision of cancer services, regular in-person and zoom check-ins with hospital stakeholders to evaluate progress, and provision of documentation and educational resources regarding standard requirements. The specific intervention actions will be tailored to the needs identified for each hospital or health system based on particular standards they currently do not meet and choose to work toward.\n\n4 years from the start of the intervention, the investigators will use Iowa Cancer Registry data to evaluate the success of the intervention by comparing rates of compliance with pre- and post-intervention treatment-related quality measures in target and control hospitals using a difference-in-difference estimator. The rural hospitals in Iowa that serve the most rural cancer patients (all care for >100 newly diagnosed cancer patients per year) and have never been accredited by the CoC were chosen for intervention targets. The remainder of rural hospitals that care for >100 newly diagnosed cancer patients per year (n=4) were chosen as a comparison group. They were not contacted, as they will not be providing us with any data. Rather, the investigators will use data routinely collected by the Iowa Cancer Registry to compare aggregate compliance with quality measures for cancer care between the hospitals included in the intervention and hospitals that were not.\n\nThese variables needed to compute compliance with quality measures by hospital are routinely collected by the Iowa Cancer Registry from all hospitals in Iowa as part of routine public health surveillance. The investigators will only be using data provided to us by the Iowa Cancer Registry to calculate these measures for both intervention and control hospitals and will not be accessing medical record data from the intervention or control hospitals.\n\nInterviews: Subjects from intervention hospitals will be asked to reply to the recruitment email and provide times over the subsequent two weeks that would for them to participate in a one-time audio/video-recorded telephone interview which will take approximately 30-45 minutes. Subjects will be asked prior to recording whether recording is permitted. If permitted, the interview will be recorded on zoom and converted to an audio file using UI (University of Iowa)-Capture. The recordings will be used to audio-transcribe the interview so that they transcript can be used in qualitative data-analysis. Only members of the research team will have access to the recordings. The audio-transcriptions will be done using the web-based service Rev.com. The recordings will be destroyed on completion of the data-analysis. The interview will include questions about the culture, structure, changes and current processes at their hospital for providing cancer care and the impact of the intervention. They will be mailed a $50 check in appreciation of their time after the interview has been conducted. There will be no additional follow-up to the interviews.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer']}, 'KeywordList': {'Keyword': ['Health system intervention', 'Rural health', 'Quality improvement', 'Implementation science']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '100', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention Hospital Administrators, Providers, and Data Monitoring Staff', 'ArmGroupDescription': 'This is a health-system-level intervention, designed as single-arm intervention trial, where four participating hospitals will be offered support in the areas of training and education, cancer data collection and reporting, quality improvement and clinical peer-to-peer support.\n\nHospitals that are eligible for the intervention had to be located in an Iowa county classified as non-metropolitan according to rural urban continuum codes (RUCC) 4 through 9 and diagnose or treat at least 100 cancer patients each year.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Iowa Cancer Affiliate Network (ICAN)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Iowa Cancer Affiliate Network (ICAN)', 'InterventionDescription': 'Each hospital in the intervention has undergone interviews in which the investigators elicited program goals, challenges, and readiness for change. Prior to the intervention, the cancer centers will be provided a document specifying current status for meeting Commission on Cancer (CoC) accreditation standards, gaps identified, suggestions and resources for the next steps to meet goals, and progress toward fulfilling CoC accreditation standards. The hospitals will be offered support, expertise, and resources to facilitate them in achieving the CoC standards. Support will be offered in the form of education/training regarding the standards and provision of cancer services, regular in-person/zoom check-ins with hospital stakeholders to evaluate progress, and provision of documentation/educational resources regarding standard requirements. The intervention actions will be tailored to the needs of each hospital based on standards they currently do not meet and choose to work toward.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention Hospital Administrators, Providers, and Data Monitoring Staff']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Compliance with CoC quality of cancer care measures: Hormone therapy (HT)', 'PrimaryOutcomeDescription': 'primary quality measure for breast cancer: percent of patients receiving tamoxifen or 3rd gen aromatase inhibitor within 1 year of diagnosis for women with T1cN0M0 or stage IB-III hormone receptor-positive cancer', 'PrimaryOutcomeTimeFrame': '36 months post implementation of intervention'}, {'PrimaryOutcomeMeasure': 'Compliance with CoC quality of cancer care measures: 12 regional lymph nodes (12RLN)', 'PrimaryOutcomeDescription': 'primary quality measure for colon cancer: percent of patients having >12 regional lymph nodes removed and examined', 'PrimaryOutcomeTimeFrame': '36 months post implementation of intervention'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Compliance with CoC quality of cancer care measures: Breast conserving surgery radiation therapy (BCSRT)', 'SecondaryOutcomeDescription': 'percent of patients receiving radiation within 1 year of diagnosis for women <70 years old receiving breast conserving surgery for breast cancer', 'SecondaryOutcomeTimeFrame': '36 months post implementation of intervention'}, {'SecondaryOutcomeMeasure': 'Compliance with CoC quality of cancer care measures: Multi-agent chemotherapy (MAC)', 'SecondaryOutcomeDescription': 'percent of patients receiving combination chemomotherapy within 4 months of diagnosis for women <70 years old with T1cN0M0 or stage IB-III hormone receptor-negative breast cancer', 'SecondaryOutcomeTimeFrame': '36 months post implementation of intervention'}, {'SecondaryOutcomeMeasure': 'Compliance with CoC quality of cancer care measures: Adjuvant chemotherapy (ACT)', 'SecondaryOutcomeDescription': 'percent of patients receiving adjuvant chemotherapy within 4 months of diagnosis for patients <80 years old with AJCC Stage III (lymph node positive) colon cancer', 'SecondaryOutcomeTimeFrame': '36 months post implementation of intervention'}, {'SecondaryOutcomeMeasure': 'Percentage of CoC evidence-based standards of cancer care implemented', 'SecondaryOutcomeDescription': 'Number and percentage of the 38 evidence-based CoC standards being met by each hospital', 'SecondaryOutcomeTimeFrame': '36 months post implementation of intervention'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAdministrators, clinicians, and data monitoring staff who help provide cancer related care at one of the four hospitals that have been included in our study.\n\nExclusion Criteria:\n\nNone', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '100 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Our study population will include administrators, clinicians, data monitoring staff who provide cancer related care at one of the four hospitals that will be included in the study intervention. Hospitals that are eligible for the intervention had to be located in an Iowa county classified as non-metropolitan according to rural urban continuum codes (RUCC) 4 through 9 and diagnose or treat at least 100 cancer patients each year.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Mary E Charlton, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '319-384-1564', 'CentralContactEMail': 'mary-charlton@uiowa.edu'}, {'CentralContactName': 'Mary Schroeder, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '319-384-4516', 'CentralContactEMail': 'mary-schroeder@uiowa.edu'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Iowa', 'LocationStatus': 'Recruiting', 'LocationCity': 'Iowa City', 'LocationState': 'Iowa', 'LocationZip': '52240', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Mary E Charlton, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '319-384-1564', 'LocationContactEMail': 'mary-charlton@uiowa.edu'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}}}}, {'Rank': 86, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04549064', 'OrgStudyIdInfo': {'OrgStudyId': '81672921'}, 'Organization': {'OrgFullName': "First Affiliated Hospital Xi'an Jiaotong University", 'OrgClass': 'OTHER'}, 'BriefTitle': 'Biomarkers of Pancreatic Cancer and New Way to Detection', 'OfficialTitle': 'Identification of AREG for the Detection of Pancreatic Cancer By Biosensor'}, 'StatusModule': {'StatusVerifiedDate': 'August 2021', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 1, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 1, 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 30, 2021', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'September 9, 2020', 'StudyFirstSubmitQCDate': 'September 14, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 16, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 20, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 23, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': "First Affiliated Hospital Xi'an Jiaotong University", 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'West China Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': "Health Science Center of Xi'an Jiaotong University", 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Amphoteric regulatory protein (AREG), a member of epidermal growth factor (EGF) family, is expressed in many tumors.Our study confirmed that the expression of AREG in the serum of patients with pancreatic cancer is significantly higher than that of patients with benign pancreatic diseases and healthy people, which is expected to become a new early serum marker of pancreatic cancer. The serum concentration of AREG was detected by traditional ELISA and compared with CA-199, which was a conventional tumor marker of pancreatic cancer. Next, we compare the advantages of using sensor to detect AREG compared with ELISA.', 'DetailedDescription': 'Serum was collected ： pancreatic cancer : healthy control =200:200 Clinical data were collected: age, gender, diagnosis, cancer stage, CA199 level at initial diagnosis, histopathological type, etc. The informed consent of the subjects was obtained before the study, and all experimental procedures were approved by ethics.\n\nDraw a summary table of patient characteristics. The level of AREG was detected by ELISA kit and compared with CA199.\n\nFabrication of a new electrochemical biosensor. Characterization of sensor performance.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Pancreatic Cancer']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'Serum from pancreatic cancer patients and healthy controls'}, 'EnrollmentInfo': {'EnrollmentCount': '600', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Patients with pancreatic cancer', 'ArmGroupDescription': 'Patients with pancreatic cancer did not receive any anti-cancer treatment and had no history of other malignant tumors.The diagnosis of pancreatic cancer patients is based on the final pathological diagnosis; the cancer staging is based on AJCC staging manual.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: diagnosis of pancreatic cancer']}}, {'ArmGroupLabel': 'Healthy Control', 'ArmGroupDescription': 'healthy controls had no history of benign pancreatic diseases and other benign and malignant tumors.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: diagnosis of pancreatic cancer']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test', 'InterventionName': 'diagnosis of pancreatic cancer', 'InterventionDescription': 'Diagnosis of pancreatic cancer based on the concentration of serum biomarkers', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy Control', 'Patients with pancreatic cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Diagnosis of Pancreatic Cancer', 'PrimaryOutcomeDescription': 'Diagnosis based on the concentration of serum biomarkers', 'PrimaryOutcomeTimeFrame': 'through study completion, an average of 1 year'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nThe healthy control group had no history of benign pancreatic diseases and other benign and malignant tumors.\nPatients with pancreatic cancer did not receive any anti-cancer treatment and had no history of other malignant tumors.The diagnosis of pancreatic cancer patients is based on the final pathological diagnosis; the cancer staging is based on AJCC staging manual.\n\nExclusion Criteria:\n\nUncontrolled active infection.\nAcute or chronic pancreatitis.\nIt is accompanied by other uncontrolled malignant tumors.\nAny other uncontrolled active disease that prevents participation in the trial.\nHaving a history of mental illness that is difficult to control.\nIn the opinion of the investigator, the presence of medical or psychiatric history or laboratory abnormalities may increase the risk associated with participation in the study or the administration of the study drug, or may interfere with the interpretation of the results.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '90 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Total collection of pancreatic cancer: healthy control about 300：300. The study population met the inclusion and exclusion criteria.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'wang qi, master', 'CentralContactRole': 'Contact', 'CentralContactPhone': '0086-15991439170', 'CentralContactEMail': 'wangqill1024@163.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'han su xia, professor', 'OverallOfficialAffiliation': 'First Affiliated Hospital of Xian Jiaotong University', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'First Affiliated Hospital of Xian Jiaotong University', 'LocationStatus': 'Recruiting', 'LocationCity': "Xi'an", 'LocationState': 'Shanxi', 'LocationZip': '710061', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'han su xia, professor', 'LocationContactRole': 'Contact', 'LocationContactPhone': '0086-18991232029', 'LocationContactEMail': 'shan87@mail.xjtu.edu.cn'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010190', 'ConditionMeshTerm': 'Pancreatic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010182', 'ConditionAncestorTerm': 'Pancreatic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12262', 'ConditionBrowseLeafName': 'Pancreatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7015', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12254', 'ConditionBrowseLeafName': 'Pancreatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7014', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4387', 'ConditionBrowseLeafName': 'Pancreatic Cancer', 'ConditionBrowseLeafAsFound': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 87, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02808884', 'OrgStudyIdInfo': {'OrgStudyId': 'H16-00519'}, 'Organization': {'OrgFullName': 'British Columbia Cancer Agency', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Cancer DNA Screening Pilot Study (CANDACE)', 'OfficialTitle': 'Cancer DNA Screening Pilot Study (CANDACE)', 'Acronym': 'CANDACE'}, 'StatusModule': {'StatusVerifiedDate': 'August 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 19, 2016', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 10, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 10, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 7, 2016', 'StudyFirstSubmitQCDate': 'June 17, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 22, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 21, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 24, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'British Columbia Cancer Agency', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of British Columbia', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'University of Utah', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Pathway Genomics', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'Boreal Genomics', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The investigators have developed an assay that can sensitively and specifically detect DNA mutations circulating in human plasma that may be indicators of the presence of a solid tumor. This study is a pilot study to measure positive and negative predictive values of this assay as an indicator of the presence of a tumor in normal subjects', 'DetailedDescription': "Participants consenting for the study will be requested to consent for an initial collection of two vials of blood (~ 20 ml total) and to answer questions regarding aspects of their medical history and lifestyle that are relevant to cancer risk. Participants in the study will also be asked to provide consent for follow-up blood samples, and if the confirmatory tests show a positive result, follow-up PET/CT scans and other investigations.\n\n1,000 participants between the ages of 55 and 75 will be enrolled through BC Generations Project. This is a invite-only study.\n\nRespondents who provide consent and choose to be enrolled in the study will then be directed to an online questionnaire where they will be asked to answer questions regarding their lifestyle and medical history.\nThe consent form and questionnaire results will be electronically received at the UBC study site.\nOnce participant information has been received at UBC, it will be entered into a password protected spreadsheet on a UBC server. At that point, participants will be sent a requisition form directing them to one of several possible blood collection sites (LifeLabs), where two 10mL blood draws will be collected by a phlebotomist. Blood collections will be paid for by Boreal through a contract with LifeLabs, and will be performed in Streck stabilized cfDNA blood collection tubes (capable of storing blood at room temperature for over a week).\nOnce collected, the two blood tubes will be delivered by LifeLabs to BC Cancer Research Center within 24-48 hrs of collection. The tubes will be collected by study staff (within 5 days of the initial blood draw) and transported to UBC, where they will be de-identified and assigned a random identifier (UBC study number). Any personal identification on the tubes will be completely removed, by abrasion if necessary. Identifying information will be entered in a password protected spreadsheet (on a UBC server) linking the participant information to the UBC study number. From this point on, the blood samples, and subsequent fractions and results, will only be identified by the study number. The de-identified tubes will be transported to Boreal Genomics where they will be separated into plasma and cellular fraction including erythrocytes and buffy coat. The non-plasma components of the blood samples will be pooled and subsequently discarded. The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. The original blood tubes (now empty), will be destroyed.\nFrozen plasma samples, now de-identified, will be delivered to Pathway Genomics (San Diego, CA) where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Any plasma not consumed in the assay will be destroyed. No plasma, blood or other samples will be stored at either Pathway Genomics or UBC, beyond any temporary storage (1-2 weeks) required to perform the assay.\nCirculating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.\nOnce the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.\nParticipants whose sample provided a positive result will be contacted immediately by telephone by an oncologist co-investigator and concurrently sent a letter by mail informing them of the result and asking them to return for a second blood draw. The investigators expect that this communication will happen with about a month of the original blood draw. The letter will include contact information for the study team and the oncologist co-investigators, in case the participant has any questions or concerns at this stage. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn at the blood collection visit, to allow repeat testing and confirmation that the mutation is present consistently.\nSamples from the additional draw will be treated as described above for the initial samples, with two exceptions. One, the samples will be processed at Boreal Genomics instead of being shipped to Pathway Genomics. Two, some buffy coat DNA (germline DNA) will also be tested for the 96 cancer mutations present on the Boreal panel to detect rare cases where the circulating tumor DNA signal derives from low level germline mutations instead of tumor DNA. This testing will be done at Boreal Genomics and any remaining buffy coat or DNA not consumed in the test will be discarded. Data from the circulating tumor DNA assay and buffy coat test will be returned to UBC and compared to the initial blood result.\nParticipants who are found to have a cancer-associated germline mutation during the foregoing testing will be informed by the oncologist co-investigators and will be offered a consultation with the Hereditary Cancer Program at the BC Cancer Agency where they can meet with a medical geneticist for a consultation. If they wish it, these participants would have access to clinically validated retesting for the germline mutation.\nParticipants for which the additional blood sample does not yield positive results for cancer mutations, will be contacted by telephone to explain the results.\nParticipants for whom the additional blood sample yields a positive result for the same cancer mutations seen in the first blood draw will be contacted by telephone by an oncologist co-investigator, to explain the results and next steps. They will also be sent a letter. The investigators expect this communication to happen within about a week of the second blood draw. Pending oncological evaluation of the participant (see below) and study results, a PET-CT scan with fluorodeoxyglucose (FDG) agent, and possibly other tests will be requested. Unless the oncological exams suggest otherwise, the default follow-up will be a full body PET-CT. The participants undergoing medical imaging scans will be given a requisition form and directed to have the requested scan, which will be paid for by the study sponsor (Boreal Genomics).\nRecognizing that being advised of an abnormal DNA test may cause participants distress, the investigators have committed to (a) complete testing and to contact the participant about the result of 2nd test within 14 days of the blood being drawn; (b) notification of 2nd result (abnormal or normal) being done by phone by the study oncologist (c) pre-booking the follow-up oncological evaluation appointment and offering the participant two options when phoned to advise of the 2nd abnormal result (d) completing the oncological evaluation within 3 weeks of the patient being advised that the 2nd test is abnormal.\n\nThe oncological evaluation will be performed at the Vancouver Centre of the BC Cancer Agency and is likely to include:\n\nA full history, including risk factors for cancer and a review of systems to seek symptoms that could be from cancer.\n\nA physical examination of:\n\n- Head and neck, thorax, abdomen, skin, neurological system lymphatic system and rectum. In men: prostate examination. In women: breast and gynecological examinations\n\nA whole-body PET-CT scan\nStandard age-appropriate cancer screening investigations such as the fecal immunochemical test (FIT) for colorectal cancer, Papanicolaou test for cervix cancer and mammography for breast cancer, if they have not been completed, are due, or are overdue.\nAdditional investigations will be guided by the history, physical examination, whole-body PET-CT and standard screening investigations.\nInvestigations may include: complete blood count, liver enzymes, tumour markers, urinalysis, contrast-enhanced MRI, contrast-enhanced CT, as well as endoscopy of the head and neck, bronchi, bladder, upper GI tract and lower GI tract.\nResults of these tests will be returned to the oncologist investigators and to Dr. Marziali and then entered into the study database. The results will be communicated to the participant in writing as well as in person or by phone. The oncologist will refer participants for additional testing and to appropriate clinicians for follow up for additional investigations. The oncologist will also offer a referral of participants to supportive counseling at this stage.\nThe results will be communicated to the participant's family physician, if the participant has one, by an oncologist investigator.\nParticipants whose investigations detect a potentially malignant mass will have a biopsy, either with imaging guidance, or through referral to an appropriate specialist.\nParticipants, whose investigations do not detect a potentially malignant mass, will be informed in writing, as well as in person or by phone that the circulating tumor DNA test gave a false positive result and will be advised to continue with appropriate cancer screening for their age and family history.\nParticipants with positive circulating tumor DNA results who are unwilling to undergo further testing including possible PET-CTs will still be offered a follow up visit with the oncologist co-investigator to discuss the results and to offer supportive counseling as described above.\nA year following the initial blood draw, participants will be contacted by email to determine if a cancer diagnosis has been made during that time. For non-responding participants, they will be telephoned and their family physicians will be sent a letter inquiring whether the participant was diagnosed with cancer.\n\nData collected in this study will be provided to BC Generations Project."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Circulating Tumor Cells']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Single Group Assignment', 'DesignInterventionModelDescription': 'Blood test screening for all who wish to participant. Additional screening test for those who test positive twice.', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '1514', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Circulating tumor DNA assay- First test - Negative result', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: Circulating tumor DNA assay']}}, {'ArmGroupLabel': 'Circulating tumor DNA assay - Second test- Negative result', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants whose sample provided a positive result after first test, will be contacted immediately by telephone by an oncologist co-investigator and concurrently sent a letter by mail informing them of the result and asking them to return for a second blood draw. We expect that this communication will happen with about a month of the original blood draw. The letter will include contact information for the study team and the oncologist co-investigators, in case the participant has any questions or concerns at this stage. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn at the blood collection visit, to allow repeat testing and confirmation that the mutation is present consistently. Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: Circulating tumor DNA assay']}}, {'ArmGroupLabel': 'Circulating tumor DNA assay - Second test- Positive result', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants with positive results after first test will be contacted by an oncologist and sent a letter informing them of the result. They will be ask to return for a second blood draw. The letter will include contact info of the study team and the oncologist co-investigators. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn to allow repeat testing and confirmation that the mutation is consistently present. Participants whom additional blood sample yields a positive result for the same cancer mutations seen in the first blood draw, will be contacted by an oncologist to explain the results and next steps. This should happen within about a week of the second blood draw. Pending oncological evaluation of the participant and study results, a PET-CT scan with FDG agent, and possibly other tests will be requested. Unless exams suggest otherwise, the default follow-up will be a full body PET-CT.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: Circulating tumor DNA assay']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Genetic', 'InterventionName': 'Circulating tumor DNA assay', 'InterventionDescription': "Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Circulating tumor DNA assay - Second test- Negative result', 'Circulating tumor DNA assay - Second test- Positive result', 'Circulating tumor DNA assay- First test - Negative result']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Measuring the positive and negative predictive value of a circulating tumor DNA blood test in detecting the presence of cancer or pre-cancerous lesions', 'PrimaryOutcomeDescription': 'Within a year of all blood sample collections, the following will be determined:\n\nNumber of False Positive Tests - The number of participants with a confirmed positive blood test who participated in a diagnostic evaluation during which no cancer was found.\nNumber of True Positive Tests - The number of participants with a confirmed blood test who participated in a diagnostic evaluation during which a cancer was found.', 'PrimaryOutcomeTimeFrame': '1-2 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'The enrollment rates for this study', 'SecondaryOutcomeDescription': 'Based on the recruitment data from the participants of the BC Generations Project, the participant enrollment rates will be determine quarterly, semi-annually and yearly.', 'SecondaryOutcomeTimeFrame': '1-2 years'}, {'SecondaryOutcomeMeasure': 'The number of repeated versus sporadic positive test results within a year of the last blood draw.', 'SecondaryOutcomeDescription': 'After the last blood draw, data will be analyzed to determine the number of repeated versus sporadic positive test results (i.e. how often does the test provide the same results on separate blood draws from the same individual, versus different results).', 'SecondaryOutcomeTimeFrame': '1-2 years'}, {'SecondaryOutcomeMeasure': 'The rate of participation in the medical imaging component of the study once a positive test result has been confirmed.', 'SecondaryOutcomeDescription': 'After the last blood draw, data will be analyzed to determine the rate of participation in the medical imaging component of the study once a positive test result has been confirmed within a year.', 'SecondaryOutcomeTimeFrame': '1-2 years'}, {'SecondaryOutcomeMeasure': 'The number of medical imaging scans required per thousand individuals enrolled in the study.', 'SecondaryOutcomeDescription': 'After the last blood draw, data will be analyzed to determine how often medical imaging scans were required per thousand of enrolled participants.', 'SecondaryOutcomeTimeFrame': '1-2 years'}, {'SecondaryOutcomeMeasure': 'The number of participants with abnormal medical imaging scans and of those cohorts, what fraction is cancer found.', 'SecondaryOutcomeDescription': 'After the last blood draw, data will be analyzed to determine:\n\nOf the participants with abnormal medical imaging scans\n\nwhat fraction is conclusively diagnosed with cancer within 2 months.\nThe number of curable cancers found\nThe number of incurable metastatic cancers found\nThe number of participants in whom cancer is found by one year after the blood sample, by any means.', 'SecondaryOutcomeTimeFrame': '1-2 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nHave never been diagnosed with cancer (except for non-melanoma skin cancer)\nMust be able to read and understand a consent form in English\nBe willing to consent to the required blood draws, medical exam and PET-CT scans\nBe willing to consent to any medical data related to this test, the imaging scans, and related follow up, being shared with the study investigators for the following year\nBe in good health and able to donate three tubes of blood\nMust have email\nMust be able to have blood work in the greater Vancouver area\n\nExclusion Criteria:\n\nImmunocompromised individuals\nContra-indications to MRI or PET-CT\nIndividuals with bleeding disorders', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '55 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Alan M Nichol, MD', 'OverallOfficialAffiliation': 'British Columbia Cancer Agency', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'BC Cancer Agency- Vancouver Centre', 'LocationCity': 'Vancouver', 'LocationState': 'British Columbia', 'LocationZip': 'V5Z 4E6', 'LocationCountry': 'Canada'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '20952405', 'ReferenceType': 'background', 'ReferenceCitation': 'Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50. doi: 10.1093/nar/gkq929. Epub 2010 Oct 15.'}, {'ReferencePMID': '24071849', 'ReferenceType': 'background', 'ReferenceCitation': 'Cancer Genome Atlas Research Network; Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013 Oct;45(10):1113-20. doi: 10.1038/ng.2764.'}, {'ReferencePMID': '22492982', 'ReferenceType': 'background', 'ReferenceCitation': 'Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012 Apr 15;18(8):2391-401. doi: 10.1158/1078-0432.CCR-11-3148. Epub 2012 Apr 5.'}, {'ReferencePMID': '22228631', 'ReferenceType': 'background', 'ReferenceCitation': 'Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012 Feb 15;18(4):1177-85. doi: 10.1158/1078-0432.CCR-11-0564. Epub 2012 Jan 6.'}, {'ReferencePMID': '22722830', 'ReferenceType': 'background', 'ReferenceCitation': 'Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.'}, {'ReferencePMID': '25575824', 'ReferenceType': 'background', 'ReferenceCitation': 'Kidess E, Heirich K, Wiggin M, Vysotskaia V, Visser BC, Marziali A, Wiedenmann B, Norton JA, Lee M, Jeffrey SS, Poultsides GA. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget. 2015 Feb 10;6(4):2549-61. doi: 10.18632/oncotarget.3041.'}, {'ReferencePMID': '24553385', 'ReferenceType': 'background', 'ReferenceCitation': 'Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': 'Only participants have the option of receiving their own personal data.'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000009360', 'ConditionMeshTerm': 'Neoplastic Cells, Circulating'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009362', 'ConditionAncestorTerm': 'Neoplasm Metastasis'}, {'ConditionAncestorId': 'D000009385', 'ConditionAncestorTerm': 'Neoplastic Processes'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M11457', 'ConditionBrowseLeafName': 'Neoplastic Cells, Circulating', 'ConditionBrowseLeafAsFound': 'Circulating Tumor Cells', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11459', 'ConditionBrowseLeafName': 'Neoplasm Metastasis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11482', 'ConditionBrowseLeafName': 'Neoplastic Processes', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 88, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05359016', 'OrgStudyIdInfo': {'OrgStudyId': '2020-0651'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'NCI-2022-03767', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'NCI-CTRP-Clinical Trial Reporting Registry'}]}, 'Organization': {'OrgFullName': 'M.D. Anderson Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique', 'OfficialTitle': 'Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique'}, 'StatusModule': {'StatusVerifiedDate': 'December 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 14, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 30, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 30, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 25, 2022', 'StudyFirstSubmitQCDate': 'April 28, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 3, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'December 16, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 20, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'M.D. Anderson Cancer Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Population Services International', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Eduardo Mondlane University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'William Marsh Rice University', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The goal of this operational research study is to develop, implement and test integrated CCS&PT and voluntary FP service delivery models to evaluate whether integrated service delivery can optimize uptake and health impact of both services. The study objectives and learning questions are listed below, along with key outcomes that will be measured.', 'DetailedDescription': 'Objectives:\n\nThe study objectives are outlined below:\n\nTo quantify the health impact of CCS&PT on the uptake of voluntary FP services.\nTo quantify the health impact of voluntary FP on the uptake of CCS&PT services.\nTo determine which promotional strategies are most effective to increase uptake of CCS&PT services.\nTo identify cost to deliver high quality CCS&PT services integrated into existing voluntary FP programs.\nTo determine client and provider acceptability of integrated CCS&PT and voluntary FP services using new screen and treat technologies.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cervical Cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '14600', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'HPV testing of women for cervical cancer screening', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: HPV testing of women for cervical cancer screening']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'HPV testing of women for cervical cancer screening', 'InterventionDescription': 'Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['HPV testing of women for cervical cancer screening']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Number of women who will undergo Cervical Cancer Screening by HPV testing', 'PrimaryOutcomeTimeFrame': 'through study completion, an average of 1 year'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nWomen 30 - 49 years or all women living with HIV\nNot currently pregnant\nPatients with a cervix (women who have undergone a total hysterectomy with removal of the cervix are not eligible)\nLiving in Maputo or Gaza\nWilling and able to provide informed consent for services.\n\nExclusion Criteria:\n\nNot meeting the inclusion criteria\nPhysical or mental impairment that inhibits participation in the study\nPregnant women', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'GenderBased': 'Yes', 'MinimumAge': '30 Years', 'MaximumAge': '49 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Mila Salecedo, MD, PHD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '832-696-6794', 'CentralContactEMail': 'mpsalcedo@mdanderson.org'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kathleen Schmeler, MD', 'OverallOfficialAffiliation': 'M.D. Anderson Cancer Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'M D Anderson Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kathleen Schmeler, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '713-854-9150', 'LocationContactEMail': 'kschmele@mdanderson.org'}, {'LocationContactName': 'Kathleen Schmeler, MD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'M D Anderson Cancer Center', 'SeeAlsoLinkURL': 'http://www.mdanderson.org'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000002583', 'ConditionMeshTerm': 'Uterine Cervical Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000014594', 'ConditionAncestorTerm': 'Uterine Neoplasms'}, {'ConditionAncestorId': 'D000005833', 'ConditionAncestorTerm': 'Genital Neoplasms, Female'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000002577', 'ConditionAncestorTerm': 'Uterine Cervical Diseases'}, {'ConditionAncestorId': 'D000014591', 'ConditionAncestorTerm': 'Uterine Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4982', 'ConditionBrowseLeafName': 'Uterine Cervical Neoplasms', 'ConditionBrowseLeafAsFound': 'Cervical Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16494', 'ConditionBrowseLeafName': 'Uterine Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8097', 'ConditionBrowseLeafName': 'Genital Neoplasms, Female', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4977', 'ConditionBrowseLeafName': 'Uterine Cervical Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16491', 'ConditionBrowseLeafName': 'Uterine Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 89, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02377232', 'OrgStudyIdInfo': {'OrgStudyId': '14-1976'}, 'Organization': {'OrgFullName': 'University of Colorado, Denver', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Simultaneous Improvement in Colon Cancer Screening Rates and Patient-Centered Care', 'OfficialTitle': 'Simultaneous Improvement in Colon Cancer Screening Rates and Patient-Centered Care', 'Acronym': 'CRCSreening'}, 'StatusModule': {'StatusVerifiedDate': 'June 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2015', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'July 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 25, 2015', 'StudyFirstSubmitQCDate': 'March 2, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 3, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'June 22, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 26, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of Colorado, Denver', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Several screening methods exist to screen patients for CRC ranging from invasive (i.e., colonoscopy) to less invasive (i.e., testing the stool for blood). Although choice between screening methods is recommended, patients are not currently offered an unbiased choice and physicians generally recommend only colonoscopy. In this project, the investigators will answer the following questions: 1) Is it feasible to incorporate a DA in the AHP protocol?; 2) Is it feasible to incorporate mailing patients a stool blood test?; 3) Does the DA change CRC screening decision quality, using proxy measures such as knowledge and intent; and 4) Does the DA change the proportion of participants that complete a CRC screening test? To answer these questions the investigators will compare survey responses and CRC test type completed between two AHP CRC surveillance patients groups - those that received usual care versus those that received the DA.', 'DetailedDescription': 'At the University of Colorado Hospital primary care clinics, only 59% of eligible patients are up to date with current colorectal cancer (CRC) screening. This is below the national average of 65% and well below the healthy people 2020 goal of 70.5%. Several screening methods exist to screen patients for CRC ranging from invasive (i.e., colonoscopy) to less invasive (i.e., testing the stool for blood). Although choice between screening methods is recommended, patients are not currently offered an unbiased choice and physicians generally recommend only colonoscopy. Further, the investigators know from research that choice increases screening rates. Unfortunately, many people do not follow through when only colonoscopy is offered. However, participants in one study were nearly twice as likely to be screened if they were offered a choice between colonoscopy and fecal occult blood testing rather than being offered colonoscopy alone. Thus, in this project, the investigators aim to examine the feasibility of incorporating a patient decision aid (DA) for patients in CRC screening surveillance with the Ambulatory Health Promotion (AHP) using a pre/post design. The investigators will answer the following questions: 1) Is it feasible to incorporate a DA in the AHP protocol?; 2) Is it feasible to incorporate mailing patients a stool blood test?; 3) Does the DA change CRC screening decision quality, using proxy measures such as knowledge and intent; and 4) Does the DA change the proportion of participants that complete a CRC screening test? To answer these questions the investigators will compare survey responses and CRC test type completed between two AHP CRC surveillance patients groups - those that received usual care versus those that received the DA.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Colon Cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'Triple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider', 'Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '424', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Usual Care Outreach for Colon Cancer Screening', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Receives standard of care outreach concerning colon cancer screening.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Usual Care Outreach for Colon Cancer Screening']}}, {'ArmGroupLabel': 'Decision Aid for Colon Cancer Screening', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Receives colon cancer screening decision aid intervention in addition to outreach.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Decision Aid for Colon Cancer Screening']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Decision Aid for Colon Cancer Screening', 'InterventionDescription': 'Paper decision aid describing different screening options for colon cancer', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Decision Aid for Colon Cancer Screening']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Usual Care Outreach for Colon Cancer Screening', 'InterventionDescription': 'Patients overdue for colon cancer screening are contacted and outreach is performed in an effort to schedule colonoscopy', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Usual Care Outreach for Colon Cancer Screening']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Colon Cancer Screening Intent', 'PrimaryOutcomeDescription': 'Measured using a survey instrument to assess intent', 'PrimaryOutcomeTimeFrame': '6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Colon Cancer Screening Completed', 'SecondaryOutcomeDescription': 'Measured through retrospective chart reviews to check for completed screening', 'SecondaryOutcomeTimeFrame': '6 Months'}]}}, 'EligibilityModule': {'EligibilityCriteria': "Inclusion Criteria:\n\nIndividuals that fall within the age range for CRC screening surveillance (age 50 to < = 75 years) from AHP\nAre eligible for CRC screening surveillance from AHP\nWere seen in the last 18 months by a provider at one of the primary medical care clinics from the University of Colorado General Internal Medicine, Family Medicine, or the Women's Integrated Services in Health clinic, and the individual's primary medical care provider has provided approval for AHP CRC outreach to an AHP staff person\nHave no record of a colonoscopy within the last 10 years,\nHave no record of flexible sigmoidoscopy or double-contrast barium enema within the past 5 years, or\nHave no record of FOBT within the past year.\n\nExclusion Criteria:\n\nIndividuals that do not speak English\nIndividuals that have limited cognitive function/developmental disabilities\nIndividuals that have a personal or family history of CRC (previous adenomatous polyp), and/or, have a signs and symptoms colonoscopy order from their primary care physician\nNot eligible for CRC screening surveillance from AHP\nHave a terminal medical illness that would otherwise categorize them as inappropriate candidates for CRC screening as noted in their EPIC EMR:\n\nThe individual exhibits any of the following:\n\npersonal history of CRC, colectomy, colostomy, or ileostomy; currently prescribed anti-coagulation medications (ReoPro (abciximab), Aggrenox (aspirin plus dipyridamole), Persantine (dipyridamole), Integrilin (eptifibatide), Ticlid (ticlopidine), Aggrastat (tirofiban), Heparin, Coumadin (warfarin), Pradaxa (dabigatran), Xarelto (rivaroxaban)); currently prescribed plavix (clopidogrel); on chronic oxygen; have end-stage renal disease; have unstable angina; have arrhythmia/atrial fibrillation; have cardiomyopathy; currently weighs >350 pounds; have cystic fibrosis; and/or, are insured by the Colorado indigent care program (CICP) or Medicaid-Old age pension, AARP Medicare/Secure Horizons (except PFFS), Denver Health Managed Medicaid, Evercare; Kaiser (not the prescriber of origin), Medicare Complete, New Medicaid, New CICP. Furthermore, dependent on the severity of the condition, the following are gauged for exclusion criteria and noted in the AHP CRC screening surveillance test notes to then inquire about appropriate candidacy for a colonoscopy: diabetes mellitus (insulin, oral, or both), chronic obstructive pulmonary disease, emphysema, reactive airway disease; chronic renal disease; multiple sclerosis; seizure disorder; murmurs; hepatitis; human immunodeficiency virus /acquired immunodeficiency syndrome ; congestive heart failure; coronary artery disease; aortic aneurysm; history of coronary artery bypass graft; heart valve issues (prolapse, regurgitation, etc.); tachycardia; bradycardia; history of myocardial infarction.", 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '50 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Carmen L Lewis, MD', 'OverallOfficialAffiliation': 'University of Colorado, Denver', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Colorado Anschutz Medical Campus', 'LocationCity': 'Aurora', 'LocationState': 'Colorado', 'LocationZip': '80045', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003110', 'ConditionMeshTerm': 'Colonic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000015179', 'ConditionAncestorTerm': 'Colorectal Neoplasms'}, {'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5490', 'ConditionBrowseLeafName': 'Colonic Neoplasms', 'ConditionBrowseLeafAsFound': 'Colon Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T120', 'InterventionBrowseLeafName': 'Cola', 'InterventionBrowseLeafAsFound': 'Estrogen', 'InterventionBrowseLeafRelevance': 'high'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 90, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05572944', 'OrgStudyIdInfo': {'OrgStudyId': 'MOHW111-TDU-B-221-114019'}, 'Organization': {'OrgFullName': 'Chung Shan Medical University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Multidimensional Modeling for Never Smoking Lung Cancer Risk Prediction', 'OfficialTitle': 'Validation and Optimization of Multidimensional Modelling for Never Smoking Lung Cancer Risk Prediction by Multicenter Prospective Study'}, 'StatusModule': {'StatusVerifiedDate': 'December 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 15, 2022', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 31, 2025', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'January 31, 2029', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'September 29, 2022', 'StudyFirstSubmitQCDate': 'October 7, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 10, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'December 26, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 28, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Gee-Chen Chang', 'ResponsiblePartyInvestigatorTitle': 'Vice president of Chung Shan Medical University', 'ResponsiblePartyInvestigatorAffiliation': 'Chung Shan Medical University'}, 'LeadSponsor': {'LeadSponsorName': 'Chung Shan Medical University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Ministry of Health and Welfare, Taiwan', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Lung Cancer is the leading cause of cancer-related deaths in Taiwan and worldwide and the incidence is also increasing. The payment for lung cancer which occupies the largest part of National Health Insurance expense is over 15 billion in 2018. Because about 80% lung cancer patients are smokers in western countries the low-dose computed tomography screening focuses on the smoking population It is quite different in South-East Asia particularly in Taiwan that 53% of Taiwan lung cancer are never-smokers and the etiology and the underlying mechanisms are still unknown. The preliminary results of prospective TALENT study indicated that family history plays a key role in tumorigenesis of Taiwan lung cancers but several important variables such as air pollution, biomarkers, radiomics analysis are not available limits the accuracy of lung cancer identification. Hence, it is critical to integrate most of factors involved in lung cancer formation into a multidimensional lung cancer prediction model which could benefit never-smoker lung cancers in Taiwan and East Asia even in the western countries. The investigators initiate a clinical study to validate the multidimensional lung cancer prediction model for never-smoking population by multicenter prospective study.', 'DetailedDescription': 'To achieve the goal there are four programs proposed.\n\nProgram 1: Validating non-smoker lung cancer prediction model among Taiwanese population: Integration with environmental and occupational factors. The investigators aim to enhance the accuracy of lung cancer prediction among Taiwanese non-smokers by incorporating environmental and occupational risk factors. The main aim of this program is to validate and optimize existing prediction models with more comprehensive epidemiologic, environmental and occupational factors with machine learning algorithms. The other aim is to validate current PM2.5-based lung cancer risk prediction models among nonsmokers, and optimize existing model with environmental and occupational factors in higher resolution. The investigators hypothesize adding more GIS-based environmental exposure measurements, and occupational exposure using job-exposure matrix as proxy can increase the predictive power of lung cancer risk model.\n\nProgram 2: Validation of autoantibody- and genetic prediction model for non-smoker lung cancer. The investigators detect the autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data. The investigators will validate the prediction power of these autoantibodies and genetic biomarkers in the early diagnosis of patients with high risk of acquiring lung cancer in Taiwan.\n\nProgram 3: Detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics. The investigators propose an integrated platform for detecting and following up lung nodules. A similarity measurement approach between two nodules is proposed. Base on Lung RADS assessment, the investigators plan to perform CT-radiomic analysis for nodules larger than or equal to 6-8 mm diameter aimed to find nodules in higher risk of developing lung cancer. The lung nodules will be detected and followed up by using a series of AIs. The detected nodules could be used for producing report and estimating Lung-RADS. Though Lung-RADS has considered the risk of malignancy based on their categories, the expectation of this project is to efficiently select CT screen high risk lung nodule(s) by using volume measurement, morphology, texture and CT radiomics of the detected nodules in addition to Lung-RADS criteria based on nodule size and characters.\n\nProgram 4: Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study. The program 4 will first use retrospective cohort based the case control research design to optimize the lung cancer risk models from program 1 and the biomarker and imaging models from program 2 and 3, respectively. The prospective multi-center research design will further use to verify the optimized predictive model. The high-risk participants will be selected to measure for biomarkers and undergo LDCT. The optimized biomarker model and image feature models will be performed to predict the probability of lung cancer and compared it with conventional clinical diagnosis methods and low risk participants. Finally, the Taiwanese population suitable lung cancer screening strategy will be proposed.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Lung Cancer']}, 'KeywordList': {'Keyword': ['Lung cancer', 'Low-dose computed tomography', 'Machine learning']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '10000', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Never smoker with lung cancer high risk assessment', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'High risk: above the median of the initial risk model from retrospective study', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: to develop a risk model and assess the lung cancer risk']}}, {'ArmGroupLabel': 'Never smoker with lung cancer low risk assessment', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Low risk: below the median of the initial risk model from retrospective study', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: to develop a risk model and assess the lung cancer risk']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'to develop a risk model and assess the lung cancer risk', 'InterventionDescription': 'Participants will receive the following things in sequence\n\nNon-smoker lung cancer prediction model among Taiwanese population by questionnaire\nCheck autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data\nIn high risk group,arrange chest CT and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics\nOptimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Never smoker with lung cancer high risk assessment', 'Never smoker with lung cancer low risk assessment']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Lung cancer detection rate differences between the high lung cancer risk group and the low lung cancer risk group.', 'PrimaryOutcomeDescription': 'Participants will receive the following things in sequence\n\n10,000 non-smoker participants will receive a prespecified questionnaire\nAutoantibodies will be checked including p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4, and SOX2 in the blood of recruited participants. All 133 SNPs and 11 mitochondrial mutations will be detected which are highly correlated with never-smoking lung cancer in our preliminary data\nIn the high-risk group, the investigators will arrange LDCT scans for four rounds to determine the lung cancer detection rate. Also, the pulmonary nodule lesions detected will be classified by Lung-RADS and prediction of lung cancer risk in CT scans using deep learning and radiomics. In the low-risk group, the matched participants will receive LDCT scans for two rounds to determine the lung cancer detection rate.', 'PrimaryOutcomeTimeFrame': '4 years'}, {'PrimaryOutcomeMeasure': 'Predicted Area under curve (AUC) value > 0.8 of the lung cancer risk model', 'PrimaryOutcomeDescription': 'Through steps 1,2, and 3 of the above column in primary outcome 1, the lung cancer risk model will be developed with optimization and validation of lung cancer risk and probability prediction model by this prospective multicenter clinical trial.\n\n( predicted Area under curve (AUC) > 0.8)', 'PrimaryOutcomeTimeFrame': '4 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAge 50-80 years old\n\nFirst-degree relatives of lung cancer patients\n\naged more than 50 - 80 years old\nor older than the age at diagnosis of the youngest lung cancer the proband in the family if they are less than 50 years old\n\nExclusion Criteria:\n\nPrevious history of lung cancer\nAnother malignancy except for cervical carcinoma in situ or non-melanomatous carcinoma of the skin within 5 years\nAn inability to tolerate transthoracic procedures or thoracotomy\nChest CT examination was performed within 18 months\nHemoptysis of unknown etiology within one month\nBody weight loss of more than 6 kg within one year without an evident cause\nA known pregnancy', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'GEECHEN CHANG, MD. PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+886-4-24739595', 'CentralContactPhoneExt': '34414', 'CentralContactEMail': 'geechen@gmail.com'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Chung Shan Medical University Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Taichung', 'LocationZip': '402', 'LocationCountry': 'Taiwan', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'GEECHEN CHANG, MD, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+886-4-24739595', 'LocationContactPhoneExt': '34414', 'LocationContactEMail': 'geechen@gmail.com'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000008175', 'ConditionMeshTerm': 'Lung Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000012142', 'ConditionAncestorTerm': 'Respiratory Tract Neoplasms'}, {'ConditionAncestorId': 'D000013899', 'ConditionAncestorTerm': 'Thoracic Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10324', 'ConditionBrowseLeafName': 'Lung Neoplasms', 'ConditionBrowseLeafAsFound': 'Lung Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14131', 'ConditionBrowseLeafName': 'Respiratory Tract Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15810', 'ConditionBrowseLeafName': 'Thoracic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10320', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14129', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M3777', 'InterventionBrowseLeafName': 'Autoantibodies', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 91, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02743910', 'OrgStudyIdInfo': {'OrgStudyId': 'TBCRC040'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'TBCRC 040', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Translational Breast Cancer Research Consortium (TBCRC)'}, {'SecondaryId': 'IRB00093688', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'JHMIRB'}]}, 'Organization': {'OrgFullName': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer', 'OfficialTitle': 'Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'August 2022', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2016'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 15, 2016', 'StudyFirstSubmitQCDate': 'April 15, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 19, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 4, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 8, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Translational Breast Cancer Research Consortium', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study is being done to see if it is possible to use blood samples to predict response to treatment in breast cancer patients receiving preoperative (or neoadjuvant) therapy. Research has shown that most breast cancers release tumor-specific DNA into the blood (that is, DNA that is specific to the tumor cells or cancer). This DNA can be detected in blood testing known as plasma tumor-DNA or "ptDNA." This DNA is separate from that found in the blood and tissue samples which serve as the "instruction book" or "genetic code" for the cells that make-up the human body. The changes in ptDNA before and after treatment, as well as after surgery, may also help investigators to understand more about a patient\'s risk of cancer returning and long-term outcomes.', 'DetailedDescription': 'This is a prospectively designed study. Up to 229 newly diagnosed invasive HER2-positive or triple-negative breast cancer patients planning neoadjuvant therapy (NAT) will be enrolled. Blood samples will be collected pre-operatively at the time of diagnosis/prior to NAT, post-cycle 1/pre-cycle 2 of NAT, after all NAT/immediately before surgery, and post-operatively at 6, 12, 24, and 36 months, and annually thereafter if funding allows. Researchers will also collect representative tissue samples from the diagnostic biopsy (in all participants) and definitive surgery (if available). Additionally, to look at feasibility of tumor DNA analyses in urine samples, urine samples will be collected along with blood samples (urine tumor DNA or utDNA).\n\nNext generation sequencing will be performed on core biopsies of all enrolled patients for tumor-specific mutations (TSM) discovery. Based on those findings, droplet digital PCR (ddPCR) on plasma DNA samples will also be performed to confirm the presence of the TSM in the plasma on diagnosis, and one TSM will be chosen to track as the plasma tumor DNA (ptDNA) mutation of interest. Investigators will perform ddPCR on pre-operative plasma DNA samples and will assess for the presence of ptDNA. Pathologists will assess surgical specimens for pathologic response (such as complete response/pCR and residual cancer burden/RCB). As primary endpoint, investigators will assess the number of patients with and without preoperative ptDNA who have pCR versus residual disease. As exploratory endpoints, the following will also be performed: (a) quantitative multiplex methylation-specific PCR (QM-MSP) in diagnostic biopsy and definitive residual surgery specimen; and, (b) the circulating methylated tumor DNA (cMethDNA) assay in plasma specimens (baseline and after NAT), and evaluate associations with pathologic response.\n\nAdditional endpoints include the association between plasma and tissue markers at baseline, after NAT, and (if available) during surveillance with long-term prognosis (invasive disease-free survival/IDFS and distant disease-free survival/DDFS).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['preoperative', 'neoadjuvant', 'plasma tumor DNA', 'ptDNA']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Blood and tissue samples'}, 'EnrollmentInfo': {'EnrollmentCount': '229', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Stage II-III breast cancer', 'ArmGroupDescription': 'Up to 229 newly diagnosed stage II-III invasive HER2-positive or triple-negative breast cancer patients planning neoadjuvant therapy (NAT) will be enrolled. ptDNA blood samples as well as a representative tumor tissue sample from both the diagnostic and surgical procedure (if available) will be collected.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: ptDNA', 'Other: Tissue sample']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'ptDNA', 'InterventionDescription': 'Pre-operative blood samples for ptDNA will be collected at the time of diagnosis/prior to NAT, post-cycle 1/pre-cycle 2 of NAT, after all NAT/immediately before surgery, and post-operatively at 6, 12, 24, and 36 months, and annually thereafter if funding allows.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stage II-III breast cancer']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Blood sample']}}, {'InterventionType': 'Other', 'InterventionName': 'Tissue sample', 'InterventionDescription': 'Representative tissue sample will be collected from the diagnostic biopsy (in all participants) and definitive surgery (if available)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stage II-III breast cancer']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Correlation of absence of plasma tumor DNA (ptDNA) with pathologic complete response (pCR)', 'PrimaryOutcomeDescription': 'To estimate the negative predictive value (NPV) of the absence of plasma tumor DNA (ptDNA) Tumor Specific Mutations (TSMs) after neoadjuvant therapy (NAT) for the absence of residual disease as defined by pathologic complete response (pCR) in stage II-III HER2-positive or triple negative breast cancer (TNBC)\n\nNPV = True Negative/True Negative + False Negative (probability that the disease is not present when the test is negative)', 'PrimaryOutcomeTimeFrame': '6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Prognostic value of ptDNA for invasive disease-free survival and distant disease-free survival', 'SecondaryOutcomeDescription': 'To estimate the prognostic value of ptDNA for 5-year invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) in TNBC patients following completion of loco-regional and systemic therapy', 'SecondaryOutcomeTimeFrame': '5 years'}, {'SecondaryOutcomeMeasure': 'Correlation of absence of ptDNA with residual cancer burden (RCB)', 'SecondaryOutcomeDescription': 'To estimate the NPV of the absence of ptDNA TSMs after NAT for the absence of residual disease as defined by residual cancer burden (RCB) 0 or 1', 'SecondaryOutcomeTimeFrame': '6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nNewly diagnosed, histologically confirmed invasive breast cancer that is triple negative (estrogen receptor [ER], progesterone receptor [PR], and HER2-neu negative) or HER2-positive (any ER/PR status)\nUnresected, untreated breast cancer that is T2, T3, or T4a-c; any N (nodal status); and M0 (not metastatic)\nECOG Performance Status of 0 or 1\nPlanning to receive a neoadjuvant chemotherapy regimen containing a taxane ± an anthracycline for at least 4 cycles. Patients with HER2-positive disease must also be planning to receive HER2-targeted therapy.\nDiagnostic tumor material must be available for correlative analyses\nPatients must have the ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nNo prior treatment for the current breast cancer, though prior use of selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs) for the prevention of breast cancer is acceptable.\nWomen who are pregnant or nursing are excluded.\nNo history of another primary malignancy in the last 5 years prior to registration. Patients with prior history of in situ cancer or basal or localized squamous cell skin cancer are eligible.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Newly diagnosed invasive HER2-positive or triple-negative breast cancer patients planning neoadjuvant therapy (NAT)', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Antonio C Wolff, M.D.', 'OverallOfficialAffiliation': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21287', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 92, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04259762', 'OrgStudyIdInfo': {'OrgStudyId': '18-264'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'P20GM103451', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/P20GM103451'}]}, 'Organization': {'OrgFullName': 'New Mexico Cancer Care Alliance', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Enhancing Cancer Prevention and Control Pathways-Native Health Initiative', 'OfficialTitle': 'Enhancing Cancer Prevention and Control Pathways-Native Health Initiative'}, 'StatusModule': {'StatusVerifiedDate': 'February 2023', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 1, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'January 30, 2020', 'StudyFirstSubmitQCDate': 'February 5, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 6, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 17, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 21, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'New Mexico Cancer Care Alliance', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of General Medical Sciences (NIGMS)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'There are continued disparities in cancer incidence, mortality, and survival between American Indians (AIs) and Whites on cancers responsive to early screening (i.e., breast, colorectal, and cervical) in the US. In New Mexico (NM), AIs compared with other racial/ethnic populations are significantly less likely to adhere to recommended screening guidelines. The purpose of this trial is to develop and pilot test multilevel/multicomponent intervention strategies to enhance screening for breast, colorectal, and cervical cancers.', 'DetailedDescription': 'There are continued disparities in cancer incidence, mortality, and survival between American Indians (AIs) and Whites on cancers responsive to early screening (i.e., breast, colorectal, and cervical) in the US. Between 1990-2009, based on data from Contract Health Service Delivery Area Counties across the US, the mortality-to-incidence ratios for these cancers were significantly higher for American Indian/Alaska Natives compared to Whites (breast: 1.22, colorectal: 1.16, cervix: 1.36), indicating poorer survival. New Mexico (NM) AIs also experience substantial cancer disparities. Between 2010-2014, AIs compared to Whites had higher incidence (per 100,000) for cervical (7.9 vs. 6.9) and colorectal (male: 46.5 vs. 35.2; female: 29.2 vs. 28.2) cancers, and higher mortality for cervical (3.7 vs. 1.3) and colorectal (males only; 18.9 vs. 15.6) cancers. AIs were more likely to receive a late-stage (i.e., regional or distant) cancer diagnosis for all 3 screen detectable cancers. AIs have some of the lowest cancer screening rates compared with other racial/ethnic groups. In NM, AIs listed in the Indian Health Service (IHS) Albuquerque Area have substantially lower screening rates than the state\'s White population do. AIs had screening rates of: breast (58.5%, women ages 52-64), colorectal (41.9%, ages 50-75), and cervical (63.9%, women ages 24-64) cancers; whereas, screening rates for Whites were: breast (70.0%, ages 50-74), colorectal (69.2%, ages 50-75), and cervical (77.8%, women 21-65).\n\nThe Community Prevention Services Task Force\'s Guide to Community Preventive Services ("The Community Guide") recommends evidence-based strategies for multicomponent interventions to promote breast, colorectal, and cervical cancer screening. Multicomponent interventions combine approaches to enhance community demand for and access to, and provider delivery of screening services. Evidence suggests that interventions that combine approaches from the 3 strategies or that combine approaches to increase community demand and access result in the largest increases in screening rates.\n\nThe overall objective is to develop and pilot test culturally and linguistically appropriate interventions to enhance age- and risk-appropriate breast, colorectal, and cervical cancer screening in concordance with the U.S. Preventive Services Task Force recommended guidelines. The aims are to:\n\nAim 1. Continue to foster a sustainable multi-directional, participatory collaboration ("community collaborative" through a Tribal Advisory Panel (TAP)) between the Zuni\'s tribal leadership, stakeholders, Zuni Indian Health Service Comprehensive Health Center, and UNM Comprehensive Cancer Center (UNMCCC) researchers to enhance community-engaged cancer control training, education, and research.\n\nAim 2. Using participatory approaches by engaging the TAP, finalize multilevel/multicomponent intervention strategies to increase provider delivery of, community access to, and community demand for screening for the screen-detectable cancers.\n\nAim 3. Pilot test (using a stepped-wedge trial design and qualitative methods) the multilevel/multicomponent culturally and linguistically appropriate intervention strategies on outcomes such as: impact on screening practices; feasibility of implementation and acceptability of the intervention; and cost effectiveness of the intervention.\n\nAim 4. Disseminate findings appropriately tailored to the needs of targeted non-scientific and scientific audiences (i.e., TAP, tribal leaders, Zuni community, Zuni IHS healthcare providers; annual NM Institutional Development Award (IDeA) Networks of Biomedical Research Excellence symposium and national conference attendees, and peer-reviewed publications).\n\nProtocol A. Aim 1-Foster a Community Collaborative (TAP) Procedure-Fostering the Community Collaborative: The 9-member community collaborative, Tribal Advisory Panel, represents the Zuni tribal leadership, Zuni stakeholders and local organizations (i.e., Health and Wellness program directors, Community Health Representatives [CHRs], cancer survivors), healthcare providers (i.e., Zuni IHS Comprehensive Health Center, hereafter "health center"), and UNMCCC researchers. The TAP ensures active community engagement and a non-hierarchical partnership model. The TAP brings expertise in tribal health priorities and policies, cultural and linguistic sensitivities, development and delivery of intervention, education and training needs for students and CHRs, and delivery of healthcare services. The TAP will meet quarterly, or more often if necessitated.\n\nB. Aim 2-Finalize the Multilevel/Multicomponent Intervention Strategies Procedure-Finalization of Intervention Strategies: To finalize the intervention, the investigators will: (a) map data collected through on-going research with The Community Guide\'s recommendations of evidence-based strategies to enhance cancer screening; (b) develop small media for the 3 screen-detectable cancers.\n\nB1. Data mapping and participatory engagement of the TAP: The investigators will map and present data, along with evidence-based recommendations from The Community Guide, to the TAP for participatory input on appropriate multilevel/multicomponent intervention strategies that can enhance screening. These data were collected through prior research and consist of environmental scans of resources available to offer screening services, and structural/system-level promoters and barriers to providing screening and qualitative and quantitative assessments of cancer related knowledge, attitudes, screening practices, and screening barriers in the Zuni Pueblo.\n\nThe overall focus of the intervention model, per The Community Guide, is on intervention strategies that fall into 3 categories. First, increase community access by reducing structural/systemic barriers (e.g., reduce administrative barriers, patient navigation, assist in appointment scheduling, set up alternative screening sites, and modify screening clinic hours). Second, increase community demand using culturally, linguistically, and health literacy appropriate group education, 1-on-1 education, client reminders and incentives, mass media, and small media (i.e., educational brochures). Third, increase provider delivery of screening services through, improved provider recommendations, provider reminder/recall systems, and shared-decision making tools. Evidence suggests that a combination of strategies from each category leads to greater effects. The investigators will conjointly work with the TAP to select evidence-based intervention strategies (at least 1 strategy from at least 2 [preferably all 3] categories) that can best address barriers identified through the qualitative and quantitative research, can leverage existing resources at the health center, and meet the cancer control needs of the Zuni people.\n\nB2. Develop small media: The investigators will develop small media (i.e., educational brochure) on the 3 cancers. The Community Guide recommended strategies to increase demand for and access to screening require the ability to understand cancer risk, screening benefits, health system navigation-all to make informed decisions and take appropriate action. The investigators will use small media to convey this information. The investigators will operationalize the Multi-level Health Outcomes Framework (MHOF) constructs such as knowledge, susceptibility, severity, norms, and self-efficacy in the small media, and document health literacy using the Suitability Assessment of Materials and Comprehensibility of Materials (SAM+CAM) instrument.\n\nResearch Design: Qualitative design, using focus group methodology\nStudy Population: Zuni men age 50-75 years and Zuni women age 21-75 years\nRecruitment Target: about 30-36 eligible persons (assuming attrition)\nRecruitment Methods: Purposive sampling methods\nProcedures: Conduct three focus groups, with each group consisting of 6 to 8 participants. Each session will meet for approximately two hours. Before starting the discussion, participants will provide informed consent and complete a survey collecting socio-demographic information. The purpose of these focus groups is to finalize the intervention\'s educational materials, ensuring they are culturally appropriate and contain messages operationalizing various constructs of the theory guiding the study (MHOF).\nData Analysis: Each team member will read the transcripts independently and create individual summaries in accordance with each domain area. The investigators will then meet as a group to review the summaries and through a process of comparing/contrasting observations, the investigators will distill the input into a series of recommendations from which the investigators will modify the 3 brochures. Following the creation of subsequent versions of the brochures, the investigators will then send them to participants from the 3 groups for further review and comments.\nSample Size Considerations: While the number of focus groups cannot be precisely determined prior to data collection, based on prior experience, 3 groups should be sufficient to capture the full range of salient themes.\n\nC. Aim 3: Pilot Test the Multilevel/Multicomponent Intervention C1. Quantitative Research (Pilot Test Effectiveness of the Intervention [INT])\n\nResearch Design: Cluster randomized stepped-wedge\nResearch Setting: Zuni Pueblo\nClusters and Randomization: The investigators will form 4 cluster categories stratified by gender and age. In all, the investigators will form 12 clusters, each comprising 10 participants. The cluster categories, number of clusters per category, and cancer-specific INTs that the clusters will receive are as follows. (1) 5 clusters of men aged 50-75 (for colorectal cancer INT). (2) 3 clusters of women aged 50-75 (for breast, colorectal, and cervical cancer INTs). (3) 2 clusters of women aged 50-75 (for breast and colorectal cancer INTs). (4) 2 clusters of women aged 21-49 (for cervical cancer INT). The investigators will randomize each cluster and offer the cluster category specific cancer INT(s).\nParticipant Identification and Sampling: The investigators will use a combination of community meetings, posters, health fairs, and announcements on Zuni Radio to inform the Pueblo residents of the study. The investigators will maintain a list by contact information, gender, and age of those who are willing to participate in the study. The investigators will select all members of a household eligible for any of the 3 cancer-specific INTs.\nInterventions: Educational and behavioral interventions on cancers of the breast, colorectal, and cervix (breast cancer screening intervention; colorectal cancer screening intervention; and cervical cancer screening intervention).\nProcedures: The investigators will contact (in-person) interested participants just prior to their cluster being randomized to the INT condition and provide them with a recruitment packet. The packet will contain materials describing the study, PI contact information, description of the overall benefits and risks of participation, consent letter for the surveys, and date for the first study activity (i.e., baseline survey and first INT session). The packet will also contain a card with a unique identifier that links the participants to the surveys and INT. The card will also contain a scheduling calendar to inform participants about the date and time for the next project activity (survey, INT session, focus group). Zuni students and CHRs will administer the surveys. The investigators will conduct 3 waves of outcomes evaluation surveys: baseline, posttest #1, and posttest #2. The investigators will administer all surveys in-person and each will last approximately 20 minutes. Prior to each project activity, the investigators will contact (phone or in-person) participants informing them of the date, time and place of the upcoming activity. During each project activity, the investigators will confirm/update the participants\' contact information. Between posttest #1, and posttest #2, the investigators will remind (phone or in-person; at 3-monthly intervals), if necessary, participants to complete their screening exam.\nImplementation of the Intervention [INT]: The TAP will finalize the INT strategies (Aim 2). The overall INT will be bounded by contextual realities (rurality of the Zuni Pueblo, resources at the health center, budget for the project). With this context in mind, the investigators could operationalize The Community Guide\'s recommended strategies that the TAP may plausibly identify as follows: To increase community access, the investigators could: (a) Identify a point-person (i.e., Public Health Nurse) at the health center who will triage participants to and schedule them for appropriate screening(s). (b) Remind (phone or in-person) participants (between posttest #1, and posttest #2) to complete their screening exam(s), offer assistance in scheduling a screening appointment and a ride to the health center. These strategies would reduce administrative barriers, navigate participants, and assist with transportation and in scheduling an appointment. To increase community demand, the investigators could consider: (a) Small media. (b) 1-on-1 education (supplemented by the small media) by the project\'s CHRs. (c) Reminders between posttest #1, and posttest #2. (d) Cognitive-behavioral group education and incentives. To increase provider delivery, the investigators could: (a) Reduce health center-specific systemic barriers by identifying a point-person to promote and facilitate screening services.\nBaseline and Posttest Surveys: The investigators will collect data on demographics, knowledge, attitudes, perceived control, perceived susceptibility and severity, social support, self-efficacy, and patient activation. At posttest #1, and posttest #2, the investigators will inquire with whom and with how many persons they discussed the intervention.\nPrimary Outcome: Uptake of any combination of FOBT/FIT, Pap smear, or mammogram screening.\nSecondary Outcome: Temporal changes on MHOF constructs and their predictive value on screening; feasibility and acceptability (described below); cost-effectiveness (described below); and promoters/barriers to screening (described below).\nData Management and Analysis:\n\ni. Primary outcome: Completion of cancer screening. The investigators will compare the number of cancer screening approaches undertaken by study participants, offset by the number of possible screening tests, using Poisson regression approaches between those who are and are not receiving active intervention. This will enable the estimation and comparison of screening uptake between treatment arms, even when there are different numbers of possible screening tests for groups of participants. The investigators will account for within-cluster correlations using generalized estimating equations, and the investigators will explore the impact on screening uptake of patient characteristics (e.g. sex) using fixed effects.\n\nii. Secondary outcomes. I. Feasibility/acceptability: The investigators will summarize the various measures feasibility with descriptive statistics. The investigators will use count and percentages for most measures, but for others, such as measures of study promotion, the investigators will summarize the efforts undertaken using means and standard deviations, or medians and interquartile ranges, as appropriate for the data type.\n\nII. Promoters/barriers to screening: Analysis discussed under implementation of qualitative data collection (Aim 3).\n\nIII. Positive changes in MHOF constructs: The investigators will also compare changes in MHOF constructs (knowledge, attitudes, beliefs), perceived control, self-efficacy, and patient activation, using linear mixed effects approaches that simultaneously account for within-person and within-cluster correlations.\n\nIV. Cost-effectiveness (CE) analysis: The investigators will utilize a Markov decision analytical model to simulate the progression of our cohorts (across the 3 cancers: breast, colorectal, and cervical) through predefined states: normal, local, regional, disseminated, and death. The likelihood of progressing through states (or remaining within states) will be derived from the literature. All 3 cancer-specific INTs will be compared to a no-screen pathway. The difference between each INT-based pathway and its respective no-screen pathway is a function of the change in the probability of detection across each state of cancer progression. The analysis compares the costs and outcomes over a predetermined timeframe (likely to be longer (20+ years) for breast and cervical and shorter for colorectal (10-20 years)). Costs and benefits will be discounted. Our main CE outcome measures will be years of life saved (YLS), lifetime costs, and incremental cost-effectiveness ratios (cost per YLS). Additional CE outcome measures will include: the number of new cases and deaths from cancer, the number of new screenings, and potential deaths from new screenings (colonoscopy).\n\nl. Sample Size Considerations: The investigators will enroll 10 participants into 12 different clusters, for a total of 120 participants. With this number of participants, and assuming that those not in the active intervention group have historical screening uptake levels (a weighted average of roughly 50%), then the study will have at least 80% power to detect a relative increase in screening uptake of 20%, using a two-sided type I error level of 5%, as long as the intra-cluster correlation is no larger than 0.62. As this degree of intra-cluster correlation is very large, the study is well positioned to detect meaningful intervention effects on screening uptake.\n\nC2. Qualitative Research (Understand Behavior Change Context)\n\nResearch Design: Qualitative design, using focus group methodology\nStudy Population: Zuni men age 50-75 years and Zuni women age 21-75 years. Those who completed at least 1 screening exam and those who did not complete any exam (Section C2).\nRecruitment Target: about 30-36 eligible persons (assuming attrition)\nRecruitment Methods: Purposive sampling methods\nProcedures: Conduct three focus groups, with each group consisting of 6 to 8 participants. Each session will meet for approximately two hours. Before starting the discussion, participants will provide informed consent and complete a survey collecting socio-demographic information. The purpose of these focus groups is to finalize the intervention\'s educational materials, ensuring they are culturally appropriate and contain messages operationalizing various constructs of the theory guiding the study (MHOF).\nData Analysis: Each team member will read the transcripts independently and create individual summaries in accordance with each domain area. The investigators will then meet as a group to review the summaries and through a process of comparing/contrasting observations, the investigators will distill the input into a series of recommendations from which the investigators will modify the 3 brochures. Following the creation of subsequent versions of the brochures, the investigators will then send them to participants from the 3 groups for further review and comments.\nSample Size Considerations: While the number of focus groups cannot be precisely determined prior to data collection, based on prior experience, 3 groups should be sufficient to capture the full range of salient themes.\n\nC3. Assessment of Feasibility and Acceptability C3a. Procedure: The investigators will analyze project records to quantify each feasibility measure. (1) Accrual (completion of targeted enrollment): Number of eligible participants enrolled. (2) Attrition rate (<20%): Numerator=Number of enrollees who completed the baseline survey but subsequently dropped-out of the study at various intervals (i.e., before, during, or after completing INT, or before either of posttest #1, and posttest #2assessments). Denominator=Total number of enrollees. (3) Study promotion: Number of flyers distributed, nature and number of inquiries received, and sources of such inquiries. (4) Fidelity of INT implementation (per protocol): The investigators will define the implementation protocols to document fidelity after the TAP finalizes the overall INT.\n\nC4. Cost-Effectiveness Analysis C4a. Procedure: The investigators will collect and use primary and secondary data to define parameters for the Markov models of cost-effectiveness (CE). Primary data used for determining the CE of the intervention will include: compliance improvements, costs related to the intervention (at both the patient (indirect) and provider (direct) levels), age- and gender-stratified participation rates, and cancer detection rates of the study population. Secondary data used for determining the CE of the intervention will include: NM-specific cancer incidence, staging, and mortality rates, and direct medical costs related to both the screening (primary costs) and treatment/management (secondary costs) of screen-positive participants. Our data will allow estimates of screening uptake, cancer incidence, cancer staging, treatment costs, and cancer mortality across the 3 cancer screening interventions. The investigators will collect data on all direct medical costs associated with the INT and follow-up, and indirect medical and non-medical costs (e.g., work loss, travel, etc.) when possible. The investigators will assess direct medical costs through the IHS Resource and Patient Management System (RPMS), which contains patient encounter-level data by outpatient International Classification of Disease (ICD)-10 diagnoses and procedure codes. The investigators will collect cancer diagnostic, treatment and inpatient data through hospital discharge abstracts included in IHS contract billing. The investigators will use a micro-costing approach to assess the cost of resources used or median cost of encounter based on a resource-based relative value unit (RBRVU) system. The RBRVU is Medicare\'s reimbursement rate for outpatient visits based on the procedure codes recorded for the encounter and is used to estimate the healthcare system cost of procedures performed. Our main outcome measures will be years of life saved (YLS), lifetime costs, and incremental cost-effectiveness ratios (cost per YLS). Secondary outcome measures will include: the number of new cases and deaths from cancer, the number of screenings, and potential deaths from screenings (colonoscopy).\n\nD. Aim 4-Dissemination D1. Procedure: The investigators will disseminate findings tailored to targeted non-scientific and scientific audiences. The investigators present preliminary results on an annual basis to the Zuni Tribal leadership. The investigators will also present findings to the Tribal Advisory Panel, general community, health center providers, and the IHS health board. The TAP will assist in these dissemination efforts. After approval from the tribal leadership, the investigators will publish the study findings.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer, Breast', 'Cancer, Colon', 'Cancer, Cervix']}, 'KeywordList': {'Keyword': ['breast neoplasm', 'colorectal neoplasm', 'cervical neoplasm', 'screening', 'behavioral interventions', 'American Indians', 'cost-effectiveness analysis', 'cluster randomization', 'community-based participatory research']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Crossover Assignment', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '200', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast, Colorectal, and Cervical Cancer Screening', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The investigators will train Community Health Representatives (CHRs) in interactive group discussions techniques. CHRs will administer 1 session/week, lasting approximately 2 hours, and conducted among 12 men or women ages 21-75 per cluster. The CHRs will distribute the cancer-specific (i.e., breast, colorectal, and cervical) small media during the first session and refer to it during the course of the 4 sessions. During the sessions, the CHRs will function as a facilitator linking information with practical skills. At the end of the 4-week INT, participants will receive a voucher to present to a designated point-person at the health center who would schedule the screening for the age- and gender-specific cancers.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Breast, Colorectal, and Cervical Cancer Screening Interventions']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Historical control'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Breast, Colorectal, and Cervical Cancer Screening Interventions', 'InterventionDescription': 'Adult men and women will receive age- and gender-specific interventions. Women age 50-75 years will receive the interventions for breast, colorectal, and cervical cancers screening. Men age 50-75 years will receive the intervention for colorectal cancer screening. Women age 21-49 years will receive the intervention for cervical cancer screening. The 4-week interventions, delivered once a week, will consist of educational sessions that discuss cancer-specific information (i.e., breast, colorectal, and cervical cancer): breast (colorectal, cervical) cancer myths and facts, risk factors and symptoms, screening, and review/action plan. The educational sessions will be complemented by cancer-specific small media (brochure).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Breast, Colorectal, and Cervical Cancer Screening']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Completion of a Mammogram exam to screen for breast cancer', 'PrimaryOutcomeDescription': 'Percentage of women 50-75 years who obtain a mammogram exam', 'PrimaryOutcomeTimeFrame': 'Within 6 months from end of the intervention'}, {'PrimaryOutcomeMeasure': 'Completion of a Fecal Immunochemical Test kit to screen for colorectal cancer', 'PrimaryOutcomeDescription': 'Percentage of men and women 50-75 years who complete a fecal immunochemical test kit', 'PrimaryOutcomeTimeFrame': 'Within 6 months from end of the intervention'}, {'PrimaryOutcomeMeasure': 'Completion of a Pap Smear test to screen for cervical cancer', 'PrimaryOutcomeDescription': 'Percentage of women 21-64 years who complete a Pap Smear test', 'PrimaryOutcomeTimeFrame': 'Within 6 months from end of the intervention'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Knowledge measured using the Health Behavior Survey', 'SecondaryOutcomeDescription': 'Change in Knowledge', 'SecondaryOutcomeTimeFrame': 'Baseline (Day 0), Posttest 1 (1 month post-baseline), Posttest 2 (12 months post-baseline)'}, {'SecondaryOutcomeMeasure': 'Change in Attitudes measured using the Health Behavior Survey', 'SecondaryOutcomeDescription': 'Change in Attitudes', 'SecondaryOutcomeTimeFrame': 'Baseline (Day 0), Posttest 1 (1 month post-baseline), Posttest 2 (12 months post-baseline)'}, {'SecondaryOutcomeMeasure': 'Change in Perceived Control measured using the Health Behavior Survey', 'SecondaryOutcomeDescription': 'Change in Perceived Control', 'SecondaryOutcomeTimeFrame': 'Baseline (Day 0), Posttest 1 (1 month post-baseline), Posttest 2 (12 months post-baseline)'}, {'SecondaryOutcomeMeasure': 'Change in Perceived Susceptibility measured using the Health Behavior Survey', 'SecondaryOutcomeDescription': 'Change in Perceived Susceptibility', 'SecondaryOutcomeTimeFrame': 'Baseline (Day 0), Posttest 1 (1 month post-baseline), Posttest 2 (12 months post-baseline)'}, {'SecondaryOutcomeMeasure': 'Change in Perceived Severity measured using the Health Behavior Survey', 'SecondaryOutcomeDescription': 'Change in Perceived Severity', 'SecondaryOutcomeTimeFrame': 'Baseline (Day 0), Posttest 1 (1 month post-baseline), Posttest 2 (12 months post-baseline)'}, {'SecondaryOutcomeMeasure': 'Change in Self-Efficacy measured using the Health Behavior Survey', 'SecondaryOutcomeDescription': 'Change in Self-Efficacy', 'SecondaryOutcomeTimeFrame': 'Baseline (Day 0), Posttest 1 (1 month post-baseline), Posttest 2 (12 months post-baseline)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria: Breast Cancer Screening Intervention\n\nWomen age 50-75\nAverage risk for breast cancer\nNever had a mammogram OR not had a mammogram within the past 2 years\nResiding in the Zuni Pueblo\n\nExclusion Criteria: Breast Cancer Screening Intervention. Meeting at least one of the following criteria:\n\nWomen with breast implants, pregnant, or breast feeding\nHistory of breast cancer\nHave new breast complaints such as lump or nipple discharge\n\nInclusion Criteria: Colorectal Cancer Screening Intervention\n\nMen and women aged 50-75\nAverage risk for colorectal cancer\nNever had a fecal occult blood test (FOBT), or fecal immunochemical test (FIT) or a colonoscopy OR not had a FOBT or FIT in the past year, OR no colonoscopy in the past 10 years\nResiding in the Zuni Pueblo\n\nExclusion Criteria: Colorectal Cancer Screening Intervention. Meeting at least one of the following criteria:\n\nHistory of colorectal cancer, total colectomy, adenomatous polyps, or inflammatory bowel disease\nUp-to-date with colorectal cancer screening\nSevere comorbidity\nIncarceration\nFamily history of colorectal cancer\nHospice/terminal care status\n\nInclusion Criteria: Cervical Cancer Screening Intervention\n\nWomen aged 21-65\nNever had a cytology (Pap smear) OR had a Pap smear more than 3 years ago OR women aged 30-75, and never had screening with a combination of cytology and human papillomavirus testing OR no combination of testing in the past 5 years\nResiding in the Zuni Pueblo\n\nExclusion Criteria: Cervical Cancer Screening Intervention. Meeting at least one of the following criteria:\n\nHistory of total hysterectomy\nHigh risk for cervical cancer due to suppressed immune system (e.g., HIV infection, organ transplant, long-term steroid use)\nWomen over age 65 who have had regular screenings with normal results', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '21 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Shiraz I Mishra, MBBS, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '505-925-6085', 'CentralContactEMail': 'smishra@salud.unm.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Shiraz I Mishra, MBBS, PhD', 'OverallOfficialAffiliation': 'University of New Mexico School of Medicine', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of New Mexico - Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Albuquerque', 'LocationState': 'New Mexico', 'LocationZip': '87106', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ellen Wojcik, MBA-HCM', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'ewojcik@salud.unm.edu'}, {'LocationContactName': 'Shiraz Mishra, MBBS, PhD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}, {'ConditionMeshId': 'D000003110', 'ConditionMeshTerm': 'Colonic Neoplasms'}, {'ConditionMeshId': 'D000002583', 'ConditionMeshTerm': 'Uterine Cervical Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}, {'ConditionAncestorId': 'D000015179', 'ConditionAncestorTerm': 'Colorectal Neoplasms'}, {'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000014594', 'ConditionAncestorTerm': 'Uterine Neoplasms'}, {'ConditionAncestorId': 'D000005833', 'ConditionAncestorTerm': 'Genital Neoplasms, Female'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000002577', 'ConditionAncestorTerm': 'Uterine Cervical Diseases'}, {'ConditionAncestorId': 'D000014591', 'ConditionAncestorTerm': 'Uterine Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Cancer, Breast', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4982', 'ConditionBrowseLeafName': 'Uterine Cervical Neoplasms', 'ConditionBrowseLeafAsFound': 'Cancer, Cervix', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5490', 'ConditionBrowseLeafName': 'Colonic Neoplasms', 'ConditionBrowseLeafAsFound': 'Cancer, Colon', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16494', 'ConditionBrowseLeafName': 'Uterine Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8097', 'ConditionBrowseLeafName': 'Genital Neoplasms, Female', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4977', 'ConditionBrowseLeafName': 'Uterine Cervical Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16491', 'ConditionBrowseLeafName': 'Uterine Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}}}}, {'Rank': 93, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03853278', 'OrgStudyIdInfo': {'OrgStudyId': '107-2314-B-227-001-MY2'}, 'Organization': {'OrgFullName': 'National Taipei University of Nursing and Health Sciences', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Self-management Support for Colorectal Cancer Survivors Colorectal Cancer Survivors: A Mixed-methods Study', 'OfficialTitle': 'Developing and Testing a Self-management Support Intervention in Colorectal Cancer Survivors: A Mixed-methods Study'}, 'StatusModule': {'StatusVerifiedDate': 'August 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 15, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 31, 2021', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'August 31, 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 20, 2019', 'StudyFirstSubmitQCDate': 'February 22, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 25, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 30, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 31, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Tsae Jyy, Wang', 'ResponsiblePartyInvestigatorTitle': 'RN PhD Professor', 'ResponsiblePartyInvestigatorAffiliation': 'National Taipei University of Nursing and Health Sciences'}, 'LeadSponsor': {'LeadSponsorName': 'National Taipei University of Nursing and Health Sciences', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Ministry of Science and Technology, Taiwan', 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': 'Mackay Memorial Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Cathay General Hospital', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': "Background: Survivors of colorectal cancer have to face long-term consequences of the disease and its treatment side effects, which in turn affect mood and psychological well-being. Self-management support may help colorectal cancer survivors to achieve healthy lifestyle and better adjustment.\n\nHowever, there is little research evidence to support it and also no theory-based self-management support interventions specifically designed for colorectal cancer survivors in Taiwan.\n\nAim: The study aims is to test the efficacy of the Acceptance and Commitment Therapy -based self-management support program on the primary outcome, quality of life, and secondary outcomes, physical activity, fruit and vegetative intake, body mass index, sleep quality, emotion distress, and fatigue in colorectal cancer survivors .\n\nDesign: An experimental design with repeated measures will be used to test the intervention efficacy. A convenient sample of 250 colorectal cancer (stage I-III) survivors who has completed initial treatments will be recruited and randomized to the control or intervention group. The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill trainings and 12 follow-up telephone calls. These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables. The control group will receive health education leaflets. Outcome variables will be assessed on the baseline, 2th, 4th, and 6th month in both groups. Descriptive analysis will be used to describe patients' demographics, disease variables, and outcome variables. The Chi-square, t-test, and General Linear Mix-effect Model will be used to test the efficacy of the study interventions.", 'DetailedDescription': "Background: Colorectal cancer is the second most commonly diagnosed cancer in Taiwan. The five year relative survival rate of colorectal cancer is 61% and has become the third largest cancer survivor group. Survivors of colorectal cancer have to face long-term consequences of the disease and its treatment side effects, which in turn affect mood and psychological well-being. Overweight and unhealthy lifestyles will further impact on patient's prognosis and quality of life. The current follow-up systems often fail to adequately address patients' complex physical and mental needs. Self-management support may help colorectal cancer survivors to achieve healthy lifestyle and better adjustment. However, there is little research evidence to support it and also no theory-based self-management support interventions specifically designed for colorectal cancer survivors in Taiwan.\n\nAim: The study aims is to test the efficacy of the Acceptance and Commitment Therapy -based self-management support program on the primary outcome, quality of life, and secondary outcomes, physical activity, fruit and vegetative intake, body mass index, sleep quality, emotion distress, and fatigue in colorectal cancer survivors .\n\nDesign: An experimental design with repeated measures will be used to test the intervention efficacy. A convenient sample of 250 colorectal cancer (stage I-III) survivors who has completed initial treatments will be recruited and randomized to the control or intervention group. The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill trainings and 12 follow-up telephone calls. These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables. The control group will receive health education leaflets. Outcome variables will be assessed on the baseline, 2th, 4th, and 6th month in both groups.\n\nInstruments: The study instruments include a body weight scale, Hospital Anxiety and Depression Scale, International Physical Activity Questionnaire, Eating at America's Table Study-Quick Food Scan, Pittsburgh Sleep Quality Index, FACIT-Fatigue, and FACT-C.\n\nData analysis: Descriptive analysis will be used to describe patients' demographics, disease variables, and outcome variables. The Chi-square, t-test, and General Linear Mix-effect Model will be used to test the efficacy of the study interventions.\n\nSignificance: The study results will provide evidence for the efficacy of the self-management support intervention for enhancing healthy life style and quality of life in colorectal cancer survivors."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Colorectal Neoplasms']}, 'KeywordList': {'Keyword': ['Colorectal Neoplasms', 'self-management support', 'cancer survivor', 'healthy life styles']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': "The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill training and 12 follow-up telephone calls. These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables. The control group will receive health education leaflets.", 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Quadruple', 'DesignMaskingDescription': 'The randomization procedure was handled by an independent research assistant. Participants, care providers, investigator and outcomes assessors are blind to the group assignment.', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider', 'Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '165', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'colorectal cancer self-management', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': "The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill trainings and 12 follow-up telephone calls.These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: colorectal cancer self-management']}}, {'ArmGroupLabel': 'No intervention control group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'The control group will receive health education leaflets.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'colorectal cancer self-management', 'InterventionDescription': "The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill training and 12 follow-up telephone calls. These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['colorectal cancer self-management']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Functional Assessment of Cancer Therapy- Colorectal', 'PrimaryOutcomeDescription': 'There are two subscales, 27 items of FACT-General and 9 items of Colorectal Cancer Subscale. Each item is rated on a 5-point Likert scale (0-4). The total score of the 36 items represents the score of the scale. The possible score for the scale ranges from 0 to 136. The higher values represent better quality of life.', 'PrimaryOutcomeTimeFrame': 'Change from Baseline to 6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'International Physical Activity Questionnaire', 'SecondaryOutcomeDescription': "The Taiwan Version of International Physical Activity Questionnaire is used to measure a patient's physical activity. The scale has 7 items, asking patients the time they spent on walking, moderate, and vigorous physical activities during the past 7 days. The amounts of time spent on walking, moderate and vigorous physical activities are then multiplied by 3.3, 4.0, and 8.0 MET, respectively. The sum of the METs-min/wk for three types physically actives is the total score of the scale.", 'SecondaryOutcomeTimeFrame': 'Change from Baseline to 6 months'}, {'SecondaryOutcomeMeasure': "Eating at America's Table Study-Quick Food Scan", 'SecondaryOutcomeDescription': "The scale measures a patient's intake of vegetables and fruits in the past month. There are 10 items in the scale, asking the amount and frequency of eating nine different types of vegetables and fruits. The frequency multiplied by the amount represents the total amount of vegetables and fruits consumed in the past month. The higher values indicate more vegetables and fruits patient consumed.", 'SecondaryOutcomeTimeFrame': 'Change from Baseline to 6 months'}, {'SecondaryOutcomeMeasure': 'Body weight scale', 'SecondaryOutcomeDescription': "The Body Mass Index (BMI) is calculated by the patient's body weight (kilograms) divided by height (meters) to the second power. Underweight is the BMI lower than18.5. Normal weight is the BMI higher or equal than18.5 and lower than 24. The overweight is the BMI higher or equal than 24 and lower than 27. The obese is the BMI higher or equal than 35.", 'SecondaryOutcomeTimeFrame': 'Change from Baseline to 6 months'}, {'SecondaryOutcomeMeasure': 'Pittsburgh Sleep Quality Index', 'SecondaryOutcomeDescription': 'There are 10 items in the scale. Each item is rated on a 4-point Likert scale (0-3). The 10 items consist 7 dimensions. The total score of seven dimensions represents the scale score. The possible score for the scale ranges from 0 to 21. The higher values represent worse sleep quality.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline to 6 months'}, {'SecondaryOutcomeMeasure': 'Hospital Anxiety and Depression Scale', 'SecondaryOutcomeDescription': 'There are two subscales, HADS Anxiety and HADS Depression. Each subscale has 7 items. The possible score for each subscale scale ranges from 0 to 21. The higher values represent more anxiety or depression.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline to 6 months'}, {'SecondaryOutcomeMeasure': 'The Functional Assessment of Chronic Illness Therapy-Fatigue', 'SecondaryOutcomeDescription': 'There are 13 items in the scale. Each item is rated on a 5-point Likert scale (0-4). The total score of the 13 items represents the score of the scale. The possible score for the scale ranges from 0 to 52. The higher values represent more fatigue.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline to 6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': "Inclusion Criteria:\n\nDiagnose with Colonrectal cancer (ICD-10 code: C18-C20, C21.8)\nStage I-III Colonrectal cancer\nOne month post curative cancer incision surgery for patients with cancer stage I-IIA\nOne month chemotherapy for patients with cancer stage IIB-III\nAged 20 and above\nWith the permission of the patient's doctor\nAble to understand and sign the study inform consent\n\nExclusion Criteria:\n\nThe Eastern Cooperative Oncology Group ,( ECOG) performance score greater or equal to 3.\nDiagnose with severe psychological diseases.\nLife expectancy less than 3 month.\nHad cancers before\nNot able to communicate verbally or with writing", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Tsae Jyy Wang, PhD', 'OverallOfficialAffiliation': 'National Taipei University of Nursing and Health Sciences', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Mackay Memorial Hospital', 'LocationCity': 'Taipei', 'LocationZip': '104', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'Cathay General Hospital', 'LocationCity': 'Taipei', 'LocationZip': '106', 'LocationCountry': 'Taiwan'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28280612', 'ReferenceType': 'background', 'ReferenceCitation': 'Aminisani N, Nikbakht H, Asghari Jafarabadi M, Shamshirgaran SM. Depression, anxiety, and health related quality of life among colorectal cancer survivors. J Gastrointest Oncol. 2017 Feb;8(1):81-88. doi: 10.21037/jgo.2017.01.12.'}, {'ReferencePMID': '28248415', 'ReferenceType': 'background', 'ReferenceCitation': 'Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017 May 6;67(3):177-193. doi: 10.3322/caac.21395. Epub 2017 Mar 1.'}, {'ReferencePMID': '29052663', 'ReferenceType': 'background', 'ReferenceCitation': 'Kim SH, Kim K, Mayer DK. Self-Management Intervention for Adult Cancer Survivors After Treatment: A Systematic Review and Meta-Analysis. Oncol Nurs Forum. 2017 Nov 1;44(6):719-728. doi: 10.1188/17.ONF.719-728.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000015179', 'ConditionMeshTerm': 'Colorectal Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000012002', 'ConditionAncestorTerm': 'Rectal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafAsFound': 'Colorectal Neoplasms', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13996', 'ConditionBrowseLeafName': 'Rectal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 94, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05297734', 'OrgStudyIdInfo': {'OrgStudyId': '63646'}, 'Organization': {'OrgFullName': 'Stanford University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer', 'OfficialTitle': 'Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'November 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 24, 2022', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 15, 2026', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'October 15, 2026', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 17, 2022', 'StudyFirstSubmitQCDate': 'March 17, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 28, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'November 3, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 4, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Manali Indravadan Patel', 'ResponsiblePartyInvestigatorTitle': 'Assistant Professor of Medicine', 'ResponsiblePartyInvestigatorAffiliation': 'Stanford University'}, 'LeadSponsor': {'LeadSponsorName': 'Stanford University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Patient-Centered Outcomes Research Institute', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.', 'DetailedDescription': 'PRIMARY OBJECTIVES:\n\nI. Greater intervention effects on health-related quality of life\n\nSECONDARY OBJECTIVES:\n\nI. Greater intervention effects on patient activation II. Greater satisfaction with care and decision-making III. Greater documentation of goals of care and symptoms IV. To lower acute care V. Greater palliative care and hospice\n\nOUTLINE: Sites are randomized to 1 of 2 arms.\n\nARM A: Patients receive educational materials to assist with advance care planning and symptom management through a technology-based supportive cancer care weekly during months 1-4 and every other week during months 5-12.\n\nARM B: Patients are paired with a lay health worker who will discuss the same educational materials from ARM A either in person or by telephone discussions weekly during months 1-4 and every other week during months 5-12.\n\nAll participants complete a baseline interview upon enrollment during the initial consent phone contact and then a survey at 3-, 6-and 12-months post enrollment.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['End of Life', 'Cancer']}, 'KeywordList': {'Keyword': ['Carcinoma', 'Lung Neoplasms', 'Carcinoma, Non-Small-Cell Lung', 'Melanoma', 'Pancreatic Neoplasms', 'Sarcoma', 'Ovarian Neoplasms', 'Carcinoma, Ovarian Epithelial', 'Stomach Neoplasms', 'Glioblastoma', 'Rectal Neoplasms', 'Colonic Neoplasms', 'Esophageal Neoplasms', 'Breast Neoplasms', 'Carcinoma, Renal Cell', 'Skin Neoplasms', 'Small Cell Lung Carcinoma', 'Osteosarcoma', 'Myelodysplastic Syndromes', 'Disease Progression', 'Neoplasms, Glandular and Epithelial', 'Neoplasms by Histologic Type', 'Neoplasms', 'Respiratory Tract Neoplasms', 'Thoracic Neoplasms', 'Neoplasms by Site', 'Lung Diseases', 'Respiratory Tract Diseases', 'Urogenital Neoplasms', 'Carcinoma, Bronchogenic']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Cluster Randomized Controlled Trial among 24 clinics', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '2996', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Technology-based supportive cancer care', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Patients receive educational materials to assist with advance care planning and symptom management through a technology-based supportive cancer care weekly during months 1-4 and every other week during months 5-12.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Receive technology-based supportive cancer care']}}, {'ArmGroupLabel': 'Redesigned team-based supportive cancer care', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients are paired with a health educator who will discuss the same educational materials from ARM A either in person or by telephone discussions weekly during months 1-4 and every other week during months 5-12.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Receive redesigned team-based supportive cancer care']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Receive technology-based supportive cancer care', 'InterventionDescription': 'All participants will receive an electronic health record message or email with standardized information provided regarding advance care planning and symptom management.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Technology-based supportive cancer care']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Technology-based SCC approach']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Receive redesigned team-based supportive cancer care', 'InterventionDescription': 'Lay Health Workers will meet with 1:1 with participants over 12 months to discuss advance care planning, surrogate decision-makers, advance directives and physician orders for life sustaining treatment.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Redesigned team-based supportive cancer care']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Patients Activated in Cancer care through Teams (PACT), Redesigned SCC team-based approach']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in health-related quality of life as assessed by the Functional Assessment of Cancer Therapy (FACT-G).', 'PrimaryOutcomeDescription': 'Each patient will receive a health-related quality of life survey (FACT-G) at baseline, 3 months, 6 months, and 12 months.', 'PrimaryOutcomeTimeFrame': 'Change in health-related quality of life from baseline to 3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in health-related quality of life as assessed by the Functional Assessment of Cancer Therapy (FACT-G).', 'SecondaryOutcomeDescription': 'Each patient will receive a health-related quality of life survey (FACT-G) at baseline, 3 months, 6 months, and 12 months.', 'SecondaryOutcomeTimeFrame': 'Change in health-related quality of life from baseline to 6, and 12 months'}, {'SecondaryOutcomeMeasure': 'Change in patient activation using the Patient Activation Measure (PAM-13).', 'SecondaryOutcomeDescription': 'Each patient will receive a validated patient activation survey (PAM-13) to assess their activation at baseline, 3 months, 6 months, and 12 months.', 'SecondaryOutcomeTimeFrame': 'Change in patient activation from baseline to 3, 6, and 12 months'}, {'SecondaryOutcomeMeasure': 'Change in satisfaction with care using the Consumer Assessment of Health Care (Providers and Systems (CAHPS) Cancer Care Survey Questions #39 and #42.', 'SecondaryOutcomeDescription': 'Each patient will receive a validated satisfaction with care survey at baseline, 3 months, 6 months, and 12 months.', 'SecondaryOutcomeTimeFrame': 'Change in satisfaction with care from baseline to 3, 6, and 12 months'}, {'SecondaryOutcomeMeasure': 'Change in satisfaction with decision using the Satisfaction with Decision Scale (SWD)', 'SecondaryOutcomeDescription': 'Each patient will receive a validated satisfaction with decision survey at baseline, 3 months, 6 months and 12 months.', 'SecondaryOutcomeTimeFrame': 'Change in satisfaction with decision from baseline to 3, 6, and 12 months'}, {'SecondaryOutcomeMeasure': 'Palliative Care Use (Self-reported and Chart Review)', 'SecondaryOutcomeDescription': 'Palliative care use will be self-reported by each patient or abstracted by electronic medical record at 3, 6 and 12 months after patient enrollment.', 'SecondaryOutcomeTimeFrame': '3, 6, and 12 months after patient enrollment'}, {'SecondaryOutcomeMeasure': 'Hospice Care Use (Self-reported and Chart Review)', 'SecondaryOutcomeDescription': 'Hospice care use will be self-reported by each patient or abstracted by electronic medical record at 3, 6, and 12 months after patient enrollment.', 'SecondaryOutcomeTimeFrame': '3, 6, and 12 months after patient enrollment'}, {'SecondaryOutcomeMeasure': 'Emergency Department Visits (Self-reported and Chart Review)', 'SecondaryOutcomeDescription': 'Emergency Department use will be self-reported by each patient or abstracted by electronic medical record at 3, 6, and 12 months after enrollment.', 'SecondaryOutcomeTimeFrame': '3, 6, and 12 months after patient enrollment'}, {'SecondaryOutcomeMeasure': 'Hospitalization Visits (Self-reported and Chart Review)', 'SecondaryOutcomeDescription': 'Hospital use for each patient will be self-reported by each patient or abstracted by electronic medical record at 3, 6, and 12 months after enrollment.', 'SecondaryOutcomeTimeFrame': '3, 6, and 12 months after patient enrollment'}, {'SecondaryOutcomeMeasure': 'Documentation of goals of care discussions (Chart Review)', 'SecondaryOutcomeDescription': 'Documentation of goals of care discussions will be abstracted by electronic medical record chart review for each patient at 3, 6, and 12 months after enrollment.', 'SecondaryOutcomeTimeFrame': '3, 6, and 12 months after patient enrollment'}, {'SecondaryOutcomeMeasure': 'Documentation of symptom discussions (Chart Review)', 'SecondaryOutcomeDescription': 'Documentation of symptom discussions will be abstracted by electronic medical record chart review for each patient at 3, 6, and 12 months after enrollment.', 'SecondaryOutcomeTimeFrame': '3, 6, and 12 months after patient enrollment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nNewly diagnosed patients with a solid tumor cancer diagnosis or hematologic malignancy\nPatients must have the ability to understand and willingness to provide consent\nParticipants must speak English or Spanish\n\nExclusion Criteria:\n\nInability to consent to the study\nPlans to change oncologist within 12 months\nEmployed by the practice site\nPatients who anticipate moving from the area within 12 months', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '21 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Manali I Patel, MD MPH MS', 'CentralContactRole': 'Contact', 'CentralContactPhone': '6507234000', 'CentralContactEMail': 'manalip@stanford.edu'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Alabama at Birmingham', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Birmingham', 'LocationState': 'Alabama', 'LocationZip': '35294', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Gabrielle Rocque, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'University of South Alabama', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Mobile', 'LocationState': 'Alabama', 'LocationZip': '36688', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jennifer Y Pierce, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Beckman Research Institute of City of Hope', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Duarte', 'LocationState': 'California', 'LocationZip': '91010', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Finly Zachariah, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '800-826-4673'}]}}, {'LocationFacility': 'VA Medical Center, Fresno', 'LocationStatus': 'Recruiting', 'LocationCity': 'Fresno', 'LocationState': 'California', 'LocationZip': '93703', 'LocationCountry': 'United States'}, {'LocationFacility': 'Santa Clara Valley Medical Center', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Fruitdale', 'LocationState': 'California', 'LocationZip': '95128', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Sangeeta Aggarwal, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'St Jude Heritage Medical Group', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Fullerton', 'LocationState': 'California', 'LocationZip': '92835', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'David Park, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Oncology Institute for Hope and Innovation', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90017', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Richy Agajanian, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Sacramento VA Medical Center - VA Northern California Health Care System', 'LocationStatus': 'Recruiting', 'LocationCity': 'Mather', 'LocationState': 'California', 'LocationZip': '95655', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pacific Cancer Care', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Monterey', 'LocationState': 'California', 'LocationZip': '93940', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zach Koontz, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'VA Palo Alto', 'LocationStatus': 'Recruiting', 'LocationCity': 'Palo Alto', 'LocationState': 'California', 'LocationZip': '94305', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Manali I Patel, MD MPH MS', 'LocationContactRole': 'Contact'}, {'LocationContactName': 'Manali I Patel, MD MPH MS', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Zuckerberg San Francisco General', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'San Francisco', 'LocationState': 'California', 'LocationZip': '94110', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Niharika Dixit, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Kaiser Foundation Research Institute', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'San Francisco', 'LocationState': 'California', 'LocationZip': '94115', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Raymond Liu, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'University of San Francisco', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'San Francisco', 'LocationState': 'California', 'LocationZip': '94117', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kim Rhoads, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'San Francisco VA Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'San Francisco', 'LocationState': 'California', 'LocationZip': '94121', 'LocationCountry': 'United States'}, {'LocationFacility': 'Spark M. Matsunaga VA Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Honolulu', 'LocationState': 'Hawaii', 'LocationZip': '96819', 'LocationCountry': 'United States'}, {'LocationFacility': 'North Las Vegas VA Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Las Vegas', 'LocationState': 'Nevada', 'LocationZip': '89086', 'LocationCountry': 'United States'}, {'LocationFacility': 'George E. Wahlen Department of Veterans Affairs Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Salt Lake City', 'LocationState': 'Utah', 'LocationZip': '84148', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003643', 'ConditionMeshTerm': 'Death'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4686', 'ConditionBrowseLeafName': 'Carcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15507', 'ConditionBrowseLeafName': 'Syndrome', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10320', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M19712', 'ConditionBrowseLeafName': 'Disease Progression', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14129', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10324', 'ConditionBrowseLeafName': 'Lung Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M27476', 'ConditionBrowseLeafName': 'Small Cell Lung Carcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4700', 'ConditionBrowseLeafName': 'Carcinoma, Renal Cell', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12126', 'ConditionBrowseLeafName': 'Ovarian Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M1704', 'ConditionBrowseLeafName': 'Carcinoma, Ovarian Epithelial', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12262', 'ConditionBrowseLeafName': 'Pancreatic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13998', 'ConditionBrowseLeafName': 'Rectal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7240', 'ConditionBrowseLeafName': 'Esophageal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8171', 'ConditionBrowseLeafName': 'Glioblastoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4698', 'ConditionBrowseLeafName': 'Carcinoma, Non-Small-Cell Lung', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10680', 'ConditionBrowseLeafName': 'Melanoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14479', 'ConditionBrowseLeafName': 'Sarcoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15216', 'ConditionBrowseLeafName': 'Stomach Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5490', 'ConditionBrowseLeafName': 'Colonic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14486', 'ConditionBrowseLeafName': 'Osteosarcoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11297', 'ConditionBrowseLeafName': 'Myelodysplastic Syndromes', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5997', 'ConditionBrowseLeafName': 'Death', 'ConditionBrowseLeafAsFound': 'End of Life', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14833', 'ConditionBrowseLeafName': 'Skin Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13316', 'ConditionBrowseLeafName': 'Preleukemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11472', 'ConditionBrowseLeafName': 'Neoplasms, Glandular and Epithelial', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16467', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11467', 'ConditionBrowseLeafName': 'Neoplasms by Histologic Type', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14131', 'ConditionBrowseLeafName': 'Respiratory Tract Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4692', 'ConditionBrowseLeafName': 'Carcinoma, Bronchogenic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15810', 'ConditionBrowseLeafName': 'Thoracic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T5271', 'ConditionBrowseLeafName': 'Small Cell Lung Cancer', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4352', 'ConditionBrowseLeafName': 'Ovarian Cancer', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4387', 'ConditionBrowseLeafName': 'Pancreatic Cancer', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T2141', 'ConditionBrowseLeafName': 'Esophageal Cancer', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T2518', 'ConditionBrowseLeafName': 'Glioblastoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T5284', 'ConditionBrowseLeafName': 'Soft Tissue Sarcoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T5486', 'ConditionBrowseLeafName': 'Stomach Cancer', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4340', 'ConditionBrowseLeafName': 'Osteosarcoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T3993', 'ConditionBrowseLeafName': 'Myelodysplastic Syndromes', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC15', 'ConditionBrowseBranchName': 'Blood and Lymph Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T120', 'InterventionBrowseLeafName': 'Cola', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 95, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03560817', 'OrgStudyIdInfo': {'OrgStudyId': '2017-1490'}, 'Organization': {'OrgFullName': 'Centre de recherche du Centre hospitalier universitaire de Sherbrooke', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Survey of Health Preferences in Cancer Patients (QALY-Cancer)', 'OfficialTitle': 'Survey of Health Preferences in Cancer Patients: a Study Protocol for a Prospective, Longitudinal Cohort Using Online Survey', 'Acronym': 'QALY-Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'August 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 4, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 28, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 28, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 27, 2018', 'StudyFirstSubmitQCDate': 'June 15, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 18, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 5, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 7, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Thomas G. Poder', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Centre de recherche du Centre hospitalier universitaire de Sherbrooke'}, 'LeadSponsor': {'LeadSponsorName': 'Centre de recherche du Centre hospitalier universitaire de Sherbrooke', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study will evaluate health utilities in patients with breast or colorectal cancer.', 'DetailedDescription': 'The cost-utility analysis (CUA) is an increasingly used method to help health decision-maker. The CUA uses the Quality Adjusted Life Years (QALY) that combines the length of life with the health related quality of life (HRQoL) into a single score.\n\nIn Quebec, no QALY calculation tool has been adapted to its linguistic and socio-cultural context, neither for its general population nor for a particular subpopulation, like patients with cancer.\n\nThe objectives will be to analyze the extent of the divergence in terms of health states utilities between the general population and patients with breast or colorectal cancer; to develop a QALY preference weights dataset for patients with cancer; to perform "mapping" with different health-related quality of life questionnaires by correlating SF6Dv2 with EQ-5D-5L, EORTC QLQ-C30 and FACT- G. The data will be collected with a self-administered online survey. Patients outcomes will be measured at the beginning of the chemotherapy treatment cycle and about 8 days after the start of chemotherapy. Health utilities will be measured with a hybrid method using the time-trade-off (TTO) and the discrete experimental choice (DCE) method using SF6Dv2 questionnaire for health states.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer', 'Colorectal Cancer']}, 'KeywordList': {'Keyword': ['QALY', 'Cost-utility analysis', 'Time-trade-off method', 'Discrete choice experiment method']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '198', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'breast cancer', 'ArmGroupDescription': 'No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.'}, {'ArmGroupLabel': 'colorectal cancer', 'ArmGroupDescription': 'No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Health utilities for SF-6Dv2 before chemotherapy', 'PrimaryOutcomeDescription': 'Health utilities measured by SF-6Dv2 health states using a hybrid method combining time-trade-off (TTO) and discrete choice experiment (DCE)', 'PrimaryOutcomeTimeFrame': 'Within two days before the start of a chemotherapy treatment cycle (standard treatment; each cycle is 21 days)'}, {'PrimaryOutcomeMeasure': 'Health utilities for SF-6Dv2 after the start of the chemotherapy', 'PrimaryOutcomeDescription': 'Health utilities measured by SF-6Dv2 health states using a hybrid method combining time-trade-off (TTO) and discrete choice experiment (DCE)', 'PrimaryOutcomeTimeFrame': '8 days after the start of the chemotherapy'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Health utilities with the EuroQol five-dimensional questionnaire with five response levels (EQ-5D-5L) before chemotherapy', 'SecondaryOutcomeDescription': 'The EQ-5D-5L included five health dimensions with five response levels of 1 to 5. A score is calculated using an already pre-established regression equation using time-trade-off method. The health utilities range from -0.148 for the worst EQ-5D-5L state to 0.949 for the best EQ-5D-5L state.', 'SecondaryOutcomeTimeFrame': 'Within two days before the start of a chemotherapy treatment cycle (standard treatment; each cycle is 21 days)'}, {'SecondaryOutcomeMeasure': 'Health related quality of life (HRQoL) scores from EORTC QLQ-C30 questionnaire before chemotherapy before chemotherapy', 'SecondaryOutcomeDescription': 'The EORTC QLQ-C30 questionnaire were developed by the European Organisation for Research and Treatment of Cancer (EORTC). Including 30items, evaluating five functions, nine symptoms, and the overall health status of patients with cancer. Scales will be calculated by averaging the items. Items and scales will be linearly transformed to a range of 0 to 100. A higher score indicate a better quality of life or higher symptoms.', 'SecondaryOutcomeTimeFrame': 'Within two days before the start of a chemotherapy treatment cycle (standard treatment; each cycle is 21 days)'}, {'SecondaryOutcomeMeasure': 'Health related quality of life (HRQoL) scores from the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaires before chemotherapy', 'SecondaryOutcomeDescription': 'The survey assesses the impacts of cancer therapy in four domains: physical, social/family, emotional, and functional. It include 27 questions, each of which is answered using a 5-point Likert scale ranging from 0 (Not at all) to 4 (Very much). Higher numbers indicate a better health state. The score will be calculated with the sum of items and score will be normalised on a scale from 0-100.', 'SecondaryOutcomeTimeFrame': 'Within two days before the start of a chemotherapy treatment cycle (standard treatment; each cycle is 21 days)'}, {'SecondaryOutcomeMeasure': 'Health utilities with the EuroQol five-dimensional questionnaire with five response levels (EQ-5D-5L) after chemotherapy', 'SecondaryOutcomeDescription': 'The EQ-5D-5L included five health dimensions with five response levels of 1 to 5. A score is calculated using an already pre-established regression equation using time-trade-off method. The health utilities range from -0.148 for the worst EQ-5D-5L state to 0.949 for the best EQ-5D-5L state.', 'SecondaryOutcomeTimeFrame': '8 days after the start of the chemotherapy'}, {'SecondaryOutcomeMeasure': 'Health related quality of life (HRQoL) scores from EORTC QLQ-C30 questionnaire before after chemotherapy', 'SecondaryOutcomeDescription': 'The EORTC QLQ-C30 questionnaire were developed by the European Organisation for Research and Treatment of Cancer (EORTC). Including 30items, evaluating five functions, nine symptoms, and the overall health status of patients with cancer. Scales will be calculated by averaging the items. Items and scales will be linearly transformed to a range of 0 to 100. A higher score indicate a better quality of life or higher symptoms.', 'SecondaryOutcomeTimeFrame': '8 days after the start of the chemotherapy'}, {'SecondaryOutcomeMeasure': 'Health related quality of life (HRQoL) scores from the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaires after chemotherapy', 'SecondaryOutcomeDescription': 'The survey assesses the impacts of cancer therapy in four domains: physical, social/family, emotional, and functional. It include 27 questions, each of which is answered using a 5-point Likert scale ranging from 0 (Not at all) to 4 (Very much). Higher numbers indicate a better health state. The score will be calculated with the sum of items and score will be normalised on a scale from 0-100.', 'SecondaryOutcomeTimeFrame': '8 days after the start of the chemotherapy'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nto be 18 years of age or older;\nto reside in Quebec;\nhave already had a chemotherapy treatment cycle;\nbe on the eve of a new round of chemotherapy treatment;\nhave breast or colorectal cancer\n\nExclusion Criteria:\n\nbeing over 80 years of age;\nnot be able to complete a computer questionnaire;\ncan not read or write in French;\nnot be able to sign a consent form;\nthe only treatment offered is surgery;\npresence of metastases to the brain;\npatient with delirium, psychosis or severe depression (i.e. chronic condition with treatment)', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'The target population consists of the Quebec population aged 18 and over who have breast cancer or colorectal cancer.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Thomas G Poder, PhD', 'OverallOfficialAffiliation': 'Centre de recherche du Centre hospitalier universitaire de Sherbrooke', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Centre de recherche du Centre hospitalier universitaire de Sherbrooke', 'LocationCity': 'Sherbrooke', 'LocationState': 'Quebec', 'LocationZip': 'J1H 5N4', 'LocationCountry': 'Canada'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000015179', 'ConditionMeshTerm': 'Colorectal Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000012002', 'ConditionAncestorTerm': 'Rectal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17042', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafAsFound': 'Colorectal Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9600', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8038', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6408', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8035', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6407', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5488', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9596', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13996', 'ConditionBrowseLeafName': 'Rectal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}]}}}}}, {'Rank': 96, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00586937', 'OrgStudyIdInfo': {'OrgStudyId': '05-057'}, 'Organization': {'OrgFullName': 'Memorial Sloan Kettering Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Quality of Life in Lung Cancer Survivors', 'OfficialTitle': 'Quality of Life in Lung Cancer Survivors'}, 'StatusModule': {'StatusVerifiedDate': 'January 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2005', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'January 2, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'December 21, 2007', 'StudyFirstSubmitQCDate': 'December 21, 2007', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 7, 2008', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 3, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 6, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Memorial Sloan Kettering Cancer Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Fox Chase Cancer Center', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': "The purpose of this study is to find out about the quality of life of individuals who have been diagnosed and treated for lung cancer (lung cancer survivors). By quality of life, we mean how you are feeling about different aspects of your life, including your physical health, your emotional health, and your ability to carry out daily activities. We are interested in people's opinions about their quality of life, as well as the factors that affect their quality of life. Learning about quality of life will help us to develop new services for lung cancer survivors."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Lung Cancer Survivors']}, 'KeywordList': {'Keyword': ['Lung Cancer Survivors']}}, 'DesignModule': {'StudyType': 'Observational', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '193', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '1', 'ArmGroupDescription': 'Lung Cancer Survivors', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: questionnaires or telephone interview']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'questionnaires or telephone interview', 'InterventionDescription': 'In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'To describe the health-related quality of life (HQOL) of lung cancer survivors and compare their HQOL with age- and gender-appropriate, population-based normative data.', 'PrimaryOutcomeTimeFrame': '2 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'To describe and identify covariates of HQOL in lung cancer survivors.', 'SecondaryOutcomeTimeFrame': '2 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nDiagnosis of primary Stage IA or IB NSCLC;\nUnderwent surgical resection for NSCLC at MSKCC;\nFrom 1 to 5 years and 11 months post-treatment for NSCLC prior to study recruitment;\nNo evidence of disease (NED) at the time of recruitment;\nCan be reached by telephone;\nAble to provide informed consent.\n\nExclusion Criteria:\n\nUndergoing active antineoplastic treatment;\nMajor psychopathology or cognitive impairment likely in the judgment of the investigator to interfere with participation and compliance with the protocol.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'Thoracic Surgery Database', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jamie Ostroff, PhD', 'OverallOfficialAffiliation': 'Memorial Sloan Kettering Cancer Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Memorial Sloan Kettering Cancer Center', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10065', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Memorial Sloan Kettering Cancer Center', 'SeeAlsoLinkURL': 'http://www.mskcc.org'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000008175', 'ConditionMeshTerm': 'Lung Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000012142', 'ConditionAncestorTerm': 'Respiratory Tract Neoplasms'}, {'ConditionAncestorId': 'D000013899', 'ConditionAncestorTerm': 'Thoracic Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10324', 'ConditionBrowseLeafName': 'Lung Neoplasms', 'ConditionBrowseLeafAsFound': 'Lung Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14131', 'ConditionBrowseLeafName': 'Respiratory Tract Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15810', 'ConditionBrowseLeafName': 'Thoracic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10320', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14129', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T6034', 'ConditionBrowseLeafName': 'Quality of Life', 'ConditionBrowseLeafAsFound': 'Quality of Life', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 97, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04167605', 'OrgStudyIdInfo': {'OrgStudyId': 'BC-BOMET'}, 'Organization': {'OrgFullName': 'Istituto Ortopedico Galeazzi', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases', 'OfficialTitle': 'Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases', 'Acronym': 'BC-BOMET'}, 'StatusModule': {'StatusVerifiedDate': 'July 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 13, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 12, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'November 12, 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 15, 2019', 'StudyFirstSubmitQCDate': 'November 15, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 19, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 11, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 12, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Istituto Ortopedico Galeazzi', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Bone metastases represent a frequent complication of some solid tumours, particularly prostate, breast and lung carcinomas. Bone metastases can cause pain and give rise to the so-called "Skeletal-related Events" (SRE) such as pathological fractures and nerve compression. Despite advances in cancer treatment in general, treatment options for bone metastases remain inadequate and generally palliative. It is therefore necessary to identify patients at "high risk" of developing metastases at an early stage of neoplastic disease in order to counteract it. Therefore, the identification of changes in the expression of proteins that could be variously involved in the progression of breast cancer is of primary importance since they could act as prognostic factors and therefore address the therapeutic strategy. The aim of the investigators is to clarify the role of de-regulation of post-translational events (such as SUMOylation) in the progression of breast cancer.', 'DetailedDescription': 'The most serious aspect of neoplastic disease is the spread of cancer cells to secondary sites, often distant from the primary site of growth. Bone is a breeding ground for many types of cancer, especially those derived from breast, prostate and lung. Despite the enormous progress in diagnosis and therapeutic strategies, bone metastases still have a profound impact on quality of life and survival, being often responsible for the outcome of the disease. To improve the outcome of patients with poor prognosis, a deep knowledge of the mechanisms underlying dissemination, colonization and progression of cancer cells in the bone is necessary.\n\nThe investigators therefore intend to clarify some pathogenic mechanisms involved in the growth of bone metastases, and to uncover predictive signs that underlie the spread of breast cancer cells to bone.\n\nPrimary aim of the investigators is to deepen the role of the de-regulation of post-translational events, such as Small Ubiquitin-like Modifier- (SUMO) SUMO-ylation in the progression of breast cancer. The expression of SENP1 (a member of the SUMO-specific protease family) in bone metastatic and non-metastatic mammary carcinomas will be evaluated. The evaluation of the expression of SENP1 in bone metastases will be finalised to define a possible use as a therapeutic target. SENP1 could be a potential prognostic indicator of the neoplastic progression of breast cancer and a potential therapeutic target, but data on its participation in the process of metastasis to bone are still scarce. Moreover, the investigators try to deepen the knowledge of the interaction between tumour cells and bone microenvironment and the role of immunosurveillance as an important part of the immune response against to neoplastic cells. Finally, the investigators will analyze the role of autophagy and apoptosis in the dissemination and growth of metastases due to the capacity of autophagy to provide energy, nutrients and resistance to anoikis, and to promote the dissemination of cancer cells and metastatic growth.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer Metastatic', 'Bone Metastases']}, 'KeywordList': {'Keyword': ['Breast cancer', 'Bone metastases', 'SENP1']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'Biological waste material derived from patients undergoing excisional surgery and bone consolidation due to osteolytic bone metastases from breast cancer.'}, 'EnrollmentInfo': {'EnrollmentCount': '30', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Breast cancer metastatic to bone', 'ArmGroupDescription': 'No direct intervention(s) will be administer to the patients. We will use the sample (slides) recovered from the surgery on primary tumor (breast cancer responsible for metastatic disease).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Breast cancer metastatic to bone']}}, {'ArmGroupLabel': 'Bone metastasis', 'ArmGroupDescription': 'No direct intervention(s) will be administer to the patients. Waste material will be analysed for the expression of specific proteins', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Bone metastasis']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Bone metastasis', 'InterventionDescription': 'Collection of waste tissue samples during surgery and immediate immersion of the same in 10% Neutral buffered formalin. The samples will be send to the laboratory where they will be processed (decalcification, inclusion in paraffin, sectioning etc.) for subsequent analyzes.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Bone metastasis']}}, {'InterventionType': 'Other', 'InterventionName': 'Breast cancer metastatic to bone', 'InterventionDescription': 'Patients will be assisted in the recovery of samples (slides) related to surgery on primary tumor (breast cancer responsible for metastatic disease).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Breast cancer metastatic to bone']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'SENP1 expression', 'PrimaryOutcomeDescription': 'The expression of SENP1 in bone metastatic mammary carcinomas will be studied. The evaluation of the expression of SENP1 in bone metastases will be finalized to define a possible use as a therapeutic target. The expression of SENP1 in bone metastatic breast carcinoma samples will be compared with the expression of SENP1 in non-metastatic breast cancer (commercial source).', 'PrimaryOutcomeTimeFrame': '6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Identification of new predictive molecular markers of breast cancer progression towards an aggressive metastatic state.', 'SecondaryOutcomeDescription': 'Analysis of the expression of proteins involved in the interaction between tumour cells and bone microenvironment, in the immunosurveillance and in the autophagic process in sample of mammary carcinomas that gave rise to bone metastases and in sample of breast cancer without history of bone metastasis.', 'SecondaryOutcomeTimeFrame': '18 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nAdult women (≥ 18 years) candidates for excisional surgery and bone consolidation due to osteolytic bone metastases from breast cancer.\nFemale\nAbility to understand the experimental study and willingness to sign the written consent\n\nExclusion Criteria:\n\n- Retraction of written consent', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'GenderBased': 'Yes', 'GenderDescription': 'Women', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'The population consists of 30 subjects who underwent surgery for bone metastases from breast cancer disease. Within the waste material collected during surgery intervention, it is expected to have 24 samples with an adequate content of metastatic tissue. For 12 of these patients it will be possible to retrieve the sample of the primary breast cancer, and then insert it into the study design. The control group will consist of 12 breast cancer samples that have not shown metastatic development after long follow up and will instead be found in commerce.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Paola Maroni, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+39 026621', 'CentralContactPhoneExt': '4759', 'CentralContactEMail': 'paola.maroni@grupposandonato.it'}, {'CentralContactName': 'Elena Cittera, MSc', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+39 026621', 'CentralContactPhoneExt': '4057', 'CentralContactEMail': 'elena.cittera@grupposandonato.it'}]}, 'LocationList': {'Location': [{'LocationFacility': 'IRCCS Istituto Ortopedico Galeazzi', 'LocationStatus': 'Recruiting', 'LocationCity': 'Milan', 'LocationZip': '20161', 'LocationCountry': 'Italy', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Paola Maroni, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+39 026621', 'LocationContactPhoneExt': '4759', 'LocationContactEMail': 'paola.maroni@grupposandonato.it'}, {'LocationContactName': 'Elena Cittera, MSc', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+39 026621', 'LocationContactPhoneExt': '4057', 'LocationContactEMail': 'elena.cittera@grupposandonato.it'}, {'LocationContactName': 'Paola Maroni, PhD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '30918918', 'ReferenceType': 'background', 'ReferenceCitation': 'Sowder ME, Johnson RW. Bone as a Preferential Site for Metastasis. JBMR Plus. 2019 Jan 15;3(3):e10126. doi: 10.1002/jbm4.10126. eCollection 2019 Mar.'}, {'ReferencePMID': '19008217', 'ReferenceType': 'background', 'ReferenceCitation': "Yeh ET. SUMOylation and De-SUMOylation: wrestling with life's processes. J Biol Chem. 2009 Mar 27;284(13):8223-7. doi: 10.1074/jbc.R800050200. Epub 2008 Nov 13."}, {'ReferencePMID': '27573572', 'ReferenceType': 'background', 'ReferenceCitation': 'Wang Z, Jin J, Zhang J, Wang L, Cao J. Depletion of SENP1 suppresses the proliferation and invasion of triple-negative breast cancer cells. Oncol Rep. 2016 Oct;36(4):2071-8. doi: 10.3892/or.2016.5036. Epub 2016 Aug 24.'}, {'ReferencePMID': '25759175', 'ReferenceType': 'background', 'ReferenceCitation': 'Feng Y, Yao Z, Klionsky DJ. How to control self-digestion: transcriptional, post-transcriptional, and post-translational regulation of autophagy. Trends Cell Biol. 2015 Jun;25(6):354-63. doi: 10.1016/j.tcb.2015.02.002. Epub 2015 Mar 8.'}, {'ReferencePMID': '19524509', 'ReferenceType': 'background', 'ReferenceCitation': 'Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, Dipaola RS, Karantza-Wadsworth V, White E. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2009 Jun 12;137(6):1062-75. doi: 10.1016/j.cell.2009.03.048. Erratum In: Cell. 2011 Apr 15;145(2):322.'}, {'ReferencePMID': '19524504', 'ReferenceType': 'background', 'ReferenceCitation': 'Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell. 2009 Jun 12;137(6):1001-4. doi: 10.1016/j.cell.2009.05.023.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}, {'ConditionMeshId': 'D000009362', 'ConditionMeshTerm': 'Neoplasm Metastasis'}, {'ConditionMeshId': 'D000001859', 'ConditionMeshTerm': 'Bone Neoplasms'}, {'ConditionMeshId': 'D000001855', 'ConditionMeshTerm': 'Bone Marrow Diseases'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}, {'ConditionAncestorId': 'D000009385', 'ConditionAncestorTerm': 'Neoplastic Processes'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000001847', 'ConditionAncestorTerm': 'Bone Diseases'}, {'ConditionAncestorId': 'D000009140', 'ConditionAncestorTerm': 'Musculoskeletal Diseases'}, {'ConditionAncestorId': 'D000006402', 'ConditionAncestorTerm': 'Hematologic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11459', 'ConditionBrowseLeafName': 'Neoplasm Metastasis', 'ConditionBrowseLeafAsFound': 'Metastases', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4290', 'ConditionBrowseLeafName': 'Bone Neoplasms', 'ConditionBrowseLeafAsFound': 'Bone Metastases', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4286', 'ConditionBrowseLeafName': 'Bone Marrow Diseases', 'ConditionBrowseLeafAsFound': 'Bone Metastases', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11482', 'ConditionBrowseLeafName': 'Neoplastic Processes', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4278', 'ConditionBrowseLeafName': 'Bone Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11249', 'ConditionBrowseLeafName': 'Musculoskeletal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8642', 'ConditionBrowseLeafName': 'Hematologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Musculoskeletal Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC15', 'ConditionBrowseBranchName': 'Blood and Lymph Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M7833', 'InterventionBrowseLeafName': 'Formaldehyde', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 98, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00656604', 'OrgStudyIdInfo': {'OrgStudyId': 'VICC BRE 0358'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'P30CA068485', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/P30CA068485'}, {'SecondaryId': 'VU-VICC-BRE-0358'}, {'SecondaryId': 'VU-VICC-IRB-030472'}]}, 'Organization': {'OrgFullName': 'Vanderbilt-Ingram Cancer Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics', 'OfficialTitle': 'Evaluation of Patients With Breast Cancer Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, and Proteomics'}, 'StatusModule': {'StatusVerifiedDate': 'March 2013', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 2003'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2005', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'January 2008', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 10, 2008', 'StudyFirstSubmitQCDate': 'April 10, 2008', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 11, 2008', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 4, 2013', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 5, 2013', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'A Bapsi Chakravarthy, MD', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Vanderbilt-Ingram Cancer Center'}, 'LeadSponsor': {'LeadSponsorName': 'Vanderbilt-Ingram Cancer Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'RATIONALE: Diagnostic procedures, such as dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI), magnetic resonance spectroscopy (MRS), and tissue proteomics, may help doctors find and diagnose breast cancer and plan the best treatment.\n\nPURPOSE: This clinical trial is studying MRI and MRS with or without tissue proteomics analysis to see how well they work in evaluating healthy women and women who are undergoing surgery for breast cancer.', 'DetailedDescription': 'OBJECTIVES:\n\nTo correlate data obtained by DCE-MRI and MRS in healthy women and in women who are undergoing surgery for breast cancer with data obtained by conventional X-ray mammography, tissue proteomics, and histopathology.\nTo evaluate the impact of MRSI data on treatment planning for radiotherapy and/or surgery.\n\nOUTLINE: Healthy participants undergo dynamic contrast-enhanced (DCE)-MRI and magnetic resonance spectroscopic (MRS) for longitudinal studies of breast imaging and spectroscopy.\n\nPatients with breast cancers undergo DCE-MRI and MRS prior to initiation of treatment (i.e., surgery, chemotherapy, or radiotherapy). After treatment has begun, patients then undergo repeat imaging (not more than 1 per month) for follow-up assessments and longitudinal studies.\n\nBreast tissue samples are collected from patients undergoing surgery. Samples are evaluated by histopathological and proteomic analysis for correlation with DCE-MRI and MRS findings.\n\nThe study interventions are discontinued after definitive surgery is performed.\n\nPROJECTED ACCRUAL: A total of 10 healthy participants and 40 patients with breast cancer will be accrued for this study.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['recurrent breast cancer', 'stage I breast cancer', 'stage II breast cancer', 'stage IIIA breast cancer', 'stage IIIB breast cancer', 'stage IIIC breast cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Diagnostic', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '30', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Women with breast cancer', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients undergo DCE-MRI and MRS prior to their breast cancer surgery.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: proteomic profiling', 'Procedure: lumpectomy or mastectomy', 'Procedure: dynamic contrast-enhanced magnetic resonance imaging', 'Procedure: histopathologic examination', 'Procedure: magnetic resonance spectroscopy']}}, {'ArmGroupLabel': 'Healthy volunteers', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Women without breast cancer undergo DCE-MRI and MRS.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Genetic', 'InterventionName': 'proteomic profiling', 'InterventionDescription': 'at the time of each procedure.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Women with breast cancer']}, 'InterventionOtherNameList': {'InterventionOtherName': ['proteomic analysis']}}, {'InterventionType': 'Procedure', 'InterventionName': 'lumpectomy or mastectomy', 'InterventionDescription': 'removal of breast tumor or removal of the entire breast in which the tumor is located', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Women with breast cancer']}, 'InterventionOtherNameList': {'InterventionOtherName': ['None noted']}}, {'InterventionType': 'Procedure', 'InterventionName': 'dynamic contrast-enhanced magnetic resonance imaging', 'InterventionDescription': 'Prior to initiation of treatment', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Women with breast cancer']}, 'InterventionOtherNameList': {'InterventionOtherName': ['DCE-MRI']}}, {'InterventionType': 'Procedure', 'InterventionName': 'histopathologic examination', 'InterventionDescription': 'After the breast tumor has been removed, examination of the tumor under a microscope to determine the type and grade of breast cancer', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Women with breast cancer']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Not noted']}}, {'InterventionType': 'Procedure', 'InterventionName': 'magnetic resonance spectroscopy', 'InterventionDescription': 'Prior to initiation of treatment', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Women with breast cancer']}, 'InterventionOtherNameList': {'InterventionOtherName': ['MRS']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Correlation of data obtained by DCE-MRI and magnetic resonance spectroscopy (MRS) with data obtained by conventional X-ray mammography, tissue proteomics, and histopathology in women with breast cancer', 'PrimaryOutcomeDescription': "Imaging and spectroscopic studies are performed before surgery. After surgery, this data will be compared and contrast with data obtained from conventional mammograms and the patient's tissue.", 'PrimaryOutcomeTimeFrame': 'At time of breast surgery'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Evaluation of the impact of MRS data on treatment planning for radiotherapy and/or surgery in women with breast cancer', 'SecondaryOutcomeDescription': "Investigators will evaluate the effectiveness of spectroscopic data used to plan for the patient's post-imaging surgery and/or post-surgical radiotherapy.", 'SecondaryOutcomeTimeFrame': 'After the last scan'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'DISEASE CHARACTERISTICS:\n\nMeets 1 of the following criteria:\n\nWomen with breast tumors planning to undergo surgical resection\nHealthy volunteers, including any constitutionally healthy female with no history of breast cancer\nHormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\nFemale\nMenopausal status not specified\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception\nNot acutely ill\nNo non-magnetic resonance-compatible ferromagnetic materials present in the body\n\nPRIOR CONCURRENT THERAPY:\n\nPrior chemotherapy and/or radiotherapy allowed', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Female', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'A. Bapsi Chakravarthy, MD', 'OverallOfficialAffiliation': 'Vanderbilt-Ingram Cancer Center', 'OverallOfficialRole': 'Study Chair'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14002', 'ConditionBrowseLeafName': 'Recurrence', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11062', 'ConditionBrowseLeafName': 'Mitral Valve Insufficiency', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}}, {'Rank': 99, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00880464', 'OrgStudyIdInfo': {'OrgStudyId': '08-216'}, 'Organization': {'OrgFullName': 'Dana-Farber Cancer Institute', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer', 'OfficialTitle': 'A Phase Ib Study of Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete GM-CSF Following Preoperative Chemotherapy in Women With Operable Breast Cancer'}, 'StatusModule': {'StatusVerifiedDate': 'March 2022', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 1, 2006', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2011', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 10, 2009', 'StudyFirstSubmitQCDate': 'April 10, 2009', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 13, 2009', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'June 7, 2021', 'ResultsFirstSubmitQCDate': 'November 8, 2021', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'November 9, 2021', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 30, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 1, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Ana C Garrido-Castro', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Dana-Farber Cancer Institute'}, 'LeadSponsor': {'LeadSponsorName': 'Dana-Farber Cancer Institute', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': "Brigham and Women's Hospital", 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'Yes', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': "The purpose of this trial is to test the safety of a vaccine made from a patient's own breast cancer cells, and determine if this vaccine will delay or stop the growth of the cancer. The vaccine is made by genetically modifying a patient's own tumor cells to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) to activate the immune response", 'DetailedDescription': "After the patient has given their consent to participate in the trial, a series of tests will be performed to determine if the patient is eligible. These tests may take place up to 21 days before the surgery to remove a tumor sample or cancer-containing fluid, which will be used to create the vaccines. The tumor cells or fluid is then brought to a special, certified laboratory where the vaccine is made. Specially trained laboratory technicians then use a method known as adenoviral mediated gene transfer, which adds a new gene to the cancer cells. This gene causes the cells to make GM-CSF, a powerful hormone that stimulates the immune system. The cells are then given radiation so that they will not grow. Participants will start receiving vaccine on day 1, 8, 15, 29, and then every two weeks until the supply of vaccine has run out. The amount of the vaccine depends upon the total amount of cells that are obtained from the breast cancer tumor or fluid. Each time the patient is vaccinated, they will be given injections that will be placed underneath the skin. A different place will be used for each injection. If there are enough cells from the patient's tumor sample, the patient will be given an injection of non-transduced irradiated cells (the gene was not added) . These cells will help to measure how the patient's immune system is reacting to the tumor cells. This is called Delayed-Type Hypersensitivity (DTH). With vaccine #1 and #5, the patient will also receive a DTH injection. Two to three days after the vaccine and DTH injection, skin biopsies will be taken of both sites. At week 10 in the study treatment, or earlier if necessary, the patient will have a chest, abdomen, and pelvic CT scan to determine if the vaccine therapy has had an effect on their disease. A brain MRI will be performed if there were any abnormalities on the first brain MRI or if new symptoms have developed. Patients may participate in this study until one of the following happens: All vaccine created from the tumor has been given to the patient; the patient's disease worsens; the patient experiences an unacceptable and/or harmful side effect; the patient is unable to follow the study plan; or the patient's doctor feels it is no longer in the best interest of the patient to continue."}, 'ConditionsModule': {'ConditionList': {'Condition': ['Breast Cancer']}, 'KeywordList': {'Keyword': ['autologous vaccination', 'GM-CSF', 'adenoviral mediated gene transfer', 'Stage IV breast cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '8', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Vaccine', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,\n\n1x10 6 , or 1x10 5 depending on the final cell yield.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Autologous, Lethally Irradiated Breast Cancer Cells']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Biological', 'InterventionName': 'Autologous, Lethally Irradiated Breast Cancer Cells', 'InterventionDescription': 'Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Vaccine']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Minimum Number of Vaccine Doses Created Using Participant Tumor Sample', 'PrimaryOutcomeDescription': 'Tumor samples were obtained via malignant effusion or a surgically accessible tumor nodule of 2 cm in greatest diameter. Tumor cells were processed to single cell suspension and transduced with adenoviral vector encoding human Granulocyte-macrophage colony-stimulating factor (GM-CSF). Then, the cells washed extensively and irradiated with 10,000 cGy. Over the next 14 days, sterility cultures were tested for endotoxin and mycoplasma contamination. Individual vaccine cell dose and number varied depending on the final cell yield from vaccine production. For stage II-III patients, the minimal dose was 1 x 10^5 cells and the maximal dose was 4 x 10^6 cells. For metastatic patients, the minimal dose was 1 x 10^5 cells and the maximal dose was 1 x 10^7 cells.', 'PrimaryOutcomeTimeFrame': '40 Months'}, {'PrimaryOutcomeMeasure': 'Number of Participants With Grade 3 or Higher Adverse Events', 'PrimaryOutcomeDescription': 'Number of participants with grade 3 or higher adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.', 'PrimaryOutcomeTimeFrame': 'Up to 58 Months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Median Follow-up Time by Survival Status', 'SecondaryOutcomeDescription': 'Participants followed for survival status. Participants who were alive were noted as such as late as December 2020.', 'SecondaryOutcomeTimeFrame': 'Up to 14 Years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\n\nHistologically or cytologically confirmed invasive breast cancer, pre-operative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging\nCohort 1: At least 2cm of residual disease in sum of diameters by clinical or radiographic findings following their preoperative chemotherapy\nCohort 2: Patients who have not received preoperative chemotherapy must have at least 4cm of disease in the largest diameter by clinical or radiographic findings\nPrior therapy for Cohort 1 only: Must have completed preoperative (neoadjuvant) chemotherapy with either a standard regimen (containing an anthracycline and/or a taxane) or on a clinical trial\nHER2 positive tumors must have received at least one prior trastuzumab-based therapy, and may not receive concurrent trastuzumab therapy and vaccination\nMust initiate hormonal therapy (if indicated), including ovarian suppression, at least 4 weeks prior to initiation of vaccinations\nMust have completed definitive resection of primary tumor with adequated excision of gross disease. Surgery should have occured more than 28 days but within 12 weeks prior to enrollment\nMay receive concurrent hormonal therapy, such as tamoxifen, ovarian suppression, and aromatase inhibitors\nMust have had prior banked tumor of sufficient cellular yield for vaccination\nECOG Performance Status 0 or 1\n18 years of age or older\nGreater than 4 weeks from immunotherapy, or systemic glucocorticoid therapy\nAdequate recovery from recent surgery and radiation therapy\n\nExclusion Criteria:\n\nUncontrolled active infection or illness\nOther medical or psychiatric illness or social situation that would limit study compliance\nPregnancy or nursing mothers\nEvidence of HIV infection\nPrevious participation in an adenovirus-based trial\nConcurrent invasive malignancies', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Beth Overmoyer, MD', 'OverallOfficialAffiliation': 'Dana-Farber Cancer Institute', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': "Brigham and Women's Hospital", 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02115', 'LocationCountry': 'United States'}, {'LocationFacility': 'Dana-Farber Cancer Institute', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02115', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '35482127', 'ReferenceType': 'derived', 'ReferenceCitation': 'Anderson KS, Erick TK, Chen M, Daley H, Campbell M, Colson Y, Mihm M, Zakka LR, Hopper M, Barry W, Winer EP, Dranoff G, Overmoyer B. The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers. Breast Cancer Res Treat. 2022 Jul;194(1):65-78. doi: 10.1007/s10549-022-06562-y. Epub 2022 Apr 28.'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowRecruitmentDetails': 'January 2006 through May 2008', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Stage II-III Breast Cancer Cohort', 'FlowGroupDescription': 'Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out\n\nAutologous, Lethally Irradiated Breast Cancer Cells: Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '7'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '7'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Metastatic Breast Cancer Cohort', 'BaselineGroupDescription': 'Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out\n\nAutologous, Lethally Irradiated Breast Cancer Cells: Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '7'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Full Range', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '51.5', 'BaselineMeasurementLowerLimit': '32', 'BaselineMeasurementUpperLimit': '65'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '7'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '7'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Clinical Stage', 'BaselineMeasureDescription': "T1: tumor is 2 cm or less T2 tumor is between 2 and 5 cm T3: tumor is greater than 5 cm T4: tumor has spread into the the chest wall and/or skin\n\nN0: no tumor in lymph nodes N1: tumor(s) in axillary lymph nodes N2: tumor(s) in axillary lymph nodes fixed of matted or only in clinically apparent mammary nodes without clinically evident axillary lymph nodes.\n\nN3: tumor(s) in infraclavicular lymph nodes or clinically apparent internal mammary lymph nodes or supraclavicular lymph nodes\n\nM0: cancer hasn't spread to other parts of the body M1: cancer has spread to other parts of the body", 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'T3, N1', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}]}}]}}, {'BaselineClassTitle': 'T4, N0, M1', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}]}}]}}, {'BaselineClassTitle': 'T4, N1', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2'}]}}]}}, {'BaselineClassTitle': 'T4, N2', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}]}}]}}]}}, {'BaselineMeasureTitle': 'Hormone Receptor Status', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Positive', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}]}}]}}, {'BaselineClassTitle': 'Negative', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2'}]}}]}}]}}, {'BaselineMeasureTitle': 'Human Epidermal Growth Factor Receptor 2 Status', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Positive', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}]}}]}}, {'BaselineClassTitle': 'Negative', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '6'}]}}]}}]}}, {'BaselineMeasureTitle': 'Triple Negative', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Positive', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2'}]}}]}}, {'BaselineClassTitle': 'Negative', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}]}}]}}]}}, {'BaselineMeasureTitle': 'Type of Surgery', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Mastectomy', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '6'}]}}]}}, {'BaselineClassTitle': 'Lumpectomy', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}]}}]}}]}}, {'BaselineMeasureTitle': 'Pathologic Response to Neoadjuvant Therapy', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Partial Response', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '6'}]}}]}}, {'BaselineClassTitle': 'Not Available', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Minimum Number of Vaccine Doses Created Using Participant Tumor Sample', 'OutcomeMeasureDescription': 'Tumor samples were obtained via malignant effusion or a surgically accessible tumor nodule of 2 cm in greatest diameter. Tumor cells were processed to single cell suspension and transduced with adenoviral vector encoding human Granulocyte-macrophage colony-stimulating factor (GM-CSF). Then, the cells washed extensively and irradiated with 10,000 cGy. Over the next 14 days, sterility cultures were tested for endotoxin and mycoplasma contamination. Individual vaccine cell dose and number varied depending on the final cell yield from vaccine production. For stage II-III patients, the minimal dose was 1 x 10^5 cells and the maximal dose was 4 x 10^6 cells. For metastatic patients, the minimal dose was 1 x 10^5 cells and the maximal dose was 1 x 10^7 cells.', 'OutcomeMeasurePopulationDescription': 'Vaccinations prepared for "enrolled for vaccine administration" population.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'doses', 'OutcomeMeasureTimeFrame': '40 Months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Vaccine', 'OutcomeGroupDescription': 'Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out\n\nAutologous, Lethally Irradiated Breast Cancer Cells: Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '7'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Number of Participants With Grade 3 or Higher Adverse Events', 'OutcomeMeasureDescription': 'Number of participants with grade 3 or higher adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.', 'OutcomeMeasurePopulationDescription': 'Analysis population for adverse events is "Treated" population.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Up to 58 Months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Vaccine', 'OutcomeGroupDescription': 'Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out\n\nAutologous, Lethally Irradiated Breast Cancer Cells: Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '7'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Grade 3', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1'}]}}]}}, {'OutcomeClassTitle': 'Grade 4', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}]}}]}}, {'OutcomeClassTitle': 'Grade 5', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Median Follow-up Time by Survival Status', 'OutcomeMeasureDescription': 'Participants followed for survival status. Participants who were alive were noted as such as late as December 2020.', 'OutcomeMeasurePopulationDescription': 'Clinical outcomes assessed for the "treated" population.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Full Range', 'OutcomeMeasureUnitOfMeasure': 'years', 'OutcomeMeasureTimeFrame': 'Up to 14 Years', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Vaccine', 'OutcomeGroupDescription': 'Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out\n\nAutologous, Lethally Irradiated Breast Cancer Cells: Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '7'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Alive', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '2'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '9.88', 'OutcomeMeasurementLowerLimit': '9.76', 'OutcomeMeasurementUpperLimit': '9.99'}]}}]}}, {'OutcomeClassTitle': 'Dead', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '5'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6.24', 'OutcomeMeasurementLowerLimit': '1.16', 'OutcomeMeasurementUpperLimit': '8.49'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': 'Up to 14 Years', 'EventsDescription': 'Serious AEs (SAE) were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher. All remaining AEs are classified as Other AEs (OAE) including grade 3 or higher events with treatment-attribution of unlikely and unrelated plus all grade 1 and 2 events. Maximum grade toxicity by type was then calculated within SAE and OAE datasets. No further data is available to specify classification of other beyond the general term.', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Vaccine', 'EventGroupDescription': 'Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out\n\nAutologous, Lethally Irradiated Breast Cancer Cells: Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS', 'EventGroupDeathsNumAffected': '5', 'EventGroupDeathsNumAtRisk': '7', 'EventGroupSeriousNumAffected': '1', 'EventGroupSeriousNumAtRisk': '7', 'EventGroupOtherNumAffected': '7', 'EventGroupOtherNumAtRisk': '7'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Fatigue', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'CTCAE (3.0)', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '7'}]}}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Allergic Reaction', 'OtherEventOrganSystem': 'Immune system disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Alanine aminotransferase increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Aspartate aminotransferase increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'General disorders and administration site conditions - Other, specify', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Cough', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Fat atrophy', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '17', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Fever', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Anemia', 'OtherEventOrganSystem': 'Blood and lymphatic system disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Vascular disorders - Other, specify', 'OtherEventOrganSystem': 'Vascular disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Hot Flashes', 'OtherEventOrganSystem': 'Vascular disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Upper respiratory infection', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Arthralgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '7', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Memory Impairment', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Myalgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Musculoskeletal and connective tissue disorder - Other, specify', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Nervous system disorders - Other, specify', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Peripheral sensory neuropathy', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Respiratory, thoracic and mediastinal disorders - Other, specify', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Rash maculo-papular', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Skin and subcutaneous tissue disorders - Other, specify', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '7'}]}}, {'OtherEventTerm': 'Pharyngolaryngeal pain', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'CTCAE (3.0)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Beth Overmoyer', 'PointOfContactOrganization': 'Mass General Brigham', 'PointOfContactEMail': 'Beth_Overmoyer@DFCI.HARVARD.EDU', 'PointOfContactPhone': '617 632 3800'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'March 08, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4372', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4370', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14826', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16512', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}]}}]